


**CUMULATIVE
SUPPLEMENT 12
December 2024**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 12
December 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	xi
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 12
December 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACI HEALTHCARE LTD (ACI)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
EXTROVIS AG (EXTROVIS)	RISING PHARMA HOLDINGS INC (RISING)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
JOHNSON AND JOHNSON CONSUMER INC (JOHNSON AND JOHNSON)	KENVUE BRANDS LLC (KENVUE BRANDS)
JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV (J AND J CONSUMER INC)	KENVUE BANDS LLC (KENVUE BRANDS)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO PHARMA)

MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
SAPTALIS PHARMACEUTICALS LLC (SAPTALIS PHARMS)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
STERISCIENCE PTE LTD (STERISCIENCE)	STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	ESJAY PHARMA LLC (ESJAY PHARMA)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	STRIDES SOFTGELS PTE LTD (STRIDES SOFTGELS)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs,

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the

products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 (12.1%)	23058 (12.2%)	23182 (11.9%)	23346 (11.7%)	23586 (11.8%)
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)	20605 (88.3%)	20814 (88.2%)
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)	20522 (87.9%)	20741 (87.9%)
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)	83 (0.4%)	73 (0.3%)
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	32	18	14	19	43
NUMBER OF APPLICANTS	1214	1219	1214	1191	1197

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

TABLET;ORAL

ABACAVIR SULFATE

>A>	AB	CHARTWELL RX	EQ 300MG BASE	A 091050	001	Oct 28, 2016	Dec CAHN
>D>	AB	STRIDES PHARMA	EQ 300MG BASE	A 091050	001	Oct 28, 2016	Dec CAHN

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	!	CIPLA	EQ 600MG BASE;300MG	A 091144	001	Mar 28, 2017	Jan CHRS
>A>	AB	MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A 212663	001	Dec 19, 2024	Dec NEWA

TABLET, FOR SUSPENSION;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N 204311	001	Dec 22, 2023	Jan DISC
	+	@ NORVIUM BIOSCIENCE	EQ 60MG BASE;30MG	N 204311	001	Dec 22, 2023	Aug CAHN

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		MSN	500MG	A 210686	002	Apr 24, 2024	Apr NEWA
----	--	-----	-------	----------	-----	--------------	----------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

	@	GLENMARK PHARMS LTD	333MG	A 202229	001	Jul 16, 2013	Aug DISC
AB	!	ZYDUS PHARMS	333MG	A 205995	001	May 26, 2017	Aug CHRS

ACARBOSE

TABLET;ORAL

ACARBOSE

AB		SOMERSET THERAPS LLC	25MG	A 091343	001	Oct 17, 2013	Sep CAHN
AB			50MG	A 091343	002	Oct 17, 2013	Sep CAHN
AB			100MG	A 091343	003	Oct 17, 2013	Sep CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		QUAGEN	300MG;50MG	A 214305	001	Feb 01, 2024	Jan NEWA
AA			325MG;50MG	A 214291	001	Jan 18, 2024	Jan NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	@	KEY THERAP	300MG;50MG;40MG	A 206615	001	Aug 04, 2017	May DISC
AA			300MG;50MG;40MG	A 206615	001	Aug 04, 2017	Apr CAHN
AA		QUAGEN	300MG;50MG;40MG	A 214288	001	Feb 08, 2024	Jan NEWA
AA			325MG;50MG;40MG	A 216376	001	Mar 12, 2024	Mar NEWA
AA		SENORES PHARMS	300MG;50MG;40MG	A 214087	001	Aug 13, 2021	Feb CAHN
AA			325MG;50MG;40MG	A 214087	002	Aug 13, 2021	Feb CAHN

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		QUAGEN	325MG;50MG;40MG	A 214287	001	Jan 18, 2024	Jan NEWA
----	--	--------	-----------------	----------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A 075929	001	Apr 22, 2002	May DISC
---	------------------	----------------------	----------	-----	--------------	----------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

@	KEY THERAP	320.5MG;30MG;16MG	A 204785	001	Nov 26, 2014	May DISC
		320.5MG;30MG;16MG	A 204785	001	Nov 26, 2014	Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@ AKORN	120MG/5ML;12MG/5ML	A 040119	001	Apr 26, 1996	Feb	DISC
	@ PAI HOLDINGS	120MG/5ML;12MG/5ML	A 040119	001	Apr 26, 1996	May	CAHN
	@ STRIDES PHARMA	120MG/5ML;12MG/5ML	A 086366	001		Sep	CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	!	SPECGX LLC	300MG;60MG	A 040419	003	May 31, 2001	Apr	CHRS
AA		STRIDES PHARMA	300MG;15MG	A 089990	001	Sep 30, 1988	Apr	CMFD
AA			300MG;30MG	A 089805	001	Sep 30, 1988	Apr	CMFD
AA			300MG;60MG	A 089828	001	Sep 30, 1988	Apr	CMFD
	@	SUN PHARM INDS LTD	300MG;30MG	A 085868	001		Jan	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	AMNEAL PHARMS	300MG;10MG	A 207137	001	Nov 29, 2016	Jul	DISC
	@	AMNEAL PHARMS NY	300MG;5MG	A 206869	001	Jun 23, 2017	Jul	DISC
AA	!	ASCENT PHARMS INC	325MG;2.5MG	A 211487	001	Nov 07, 2018	Oct	CTEC
AA		ELITE LABS INC	325MG;2.5MG	A 209924	001	Nov 16, 2018	Oct	CTEC
	@		325MG;2.5MG	A 209924	001	Nov 16, 2018	Jun	CAHN
AA			325MG;5MG	A 209924	002	Nov 16, 2018	Oct	CTEC
	@		325MG;5MG	A 209924	002	Nov 16, 2018	Jun	CAHN
AA			325MG;7.5MG	A 209924	003	Nov 16, 2018	Oct	CTEC
	@		325MG;7.5MG	A 209924	003	Nov 16, 2018	Jun	CAHN
AA			325MG;10MG	A 209924	004	Nov 16, 2018	Oct	CTEC
	@		325MG;10MG	A 209924	004	Nov 16, 2018	Jun	CAHN
	@	ENDO OPERATIONS	300MG;5MG	A 090415	001	Jan 24, 2011	May	CAHN
	@		300MG;7.5MG	A 090415	002	Jan 24, 2011	May	CAHN
	@		300MG;10MG	A 090415	003	Jan 24, 2011	May	CAHN
AA		GRANULES	325MG;5MG	A 211729	001	Jan 03, 2020	Jul	CMFD
AA			325MG;7.5MG	A 211729	002	Jan 03, 2020	Jul	CMFD
AA			325MG;10MG	A 211729	003	Jan 03, 2020	Jul	CMFD
	@	PRINSTON INC	325MG;5MG	A 214928	001	Dec 30, 2021	Mar	DISC
	@		325MG;7.5MG	A 214928	002	Dec 30, 2021	Mar	DISC
	@		325MG;10MG	A 214928	003	Dec 30, 2021	Mar	DISC
	@	SANALUZ	325MG;5MG	A 211690	001	Feb 07, 2020	Sep	CAHN
	@		325MG;7.5MG	A 211690	002	Feb 07, 2020	Sep	CAHN
	@		325MG;10MG	A 211690	003	Feb 07, 2020	Sep	CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

COMBOGESIC

+	!	AFT PHARMS LTD	325MG;97.5MG	N 209471	001	Mar 01, 2023	Sep	CMFD
+	!	AFT PHARMS US	325MG;97.5MG	N 209471	001	Mar 01, 2023	Sep	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

	@	ENDO OPERATIONS	325MG/5ML;5MG/5ML	A 203573	001	Dec 18, 2014	May	CAHN
--	---	-----------------	-------------------	----------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA		ELITE LABS INC	325MG;5MG	A 209385	001	Jul 02, 2018	Aug	CMFD
	@		325MG;5MG	A 209385	001	Jul 02, 2018	Jun	CAHN
AA			325MG;7.5MG	A 209385	002	Jul 02, 2018	Aug	CMFD
	@		325MG;7.5MG	A 209385	002	Jul 02, 2018	Jun	CAHN
AA			325MG;10MG	A 209385	003	Jul 02, 2018	Aug	CMFD
	@		325MG;10MG	A 209385	003	Jul 02, 2018	Jun	CAHN
	@	ENDO OPERATIONS	325MG;2.5MG	A 090733	001	Jul 11, 2013	May	CAHN
	@		325MG;5MG	A 040105	001	Jul 30, 1996	May	CAHN
	@		325MG;7.5MG	A 090734	001	Jul 11, 2013	May	CAHN
	@		325MG;10MG	A 090734	002	Jul 11, 2013	May	CAHN
AA		GRANULES	325MG;2.5MG	A 211708	001	Oct 31, 2019	Jul	CMFD
AA			325MG;5MG	A 211708	002	Oct 31, 2019	Jul	CMFD
AA			325MG;7.5MG	A 211708	003	Oct 31, 2019	Jul	CMFD
AA			325MG;10MG	A 211708	004	Oct 31, 2019	Jul	CMFD
	@	SANALUZ	325MG;5MG	A 207574	001	Dec 13, 2016	Sep	CAHN
		PERCOCET						
AA	!	ENDO OPERATIONS	325MG;2.5MG	A 040330	001	Jun 25, 1999	Apr	CAHN
AA	!		325MG;5MG	A 040330	002	Jun 25, 1999	Apr	CAHN
	+ @		325MG;5MG	A 085106	002		May	CAHN

	TABLET;ORAL								
	PERCO CET								
AA	!	325MG;7.5MG		A040330	003	Nov 23, 2001		Apr	CAHN
AA	!	325MG;10MG		A040330	004	Nov 23, 2001		Apr	CAHN
	<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE</u>								
	TABLET;ORAL								
	TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN								
	@ SUN PHARM INDS INC	325MG;37.5MG		A077184	001	Dec 16, 2005		Aug	DISC
	<u>ACETAZOLAMIDE</u>								
	TABLET;ORAL								
	ACETAZOLAMIDE								
	@ AJANTA PHARMA LTD	125MG		A211151	001	Sep 11, 2023		Feb	DISC
	@	250MG		A211151	002	Sep 11, 2023		Feb	DISC
AB	EPIC PHARMA LLC	125MG		A218023	001	May 14, 2024		May	NEWA
AB		250MG		A218023	002	May 14, 2024		May	NEWA
BX	EYWA PHARMA	125MG		A211556	001	Oct 18, 2019		Jun	CTEC
BX		250MG		A211556	002	Oct 18, 2019		Jun	CTEC
BX	HIBROW HLTHCARE	125MG		A211556	001	Oct 18, 2019		Jul	CAHN
BX		250MG		A211556	002	Oct 18, 2019		Jul	CAHN
	@ TORRENT	125MG		A213706	001	Jan 26, 2024		Jan	DISC
AB		125MG		A213706	001	Jan 26, 2024		Jan	NEWA
	@	250MG		A213706	002	Jan 26, 2024		Jan	DISC
AB		250MG		A213706	002	Jan 26, 2024		Jan	NEWA
	<u>ACETAZOLAMIDE SODIUM</u>								
	INJECTABLE;INJECTION								
	ACETAZOLAMIDE SODIUM								
	@ ENDO OPERATIONS	EQ 500MG BASE/VIAL		A205358	001	Jun 20, 2017		May	CAHN
	<u>ACETIC ACID, GLACIAL</u>								
	SOLUTION/DROPS;OTIC								
	VOSOL								
	+ @ HIKMA	2%		N012179	001			Apr	CRLD
	@	2%		N012179	001			Apr	DISC
	<u>ACETYLCYSTEINE</u>								
	INJECTABLE;INTRAVENOUS								
	ACETYLCYSTEINE								
AP	GLENMARK PHARMS INC	6GM/30ML (200MG/ML)		A213693	001	Feb 03, 2022		Sep	CAHN
AP	SOMERSET THERAPS LLC	6GM/30ML (200MG/ML)		A218397	001	Jun 07, 2024		May	NEWA
	SOLUTION;INHALATION, ORAL								
	ACETYLCYSTEINE								
	@ EXELA PHARMA	20%		A205643	001	Nov 01, 2023		Feb	DISC
	<u>ACETYLCYSTEINE LYSINE</u>								
	FOR SOLUTION;ORAL								
	LEGUBETI								
	+ @ GALEPHAR	EQ 500MG BASE/PACKET		N215040	001	Feb 13, 2024		Jun	DISC
	+	EQ 500MG BASE/PACKET		N215040	001	Feb 13, 2024		Feb	NEWA
	+ @	EQ 2.5GM BASE/PACKET		N215040	002	Feb 13, 2024		Jun	DISC
	+	EQ 2.5GM BASE/PACKET		N215040	002	Feb 13, 2024		Feb	NEWA
	<u>ACITRETIN</u>								
	CAPSULE;ORAL								
	ACITRETIN								
AB	ALEMBIC	10MG		A217774	001	Aug 05, 2024		Jul	NEWA
AB		17.5MG		A217774	002	Aug 05, 2024		Jul	NEWA
AB		25MG		A217774	003	Aug 05, 2024		Jul	NEWA
	<u>ACORAMIDIS HYDROCHLORIDE</u>								
	TABLET;ORAL								
	ATTRUBY								
	+! BRIDGEBIO PHARMA	EQ 356MG BASE		N216540	001	Nov 22, 2024		Nov	NEWA
	<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	SEMPREX-D								
	+ @ ENDO OPERATIONS	8MG;60MG		N019806	001	Mar 25, 1994		May	CAHN

ACYCLOVIR

	CAPSULE; ORAL						
	ACYCLOVIR						
AB	ADAPTIS	200MG	A075090	001	Jan 26, 1999	Sep	CAHN
	CREAM; TOPICAL						
	ACYCLOVIR						
AB	TARO	5%	A205470	001	Jun 12, 2024	Jul	CAHN
AB		5%	A205470	001	Jun 12, 2024	May	NEWA
	OINTMENT; TOPICAL						
	ACYCLOVIR						
	@ COSETTE	5%	A205591	001	Nov 13, 2017	Mar	DISC
	SUSPENSION; ORAL						
	ACYCLOVIR						
	@ HIKMA	200MG/5ML	A077026	001	Jun 07, 2005	Mar	DISC
	@ VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021	Mar	CAHN

ACYCLOVIR SODIUM

	INJECTABLE; INJECTION						
	ACYCLOVIR SODIUM						
AP	DDREG PHARMA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jun	NEWA
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jul	CAHN
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Jun	CAHN
AP	SLATE RUN PHARMA	EQ 50MG BASE/ML	A218111	001	Jan 08, 2024	Sep	CAHN

ADAGRASIB

	TABLET; ORAL						
	KRAZATI						
	+! BRISTOL	200MG	N216340	001	Dec 12, 2022	Sep	CAHN

ADEFOVIR DIPIVOXIL

	TABLET; ORAL						
	ADEFOVIR DIPIVOXIL						
AB	! SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Jun	CHRS
	HEPSERA						
	+ @ GILEAD	10MG	N021449	001	Sep 20, 2002	Jun	DISC

ADENOSINE

	INJECTABLE; INJECTION						
	ADENOSINE						
	@ NORVIUM BIOSCIENCE	3MG/ML	A078640	001	Mar 21, 2014	Oct	CAHN
	SOLUTION; INTRAVENOUS						
	ADENOSINE						
	@ HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb	DISC
	@	90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb	DISC

ALBENDAZOLE

	TABLET; ORAL						
	ALBENDAZOLE						
AB	ALEMBIC	200MG	A215652	001	Sep 04, 2024	Aug	NEWA
	@ STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018	Sep	DISC

ALBUTEROL SULFATE

	AEROSOL, METERED; INHALATION						
	ALBUTEROL SULFATE						
AB2	ARMSTRONG PHARMS	EQ 0.09MG BASE/INH	A212447	001	May 21, 2024	May	NEWA
	POWDER, METERED; INHALATION						
	PROAIR DIGIHALER						
	+ @ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jun	DISC
	SOLUTION; INHALATION						
	ACCUNEB						
	+ @ NORVIUM BIOSCIENCE	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jul	CAHN
	+ @	EQ 0.042% BASE	N020949	001	Apr 30, 2001	Jul	CAHN
	ALBUTEROL SULFATE						
AN	LEXENPHARM	EQ 0.021% BASE	A215571	001	May 03, 2024	Apr	NEWA
AN		EQ 0.042% BASE	A215571	002	May 03, 2024	Apr	NEWA
AN	LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Jun	CMFD
AN		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Jun	CMFD
	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jun	CAHN
	@ WATSON LABS	EQ 0.021% BASE	A077772	001	Sep 25, 2007	Jun	DISC

	SOLUTION; INHALATION							
	ALBUTEROL SULFATE							
	@	EQ 0.042% BASE	A077772	002	Sep 25, 2007	Jun	DISC	
	SYRUP; ORAL							
	ALBUTEROL SULFATE							
	@ HIKMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar	DISC	
	TABLET; ORAL							
	ALBUTEROL SULFATE							
BX	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun	CTEC	
BX		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun	CTEC	
	@ HIBROW HLTHCARE	EQ 2MG BASE	A213524	001	Oct 08, 2020	Sep	CAHN	
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Sep	CAHN	

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED; INHALATION

AIRSUPRA

+!	ASTRAZENECA	EQ 0.09MG BASE/INH;0.08MG/INH	N214070	001	Jan 10, 2023	Jan	CPOT	
----	-------------	-------------------------------	---------	-----	--------------	-----	------	--

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@	AIPING PHARM INC	EQ 0.083% BASE;0.017% DUONEB	A076867	001	Dec 21, 2006	Sep	CAHN	
---	------------------	------------------------------	---------	-----	--------------	-----	------	--

+	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	Jul	CAHN	
---	----------------------	-----------------------	---------	-----	--------------	-----	------	--

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

+	@ BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jun	DISC	
---	------------	-----------	---------	-----	--------------	-----	------	--

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May	NEWA	
AB		EQ 35MG BASE	A206387	002	Jun 04, 2024	May	NEWA	
AB		EQ 40MG BASE	A206387	003	Jun 04, 2024	May	NEWA	
AB		EQ 70MG BASE	A206387	004	Jun 04, 2024	May	NEWA	

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

@	NORVIUM BIOSCIENCE	10MG	A079014	001	Jul 18, 2011	Jun	CAHN	
---	--------------------	------	---------	-----	--------------	-----	------	--

@	SUN PHARM	10MG	A079057	001	Jul 18, 2011	Nov	DISC	
---	-----------	------	---------	-----	--------------	-----	------	--

UROXATRAL

>A>	AB	+!	ADVANSZ PHARMA	10MG	N021287	001	Jun 12, 2003	Dec	CAHN
-----	----	----	----------------	------	---------	-----	--------------	-----	------

>D>	AB	+!	CONCORDIA	10MG	N021287	001	Jun 12, 2003	Dec	CAHN
-----	----	----	-----------	------	---------	-----	--------------	-----	------

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

AB	ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr	CAHN	
----	-----------------	---------------	---------	-----	--------------	-----	------	--

AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr	CAHN	
----	--	---------------	---------	-----	--------------	-----	------	--

ALITRETINOIN

GEL; TOPICAL

PANRETIN

>A>		+!	ADVANSZ PHARMA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Dec	CAHN
-----	--	----	----------------	--------------	---------	-----	--------------	-----	------

>D>		+!	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Dec	CAHN
-----	--	----	-----------	--------------	---------	-----	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN	
----	-----------------	-------	---------	-----	--------------	-----	------	--

AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN	
----	--	-------	---------	-----	--------------	-----	------	--

AB	HARMAN FINOCHEM	200MG	A214443	003	Jun 17, 2024	Jun	NFTG	
----	-----------------	-------	---------	-----	--------------	-----	------	--

>D>	AB		IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Dec	DISC
-----	----	--	---------------	-------	---------	-----	--------------	-----	------

>A>		@		100MG	A090637	001	Mar 16, 2011	Dec	DISC
-----	--	---	--	-------	---------	-----	--------------	-----	------

>D>	AB			300MG	A090637	002	Mar 16, 2011	Dec	DISC
-----	----	--	--	-------	---------	-----	--------------	-----	------

>A>		@		300MG	A090637	002	Mar 16, 2011	Dec	DISC
-----	--	---	--	-------	---------	-----	--------------	-----	------

@	LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr	DISC	
---	-----------	-------	---------	-----	--------------	-----	------	--

@		300MG	A211807	002	Dec 14, 2023	Apr	DISC	
---	--	-------	---------	-----	--------------	-----	------	--

TABLET;ORAL							
LOPURIN							
AB	DR REDDYS	100MG	A071586	001	Apr 02, 1987	Nov	CAHN
AB		300MG	A071587	001	Apr 02, 1987	Nov	CAHN
ZYLOPRIM							
AB	+ CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Jun	CFTG
<u>ALOSETRON HYDROCHLORIDE</u>							
TABLET;ORAL							
ALOSETRON HYDROCHLORIDE							
	@ ENDO OPERATIONS	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	May	CAHN
	@	EQ 1MG BASE	A206113	002	Feb 23, 2018	May	CAHN
	@ EYWA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN
	@ HIBROW HLTHCARE	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN
LOTRONEX							
AB	+ LEGACY PHARMA	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Nov	CAHN
AB	+!	EQ 1MG BASE	N021107	001	Feb 09, 2000	Nov	CAHN
<u>ALPELISIB</u>							
GRANULES;ORAL							
VIJOICE							
	+! NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	NEWA
<u>ALPRAZOLAM</u>							
TABLET;ORAL							
ALPRAZOLAM							
AB	CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN
TABLET, EXTENDED RELEASE;ORAL							
ALPRAZOLAM							
	@ ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
	@	1MG	A078469	002	Sep 29, 2011	Mar	DISC
	@	2MG	A078469	003	Sep 29, 2011	Mar	DISC
	@	3MG	A078469	004	Sep 29, 2011	Mar	DISC
	@ ENDO OPERATIONS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
	@	0.5MG	A078469	001	Sep 29, 2011	May	CAHN
	@	1MG	A078442	002	Oct 15, 2007	May	CAHN
	@	1MG	A078469	002	Sep 29, 2011	May	CAHN
	@	2MG	A078442	003	Oct 15, 2007	May	CAHN
	@	2MG	A078469	003	Sep 29, 2011	May	CAHN
	@	3MG	A078442	004	Oct 15, 2007	May	CAHN
	@	3MG	A078469	004	Sep 29, 2011	May	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
ALPRAZOLAM							
AB	ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN
<u>ALPROSTADIL</u>							
INJECTABLE;INJECTION							
EDEX							
	@ ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+!	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+!	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP	+!	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+!	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN
SUPPOSITORY;URETHRAL							
MUSE							
	+ @ MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
	+ @	0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
	+ @	1MG	N020700	004	Nov 19, 1996	Jun	DISC

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
AMANTADINE HYDROCHLORIDE

AB		ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	Aug NFTG
		GOCOVRI					
AB	+	SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug NFTG
	+		EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug CAHN
	+	!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

		@ CHARTWELL RX	50MG/5ML	A076352	001	Sep 10, 2004	Aug CAHN
		@ CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Oct DISC
		@ ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May CAHN
		@ GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan CAHN
AA		XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998	Oct CMFD

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

		@ ADAPTIS	100MG	A212407	001	May 27, 2022	Sep CAHN
AB		ZHEJIANG JUTAI PHARM	100MG	A218598	001	Sep 26, 2024	Sep NEWA

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+	@ ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr DISC
	+	@	EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr DISC
	+	@ SUPERNUS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug CAHN
	+	@	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug CAHN
	+	@	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug CAHN
	+	@	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug CAHN

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

		@ ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May CAHN
		@	10MG	A209509	002	Apr 10, 2019	May CAHN
		@ PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr DISC
		@	10MG	A209509	002	Apr 10, 2019	Apr DISC

AMCINONIDE

LOTION;TOPICAL

AMCINONIDE

	!	GENUS	0.1%	A076329	001	Nov 06, 2002	Jan CAHN
--	---	-------	------	---------	-----	--------------	----------

OINTMENT;TOPICAL

AMCINONIDE

AB	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Jan CAHN
----	---	-------	------	---------	-----	--------------	----------

AMIFOSTINE

INJECTABLE;INJECTION

ETHYOL

		@ COSETTE	375MG/VIAL	N020221	002	Sep 10, 1999	Oct CAHN
	+	@	500MG/VIAL	N020221	001	Dec 08, 1995	Oct DISC
	+	!	500MG/VIAL	N020221	001	Dec 08, 1995	Oct CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

AP		QILU	EQ 250MG BASE/ML	A218146	001	Mar 19, 2024	Mar NEWA
----	--	------	------------------	---------	-----	--------------	----------

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	5MG	A070346	001	Jan 22, 1986	Apr CAHN
----	---	-----------------	-----	---------	-----	--------------	----------

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	8%;14GM/100ML	N020734	019	Apr 13, 2021	Apr NEWA
--	--	-----------------	---------------	---------	-----	--------------	----------

AMINOCAPROIC ACID

SOLUTION;ORAL

AMICAR

AA	+	HIKMA	0.25GM/ML	N015230	002		Nov	CMFD
	+	@	0.25GM/ML	N015230	002		Mar	DISC

AMINOCAPROIC ACID

AA		MSN	0.25GM/ML	A215100	001	Sep 26, 2024	Sep	NEWA
AA	!	TRUPHARMA	0.25GM/ML	A212494	001	Aug 11, 2020	Sep	CAHN
AA	!	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Mar	CHRS
	@	VISTAPHARM LLC	0.25GM/ML	A212814	001	Feb 26, 2020	Mar	CAHN

TABLET;ORAL

AMICAR

AB	+	HIKMA	500MG	N015197	001		Nov	CMFD
	+	@	500MG	N015197	001		Mar	DISC
AB	+		1GM	N015197	002	Jun 24, 2004	Nov	CMFD
	+	@	1GM	N015197	002	Jun 24, 2004	Mar	DISC

AMINOCAPROIC ACID

	@	ADAPTIS	500MG	A212110	001	Jun 14, 2021	Sep	CAHN
>D>	AB	ANI PHARMS	500MG	A211629	001	Dec 14, 2020	Dec	DISC
>A>		@	500MG	A211629	001	Dec 14, 2020	Dec	DISC
AB		APPCO	500MG	A213944	001	Sep 14, 2022	Sep	CAHN
AB			1GM	A213944	002	Sep 14, 2022	Sep	CAHN

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION;TOPICAL

LEVULAN

+	!	SUN PHARM INDS INC	20%	N020965	001	Dec 03, 1999	Oct	CAHN
---	---	--------------------	-----	---------	-----	--------------	-----	------

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

	@	HOSPIRA	50MG/ML	A203884	001	Nov 25, 2013	May	DISC
AP		ZHEJIANG POLY PHARM	50MG/ML	A218253	001	Sep 11, 2024	Aug	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021	May	CMFD
AB			25MG	A212654	001	Apr 07, 2020	May	CMFD
AB			50MG	A212654	003	Sep 29, 2021	May	CMFD
AB			75MG	A212654	004	Sep 29, 2021	May	CMFD
AB			100MG	A212654	005	Sep 29, 2021	May	CMFD
AB			150MG	A212654	006	Sep 29, 2021	May	CMFD
AB		BRECKENRIDGE	10MG	A216243	001	Jun 06, 2022	Sep	CAHN
AB			25MG	A216243	002	Jun 06, 2022	Sep	CAHN
AB			50MG	A216243	003	Jun 06, 2022	Sep	CAHN
AB			75MG	A216243	004	Jun 06, 2022	Sep	CAHN
AB			100MG	A216243	005	Jun 06, 2022	Sep	CAHN
AB			150MG	A216243	006	Jun 06, 2022	Sep	CAHN
AB		CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	Aug	CAHN
AB			25MG	A216243	002	Jun 06, 2022	Aug	CAHN
AB			50MG	A216243	003	Jun 06, 2022	Aug	CAHN
AB			75MG	A216243	004	Jun 06, 2022	Aug	CAHN
AB			100MG	A216243	005	Jun 06, 2022	Aug	CAHN
AB			150MG	A216243	006	Jun 06, 2022	Aug	CAHN
	@	ENDO OPERATIONS	10MG	A040218	001	Sep 11, 1997	May	CAHN
	@		25MG	A040218	002	Sep 11, 1997	May	CAHN
	@		50MG	A040218	003	Sep 11, 1997	May	CAHN
	@		75MG	A040218	004	Sep 11, 1997	May	CAHN
	@		100MG	A040218	005	Sep 11, 1997	May	CAHN
	@		150MG	A040218	006	Sep 11, 1997	May	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	@	AIPING PHARM INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Feb	CAHN
	@		EQ 5MG BASE	A077759	002	Jul 09, 2007	Feb	CAHN
	@		EQ 10MG BASE	A077759	003	Jul 09, 2007	Feb	CAHN
>A>	@	GRAVITI PHARMS	EQ 5MG BASE	A201380	001	Apr 13, 2012	Dec	CAHN
>A>	@		EQ 10MG BASE	A201380	002	Apr 13, 2012	Dec	CAHN
>D>	BX	LUPIN	EQ 2.5MG BASE	A078043	001	Jul 12, 2007	Dec	CTEC
>A>	AB		EQ 2.5MG BASE	A078043	001	Jul 12, 2007	Dec	CTEC

TABLET;ORAL

AMLODIPINE BESYLATE

BX		EQ 2.5MG BASE	A078043	001	Jul 12, 2007	Jun CTEC	
>D>	BX	EQ 5MG BASE	A078043	002	Jul 12, 2007	Dec CTEC	
>A>	AB	EQ 5MG BASE	A078043	002	Jul 12, 2007	Dec CTEC	
	BX	EQ 5MG BASE	A078043	002	Jul 12, 2007	Jun CTEC	
>D>	BX	EQ 10MG BASE	A078043	003	Jul 12, 2007	Dec CTEC	
>A>	AB	EQ 10MG BASE	A078043	003	Jul 12, 2007	Dec CTEC	
	BX	EQ 10MG BASE	A078043	003	Jul 12, 2007	Jun CTEC	
>D>	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	Dec CAHN
>D>	@		EQ 10MG BASE	A201380	002	Apr 13, 2012	Dec CAHN
	@	SCIEGEN PHARMS INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Sep CAHN
	@		EQ 5MG BASE	A077759	002	Jul 09, 2007	Sep CAHN
	@		EQ 10MG BASE	A077759	003	Jul 09, 2007	Sep CAHN
	@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Jan DISC
	@		EQ 5MG BASE	A077974	002	Jul 09, 2007	Jan DISC
	@		EQ 10MG BASE	A077974	003	Jul 09, 2007	Jan DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

	@	AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	Apr CAHN
	@		EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	Apr CAHN
	@		EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	Apr CAHN
	@		EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	Apr CAHN
AB		HERITAGE	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013	Sep CAHN
AB			EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013	Sep CAHN
AB			EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013	Sep CAHN
AB			EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013	Sep CAHN
AB			EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013	Sep CAHN
AB			EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013	Sep CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE;12.5MG;160MG	A207299	001	Jan 07, 2025	Dec NEWA
>A>	AB		EQ 5MG BASE;25MG;160MG	A207299	002	Jan 07, 2025	Dec NEWA
>A>	AB		EQ 10MG BASE;12.5MG;160MG	A207299	003	Jan 07, 2025	Dec NEWA
>A>	AB		EQ 10MG BASE;25MG;160MG	A207299	004	Jan 07, 2025	Dec NEWA
>A>	AB		EQ 10MG BASE;25MG;320MG	A207299	005	Jan 07, 2025	Dec NEWA

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

	@	GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Sep DISC
	@		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Sep DISC
	@		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Sep DISC
	@		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Sep DISC
AB		SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb CMFD
AB			EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb CMFD
AB			EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb CMFD
AB			EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb CMFD

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

+	@	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Sep DISC
+	@		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Sep DISC
+	@		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Sep DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		MACLEODS PHARMS LTD	EQ 5MG BASE;160MG	A207292	001	Oct 11, 2024	Oct NEWA
AB			EQ 5MG BASE;320MG	A207292	003	Oct 11, 2024	Oct NEWA
AB			EQ 10MG BASE;160MG	A207292	002	Oct 11, 2024	Oct NEWA
AB			EQ 10MG BASE;320MG	A207292	004	Oct 11, 2024	Oct NEWA

AMOXAPINE

TABLET; ORAL							
AMOXAPINE							
AB		CHARTWELL RX	25MG	A 072879	002	Jun 28, 1991	Nov CMFD
	@		25MG	A 072879	002	Jun 28, 1991	Jun CMS1
AB			50MG	A 072879	003	Jun 28, 1991	Nov CMFD
	@		50MG	A 072879	003	Jun 28, 1991	Jun CMS1
AB			100MG	A 072879	004	Jun 28, 1991	Nov CMFD
	@		100MG	A 072879	004	Jun 28, 1991	Jun CMS1
AB			150MG	A 072879	001	Jun 28, 1991	Nov CMFD
AB		WATSON LABS	25MG	A 072691	002	Aug 28, 1992	Nov CTEC
AB			50MG	A 072691	003	Aug 28, 1992	Nov CTEC
AB			100MG	A 072691	004	Aug 28, 1992	Nov CTEC
AB	!		150MG	A 072691	001	Aug 28, 1992	Nov CTEC

AMOXICILLIN

FOR SUSPENSION; ORAL							
AMOXICILLIN							
AB		CHARTWELL RX	400MG/5ML	A 065319	002	Jun 18, 2007	May CAHN
	@	DAVA PHARMS INC	125MG/5ML	A 062927	001	Nov 25, 1988	Mar DISC
	@		250MG/5ML	A 062927	002	Nov 25, 1988	Mar DISC
	@	ENDO OPERATIONS	125MG/5ML	A 062927	001	Nov 25, 1988	May CAHN
	@		250MG/5ML	A 062927	002	Nov 25, 1988	May CAHN
AMOXIL							
AB	+	US ANTIBIOTICS	400MG/5ML	N 050760	002	Apr 15, 1999	Apr CMFD

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
AB		CIPLA	250MG/5ML;EQ 62.5MG BASE/5ML	A 065431	001	Nov 25, 2008	Jul CAHN
AB			600MG/5ML;EQ 42.9MG BASE/5ML	A 065420	001	Dec 02, 2013	Jul CAHN
TABLET; ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
AB	!	AUROBINDO PHARMA LTD	500MG;EQ 125MG BASE	A 091569	002	Jan 20, 2012	Oct CHRS
	@	SANDOZ INC	500MG;EQ 125MG BASE	A 065117	001	Nov 27, 2002	Oct DISC
TABLET, CHEWABLE; ORAL							
AMOXICILLIN AND CLAVULANATE POTASSIUM							
	@	CHARTWELL RX	200MG;EQ 28.5MG BASE	A 065065	001	Apr 18, 2002	Jul CAHN
	@		400MG;EQ 57MG BASE	A 065065	002	Apr 18, 2002	Jul CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL							
ADDERALL XR 10							
AB1	+	TAKEDA PHARMS USA	2.5MG; 2.5MG; 2.5MG; 2.5MG	N 021303	001	Oct 11, 2001	Jan CTEC
ADDERALL XR 15							
AB1	+	TAKEDA PHARMS USA	3.75MG; 3.75MG; 3.75MG; 3.75MG	N 021303	006	May 22, 2002	Jan CTEC
ADDERALL XR 20							
AB1	+	TAKEDA PHARMS USA	5MG; 5MG; 5MG; 5MG	N 021303	002	Oct 11, 2001	Jan CTEC
ADDERALL XR 25							
AB1	+	TAKEDA PHARMS USA	6.25MG; 6.25MG; 6.25MG; 6.25MG	N 021303	004	May 22, 2002	Jan CTEC
ADDERALL XR 30							
AB1	+!	TAKEDA PHARMS USA	7.5MG; 7.5MG; 7.5MG; 7.5MG	N 021303	003	Oct 11, 2001	Jan CTEC
ADDERALL XR 5							
AB1	+	TAKEDA PHARMS USA	1.25MG; 1.25MG; 1.25MG; 1.25MG	N 021303	005	May 22, 2002	Jan CTEC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB1		ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 077302	001	Jun 22, 2012	Jan CTEC
AB1			2.5MG; 2.5MG; 2.5MG; 2.5MG	A 077302	002	Jun 22, 2012	Jan CTEC
AB1			3.75MG; 3.75MG; 3.75MG; 3.75MG	A 077302	003	Jun 22, 2012	Jan CTEC
AB1			5MG; 5MG; 5MG; 5MG	A 077302	004	Jun 22, 2012	Jan CTEC
AB1			6.25MG; 6.25MG; 6.25MG; 6.25MG	A 077302	005	Jun 22, 2012	Jan CTEC
AB1			7.5MG; 7.5MG; 7.5MG; 7.5MG	A 077302	006	Jun 22, 2012	Jan CTEC
AB1		ANI PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 205401	001	Jan 22, 2019	Jan CTEC
AB1			2.5MG; 2.5MG; 2.5MG; 2.5MG	A 205401	002	Jan 22, 2019	Jan CTEC
AB1			3.75MG; 3.75MG; 3.75MG; 3.75MG	A 205401	003	Jan 22, 2019	Jan CTEC
AB1			5MG; 5MG; 5MG; 5MG	A 205401	004	Jan 22, 2019	Jan CTEC
AB1			6.25MG; 6.25MG; 6.25MG; 6.25MG	A 205401	005	Jan 22, 2019	Jan CTEC
AB1			7.5MG; 7.5MG; 7.5MG; 7.5MG	A 205401	006	Jan 22, 2019	Jan CTEC
AB1		ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 214959	001	Sep 29, 2021	Jan CTEC
AB1			2.5MG; 2.5MG; 2.5MG; 2.5MG	A 214959	002	Sep 29, 2021	Jan CTEC
AB1			3.75MG; 3.75MG; 3.75MG; 3.75MG	A 214959	003	Sep 29, 2021	Jan CTEC
AB1			5MG; 5MG; 5MG; 5MG	A 214959	004	Sep 29, 2021	Jan CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Jan	CTEC		
AB1	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A212037	003	Dec 11, 2019	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A212037	004	Dec 11, 2019	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A212037	005	Dec 11, 2019	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A212037	006	Dec 11, 2019	Jan	CTEC		
	@ ENDO OPERATIONS	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May	CAHN		
	@	2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May	CAHN		
	@	3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May	CAHN		
	@	5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May	CAHN		
	@	6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May	CAHN		
	@	7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May	CAHN		
AB1	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan	CTEC		
AB1	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Jan	CTEC		
AB1	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	Jan	CTEC		
AB1	LUPIN	1.25MG;1.25MG;1.25MG;1.25MG	A214777	001	Nov 07, 2024	Nov	NEWA		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A214777	002	Nov 07, 2024	Nov	NEWA		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A214777	003	Nov 07, 2024	Nov	NEWA		
AB1		5MG;5MG;5MG;5MG	A214777	004	Nov 07, 2024	Nov	NEWA		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A214777	005	Nov 07, 2024	Nov	NEWA		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A214777	006	Nov 07, 2024	Nov	NEWA		
AB1	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	Jan	CTEC		
AB1	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Jan	CTEC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Jan	CTEC		
AB2		3.125MG;3.125MG;3.125MG;3.125MG	A211546	001	Aug 31, 2023	Jan	CTEC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Jan	CTEC		
AB1		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Jan	CTEC		
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A211546	002	Aug 31, 2023	Jan	CTEC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Jan	CTEC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Jan	CTEC		
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A211546	003	Aug 31, 2023	Jan	CTEC		
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A211546	004	Aug 31, 2023	Jan	CTEC		
AB2	SUN PHARM INDS INC	3.125MG;3.125MG;3.125MG;3.125MG	A215997	001	Sep 27, 2023	Jan	CTEC		
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A215997	002	Sep 27, 2023	Jan	CTEC		
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A215997	003	Sep 27, 2023	Jan	CTEC		
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A215997	004	Sep 27, 2023	Jan	CTEC		
	@ SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jul	DISC		
AB1		1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	Jan	CTEC		
	@	2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jul	DISC		
AB1		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	Jan	CTEC		
	@	3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jul	DISC		
AB1		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	Jan	CTEC		
	@	5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jul	DISC		
AB1		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	Jan	CTEC		
	@	6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jul	DISC		
AB1		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	Jan	CTEC		
	@	7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jul	DISC		
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jan	CTEC		
AB2	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	CTEC		
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	CTEC		

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB2			9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	CTEC	
AB2			12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	CTEC	
MYDAYIS									
AB2	+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan	CTEC	
AB2	+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan	CTEC	
AB2	+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan	CTEC	
AB2	+	!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan	CTEC	

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB		ORYZA	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep	CAHN	
AB			1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep	CAHN	
AB			2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep	CAHN	
AB			3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep	CAHN	
AB			5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep	CAHN	
AB			7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep	CAHN	

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE									
AA		SANALUZ	5MG	A212582	001	Feb 04, 2020	Sep	CAHN	
AA			10MG	A212582	002	Feb 04, 2020	Sep	CAHN	
AA		SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb	CAHN	
AA			10MG	A212901	002	May 22, 2020	Feb	CAHN	
		@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar	DISC	
		@	10MG	A214574	002	Jan 27, 2021	Mar	DISC	
EVEKEO									
AA		AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN	
AA		!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN	

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT									
	+	@ AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC	
	+	@	10MG	N209905	002	Jan 30, 2019	Apr	DISC	
	+	@	15MG	N209905	003	Jan 30, 2019	Apr	DISC	
	+	@	20MG	N209905	004	Jan 30, 2019	Apr	DISC	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM									
		@ MEDIMETRIKS PHARMS	EQ 1GM BASE/VIAL;EQ 500MG	A065316	001	Jun 29, 2007	Sep	CAHN	
		@	BASE/VIAL	A065316	002	Jun 29, 2007	Sep	CAHN	
		@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep	CAHN	

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE									
		@ ENDO OPERATIONS	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	May	CAHN	
		@	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	May	CAHN	

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE									
		@ ESJAY PHARMA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Nov	CAHN	
		@	EQ 1MG BASE	A076811	002	Apr 18, 2005	Nov	CAHN	

APIXABAN

TABLET;ORAL

APIXABAN									
		@ APOTEX	2.5MG	A210091	001	Feb 16, 2024	May	DISC	
AB			2.5MG	A210091	001	Feb 16, 2024	Feb	NEWA	
		@	5MG	A210091	002	Feb 16, 2024	May	DISC	
AB			5MG	A210091	002	Feb 16, 2024	Feb	NEWA	
>A>	AB	TORRENT	2.5MG	A210156	001	Dec 17, 2024	Dec	NEWA	
>A>	AB		5MG	A210156	002	Dec 17, 2024	Dec	NEWA	

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOMORPHINE HYDROCHLORIDE									
AP		TRUPHARMA	30MG/3ML (10MG/ML)	A212025	001	Feb 23, 2022	Sep	CAHN	

APREMILAST

TABLET; ORAL

APREMILAST

AB	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024	Nov	NEWA
AB		20MG	A211788	002	Nov 25, 2024	Nov	NEWA
AB		30MG	A211788	003	Nov 25, 2024	Nov	NEWA
AB	MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan	NEWA
AB		20MG	A211734	002	Feb 07, 2024	Jan	NEWA
AB		30MG	A211734	003	Feb 07, 2024	Jan	NEWA
>A>	MSN	10MG	A211887	001	Dec 16, 2024	Dec	NEWA
>A>		20MG	A211887	002	Dec 16, 2024	Dec	NEWA
>A>		30MG	A211887	003	Dec 16, 2024	Dec	NEWA

APROCITENTAN

TABLET; ORAL

TRYVIO

+!	IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar	NEWA
----	---------	--------	---------	-----	--------------	-----	------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

AN	AIPING PHARM INC	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Aug	CAHN
AN	BE PHARMS	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Oct	CAHN
AN	CF PHARMTECH	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	May	NEWA
AN	DR REDDYS	EQ 0.015MG BASE/2ML	A215032	001	Jun 03, 2024	May	NEWA
AN	LEXENPHARM	EQ 0.015MG BASE/2ML	A218156	001	Nov 18, 2024	Nov	NEWA
AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar	NEWA
AN	WILSHIRE PHARMS INC	EQ 0.015MG BASE/2ML	A216815	001	Nov 25, 2022	Jul	CAHN

ARIMOCLOMOL CITRATE

CAPSULE; ORAL

MIPLYFFA

+	ZEVRA DENMARK	EQ 47MG BASE	N214927	001	Sep 20, 2024	Sep	NEWA
+		EQ 62MG BASE	N214927	002	Sep 20, 2024	Sep	NEWA
+		EQ 93MG BASE	N214927	003	Sep 20, 2024	Sep	NEWA
+!		EQ 124MG BASE	N214927	004	Sep 20, 2024	Sep	NEWA

ARIPIRAZOLE

FILM; ORAL

OPIPZA

+	XIAMEN LP PHARM CO	2MG	N216655	001	Jul 22, 2024	Jul	NEWA
+		5MG	N216655	002	Jul 22, 2024	Jul	NEWA
+!		10MG	N216655	003	Jul 22, 2024	Jul	NEWA

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

AP	+ OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Nov	CFTG
AP	+!	400MG/VIAL	N202971	002	Feb 28, 2013	Nov	CFTG

ARIPIRAZOLE

AP	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Nov	NFTG
AP		400MG/VIAL	A216608	002	Dec 03, 2024	Nov	NFTG

TABLET; ORAL

ABILIFY MYCITE KIT

>D>	+ OTSUKA	2MG	N207202	001	Nov 13, 2017	Dec	DISC
>A>	+ @	2MG	N207202	001	Nov 13, 2017	Dec	DISC
>D>	+!	5MG	N207202	002	Nov 13, 2017	Dec	DISC
>A>	+ @	5MG	N207202	002	Nov 13, 2017	Dec	DISC
>D>	+	10MG	N207202	003	Nov 13, 2017	Dec	DISC
>A>	+ @	10MG	N207202	003	Nov 13, 2017	Dec	DISC
>D>	+	15MG	N207202	004	Nov 13, 2017	Dec	DISC
>A>	+ @	15MG	N207202	004	Nov 13, 2017	Dec	DISC
>D>	+	20MG	N207202	005	Nov 13, 2017	Dec	DISC
>A>	+ @	20MG	N207202	005	Nov 13, 2017	Dec	DISC
>D>	+	30MG	N207202	006	Nov 13, 2017	Dec	DISC
>A>	+ @	30MG	N207202	006	Nov 13, 2017	Dec	DISC

ARIPIRAZOLE

>A>	@ AIPING PHARM INC	2MG	A091279	001	Jan 09, 2017	Dec	CAHN
>A>	@	5MG	A091279	002	Jan 09, 2017	Dec	CAHN
>A>	@	10MG	A091279	003	Jan 09, 2017	Dec	CAHN
>A>	@	15MG	A091279	004	Jan 09, 2017	Dec	CAHN
>A>	@	20MG	A091279	005	Jan 09, 2017	Dec	CAHN
>A>	@	30MG	A091279	006	Jan 09, 2017	Dec	CAHN

TABLET;ORAL

ARIPIPRAZOLE

>D>	@ BRECKENRIDGE	2MG	A091279	001	Jan 09, 2017	Dec CAHN
	@	2MG	A091279	001	Jan 09, 2017	Aug DISC
>D>	@	5MG	A091279	002	Jan 09, 2017	Dec CAHN
	@	5MG	A091279	002	Jan 09, 2017	Aug DISC
>D>	@	10MG	A091279	003	Jan 09, 2017	Dec CAHN
	@	10MG	A091279	003	Jan 09, 2017	Aug DISC
>D>	@	15MG	A091279	004	Jan 09, 2017	Dec CAHN
	@	15MG	A091279	004	Jan 09, 2017	Aug DISC
>D>	@	20MG	A091279	005	Jan 09, 2017	Dec CAHN
	@	20MG	A091279	005	Jan 09, 2017	Aug DISC
>D>	@	30MG	A091279	006	Jan 09, 2017	Dec CAHN
	@	30MG	A091279	006	Jan 09, 2017	Aug DISC
AB	LUPIN	2MG	A205589	001	Mar 18, 2024	Mar NEWA
AB		5MG	A205589	002	Mar 18, 2024	Mar NEWA
AB		10MG	A205589	003	Mar 18, 2024	Mar NEWA
AB		15MG	A205589	004	Mar 18, 2024	Mar NEWA
AB		20MG	A205589	005	Mar 18, 2024	Mar NEWA
AB		30MG	A205589	006	Mar 18, 2024	Mar NEWA

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA INITIO KIT

>D>	+ ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Dec CHRS
>A>	+	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Dec CHRS
	+	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan CPOT

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

@ EUGIA PHARMA	2MG/ML	A214011	001	Oct 15, 2021	Nov DISC
----------------	--------	---------	-----	--------------	----------

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL
SCEMBLIX

+ NOVARTIS	EQ 100MG BASE	N215358	003	Apr 18, 2024	Apr NEWA
------------	---------------	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

AA	TARO	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A207498	001	Jun 28, 2024	Jun NEWA
----	------	---	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
LANORINAL

AA	! SANDOZ	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Jan CAHN
----	----------	-----------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
INVAGESIC

@ CHARTWELL RX	385MG;30MG;25MG	A074817	001	Nov 27, 1996	Nov CAHN
@ CHARTWELL RX	770MG;60MG;50MG	A074817	002	Nov 27, 1996	Nov CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL
CARISOPRODOL AND ASPIRIN

@ GENUS	325MG;200MG	A040116	001	Apr 25, 1996	Aug CAHN
---------	-------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL
ASPIRIN AND DIPYRIDAMOLE

AB	ENDO OPERATIONS	25MG;200MG	A207944	001	Jan 18, 2017	Apr CAHN
----	-----------------	------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
 PERCODAN
 AA +! ENDO OPERATIONS 325MG;4.8355MG N007337 007 Aug 05, 2005 May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL
 PERCODAN
 @ ENDO OPERATIONS 325MG;4.5MG;0.38MG N007337 006 May CAHN
 PERCODAN-DEMI
 @ ENDO OPERATIONS 325MG;2.25MG;0.19MG N007337 005 May CAHN

ATAZANAVIR SULFATE

CAPSULE;ORAL
 ATAZANAVIR SULFATE
 @ AMNEAL EQ 150MG BASE A209717 002 Jun 01, 2020 Sep DISC
 @ EQ 200MG BASE A209717 003 Jun 01, 2020 Sep DISC
 @ EQ 300MG BASE A209717 004 Jun 01, 2020 Sep DISC

ATENOLOL

TABLET;ORAL
 ATENOLOL
 >D> AB IPCA LABS LTD 25MG A077877 001 Dec 27, 2006 Dec DISC
 >A> @ 25MG A077877 001 Dec 27, 2006 Dec DISC
 >D> AB 50MG A077877 002 Dec 27, 2006 Dec DISC
 >A> @ 50MG A077877 002 Dec 27, 2006 Dec DISC
 >D> AB 100MG A077877 003 Dec 27, 2006 Dec DISC
 >A> @ 100MG A077877 003 Dec 27, 2006 Dec DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL
 ATOMOXETINE HYDROCHLORIDE
 AB APOTEX EQ 10MG BASE A078983 001 May 30, 2017 Mar CPOT
 AB EQ 18MG BASE A078983 002 May 30, 2017 Mar CPOT
 AB EQ 25MG BASE A078983 003 May 30, 2017 Mar CPOT
 AB EQ 40MG BASE A078983 004 May 30, 2017 Mar CPOT
 AB EQ 60MG BASE A078983 005 May 30, 2017 Mar CPOT
 AB EQ 80MG BASE A078983 006 May 30, 2017 Mar CPOT
 AB EQ 100MG BASE A078983 007 May 30, 2017 Mar CPOT
 AB AUROBINDO PHARMA EQ 10MG BASE A079016 001 May 30, 2017 Mar CPOT
 AB EQ 18MG BASE A079016 002 May 30, 2017 Mar CPOT
 AB EQ 25MG BASE A079016 003 May 30, 2017 Mar CPOT
 AB EQ 40MG BASE A079016 004 May 30, 2017 Mar CPOT
 AB EQ 60MG BASE A079016 005 May 30, 2017 Mar CPOT
 AB EQ 80MG BASE A079016 006 May 30, 2017 Mar CPOT
 AB EQ 100MG BASE A079016 007 May 30, 2017 Mar CPOT
 AB DR REDDYS EQ 10MG BASE A090609 001 Feb 23, 2018 Mar CPOT
 AB EQ 18MG BASE A090609 002 Feb 23, 2018 Mar CPOT
 AB EQ 25MG BASE A090609 003 Feb 23, 2018 Mar CPOT
 AB EQ 40MG BASE A090609 004 Feb 23, 2018 Mar CPOT
 AB EQ 60MG BASE A090609 005 Feb 23, 2018 Mar CPOT
 AB EQ 80MG BASE A090609 006 Feb 23, 2018 Mar CPOT
 AB EQ 100MG BASE A090609 007 Feb 23, 2018 Mar CPOT
 AB GLENMARK PHARMS LTD EQ 10MG BASE A079019 001 May 30, 2017 Mar CPOT
 AB EQ 18MG BASE A079019 002 May 30, 2017 Mar CPOT
 AB EQ 25MG BASE A079019 003 May 30, 2017 Mar CPOT
 AB EQ 40MG BASE A079019 004 May 30, 2017 Mar CPOT
 AB EQ 60MG BASE A079019 005 May 30, 2017 Mar CPOT
 AB EQ 80MG BASE A079019 006 May 30, 2017 Mar CPOT
 AB EQ 100MG BASE A079019 007 May 30, 2017 Mar CPOT
 AB HETERO LABS LTD V EQ 10MG BASE A202682 001 Mar 11, 2021 Mar CPOT
 AB EQ 18MG BASE A202682 002 Mar 11, 2021 Mar CPOT
 AB EQ 25MG BASE A202682 003 Mar 11, 2021 Mar CPOT
 AB EQ 40MG BASE A202682 004 Mar 11, 2021 Mar CPOT
 AB EQ 60MG BASE A202682 005 Mar 11, 2021 Mar CPOT
 AB EQ 80MG BASE A202682 006 Mar 11, 2021 Mar CPOT
 AB EQ 100MG BASE A202682 007 Mar 11, 2021 Mar CPOT
 AB STRIDES PHARMA EQ 10MG BASE A079021 001 Feb 18, 2021 Aug CMFD
 @ EQ 10MG BASE A079021 001 Feb 18, 2021 Mar CPOT
 AB EQ 18MG BASE A079021 002 Feb 18, 2021 Aug CMFD
 @ EQ 18MG BASE A079021 002 Feb 18, 2021 Mar CPOT
 AB EQ 25MG BASE A079021 003 Feb 18, 2021 Aug CMFD

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

	@		EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
AB			EQ 40MG BASE	A079021	004	Feb 18, 2021	Aug	CMFD
	@		EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
AB			EQ 60MG BASE	A079021	005	Feb 18, 2021	Aug	CMFD
	@		EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
AB			EQ 80MG BASE	A079021	006	Feb 18, 2021	Aug	CMFD
	@		EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
AB			EQ 100MG BASE	A079021	007	Feb 18, 2021	Aug	CMFD
	@		EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB		TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB			EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB			EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB			EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB			EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB			EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB			EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB		ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB			EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB			18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB			EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB			25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB			EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB			40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB			EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB			60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB			EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB			80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB			EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB			100MG	A079017	006	Sep 16, 2010	Jan	CMS1

STRATTERA

	@	LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+		EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+		EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+		EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+		EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+		EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+		EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+		EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB			EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB			EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
AB			EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
	@	CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
	@		EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
	@		EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
	@		EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
AB		CHARTWELL RX	EQ 10MG BASE	A077575	001	May 29, 2012	Nov	CAHN
AB			EQ 20MG BASE	A077575	002	May 29, 2012	Nov	CAHN
AB			EQ 40MG BASE	A077575	003	May 29, 2012	Nov	CAHN
AB			EQ 80MG BASE	A077575	004	May 29, 2012	Nov	CAHN
	@	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
	@		EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@		EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@		EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB		LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB			EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB			EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB			EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
	@	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Aug	DISC
BX			EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
	@		EQ 20MG BASE	A204991	002	Mar 06, 2019	Aug	DISC
BX			EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
	@		EQ 40MG BASE	A204991	003	Mar 06, 2019	Aug	DISC
BX			EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC

TABLET; ORAL

ATORVASTATIN CALCIUM							
	@	EQ 80MG BASE		A204991	004	Mar 06, 2019	Aug DISC
BX		EQ 80MG BASE		A204991	004	Mar 06, 2019	Jun CTEC
AB	MACLEODS PHARMS LTD	EQ 10MG BASE		A208480	001	Jun 03, 2024	May NEWA
AB		EQ 20MG BASE		A208480	002	Jun 03, 2024	May NEWA
AB		EQ 40MG BASE		A208480	003	Jun 03, 2024	May NEWA
AB		EQ 80MG BASE		A208480	004	Jun 03, 2024	May NEWA
AB	SHANDONG XINHUA	EQ 10MG BASE		A211886	001	Jan 25, 2024	Mar CAHN
AB		EQ 20MG BASE		A211886	002	Jan 25, 2024	Mar CAHN
AB		EQ 40MG BASE		A211886	003	Jan 25, 2024	Mar CAHN
AB		EQ 80MG BASE		A211886	004	Jan 25, 2024	Mar CAHN
BX	UMEDICA	EQ 10MG BASE		A213853	001	Aug 19, 2020	Jun CTEC
BX		EQ 20MG BASE		A213853	002	Aug 19, 2020	Jun CTEC
BX		EQ 40MG BASE		A213853	003	Aug 19, 2020	Jun CTEC
BX		EQ 80MG BASE		A213853	004	Aug 19, 2020	Jun CTEC

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE							
	@ NORVIUM BIOSCIENCE	10MG/ML		A206096	001	Jun 22, 2017	Jun CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE						
	@ NORVIUM BIOSCIENCE	10MG/ML		A206001	001	Apr 07, 2017	Jun CAHN

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE							
AP	SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)		A215969	001	Jul 03, 2024	Jun NEWA
AP		1MG/ML (1MG/ML)		A215969	002	Jul 03, 2024	Jun NEWA

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE							
AP	SOMERSET THERAPS LLC	8MG/20ML (0.4MG/ML)		A215005	001	Nov 29, 2024	Nov NEWA

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE							
AT1	! AMNEAL	1%		A214752	001	Jul 14, 2022	Apr CTEC
AT1	APOTEX	1%		A215624	001	Nov 26, 2021	Apr CTEC
AT1	MANKIND PHARMA	1%		A218148	001	Jan 08, 2024	Apr CTEC
AT1	+ RISING	1%		N206289	001	Jul 18, 2014	Apr CTEC
AT2	SOMERSET	1%		A217791	001	Apr 29, 2024	Apr NFTG
AT1	SOMERSET THERAPS LLC	1%		A215618	001	Jul 01, 2024	Jun NEWA
	ISOPTO ATROPINE						
AT2	+! ALCON LABS INC	1%		N208151	001	Dec 01, 2016	Apr CFTG

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN							
+!	LEGACY PHARMA	0.025MG; 1MG		N017744	002		Nov CAHN
	MOTOFEN HALF-STRENGTH						
	@ LEGACY PHARMA	0.025MG; 0.5MG		N017744	001		Nov CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
	@ ANI PHARMS	0.025MG; 2.5MG		A086727	001		Mar DISC
	@ MYLAN	0.025MG; 2.5MG		A085762	001		Apr DISC
AA	UNICHEM	0.025MG; 2.5MG		A210819	001	Nov 13, 2018	Nov CAHN

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS							
	@ NORVIUM BIOSCIENCE	0.14MG/ML; 10MG/ML		N019677	001	Nov 06, 1991	Jul CAHN
	+ @	0.14MG/ML; 10MG/ML		N019678	001	Nov 06, 1991	Jul CAHN

AURANOFIN

CAPSULE; ORAL

RIDAURA							
+!	LEGACY PHARMA	3MG		N018689	001	May 24, 1985	Nov CAHN

AVACINCAPTAD PEGOL SODIUM

SOLUTION; INTRAVITREAL
IZERVAY

+! ASTELLAS EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) N217225 001 Aug 04, 2023 Jan CAHN

AVANAFIL

TABLET; ORAL
AVANAFIL

AB HETERO LABS LTD V 50MG A209266 001 Jun 14, 2024 Jun NFTG
 AB 100MG A209266 002 Jun 14, 2024 Jun NFTG
 AB 200MG A209266 003 Jun 14, 2024 Jun NFTG
 STENDRA
 AB + METUCHEN PHARMS 50MG N202276 001 Apr 27, 2012 Jun CFTG
 AB + 100MG N202276 002 Apr 27, 2012 Jun CFTG
 AB +! 200MG N202276 003 Apr 27, 2012 Jun CFTG

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; INTRAVENOUS
AVYCAZ

+! ABBVIE EQ 0.5GM BASE; 2GM/VIAL N206494 001 Feb 25, 2015 Sep CAHN

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP HETERO LABS LTD VI 100MG/VIAL A215765 001 Oct 15, 2024 Oct NEWA
 AP MSN LABS PVT LTD 100MG/VIAL A212580 001 May 16, 2024 May NEWA
 @ NORVIUM BIOSCIENCE 100MG/VIAL A204949 001 Apr 28, 2016 Oct CAHN

AZATHIOPRINE

TABLET; ORAL
IMURAN

+ @ LEGACY PHARMA 25MG N016324 002 Nov CAHN
 AB +! 50MG N016324 001 Nov CAHN

AZELAIC ACID

GEL; TOPICAL
AZELAIC ACID

AB TARO 15% A210549 001 Aug 23, 2019 Apr CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

@ SUN PHARM 0.05% A078738 001 Jun 21, 2010 Nov DISC
 OPTIVAR
 + @ NORVIUM BIOSCIENCE 0.05% N021127 001 May 22, 2000 Jul CAHN
 SPRAY, METERED; NASAL
 ASTELIN
 + @ NORVIUM BIOSCIENCE 0.137MG/SPRAY N020114 001 Nov 01, 1996 Jul CAHN
 AZELASTINE HYDROCHLORIDE
 @ HIKMA 0.137MG/SPRAY A091444 001 Oct 24, 2014 Mar DISC
 @ SUN PHARM 0.137MG/SPRAY A090423 001 May 23, 2012 Nov DISC

AZITHROMYCIN

INJECTABLE; INJECTION
AZITHROMYCIN

@ NORVIUM BIOSCIENCE EQ 500MG BASE/VIAL A065506 001 Mar 24, 2009 Jun CAHN
 @ SUN PHARM INDS LTD EQ 500MG BASE/VIAL A090923 001 Apr 02, 2013 May DISC

TABLET; ORAL
AZITHROMYCIN

>A> @ EXTROVIS EQ 500MG BASE A065366 001 May 30, 2007 Dec CAHN
 @ EQ 500MG BASE A065366 001 May 30, 2007 Jul CAHN
 @ PHARMOBEDIENT EQ 500MG BASE A211318 001 Mar 17, 2021 Sep CAHN
 >D> @ RISING EQ 500MG BASE A065366 001 May 30, 2007 Dec CAHN
 @ YUNG SHIN PHARM EQ 250MG BASE A211317 001 Jul 26, 2022 Feb DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

@ ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Jan	DISC
@	2MG/ML	A216309	002	Aug 10, 2023	Jan	DISC
@ HERITAGE	0.5MG/ML	A216309	001	Aug 10, 2023	Sep	CAHN
@	2MG/ML	A216309	002	Aug 10, 2023	Sep	CAHN

SOLUTION; ORAL

BACLOFEN

RUBICON	5MG/5ML	A214445	001	Dec 06, 2024	Nov	NFTG
---------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

BACLOFEN

AB	ANDAS 5 HOLDING	5MG	A212378	003	Apr 30, 2021	Aug	CAHN
AB		10MG	A212378	001	Oct 09, 2020	Aug	CAHN
AB		20MG	A212378	002	Oct 09, 2020	Aug	CAHN
AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr	CAHN
AB		20MG	A077068	001	Aug 30, 2005	Apr	CAHN
>D>	BX EYWA	5MG	A211555	003	Nov 30, 2021	Dec	CAHN
BX		5MG	A211555	003	Nov 30, 2021	Jul	CAHN
>D>	BX	10MG	A211555	001	Feb 01, 2019	Dec	CAHN
BX		10MG	A211555	001	Feb 01, 2019	Jul	CAHN
>D>	BX	20MG	A211555	002	Feb 01, 2019	Dec	CAHN
BX		20MG	A211555	002	Feb 01, 2019	Jul	CAHN
BX	EYWA PHARMA	5MG	A211555	003	Nov 30, 2021	Jun	CTEC
BX		10MG	A211555	001	Feb 01, 2019	Jun	CTEC
BX		20MG	A211555	002	Feb 01, 2019	Jun	CTEC
AB	GRAVITI PHARMS	5MG	A217788	003	Oct 24, 2024	Oct	NEWA
>A>	BX HIBROW HLTHCARE	5MG	A211555	003	Nov 30, 2021	Dec	CAHN
>A>	BX	10MG	A211555	001	Feb 01, 2019	Dec	CAHN
>A>	BX	20MG	A211555	002	Feb 01, 2019	Dec	CAHN
	@ IMPAX	5MG	A077971	003	Jul 07, 2021	Mar	DISC
	@	10MG	A077971	001	Oct 26, 2007	Mar	DISC
	@	20MG	A077971	002	Oct 26, 2007	Mar	DISC
	@ NORVIUM BIOSCIENCE	20MG	A077121	002	Jul 29, 2005	Jul	CAHN
AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb	CTEC
		15MG	A209102	004	Feb 05, 2024	Jan	NEWA

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

@ ESJAY PHARMA	750MG	A077807	001	Dec 28, 2007	Nov	CAHN
AB ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar	CAHN

BARICITINIB

TABLET; ORAL

BARICITINIB

@ AUROBINDO PHARMA LTD	1MG	A217542	001	Jul 22, 2024	Aug	DISC	
AB	1MG	A217542	001	Jul 22, 2024	Jul	NFTG	
@	2MG	A217542	002	Jul 22, 2024	Aug	DISC	
AB	2MG	A217542	002	Jul 22, 2024	Jul	NFTG	
	OLUMIANT						
+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug	CTEC
AB	+	1MG	N207924	002	Oct 08, 2019	Jul	CFTG
+		2MG	N207924	001	May 31, 2018	Aug	CTEC
AB	+	2MG	N207924	001	May 31, 2018	Jul	CFTG

BENDAMUSTINE HYDROCHLORIDE

POWDER; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	Dec 07, 2022	Oct	CDFR
AP		100MG/VIAL	A205574	002	Dec 07, 2022	Oct	CDFR
AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	Oct	CDFR
AP		100MG/VIAL	A204230	002	Jun 05, 2023	Oct	CDFR
@ BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Nov	DISC	
AP	25MG/VIAL	A205447	001	Feb 14, 2023	Oct	CDFR	
@	100MG/VIAL	A205447	002	Feb 14, 2023	Nov	DISC	
AP	100MG/VIAL	A205447	002	Feb 14, 2023	Oct	CDFR	
AP	DR REDDYS	25MG/VIAL	A205376	001	Dec 07, 2022	Oct	CDFR
AP		100MG/VIAL	A205376	002	Dec 07, 2022	Oct	CDFR
AP	EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	Oct	CDFR
AP		100MG/VIAL	A214739	002	Jun 05, 2023	Oct	CDFR
AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Oct	CDFR

POWDER; INTRAVENOUS

AP								
	BENDAMUSTINE HYDROCHLORIDE							
		100MG/VIAL	A211001	002	Jun 05, 2023	Oct	CDFR	
	@ NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	Oct	CDFR	
	@	100MG/VIAL	A206554	002	Jun 07, 2023	Oct	CDFR	
	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Oct	CDFR	
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Oct	CDFR	
	TREANDA							
AP	+! CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Oct	CDFR	
AP	+!	100MG/VIAL	N022249	001	Mar 20, 2008	Oct	CDFR	

POWDER; IV (INFUSION)

AP								
	BENDAMUSTINE HYDROCHLORIDE							
AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN	
AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN	
	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN	
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN	

SOLUTION; INTRAVENOUS

	BENDEKA							
	+! EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Oct	CDFR	
	TREANDA							
	+ @ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	Oct	CDFR	
	+ @	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	Oct	CDFR	
	VIVIMUSTA							
	+! AZURITY	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Jul	CAHN	

BENZGALANTAMINE GLUCONATE

TABLET, DELAYED RELEASE; ORAL
ZUNVEYL

	+! ALPHA COGNITION	EQ 5MG BASE	N218549	001	Jul 26, 2024	Jul	NEWA	
	+	EQ 10MG BASE	N218549	002	Jul 26, 2024	Jul	NEWA	
	+	EQ 15MG BASE	N218549	003	Jul 26, 2024	Jul	NEWA	

BENZONATATE

CAPSULE; ORAL
BENZONATATE

	@ ACELLA	100MG	A091310	001	Jan 16, 2015	Oct	DISC	
>D> AA		200MG	A091310	002	Jan 16, 2015	Dec	DISC	
>A>	@	200MG	A091310	002	Jan 16, 2015	Dec	DISC	
>D>	ASCENT PHARMS INC	150MG	A211518	002	Feb 22, 2019	Dec	DISC	
>A>	@	150MG	A211518	002	Feb 22, 2019	Dec	DISC	
>D>	@ THEPHARMANETWORK LLC	100MG	A040627	001	Mar 30, 2007	Dec	CMFD	
>A> AA		100MG	A040627	001	Mar 30, 2007	Dec	CMFD	
>D>	@	150MG	A040627	003	Sep 24, 2014	Dec	CMFD	
>A>	!	150MG	A040627	003	Sep 24, 2014	Dec	CMFD	
>D>	@	200MG	A040627	002	Jul 25, 2007	Dec	CMFD	
>A> AA		200MG	A040627	002	Jul 25, 2007	Dec	CMFD	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	ENCUBE	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Nov	CMFD	
AB	PADAGIS ISRAEL	3.75%;EQ 1.2% BASE	A209610	001	Aug 20, 2024	Aug	NEWA	

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL
ERYTHROMYCIN AND BENZOYL PEROXIDE

AB	RISING	5%;3%	A065385	001	Sep 18, 2015	Sep	CAHN	
----	--------	-------	---------	-----	--------------	-----	------	--

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Aug	CMFD	
AA		1MG	A040103	002	Dec 12, 1996	Aug	CMFD	
AA		2MG	A040103	003	Dec 12, 1996	Aug	CMFD	
AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN	
AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN	
AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN	
	@ INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	DISC	
	@	1MG	A090294	002	Mar 29, 2010	Mar	DISC	
	@	2MG	A090294	003	Mar 29, 2010	Mar	DISC	
AA	! NUVO PHARM	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN	
AA	!	1MG	A204713	002	Apr 14, 2015	Jul	CAHN	

	TABLET;ORAL							
	BENZTROPINE MESYLATE							
AA	!	2MG	A204713	003	Apr 14, 2015	Jul	CAHN	
	<u>BEPOTASTINE BESILATE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	BEPOTASTINE BESILATE							
AT		SOMERSET THERAPS LLC 1.5%	A217770	001	Aug 14, 2024	Aug	NEWA	
	<u>BERDAZIMER SODIUM</u>							
	GEL;TOPICAL							
	ZELSUVMI							
	+	LNHC EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan	NEWA	
	<u>BETAMETHASONE DIPROPIONATE</u>							
	LOTION, AUGMENTED;TOPICAL							
	BETAMETHASONE DIPROPIONATE							
	@	HIKMA EQ 0.05% BASE	A208849	001	Oct 11, 2019	Mar	DISC	
	OINTMENT;TOPICAL							
	BETAMETHASONE DIPROPIONATE							
>D>	AB	TASMAN PHARMA EQ 0.05% BASE	A215186	001	Feb 18, 2022	Dec	CAHN	
>A>	AB	TRUPHARMA EQ 0.05% BASE	A215186	001	Feb 18, 2022	Dec	CAHN	
	OINTMENT, AUGMENTED;TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB		AUROBINDO PHARMA LTD EQ 0.05% BASE	A218289	001	Apr 10, 2024	Mar	NEWA	
	@	PADAGIS US EQ 0.05% BASE	A206118	001	Nov 09, 2017	Jan	CAHN	
	<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE</u>							
	AEROSOL, FOAM;TOPICAL							
	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE							
	@	GLENMARK PHARMS LTD 0.064%;0.005%	A214688	001	Mar 21, 2023	Nov	DISC	
		ENSTILAR						
	+	LEO PHARMA AS 0.064%;0.005%	N207589	001	Oct 16, 2015	Nov	CTEC	
	<u>BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE</u>							
	CREAM;TOPICAL							
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	!	TARO EQ 0.05% BASE;1%	A075673	001	May 29, 2001	Apr	CAHN	
	<u>BETAMETHASONE VALERATE</u>							
	AEROSOL, FOAM;TOPICAL							
	BETAMETHASONE VALERATE							
AB		ALEMBIC 0.12%	A215832	001	Aug 22, 2024	Aug	NEWA	
	LOTION;TOPICAL							
	BETAMETHASONE VALERATE							
AB		KANCHAN HLTHCARE EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug	CAHN	
AB		SCIEGEN PHARMS INC EQ 0.1% BASE	A070052	001	Jul 31, 1985	Sep	CAHN	
	<u>BETHANECHOL CHLORIDE</u>							
	INJECTABLE;INJECTION							
	URECHOLINE							
>D>	+	@ ODYSSEY PHARMS 5MG/ML	N006536	001		Dec	CAHN	
>A>	+	@ TEVA BRANDED PHARM 5MG/ML	N006536	001		Dec	CAHN	
	TABLET;ORAL							
	URECHOLINE							
>D>	+	@ ODYSSEY PHARMS 5MG	N006536	003		Dec	CAHN	
>D>	+	@ 10MG	N006536	002		Dec	CAHN	
>D>	+	@ 25MG	N006536	004		Dec	CAHN	
>D>	+	@ 50MG	N006536	005		Dec	CAHN	
>A>	+	@ TEVA BRANDED PHARM 5MG	N006536	003		Dec	CAHN	
>A>	+	@ 10MG	N006536	002		Dec	CAHN	
>A>	+	@ 25MG	N006536	004		Dec	CAHN	
>A>	+	@ 50MG	N006536	005		Dec	CAHN	
	<u>BEXAROTENE</u>							
	CAPSULE;ORAL							
	BEXAROTENE							
AB		ASCENT PHARMS INC 75MG	A208628	001	Sep 06, 2024	Aug	NEWA	
AB		CIPLA 75MG	A210352	001	Dec 10, 2024	Nov	NEWA	

<u>BICALUTAMIDE</u>							
TABLET; ORAL							
BICALUTAMIDE							
AB	CHARTWELL RX	50MG	A091011	001	Jun 10, 2015	Jan	CAHN
	@ RISING	50MG	A079185	001	Jul 06, 2009	Feb	CAHN
<u>BIMATOPROST</u>							
SOLUTION/DROPS; TOPICAL							
BIMATOPROST							
	@ HIKMA	0.03%	A203051	001	Oct 09, 2018	Mar	DISC
<u>BIRCH TRITERPENES</u>							
GEL; TOPICAL							
FILSUVEZ							
+!	CHIESI	10%	N215064	001	Dec 18, 2023	Jan	CAHN
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE							
AB	NOVAST LABS	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Sep	CAHN
<u>BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE</u>							
TABLET, CHEWABLE, TABLET, CAPSULE; ORAL							
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE							
!	AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018	Oct	CAHN
<u>BISOPROLOL FUMARATE</u>							
TABLET; ORAL							
BISOPROLOL FUMARATE							
AB	HARMAN FINOCHEM	5MG	A217617	001	Jan 18, 2024	Jan	NEWA
AB		10MG	A217617	002	Jan 18, 2024	Jan	NEWA
AB	TRUPHARMA	5MG	A075474	001	Oct 25, 2002	Sep	CAHN
AB		10MG	A075474	002	Oct 25, 2002	Sep	CAHN
<u>BIVALIRUDIN</u>							
INJECTABLE; INTRAVENOUS							
BIVALIRUDIN							
	@ HOSPIRA	250MG/VIAL	A090811	001	Jul 14, 2015	Aug	DISC
	@	250MG/VIAL	A090816	001	Jul 14, 2015	May	DISC
<u>BLEOMYCIN SULFATE</u>							
INJECTABLE; INJECTION							
BLEOMYCIN SULFATE							
	@ TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033	001	Jun 27, 2000	Jan	DISC
	@	EQ 30 UNITS BASE/VIAL	A065033	002	Jun 27, 2000	Jan	DISC
<u>BORTEZOMIB</u>							
INJECTABLE; INTRAVENOUS, SUBCUTANEOUS							
BORTEZOMIB							
AP	HETERO LABS LTD VI	3.5MG/VIAL	A212204	001	May 03, 2024	Apr	NEWA
	@ NORVIUM BIOSCIENCE	3.5MG/VIAL	A205160	001	Oct 31, 2022	Jun	CAHN
AP	RELIANCE LIFE SCI	3.5MG/VIAL	A211898	001	Oct 11, 2022	May	CAHN
SOLUTION; INTRAVENOUS, SUBCUTANEOUS							
BORTEZOMIB							
+!	SHILPA	3.5MG/1.4ML (2.5MG/ML)	N212782	001	Aug 26, 2024	Aug	NEWA
<u>BOSENTAN</u>							
TABLET; ORAL							
BOSENTAN							
	@ ENDO OPERATIONS	62.5MG	A205699	001	Apr 26, 2019	Apr	CAHN
	@	125MG	A205699	002	Apr 26, 2019	Apr	CAHN
<u>BREMELANOTIDE ACETATE</u>							
SOLUTION; SUBCUTANEOUS							
VYLEESI (AUTOINJECTOR)							
+!	COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Apr	CAHN

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

@	ALKEM LABS LTD	0.25MG	A213782	001	Nov 28, 2023	Sep	DISC
@		0.5MG	A213782	002	Nov 28, 2023	Sep	DISC
@		1MG	A213782	003	Nov 28, 2023	Sep	DISC
@		2MG	A213782	004	Nov 28, 2023	Sep	DISC
@		3MG	A213782	005	Nov 28, 2023	Sep	DISC
@		4MG	A213782	006	Nov 28, 2023	Sep	DISC
@	ANDA REPOSITORY	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN
@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN
@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN
@	CELLTRION	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN
@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN
@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN
@	HETERO LABS LTD V	0.25MG	A213669	001	Nov 20, 2023	Sep	DISC
@		0.5MG	A213669	002	Nov 20, 2023	Sep	DISC
@		1MG	A213669	003	Nov 20, 2023	Sep	DISC
@		2MG	A213669	004	Nov 20, 2023	Sep	DISC
@		3MG	A213669	005	Nov 20, 2023	Sep	DISC
@		4MG	A213669	006	Nov 20, 2023	Sep	DISC
@	OPTIMUS	0.25MG	A213758	001	Oct 25, 2023	Sep	DISC
@		0.5MG	A213758	002	Oct 25, 2023	Sep	DISC
@		1MG	A213758	003	Oct 25, 2023	Sep	DISC
@		2MG	A213758	004	Oct 25, 2023	Sep	DISC
@		3MG	A213758	005	Oct 25, 2023	Sep	DISC
@		4MG	A213758	006	Oct 25, 2023	Sep	DISC

REXULTI

+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Sep	CTEC
+		0.5MG	N205422	002	Jul 10, 2015	Sep	CTEC
+		1MG	N205422	003	Jul 10, 2015	Sep	CTEC
+		2MG	N205422	004	Jul 10, 2015	Sep	CTEC
+		3MG	N205422	005	Jul 10, 2015	Sep	CTEC
+		4MG	N205422	006	Jul 10, 2015	Sep	CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AB	LUPIN LTD	0.1%	A213215	001	Aug 26, 2024	Aug	NEWA
AB	SANDOZ	0.1%	A203172	001	Mar 04, 2024	Feb	NEWA
AB	SOMERSET THERAPS LLC	0.1%	A216906	001	Aug 09, 2024	Aug	NEWA
	@ UPSHER SMITH LABS	0.15%	A216772	001	Jun 12, 2024	Nov	DISC
AT		0.15%	A216772	001	Jun 12, 2024	May	NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

>A>	AB	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Dec	NEWA
	AB	GLENMARK PHARMS LTD	0.2%;EQ 0.5% BASE	A214987	001	May 16, 2024	May	NEWA
	AB	SOMERSET	0.2%;EQ 0.5% BASE	A216114	001	Sep 10, 2024	Aug	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AB	ALEMBIC	EQ 0.07% ACID	A214340	001	Jul 08, 2024	Jun	NEWA	
AB	AMNEAL	EQ 0.07% ACID	A210962	001	Jul 29, 2024	Jul	NEWA	
AB	APOTEX	EQ 0.07% ACID	A207334	001	Jul 08, 2024	Jun	NEWA	
AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan	NFTG	
AB	+!	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan	CFTG

BROMOCRIPTINE MESYLATE

		CAPSULE; ORAL							
		PARLODEL							
AB	+	ESJAY PHARMA	EQ 5MG BASE	N017962	002	Mar 01, 1982	Oct	CAHN	
		TABLET; ORAL							
		PARLODEL							
AB	+	ESJAY PHARMA	EQ 2.5MG BASE	N017962	001		Oct	CAHN	

BUDESONIDE

		AEROSOL, FOAM; RECTAL							
		BUDESONIDE							
AB	!	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun	CHRS	
		UCERIS							
AB	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun	CHRS	
		POWDER, METERED; INHALATION							
		PULMICORT FLEXHALER							
	+	CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Jun	CAHN	
	+	!	0.16MG/INH	N021949	002	Jul 12, 2006	Jun	CAHN	
		SUSPENSION; INHALATION							
		BUDESONIDE							
	@	EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	May	DISC	
		SUSPENSION; ORAL							
		EOHILIA							
	+	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA	

BUMETANIDE

		INJECTABLE; INJECTION							
		BUMETANIDE							
	@	HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC	
AP		LUPIN LTD	0.25MG/ML	A217153	001	Sep 17, 2024	Sep	NEWA	
AP		QILU PHARM HAINAN	0.25MG/ML	A219116	001	Sep 19, 2024	Sep	NEWA	
		TABLET; ORAL							
		BUMETANIDE							
AB		APPCO	0.5MG	A212931	001	Sep 18, 2024	Sep	NEWA	
AB			1MG	A212931	002	Sep 18, 2024	Sep	NEWA	
AB			2MG	A212931	003	Sep 18, 2024	Sep	NEWA	
AB		RISING	0.5MG	A212019	001	Dec 12, 2019	Jun	CTEC	
AB			1MG	A212019	002	Dec 12, 2019	Jun	CTEC	
AB			2MG	A212019	003	Dec 12, 2019	Jun	CTEC	
>A>	AB	RUBICON	0.5MG	A213942	001	Dec 27, 2024	Dec	NEWA	
>A>	AB		1MG	A213942	002	Dec 27, 2024	Dec	NEWA	
>A>	AB		2MG	A213942	003	Dec 27, 2024	Dec	NEWA	

BUPIVACAINE

		INJECTABLE, LIPOSOMAL; INJECTION							
		BUPIVACAINE LIPOSOME							
AP		HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Jun	NFTG	
AP			266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Jun	NFTG	
		EXPAREL							
AP	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG	
AP	+	!	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG	
		SOLUTION; INFILTRATION							
		POSIMIR							
	+	@ INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Nov	DISC	
	+	!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Aug	CDFR	

BUPIVACAINE HYDROCHLORIDE

		IMPLANT; IMPLANTATION							
		XARACOLL							
	+	@ INNOCOLL PHARMS	100MG	N209511	001	Aug 28, 2020	Nov	DISC	
		INJECTABLE; INJECTION							
		BUPIVACAINE HYDROCHLORIDE							
AP		ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA	
AP			0.5%	A217821	002	Mar 27, 2024	Mar	NEWA	
AP			0.75%	A217821	003	Mar 27, 2024	Mar	NEWA	
AP		MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN	
AP			0.25%	A216040	001	Dec 27, 2023	Jun	CAHN	
AP			0.5%	A216039	002	Jun 23, 2023	Jun	CAHN	
AP			0.5%	A216040	002	Dec 27, 2023	Jun	CAHN	
AP			0.75%	A216040	003	Dec 27, 2023	Jun	CAHN	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
VIVACAINE

! SEPTODONT 0.5%;0.0091MG/ML A077250 001 Sep 27, 2006 Jan CTNA

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

AB DIFGEN PHARMS 5MCG/HR A210272 001 Sep 23, 2021 Sep CAHN
 AB 7.5MCG/HR A210272 002 Sep 23, 2021 Sep CAHN
 AB 10MCG/HR A210272 003 Sep 23, 2021 Sep CAHN
 AB 15MCG/HR A210272 004 Sep 23, 2021 Sep CAHN
 AB 20MCG/HR A210272 005 Sep 23, 2021 Sep CAHN

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION
PROBUPHINE

+ @ REACX PHARMS EQ 80MG BASE/IMPLANT N204442 001 May 26, 2016 Apr CAHN

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

@ AM REGENT EQ 0.3MG BASE/ML A078331 001 Mar 27, 2007 Jan DISC

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@ NORVIUM BIOSCIENCE EQ 2MG BASE A201066 001 Mar 06, 2015 Jun CAHN
 @ EQ 8MG BASE A201066 002 Mar 06, 2015 Jun CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB DIFGEN PHARMS EQ 8MG BASE; EQ 2MG BASE A212756 001 Jun 02, 2022 Sep CAHN
 AB EQ 12MG BASE; EQ 3MG BASE A212756 002 Jun 02, 2022 Sep CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB AUROBINDO PHARMA USA 75MG A075491 001 Apr 17, 2000 Apr CMFD
 AB 100MG A075491 002 Apr 17, 2000 Apr CMFD
 @ INVAGEN PHARMS 75MG A207389 001 Sep 18, 2017 Mar DISC
 @ 100MG A207389 002 Sep 18, 2017 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ ANCHEN PHARMS 100MG A091459 001 Jun 09, 2011 Feb DISC
 @ 150MG A091459 002 Jun 09, 2011 Feb DISC
 @ 150MG A091520 001 Jun 09, 2011 Feb DISC
 @ 200MG A091459 003 Jun 09, 2011 Feb DISC
 >A> @ CHARTWELL RX 150MG A076834 001 Jul 14, 2005 Dec CAHN
 @ ENDO OPERATIONS 100MG A091459 001 Jun 09, 2011 May CAHN
 @ 150MG A077284 001 Dec 14, 2006 May CAHN
 @ 150MG A091459 002 Jun 09, 2011 May CAHN
 @ 150MG A091520 001 Jun 09, 2011 May CAHN
 @ 200MG A091459 003 Jun 09, 2011 May CAHN
 @ 300MG A077284 002 Dec 14, 2006 May CAHN
 AB1 GRANULES 100MG A218385 001 Oct 17, 2024 Oct NEWA
 AB1 150MG A218385 002 Oct 17, 2024 Oct NEWA
 AB1 200MG A218385 003 Oct 17, 2024 Oct NEWA
 @ INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Mar DISC
 @ 150MG A206556 001 Aug 26, 2016 Mar DISC
 @ 150MG A206674 002 Feb 09, 2016 Mar DISC
 @ 200MG A206674 003 Feb 09, 2016 Mar DISC
 @ 300MG A206556 002 Aug 26, 2016 Mar DISC
 @ RISING 150MG A090941 001 May 03, 2010 Feb CAHN
 >D> @ SANDOZ 150MG A076834 001 Jul 14, 2005 Dec CAHN
 @ SUN PHARM 150MG A078866 002 Apr 06, 2010 Jul DISC
 @ 200MG A078866 003 Apr 06, 2010 May DISC
 AB3 TWI PHARMS 150MG A210081 001 Nov 03, 2017 Mar CAHN
 AB3 300MG A210081 002 Nov 03, 2017 Mar CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB		AIPING PHARM INC	5MG	A202087	001	Dec 16, 2015	Jan CAHN
AB			10MG	A202087	002	Dec 16, 2015	Jan CAHN
AB			15MG	A202087	003	Dec 16, 2015	Jan CAHN
AB			30MG	A202087	004	Dec 16, 2015	Jan CAHN
	@	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	Mar DISC
	@		7.5MG	A208829	002	May 24, 2017	Mar DISC
	@		10MG	A208829	003	May 24, 2017	Mar DISC
	@		15MG	A208829	004	May 24, 2017	Mar DISC
	@		30MG	A208829	005	May 24, 2017	Mar DISC

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

>D>	AP	EUGIA PHARMA	6MG/ML	A215102	001	Jun 25, 2024	Dec DISC
>A>		@	6MG/ML	A215102	001	Jun 25, 2024	Dec DISC
	AP		6MG/ML	A215102	001	Jun 25, 2024	Jun NEWA
		@ NORVIUM BIOSCIENCE	6MG/ML	A205184	001	Jul 13, 2018	Jun CAHN
	AP	PRINSTON INC	6MG/ML	A215235	001	Sep 11, 2024	Aug NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

	@	NORVIUM BIOSCIENCE	15MG	N000793	002		Jun CAHN
	+ @		30MG	N000793	004		Jun CAHN
	@		50MG	N000793	003		Jun CAHN
	@		100MG	N000793	005		Jun CAHN

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

	+ @	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jun DISC
	+ @	ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Sep DISC
	+!		60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Mar NEWA

CABERGOLINE

TABLET; ORAL

CABERGOLINE

	@	NORVIUM BIOSCIENCE	0.5MG	A202947	001	Dec 02, 2013	Jun CAHN
AB		SKG PHARMA	0.5MG	A218618	001	Jun 26, 2024	Jun NEWA
AB		SOMERSET THERAPS LLC	0.5MG	A218109	001	Sep 09, 2024	Oct CAHN
AB		WELDING	0.5MG	A218109	001	Sep 09, 2024	Aug NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

CAFERGOT

	+ @	CHARTWELL RX	100MG;1MG	A084294	001		Nov CAHN
--	-----	--------------	-----------	---------	-----	--	----------

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

	@	HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar DISC
--	---	-------	--------	---------	-----	--------------	----------

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

AP		CIPLA	200 IU/ML	A213766	001	Sep 20, 2024	Sep NEWA
AP		DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr NEWA
AP		FRESENIUS KABI USA	200 IU/ML	A212675	001	Dec 05, 2024	Nov NEWA

SPRAY, METERED; NASAL

CALCITONIN-SALMON

AB	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul CTEC
AB		ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul CMFD
	@		200 IU/SPRAY	A076979	001	Jun 08, 2009	May CAHN
		MIACALCIN					
	+ @	NORVIUM BIOSCIENCE	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul CAHN

CALCITRIOL

	CAPSULE;ORAL						
	CALCITRIOL						
	@	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Oct DISC
	@		0.5MCG	A204556	002	Feb 21, 2019	Oct DISC
	ROCALTROL						
AB	+	ESJAY PHARMA	0.25MCG	N018044	001		Oct CAHN
AB	+		0.5MCG	N018044	002		Oct CAHN
	SOLUTION;ORAL						
	CALCITRIOL						
AA		ANDA REPOSITORY	1MCG/ML	A203973	001	Jul 28, 2023	Sep CAHN
	ROCALTROL						
AA	+	ESJAY PHARMA	1MCG/ML	N021068	001	Nov 20, 1998	Oct CAHN

CALCIUM ACETATE

	CAPSULE;ORAL						
	CALCIUM ACETATE						
AB	!	INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr CHRS
		PHOSLO GELCAPS					
	+	@ FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr DISC

CALCIUM CHLORIDE

	INJECTABLE;INJECTION						
	CALCIUM CHLORIDE						
AP		AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Jun NEWA
		CALCIUM CHLORIDE 10%					
AP		AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Nov CMS1
AP		EXTROVIS	100MG/ML	A219342	001	Nov 27, 2024	Nov NEWA
>A>	AP	SOMERSET	100MG/ML	A218133	001	Dec 17, 2024	Dec NEWA

CALCIUM GLUCONATE

	SOLUTION;INTRAVENOUS						
	CALCIUM GLUCONATE						
AP		AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May NEWA
AP			5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May NEWA
AP			10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May NEWA
AP		NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr NEWA

CANDESARTAN CILEXETIL

	TABLET;ORAL						
	CANDESARTAN CILEXETIL						
>D>	AB	ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017	Dec DISC
>A>		@	4MG	A091390	001	Aug 23, 2017	Dec DISC
>D>	AB		8MG	A091390	002	Aug 23, 2017	Dec DISC
>A>		@	8MG	A091390	002	Aug 23, 2017	Dec DISC
>D>	AB		16MG	A091390	003	Aug 23, 2017	Dec DISC
>A>		@	16MG	A091390	003	Aug 23, 2017	Dec DISC
>D>	AB		32MG	A091390	004	Aug 23, 2017	Dec DISC
>A>		@	32MG	A091390	004	Aug 23, 2017	Dec DISC

CAPECITABINE

	TABLET;ORAL						
	CAPECITABINE						
AB		HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb NEWA
AB			500MG	A210203	002	Mar 05, 2024	Feb NEWA
		@ HIKMA	150MG	A200483	001	Jul 14, 2016	Sep DISC
		@	500MG	A200483	002	Jul 14, 2016	Sep DISC
		@ SUN PHARM	150MG	A204668	001	Jun 21, 2019	Nov DISC
		@	500MG	A204668	002	Jun 21, 2019	Nov DISC

CAPREOMYCIN SULFATE

	INJECTABLE;INJECTION						
	CAPREOMYCIN SULFATE						
		@ NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017	Jun CAHN

CAPTOPRIL

	TABLET;ORAL						
	CAPTOPRIL						
AB		ANDAS 5 HOLDING	12.5MG	A074677	004	May 30, 1997	Aug CAHN
AB			25MG	A074677	002	May 30, 1997	Aug CAHN
AB			50MG	A074677	001	May 30, 1997	Aug CAHN

TABLET;ORAL
CAPTOPRIL

AB		100MG	A074677	003	May 30, 1997	Aug CAHN
AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar CAHN
AB		25MG	A074677	002	May 30, 1997	Mar CAHN
AB		50MG	A074677	001	May 30, 1997	Mar CAHN
AB		100MG	A074677	003	May 30, 1997	Mar CAHN
AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb CAHN
AB		25MG	A074677	002	May 30, 1997	Feb CAHN
AB		50MG	A074677	001	May 30, 1997	Feb CAHN
AB		100MG	A074677	003	May 30, 1997	Feb CAHN

CARBAMAZEPINE

TABLET;ORAL
CARBAMAZEPINE

AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb NEWA	
>D>	AB	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Dec DISC
>A>	@	100MG	A077272	001	Dec 07, 2005	Dec DISC	
>D>		300MG	A077272	003	Dec 07, 2005	Dec DISC	
>A>	@	300MG	A077272	003	Dec 07, 2005	Dec DISC	
>D>		400MG	A077272	004	Dec 07, 2005	Dec DISC	
>A>	@	400MG	A077272	004	Dec 07, 2005	Dec DISC	
BX	UMEDICA	100MG	A207798	001	Apr 15, 2020	Jun CTEC	
BX		200MG	A207798	002	Apr 15, 2020	Jun CTEC	

TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

@	AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb DISC
@		200MG	A212704	002	Sep 22, 2023	Feb DISC
@		400MG	A212704	003	Sep 22, 2023	Feb DISC
@	APOTEX	100MG	A213159	001	Mar 08, 2024	May DISC
AB		100MG	A213159	001	Mar 08, 2024	Mar NEWA
	@	200MG	A213159	002	Mar 08, 2024	May DISC
AB		200MG	A213159	002	Mar 08, 2024	Mar NEWA
	@	400MG	A213159	003	Mar 08, 2024	May DISC
AB		400MG	A213159	003	Mar 08, 2024	Mar NEWA
AB	EPIC PHARMA LLC	100MG	A216235	001	Mar 02, 2023	Sep CAHN
AB		200MG	A216235	002	Mar 02, 2023	Sep CAHN
AB		400MG	A216235	003	Mar 02, 2023	Sep CAHN
AB	NOVAST LABS	100MG	A216404	001	Dec 02, 2022	Sep CAHN
AB		200MG	A216404	002	Dec 02, 2022	Sep CAHN
AB		400MG	A216404	003	Dec 02, 2022	Sep CAHN
AB	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Oct NEWA
AB		200MG	A215664	002	Oct 22, 2024	Oct NEWA
AB		400MG	A215664	003	Oct 22, 2024	Oct NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL
CARBIDOPA, LEVODOPA AND ENTACAPONE

@	NORVIUM BIOSCIENCE	12.5MG;200MG;50MG	A203424	001	Aug 13, 2020	Jun CAHN
@		18.75MG;200MG;75MG	A203424	002	Aug 13, 2020	Jun CAHN
@		25MG;200MG;100MG	A203424	003	Aug 13, 2020	Jun CAHN
@		31.25MG;200MG;125MG	A203424	004	Aug 13, 2020	Jun CAHN
@		37.5MG;200MG;150MG	A203424	005	Aug 13, 2020	Jun CAHN
@		50MG;200MG;200MG	A203424	006	Aug 13, 2020	Jun CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL
CREXONT

+	IMPAX	35MG;140MG	N217186	001	Aug 07, 2024	Aug NEWA
+		52.5MG;210MG	N217186	002	Aug 07, 2024	Aug NEWA
+		70MG;280MG	N217186	003	Aug 07, 2024	Aug NEWA
+	!	87.5MG;350MG	N217186	004	Aug 07, 2024	Aug NEWA
	RYTARY					
+	IMPAX	23.75MG;95MG	N203312	001	Jan 07, 2015	May CAHN
+		36.25MG;145MG	N203312	002	Jan 07, 2015	May CAHN
+		48.75MG;195MG	N203312	003	Jan 07, 2015	May CAHN
+	!	61.25MG;245MG	N203312	004	Jan 07, 2015	May CAHN

TABLET, EXTENDED RELEASE;ORAL
CARBIDOPA AND LEVODOPA

AB	RUBICON	25MG;100MG	A217482	001	Jun 04, 2024	May NEWA
AB		50MG;200MG	A217482	002	Jun 04, 2024	May NEWA

CARBINOXAMINE MALEATE

		SOLUTION; ORAL							
		CARBINOXAMINE MALEATE							
		@ ENDO OPERATIONS		4MG/5ML	A040814	001	Feb 26, 2008	May	CAHN
		TABLET; ORAL							
		CARBINOXAMINE MALEATE							
		@ INVAGEN PHARMS		4MG	A090435	001	Apr 15, 2010	Mar	DISC
>A>	AA	LEADING		6MG	A215476	001	Dec 19, 2024	Dec	NEWA
>D>		! MIKART		6MG	A207484	001	May 31, 2016	Dec	CTEC
>A>	AA	!		6MG	A207484	001	May 31, 2016	Dec	CTEC

CARBOPLATIN

INJECTABLE; INTRAVENOUS
CARBOPLATIN

		@ NORVIUM BIOSCIENCE		50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Jul	CAHN
				150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Jul	CAHN
		@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Jul	CAHN

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION
CARBOPROST TROMETHAMINE

		@ ANI PHARMS		EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jul	DISC
AP				EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan	NEWA
AP		MICRO LABS		EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar	NEWA
AP		STERISCIENCE SPECLTS		EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Aug	CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

>D>		@ ALLIED		350MG	A211789	001	Oct 20, 2021	Dec	CMFD
>A>	AA			350MG	A211789	001	Oct 20, 2021	Dec	CMFD
		@		350MG	A211789	001	Oct 20, 2021	Aug	CAHN
AB		CHARTWELL RX		250MG	A205126	001	Jul 08, 2015	Sep	CAHN
AA				350MG	A205126	002	Jul 08, 2015	Sep	CAHN
		@ MLV		350MG	A211789	001	Oct 20, 2021	Jul	DISC

CARMUSTINE

INJECTABLE; INJECTION
CARMUSTINE

		@ NORVIUM BIOSCIENCE		100MG/VIAL	A215368	001	Mar 03, 2023	Jun	CAHN
--	--	----------------------	--	------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS
CARMUSTINE

		+ @ ACCORD HLTHCARE		50MG/VIAL	N215000	001	May 16, 2022	May	DISC
		+ @		300MG/VIAL	N215000	002	May 16, 2022	May	DISC

CARVEDILOL

TABLET; ORAL
CARVEDILOL

AB		MLV		3.125MG	A078786	001	Dec 22, 2009	Nov	CMFD
		@		3.125MG	A078786	001	Dec 22, 2009	Aug	CAHN
AB				6.25MG	A078786	002	Dec 22, 2009	Nov	CMFD
		@		6.25MG	A078786	002	Dec 22, 2009	Aug	CAHN
AB				12.5MG	A078786	003	Dec 22, 2009	Nov	CMFD
		@		12.5MG	A078786	003	Dec 22, 2009	Aug	CAHN
AB				25MG	A078786	004	Dec 22, 2009	Nov	CMFD
		@		25MG	A078786	004	Dec 22, 2009	Aug	CAHN
		@ MYLAN		3.125MG	A077316	001	Sep 05, 2007	Apr	DISC
		@ SUN PHARM INDS LTD		3.125MG	A076989	001	Sep 05, 2007	Jan	DISC
		@		6.25MG	A076989	002	Sep 05, 2007	Jan	DISC
		@		12.5MG	A076989	003	Sep 05, 2007	Jan	DISC
		@		25MG	A076989	004	Sep 05, 2007	Jan	DISC
		COREG							
AB	+	WAYLIS THERAP		3.125MG	N020297	004	May 29, 1997	Apr	CAHN
AB	+			6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN
AB	+	!		12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN
AB	+			25MG	N020297	001	Sep 14, 1995	Apr	CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE;ORAL
CARVEDILOL PHOSPHATE

>D>	AB	SUN PHARM INDUSTRIES	40MG	A090132	003	Oct 25, 2017	Dec	CHRS
>A>	AB	!	40MG	A090132	003	Oct 25, 2017	Dec	CHRS
>D>		COREG CR						
>D>	AB	+ WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Dec	DISC
>A>		+ @	10MG	N022012	001	Oct 20, 2006	Dec	DISC
	AB	+	10MG	N022012	001	Oct 20, 2006	Apr	CAHN
>D>	AB	+	20MG	N022012	002	Oct 20, 2006	Dec	DISC
>A>		+ @	20MG	N022012	002	Oct 20, 2006	Dec	DISC
	AB	+	20MG	N022012	002	Oct 20, 2006	Apr	CAHN
>D>	AB	+!	40MG	N022012	003	Oct 20, 2006	Dec	DISC
>A>		+ @	40MG	N022012	003	Oct 20, 2006	Dec	DISC
	AB	+!	40MG	N022012	003	Oct 20, 2006	Apr	CAHN
>D>	AB	+	80MG	N022012	004	Oct 20, 2006	Dec	DISC
>A>		+ @	80MG	N022012	004	Oct 20, 2006	Dec	DISC
	AB	+	80MG	N022012	004	Oct 20, 2006	Apr	CAHN

CASPOFUNGIN ACETATEPOWDER; INTRAVENOUS
CANCIDAS

>D>								
>D>	AP	+! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Dec	DISC
>A>		+ @	50MG/VIAL	N021227	001	Jan 26, 2001	Dec	DISC
>D>	AP	+!	70MG/VIAL	N021227	002	Jan 26, 2001	Dec	DISC
>A>		+ @	70MG/VIAL	N021227	002	Jan 26, 2001	Dec	DISC
		CASPOFUNGIN ACETATE						
	AP	AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
	AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN
>D>	AP	HENGRUI PHARMA	50MG/VIAL	A200833	001	Jun 28, 2018	Dec	CHRS
>A>	AP	!	50MG/VIAL	A200833	001	Jun 28, 2018	Dec	CHRS
>D>	AP		70MG/VIAL	A200833	002	Jun 28, 2018	Dec	CHRS
>A>	AP	!	70MG/VIAL	A200833	002	Jun 28, 2018	Dec	CHRS

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN AND DEXTROSE

>A>		+! B BRAUN	EQ 3GM BASE/VIAL	N050779	004	Aug 26, 2024	Dec	NEWA
		CEFAZOLIN SODIUM						
		QILU	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	NEWA
		SOLUTION; INTRAVENOUS						
		CEFAZOLIN IN DEXTROSE						
		+! BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May	CTNA
		+!	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May	CTNA
		+!	EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024	May	NEWA

CEFDINIRCAPSULE; ORAL
CEFDINIR

AB	!	CHARTWELL RX	300MG	A065330	001	Apr 06, 2007	Nov	CAHN
		FOR SUSPENSION; ORAL						
		CEFDINIR						
AB		CHARTWELL RX	125MG/5ML	A065337	001	Apr 06, 2007	Nov	CAHN
AB			250MG/5ML	A065337	002	Apr 06, 2007	Nov	CAHN

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

		+! B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CHRS
		+	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD
		+!	EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CHRS
		+	EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD
		CEFEPIME HYDROCHLORIDE						
		@ CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun	CAHN
		@	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun	CAHN
		@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun	CAHN
AP		HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA
AP			EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA

POWDER;INTRAVENOUS
 CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
 ! SAMSON MEDCL EQ 100GM BASE

A209408 001 Aug 21, 2018 Apr CHRS

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

POWDER;INTRAVENOUS
 EXBLIFEP
 + @ ALLECRA THERAPS EQ 2GM BASE/VIAL;0.5GM/VIAL
 +! EQ 2GM BASE/VIAL;0.5GM/VIAL

N216165 001 Feb 22, 2024 May DISC
 N216165 001 Feb 22, 2024 Feb NEWA

CEFIXIME

FOR SUSPENSION;ORAL
 CEFIXIME
 @ CHARTWELL RX 100MG/5ML
 @ 200MG/5ML

A206144 001 Nov 17, 2017 Jul CAHN
 A206144 002 Nov 17, 2017 Jul CAHN

TABLET;ORAL
 CEFIXIME

>A> ! FDC LTD 400MG

A206358 001 Dec 17, 2024 Dec NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
 CLAFORAN
 + @ STERIMAX EQ 500MG BASE/VIAL
 + @ EQ 1GM BASE/VIAL
 + @ EQ 2GM BASE/VIAL
 + @ EQ 10GM BASE/VIAL
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ STERIMAX EQ 20MG BASE/ML
 @ EQ 40MG BASE/ML
 CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 @ STERIMAX EQ 20MG BASE/ML
 @ EQ 40MG BASE/ML

N050547 001 Jan CAHN
 N050547 002 Jan CAHN
 N050547 003 Jan CAHN
 N050547 004 Dec 29, 1983 Jan CAHN
 N050596 002 May 20, 1985 Jan CAHN
 N050596 004 May 20, 1985 Jan CAHN
 N050596 001 May 20, 1985 Jan CAHN
 N050596 003 May 20, 1985 Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE;INJECTION
 CEFOTAN
 AP + PAI HOLDINGS PHARM EQ 1GM BASE/VIAL
 AP + EQ 2GM BASE/VIAL
 CEFOTETAN
 AP ! FRESENIUS KABI USA EQ 1GM BASE/VIAL
 AP ! EQ 2GM BASE/VIAL

N050588 001 Dec 27, 1985 Feb CMFD
 N050588 002 Dec 27, 1985 Feb CMFD
 A065374 001 Aug 09, 2007 Feb CTEC
 A065374 002 Aug 09, 2007 Feb CTEC

CEFOXITIN SODIUM

INJECTABLE;INJECTION
 MEFOXIN
 @ NORVIUM BIOSCIENCE EQ 1GM BASE/VIAL
 + @ EQ 1GM BASE/VIAL
 @ EQ 2GM BASE/VIAL
 + @ EQ 2GM BASE/VIAL
 + @ EQ 10GM BASE/VIAL
 MEFOXIN IN PLASTIC CONTAINER
 @ NORVIUM BIOSCIENCE EQ 20MG BASE/ML
 @ EQ 40MG BASE/ML

A062757 001 Jan 08, 1987 Jul CAHN
 N050517 001 Jul CAHN
 A062757 002 Jan 08, 1987 Jul CAHN
 N050517 002 Jul CAHN
 N050517 003 Jul CAHN
 A063182 001 Jan 25, 1993 Jul CAHN
 A063182 002 Jan 25, 1993 Jul CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL
 CEFPODOXIME PROXETIL
 @ CHARTWELL RX EQ 50MG BASE/5ML
 @ EQ 100MG BASE/5ML

A090031 001 Jan 14, 2009 Jul CAHN
 A090031 002 Jan 14, 2009 Jul CAHN

CEFPROZIL

TABLET;ORAL
 CEFPROZIL
 AB ALKEM LABS LTD 250MG
 AB 500MG

A090857 001 Apr 09, 2024 Mar NEWA
 A090857 002 Apr 09, 2024 Mar NEWA

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS
ZEVTERA

+ @	BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Aug	DISC
+	!	667MG/VIAL	N218275	001	Apr 03, 2024	Apr	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFTRIAXONE

	@	DEVA HOLDING AS	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jul	DISC
AP			EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jan	NEWA
	@		EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jul	DISC
AP			EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jan	NEWA
	@		EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jul	DISC
AP			EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jan	NEWA
	@		EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jul	DISC
AP			EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jan	NEWA

CELECOXIB

CAPSULE; ORAL
CELECOXIB

	@	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	Nov	DISC
	@		100MG	A208833	002	May 31, 2018	Nov	DISC
	@		200MG	A208833	003	May 31, 2018	Nov	DISC
	@		400MG	A208833	004	May 31, 2018	Nov	DISC

SOLUTION; ORAL
ELYXYB

+	!	SCILEX PHARMS	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN
---	---	---------------	---------	---------	-----	--------------	-----	------

CELECOXIB; TRAMADOL HYDROCHLORIDE

TABLET; ORAL
SEGLENTIS

+	@	KOWA PHARMS	56MG; 44MG	N213426	001	Oct 15, 2021	Oct	DISC
---	---	-------------	------------	---------	-----	--------------	-----	------

CEPHALEXIN

TABLET; ORAL
CEPHALEXIN

AB		ALKEM LABS LTD	EQ 250MG BASE	A218947	001	Sep 27, 2024	Sep	NEWA
AB			EQ 500MG BASE	A218947	002	Sep 27, 2024	Sep	NEWA
AB		AUROBINDO PHARMA LTD	EQ 250MG BASE	A218817	001	Sep 27, 2024	Sep	NEWA
AB			EQ 500MG BASE	A218817	002	Sep 27, 2024	Sep	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL
CETIRIZINE HYDROCHLORIDE

	@	ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Feb	CDFR
AA		AMNEAL PHARMS	5MG/5ML	A090766	001	Oct 07, 2009	Feb	CDFR
AA		APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009	Jul	CMFD
	@		5MG/5ML	A078870	001	Apr 27, 2009	Feb	CDFR
	@	AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb	CDFR
AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CDFR
>D>	AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	Dec	DISC
>A>		@	5MG/5ML	A078488	001	Oct 06, 2008	Dec	DISC
AA			5MG/5ML	A078488	001	Oct 06, 2008	Feb	CDFR
AA		CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb	CDFR
	@	LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb	CDFR
AA	!	PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb	CDFR
AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb	CDFR
	@	RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb	CDFR
AA		TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb	CDFR
	@	TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC
AA			5MG/5ML	A077279	001	May 27, 2008	Feb	CDFR
	@	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb	CDFR
		ZYRTEC						
	@	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CDFR

SYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Jan	CMFD
----	--	-------------	---------	---------	-----	--------------	-----	------

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS
CETRORELIX ACETATE

AP	GLAND	EQ 0.25MG BASE/VIAL	A218150	001	Apr 25, 2024	Apr	NEWA
AP	LIVZON GRP	EQ 0.25MG BASE/VIAL	A214540	001	Apr 24, 2024	Apr	NEWA
AP	QILU	EQ 0.25MG BASE/VIAL	A217776	001	Apr 16, 2024	Apr	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
CEVIMELINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	30MG	A206808	001	Sep 20, 2024	Sep	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE

	@ FRESenius KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982	Feb	DISC
--	----------------------	------------------	---------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	WINDER LABS LLC	5MG; 2.5MG	A212344	001	Jul 08, 2024	Jun	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

	@ SAPTALIS PHARMS	0.12%	A074356	001	May 07, 1996	Jun	CAHN
	@ SCIEGEN PHARMS INC	0.12%	A074356	001	May 07, 1996	Aug	CAHN

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE

	+ @ FRESenius KABI USA	1%	N009435	001		Oct	DISC
--	------------------------	----	---------	-----	--	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

>D>	AA	IPCA LABS LTD	250MG	A090610	001	Dec 03, 2009	Dec	DISC
>A>		@	250MG	A090610	001	Dec 03, 2009	Dec	DISC
>D>	AA		500MG	A090249	001	Dec 03, 2009	Dec	DISC
>A>		@	500MG	A090249	001	Dec 03, 2009	Dec	DISC

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
CHLOROTHIAZIDE SODIUM

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A218630	001	Oct 03, 2024	Sep	NEWA
	@ RK PHARMA	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Mar	DISC
	@ SUN PHARM	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Nov	DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	@ SCIEGEN PHARMS INC	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Sep	CAHN
--	----------------------	----------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HYDROCHLORIDE

AP	ASPIRO	25MG/ML	A218272	001	Nov 18, 2024	Nov	NEWA
AP	DEVA HLDING	25MG/ML	A218229	001	Sep 24, 2024	Sep	NEWA
AP	DR REDDYS	25MG/ML	A080365	001		Apr	CMFD
AP	GLAND PHARMA LTD	25MG/ML	A216911	001	Oct 04, 2024	Sep	NEWA
AP	+! HIKMA	25MG/ML	A083329	001		Jun	CAHN
AP	THINQ PHARM-CRO PVT	25MG/ML	A216724	001	Dec 10, 2024	Nov	NEWA
AP	ZYDUS PHARMS	25MG/ML	A217275	001	Mar 13, 2024	Mar	NEWA

SYRUP; ORAL

SONAZINE
@ CHARTWELL RX 10MG/5ML

			A083040	001		May	CAHN
--	--	--	---------	-----	--	-----	------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE
@ CHARTWELL RX 10MG

			A080439	001		Jul	CAHN
--	--	--	---------	-----	--	-----	------

AB		10MG	A212630	001	Nov 29, 2021	Sep	CAHN
	@	25MG	A080439	002		Jul	CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE							
AB		25MG	A212630	002	Nov 29, 2021	Sep	CAHN
	@	50MG	A080439	003		Jul	CAHN
AB		50MG	A212630	003	Nov 29, 2021	Sep	CAHN
	@	100MG	A080439	004		Jul	CAHN
AB		100MG	A212630	004	Nov 29, 2021	Sep	CAHN
	@	200MG	A080439	005		Jul	CAHN
AB		200MG	A212630	005	Nov 29, 2021	Sep	CAHN
AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb	CAHN
AB		25MG	A212630	002	Nov 29, 2021	Feb	CAHN
AB		50MG	A212630	003	Nov 29, 2021	Feb	CAHN
AB		100MG	A212630	004	Nov 29, 2021	Feb	CAHN
AB		200MG	A212630	005	Nov 29, 2021	Feb	CAHN
AB	ZYDUS LIFESCIENCES	10MG	A213368	001	Jan 17, 2020	Aug	CAHN
AB		25MG	A213368	002	Jan 17, 2020	Aug	CAHN
AB		50MG	A213368	003	Jan 17, 2020	Aug	CAHN
AB		100MG	A213368	004	Jan 17, 2020	Aug	CAHN
AB		200MG	A213368	005	Jan 17, 2020	Aug	CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE							
AB	IPCA LABS LTD	25MG	A209162	001	Nov 12, 2024	Nov	NEWA
AB		50MG	A209162	002	Nov 12, 2024	Nov	NEWA
AB	PHARMOBEDIENT	25MG	A212878	001	Feb 24, 2022	Sep	CAHN
AB		50MG	A212875	001	Feb 24, 2022	Sep	CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE							
	@ APTAPHARMA INC	375MG	A212053	001	Sep 14, 2020	Apr	DISC
	@	750MG	A212053	002	Sep 14, 2020	Apr	DISC
	@ CHARTWELL RX	375MG	A212053	001	Sep 14, 2020	Sep	CAHN
	@	750MG	A212053	002	Sep 14, 2020	Sep	CAHN
AB	ENDO OPERATIONS	375MG	A212743	002	Apr 29, 2021	Apr	CAHN
AB		750MG	A212743	001	Nov 02, 2020	Apr	CAHN
AA	HAVIX	500MG	A210961	001	Jan 22, 2024	Jan	NEWA
	@ I3 PHARMS	375MG	A212053	001	Sep 14, 2020	Aug	CAHN
	@	750MG	A212053	002	Sep 14, 2020	Aug	CAHN
AA	RISING	250MG	A216925	001	Aug 09, 2023	Aug	CAHN
AA	SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Feb	CAHN
AA		500MG	A210961	001	Jan 22, 2024	Feb	CAHN
	@ TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020	Sep	DISC
	@	750MG	A212898	002	Jun 17, 2020	Sep	DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE							
AB	MACLEODS PHARMS LTD	EQ 4GM RESIN/PACKET	A207294	001	Nov 21, 2024	Nov	NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A207294	002	Nov 21, 2024	Nov	NEWA
CHOLESTYRAMINE LIGHT							
AB	ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A077203	001	Aug 26, 2005	May	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A077203	002	Aug 26, 2005	May	CAHN
AB	MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024	Oct	NEWA
AB		EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024	Oct	NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID							
	@ ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Mar	DISC
	@	EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Mar	DISC
	@ ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	May	CAHN
	@	EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	May	CAHN
	@ MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Aug	DISC
AB		EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Feb	NEWA
	@	EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Aug	DISC
AB		EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Feb	NEWA
AB	RISING	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
	@ TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Aug	DISC
AB		EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
	@	EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Aug	DISC

CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB EQ 135MG FENOFIBRIC ACID A210469 002 Jul 05, 2019 Mar CAHN

CHROMIC CHLORIDE

INJECTABLE;INJECTION
CHROMIC CHLORIDE

>A> AP RK PHARMA EQ 0.004MG CHROMIUM/ML A218538 001 Nov 18, 2024 Dec CAHN
>D> AP STIRA EQ 0.004MG CHROMIUM/ML A218538 001 Nov 18, 2024 Dec CAHN
AP EQ 0.004MG CHROMIUM/ML A218538 001 Nov 18, 2024 Nov NFTG
CHROMIC CHLORIDE IN PLASTIC CONTAINER
AP +! HOSPIRA EQ 0.004MG CHROMIUM/ML N018961 001 Jun 26, 1986 Nov CFTG

CICLESONIDE

AEROSOL, METERED;NASAL
ZETONNA

+ @ COVIS 0.037MG/INH N202129 001 Jan 20, 2012 Aug DISC

CICLOPIROX

CREAM;TOPICAL
CICLOPIROX

AB TARO 0.77% A076790 001 Apr 12, 2005 Jan CAHN

SOLUTION;TOPICAL
CICLOPIROX

@ COSETTE 8% A078233 001 Sep 18, 2007 Jul DISC
@ HIKMA 8% A078270 001 Sep 18, 2007 Mar DISC

CILOSTAZOL

TABLET;ORAL
CILOSTAZOL

@ RISING 50MG A077323 002 Apr 20, 2006 Feb CAHN
@ 100MG A077323 001 Apr 20, 2006 Feb CAHN

CIMETIDINE

TABLET;ORAL
CIMETIDINE

AB AUROBINDO PHARMA LTD 200MG A218997 001 Nov 12, 2024 Nov NEWA
AB 300MG A218997 002 Nov 12, 2024 Nov NEWA
AB 400MG A218997 003 Nov 12, 2024 Nov NEWA
AB 800MG A218997 004 Nov 12, 2024 Nov NEWA
AB BIONPHARMA 200MG A218220 001 Nov 07, 2024 Nov NEWA
AB 300MG A218220 002 Nov 07, 2024 Nov NEWA
AB 400MG A218220 003 Nov 07, 2024 Nov NEWA
AB 800MG A218220 004 Nov 07, 2024 Nov NEWA
AB CHARTWELL MOLECULES 200MG A074329 002 May 17, 1994 Oct CMFD
AB 300MG A074329 003 May 17, 1994 Oct CMFD
AB 400MG A074329 004 May 17, 1994 Oct CMFD
AB 800MG A074329 001 May 17, 1994 Oct CMFD

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
CIMETIDINE HYDROCHLORIDE

@ COSETTE EQ 300MG BASE/2ML A074296 001 Mar 28, 1997 Jun CAHN
@ ENDO OPERATIONS EQ 300MG BASE/2ML A074005 001 Aug 31, 1994 May CAHN
@ EQ 300MG BASE/2ML A074428 001 Apr 25, 1996 May CAHN

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

AA CHARTWELL MOLECULAR EQ 300MG BASE/5ML A074251 001 Dec 22, 1994 Nov CMFD
AA ! PAI HOLDINGS PHARM EQ 300MG BASE/5ML A074664 001 Oct 28, 1997 Nov CTEC
! EQ 300MG BASE/5ML A074664 001 Oct 28, 1997 Sep CMFD
@ EQ 300MG BASE/5ML A074664 001 Oct 28, 1997 Feb DISC
@ PHARM ASSOC EQ 300MG BASE/5ML A074553 001 Jan 27, 1997 Feb DISC

CINACALCET HYDROCHLORIDE

TABLET;ORAL
CINACALCET HYDROCHLORIDE

>D> AB STRIDES PHARMA EQ 90MG BASE A209226 003 Apr 30, 2018 Dec CHRS
>A> AB ! EQ 90MG BASE A209226 003 Apr 30, 2018 Dec CHRS
>D> AB SUN PHARM EQ 30MG BASE A207008 001 Oct 11, 2018 Dec DISC
>A> @ EQ 30MG BASE A207008 001 Oct 11, 2018 Dec DISC
@ EQ 90MG BASE A207008 003 Oct 11, 2018 Oct DISC

		TABLET; ORAL							
>D>		SENSIPAR							
>D>	AB	+	AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Dec	DISC
>A>		+	@	EQ 30MG BASE	N021688	001	Mar 08, 2004	Dec	DISC
>D>	AB	+		EQ 60MG BASE	N021688	002	Mar 08, 2004	Dec	DISC
>A>		+	@	EQ 60MG BASE	N021688	002	Mar 08, 2004	Dec	DISC
>D>	AB	+	!	EQ 90MG BASE	N021688	003	Mar 08, 2004	Dec	DISC
>A>		+	@	EQ 90MG BASE	N021688	003	Mar 08, 2004	Dec	DISC

CIPROFLOXACIN

		INJECTABLE; INJECTION							
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	AP		BAXTER HLTHCARE CORP	200MG/100ML	A078024	001	Mar 18, 2008	Dec	DISC
>A>			@	200MG/100ML	A078024	001	Mar 18, 2008	Dec	DISC
>D>	AP			400MG/200ML	A078024	002	Mar 18, 2008	Dec	DISC
>A>			@	400MG/200ML	A078024	002	Mar 18, 2008	Dec	DISC

CIPROFLOXACIN HYDROCHLORIDE

		SOLUTION/DROPS; OPHTHALMIC							
		CIPROFLOXACIN HYDROCHLORIDE							
>A>		@	RENOVA PHARMS	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Dec	CAHN
		@	SAPTALIS PHARMS	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Mar	CAHN
>D>		@	SCIENGEN PHARMS INC	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Dec	CAHN
		@	THE J MOLNER	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Jun	CAHN
		SOLUTION/DROPS; OTIC							
		CETRAXAL							
AB		+	KEY THERAP	EQ 0.2% BASE	N021918	001	May 01, 2009	Oct	CFTG
		+	!	EQ 0.2% BASE	N021918	001	May 01, 2009	Apr	CAHN
		CIPROFLOXACIN HYDROCHLORIDE							
AB			IDENTIRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Oct	NFTG
		TABLET; ORAL							
		CIPROFLOXACIN HYDROCHLORIDE							
AB			AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Apr	CMFD
AB				EQ 500MG BASE	A076593	003	Jun 09, 2004	Apr	CMFD
AB				EQ 750MG BASE	A076593	004	Jun 09, 2004	Apr	CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

		TABLET, EXTENDED RELEASE; ORAL							
		CIPROFLOXACIN EXTENDED RELEASE							
		@	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Mar	DISC
		@		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Mar	DISC
		!	DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CTEC
AB		!		425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CHRS
		@	ENDO OPERATIONS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May	CAHN
		@		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May	CAHN

CIPROFLOXACIN; DEXAMETHASONE

		SUSPENSION/DROPS; OTIC							
		CIPROFLOXACIN; DEXAMETHASONE							
AB			AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Mar	NEWA

CISATRACURIUM BESYLATE

		INJECTABLE; INJECTION							
		CISATRACURIUM BESYLATE							
>D>		@	CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Dec	CMFD
>A>	AP			EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Dec	CMFD
		@		EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Apr	DISC
>D>		@		EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Dec	CMFD
>A>	AP			EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Dec	CMFD
		@		EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Apr	DISC
AP			HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Mar	NEWA
AP		!	MEITHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	CHRS
AP		!		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	CHRS
AP		!		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	CHRS
AP			PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CMS1
		CISATRACURIUM BESYLATE PRESERVATIVE FREE							
AP			HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Aug	NEWA
AP				EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Aug	NEWA

CISPLATININJECTABLE; INJECTION
CISPLATIN

AP	QILU	1MG/ML	A218868	001	May 10, 2024	May	NEWA
----	------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDETABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Jan	CAHN
AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Jan	CAHN
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Jan	CAHN
	@ CHARTWELL RX	EQ 10MG BASE	A077040	001	Aug 17, 2005	Aug	CAHN
	@	EQ 20MG BASE	A077040	002	Aug 17, 2005	Aug	CAHN
	@	EQ 40MG BASE	A077040	003	Aug 17, 2005	Aug	CAHN
	@ COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	DISC
	@	EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	DISC
	@	EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	DISC
	@ TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006	Jan	CAHN
	@	EQ 20MG BASE	A077278	002	Mar 22, 2006	Jan	CAHN
	@	EQ 40MG BASE	A077278	003	Mar 22, 2006	Jan	CAHN

CLADRIBINEINJECTABLE; INJECTION
CLADRIBINE

	@ NORVIUM BIOSCIENCE	1MG/ML	A200510	001	Oct 06, 2011	Jun	CAHN
--	----------------------	--------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATESYRUP; ORAL
CLEMASTINE FUMARATE

AA	! GENUS	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	Aug	CTEC
	@ NEW HEIGHTS	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jan	CAHN
AA	NEW HEIGHTSRX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Aug	CMFD
	@	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jul	CAHN

TABLET; ORAL
CLEMASTINE FUMARATE

!	GENUS	2.68MG	A073283	001	Jan 31, 1992	Nov	CAHN
@	OMNIVIUM PHARMS	2.68MG	A073459	001	Oct 31, 1993	Jun	CAHN

CLINDAMYCIN HYDROCHLORIDECAPSULE; ORAL
CLINDAMYCIN HYDROCHLORIDE

@	COSETTE	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	DISC
@		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	APPCO	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Nov	CAHN
>A>	@ EXTROVIS	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Dec	CAHN
	@	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Jun	CAHN
AA	RISING	EQ 75MG BASE/5ML	A201821	001	Aug 28, 2012	Sep	CAHN
>D>	@	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Dec	CAHN

CLINDAMYCIN PHOSPHATEGEL; TOPICAL
CLINDAMYCIN PHOSPHATE

AB1	ALEMBIC	EQ 1% BASE	A212466	001	Apr 02, 2024	Mar	NEWA
	@ AMNEAL	EQ 1% BASE	A215219	001	Nov 03, 2022	Feb	DISC
AB1	QUAGEN	EQ 1% BASE	A211872	001	Jul 29, 2020	Sep	CAHN

GEL; VAGINAL
XACIATO

+	! ORGANON LLC	EQ 2% BASE	N215650	001	Dec 07, 2021	Jan	CAHN
---	---------------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

@	ENDO OPERATIONS	EQ 1% BASE	A203343	001	May 29, 2015	Apr	CAHN
---	-----------------	------------	---------	-----	--------------	-----	------

CLOBAZAM

TABLET; ORAL		CLOBAZAM					
>A>	@ ALLIED	5MG	A209308	003	Oct 19, 2021	Dec	CAHN
>A>	AB	10MG	A209308	001	Oct 22, 2018	Dec	CAHN
>A>	@	20MG	A209308	002	Oct 22, 2018	Dec	CAHN
	@ ANDA REPOSITORY	10MG	A211959	001	Dec 09, 2020	Sep	CAHN
	@	20MG	A211959	002	Dec 09, 2020	Sep	CAHN
>D>	@ BRECKENRIDGE	5MG	A209308	003	Oct 19, 2021	Dec	CAHN
>D>	AB	10MG	A209308	001	Oct 22, 2018	Dec	CAHN
>D>	@	20MG	A209308	002	Oct 22, 2018	Dec	CAHN
	@	20MG	A209308	002	Oct 22, 2018	Jan	DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL		CLOBETASOL PROPIONATE					
AB2	TARO	0.05%	A208563	001	Mar 14, 2024	Mar	NEWA
CREAM; TOPICAL		CLOBETASOL PROPIONATE					
	@ COSETTE	0.05%	A074139	001	Aug 03, 1994	Apr	DISC
AB1	TORRENT	0.05%	A211836	001	Dec 30, 2019	Nov	CMFD
CLOBETASOL PROPIONATE (EMOLLIENT)							
AB2	BEACH PRODS	0.05%	A209411	001	Aug 21, 2017	Nov	CMFD
	@	0.05%	A209411	001	Aug 21, 2017	Oct	CAHN
CORMAX							
	@ HIKMA	0.05%	A074220	001	May 16, 1997	Mar	DISC
GEL; TOPICAL		EMBELINE					
	@ HIKMA	0.05%	A076141	001	Apr 12, 2002	Mar	DISC
OINTMENT; TOPICAL		CLOBETASOL PROPIONATE					
AB	! ENCUBE	0.05%	A211295	001	Nov 15, 2019	Oct	CHRS
AB	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Oct	CHRS
EMBELINE							
	@ HIKMA	0.05%	A074221	001	Mar 31, 1995	Mar	DISC
SHAMPOO; TOPICAL		CLOBETASOL PROPIONATE					
	@ HIKMA	0.05%	A209871	001	Oct 27, 2017	Mar	DISC
SOLUTION; TOPICAL		CLOBETASOL PROPIONATE					
	@ COSETTE	0.05%	A074331	001	Dec 15, 1995	Apr	DISC
AT	ENCUBE	0.05%	A076977	001	Aug 05, 2005	May	CMFD
EMBELINE							
	@ HIKMA	0.05%	A074222	001	Dec 06, 1995	Mar	DISC
SPRAY; TOPICAL		CLOBETASOL PROPIONATE					
AT	MACLEODS PHARMS LTD	0.05%	A214345	001	Dec 02, 2024	Nov	NEWA
SUSPENSION/DROPS; OPHTHALMIC		CLOBETASOL PROPIONATE					
	+! EYENOVIA	0.05%	N218158	001	Mar 04, 2024	May	CAHN
	+! FORMOSA	0.05%	N218158	001	Mar 04, 2024	Mar	NEWA

CLOCORTOLONE PIVALATE

CREAM; TOPICAL		CLODERM					
AB	+! LEGACY PHARMA	0.1%	N017765	001		Apr	CAHN

CLOFARABINE

SOLUTION; INTRAVENOUS		CLOFARABINE						
>D>	AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Dec	DISC
>A>	@		20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Dec	DISC
>A>	AP	SCINOPHARM TAIWAN	20MG/20ML (1MG/ML)	A216233	001	Jan 03, 2025	Dec	NEWA

CLOMIPHENE CITRATE

TABLET; ORAL		CLOMIPHENE CITRATE					
AB	APPCO	50MG	A216739	001	Nov 08, 2024	Nov	NEWA
AB	! COSETTE	50MG	A075528	001	Aug 30, 1999	Nov	CTEC
AB	RUBICON	50MG	A216545	001	Nov 12, 2024	Nov	NEWA

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

>D>	AB	AJANTA PHARMA LTD	25MG	A213897	001	Oct 02, 2020	Dec	DISC
>A>	@		25MG	A213897	001	Oct 02, 2020	Dec	DISC
>D>	AB		50MG	A213897	002	Oct 02, 2020	Dec	DISC
>A>	@		50MG	A213897	002	Oct 02, 2020	Dec	DISC
>D>	AB		75MG	A213897	003	Oct 02, 2020	Dec	DISC
>A>	@		75MG	A213897	003	Oct 02, 2020	Dec	DISC
>D>	AB	AMNEAL PHARMS CO	25MG	A208632	001	Oct 31, 2018	Dec	DISC
>A>	@		25MG	A208632	001	Oct 31, 2018	Dec	DISC
>D>	AB		50MG	A208632	002	Oct 31, 2018	Dec	DISC
>A>	@		50MG	A208632	002	Oct 31, 2018	Dec	DISC
>D>	AB		75MG	A208632	003	Oct 31, 2018	Dec	DISC
>A>	@		75MG	A208632	003	Oct 31, 2018	Dec	DISC
	AB	CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar	CAHN
	AB		50MG	A074364	002	Mar 29, 1996	Mar	CAHN
	AB		75MG	A074364	003	Mar 29, 1996	Mar	CAHN
	@	MYLAN	25MG	A074947	001	Apr 30, 1998	May	DISC
	@		50MG	A074947	002	Apr 30, 1998	May	DISC
	@		75MG	A074947	003	Apr 30, 1998	May	DISC
	@	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC
	@		50MG	A213221	002	Jun 22, 2020	Mar	DISC
	@		75MG	A213221	003	Jun 22, 2020	Mar	DISC
	AB	TRUPHARMA	25MG	A210653	001	Apr 03, 2020	Sep	CAHN
	AB		50MG	A210653	002	Apr 03, 2020	Sep	CAHN
	AB		75MG	A210653	003	Apr 03, 2020	Sep	CAHN

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB		ENDO OPERATIONS	0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN
AB			0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN
AB			0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN
AB	!		1MG	A077171	004	Aug 03, 2005	Apr	CAHN
AB			2MG	A077171	005	Aug 03, 2005	Apr	CAHN

CLONIDINE

SYSTEM;TRANSDERMAL

CLONIDINE

AB		DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN
AB			0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN
AB			0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN

CLONIDINE HYDROCHLORIDE

SUSPENSION, EXTENDED RELEASE;ORAL

ONYDA XR

+!		TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024	May	NEWA
----	--	-----------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB		TRUPHARMA	0.1MG	A070923	003	Sep 04, 1987	Sep	CAHN
AB			0.2MG	A070923	002	Sep 04, 1987	Sep	CAHN
AB			0.3MG	A070923	001	Sep 04, 1987	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

@	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar	DISC
@	BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN
@	ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN
@		0.1MG	A202984	001	Sep 30, 2013	May	CAHN
@		0.2MG	A202983	002	Apr 02, 2014	May	CAHN
@		0.2MG	A202984	002	Sep 30, 2013	May	CAHN
@	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

@	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC
@		EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC
AB	DR REDDYS LABS LTD	EQ 75MG BASE	A091023	002	Aug 05, 2024	Jul	NEWA
AB	MSN	EQ 75MG BASE	A215388	001	Sep 20, 2024	Sep	NEWA

CLOTRIMAZOLE

	SOLUTION;TOPICAL							
	CLOTRIMAZOLE							
AT	TRUPHARMA	1%	A212281	001	Jul 25, 2019	Aug	CAHN	
	TROCHE/LOZENGE;ORAL							
	CLOTRIMAZOLE							
AB	THINQ PHARM-CRO PVT	10MG	A215641	001	Feb 29, 2024	Feb	NEWA	

CLOZAPINE

	SUSPENSION;ORAL							
	VERSACLOZ							
>A>	+!	DOUGLAS PHARMS	50MG/ML	N203479	001	Feb 06, 2013	Dec	CAHN
>D>	+!	TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013	Dec	CAHN
	TABLET;ORAL							
	CLOZARIL							
	+ @	HERITAGE LIFE	50MG	N019758	003	May 20, 2019	Aug	DISC
	+ @		200MG	N019758	004	May 20, 2019	Aug	DISC
	TABLET, ORALLY DISINTEGRATING;ORAL							
	CLOZAPINE							
>A>	AB	AUROBINDO PHARMA	12.5MG	A212923	001	Dec 12, 2024	Dec	NEWA
>A>	AB		25MG	A212923	002	Dec 12, 2024	Dec	NEWA
>A>	AB		100MG	A212923	003	Dec 12, 2024	Dec	NEWA
>A>	AB		150MG	A212923	004	Dec 12, 2024	Dec	NEWA
>A>	AB		200MG	A212923	005	Dec 12, 2024	Dec	NEWA
>D>		BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Dec	CTEC
>A>	AB		12.5MG	A090308	003	Apr 09, 2018	Dec	CTEC
	AB		150MG	A090308	004	Nov 25, 2015	Jun	CMS1
	AB		200MG	A090308	005	Nov 25, 2015	Jun	CMS1

COBICISTAT

	TABLET;ORAL								
	COBICISTAT								
>D>	AB	MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024	Dec	DISC	
>A>		@	150MG	A209986	001	Feb 07, 2024	Dec	DISC	
	AB		150MG	A209986	001	Feb 07, 2024	Jan	NFTG	
	TYBOST								
>D>	AB	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Dec	CTEC
>A>		+!		150MG	N203094	001	Sep 24, 2014	Dec	CTEC
	AB	+!		150MG	N203094	001	Sep 24, 2014	Jan	CFTG

COCAINE HYDROCHLORIDE

	SOLUTION;NASAL							
	GOPRELTO							
	+!	NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Jan	CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP;ORAL							
	PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
AA	!	GENUS	10MG/5ML;5MG/5ML;6.25MG/5ML	A040660	001	Dec 07, 2006	Apr	CAHN
	PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
	@	HIKMA	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Mar	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

	SYRUP;ORAL							
	PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
	@	HIKMA	10MG/5ML;6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC

COLCHICINE

	CAPSULE;ORAL								
	COLCHICINE								
AB		ANNORA PHARMA	0.6MG	A217620	001	Apr 29, 2024	Apr	NEWA	
AB		AUROBINDO PHARMA LTD	0.6MG	A215463	001	Apr 29, 2024	Apr	NEWA	
AB		GRANULES	0.6MG	A210757	001	Apr 29, 2024	Apr	NEWA	
	TABLET;ORAL								
	COLCHICINE								
AB	!	ENDO OPERATIONS	0.6MG	A203976	001	Aug 12, 2021	May	CHRS	
>D>		@	MYLAN	0.6MG	A209470	001	Sep 16, 2019	Dec	CMFD
>A>	AB		0.6MG	A209470	001	Sep 16, 2019	Dec	CMFD	
		@	0.6MG	A209470	001	Sep 16, 2019	Apr	DISC	

	TABLET;ORAL								
	COLCRYS								
	+ @ TAKEDA PHARMS USA	0.6MG			N022352	001	Jul 29, 2009	May	DISC
	<u>COLESEVELAM HYDROCHLORIDE</u>								
	FOR SUSPENSION;ORAL								
	COLESEVELAM HYDROCHLORIDE								
	@ IMPAX	3.75GM/PACKET			A212886	001	Jan 18, 2023	May	DISC
	<u>COLESTIPOL HYDROCHLORIDE</u>								
	GRANULE;ORAL								
	FLAVORED COLESTID								
	+ @ PFIZER	5GM/PACKET			N017563	001		Jun	DISC
	+ @	5GM/SCOOPFUL			N017563	002		Jun	DISC
	TABLET;ORAL								
	COLESTIPOL HYDROCHLORIDE								
AB	EDENBRIDGE PHARMS	1GM			A217667	001	Aug 16, 2024	Aug	NEWA
AB	RICONPHARMA LLC	1GM			A217462	001	Dec 03, 2024	Nov	NEWA
	<u>COLISTIMETHATE SODIUM</u>								
	INJECTABLE;INJECTION								
	COLISTIMETHATE SODIUM								
AP	ADRASTEIA PHARMA	EQ 150MG BASE/VIAL			A064216	001	Feb 26, 1999	Jul	CAHN
	<u>COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE</u>								
	SUSPENSION/DROPS;OTIC								
	COLY-MYCIN S								
	+! ENDO OPERATIONS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML			N050356	001		Apr	CAHN
	<u>COPPER</u>								
	SYSTEM;INTRAUTERINE								
	PARAGARD T 380A								
	+! COOPERSURGICAL	309MG/COPPER			N018680	001	Nov 15, 1984	Jun	CDFR
	<u>CORTICOTROPIN</u>								
	INJECTABLE;INJECTION								
	ACTHAR GEL								
>D>	@ MALLINCKRODT ARD	40 UNITS/ML			N008372	006		Dec	CAHN
>D>	+!	80 UNITS/ML			N008372	008		Dec	CAHN
>A>	@ MALLINCKRODT IRELAND	40 UNITS/ML			N008372	006		Dec	CAHN
>A>	+!	80 UNITS/ML			N008372	008		Dec	CAHN
	ACTHAR GEL (AUTOINJECTOR)								
>D>	+! MALLINCKRODT ARD	40 UNITS/0.5ML			N008372	003	Feb 29, 2024	Dec	CAHN
	+!	40 UNITS/0.5ML			N008372	003	Feb 29, 2024	Mar	NEWA
>D>	+!	80 UNITS/ML			N008372	004	Feb 29, 2024	Dec	CAHN
	+!	80 UNITS/ML			N008372	004	Feb 29, 2024	Mar	NEWA
>A>	+! MALLINCKRODT IRELAND	40 UNITS/0.5ML			N008372	003	Feb 29, 2024	Dec	CAHN
>A>	+!	80 UNITS/ML			N008372	004	Feb 29, 2024	Dec	CAHN
	<u>COSYNTROPIN</u>								
	INJECTABLE;INJECTION								
	COSYNTROPIN								
	@ MYLAN INSTITUTIONAL	0.25MG/VIAL			A090574	001	Dec 17, 2009	May	DISC
	@ NORVIUM BIOSCIENCE	0.25MG/VIAL			A090574	001	Dec 17, 2009	Oct	CAHN
>A>	<u>CRINECEFONTE</u>								
>A>	CAPSULE;ORAL								
>A>	CRENESSITY								
>A>	+ NEUROCRINE	25MG			N218808	001	Dec 13, 2024	Dec	NEWA
>A>	+	50MG			N218808	002	Dec 13, 2024	Dec	NEWA
>A>	+!	100MG			N218808	003	Dec 13, 2024	Dec	NEWA
>A>	SOLUTION;ORAL								
>A>	CRENESSITY								
>A>	+! NEUROCRINE	50MG/ML			N218820	001	Dec 13, 2024	Dec	NEWA

CUPRIC CHLORIDE

INJECTABLE; INJECTION
CUPRIC CHLORIDE

AP	RK PHARMA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	May	CAHN
AP	SOMERSET	EQ 0.4MG COPPER/ML	A216113	001	Apr 30, 2024	Apr	NEWA
AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr	NEWA

CUPRIC SULFATE

INJECTABLE; INJECTION
CUPRIC SULFATE

AP	! AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Aug	CTEC
AP	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Aug	NEWA

CYANOCOBALAMIN

GEL, METERED; NASAL
NASCOBAL

	@ ENDO OPERATIONS	0.5MG/INH	N019722	001	Nov 05, 1996	May	CAHN
--	-------------------	-----------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
CYANOCOBALAMIN

	@ EUGIA PHARMA	1MG/ML	A213874	001	Dec 08, 2020	Jun	DISC
AP	MANKIND PHARMA	1MG/ML	A217839	001	Jul 10, 2024	Jun	NEWA
AP	NANJING KING-FRIEND	1MG/ML	A214316	001	Nov 15, 2024	Nov	NEWA

SPRAY, METERED; NASAL
CALOMIST

	@ ENDO OPERATIONS	25MCG/SPRAY	N022102	001	Jul 27, 2007	May	CAHN
--	-------------------	-------------	---------	-----	--------------	-----	------

AB	! PADAGIS ISRAEL	0.5MG/SPRAY	A212458	001	Sep 09, 2020	Jul	CHRS
----	------------------	-------------	---------	-----	--------------	-----	------

NASCOBAL

	+ @ ENDO OPERATIONS	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Jul	DISC
--	---------------------	-------------	---------	-----	--------------	-----	------

AB	+!	0.5MG/SPRAY	N021642	001	Jan 31, 2005	May	CAHN
----	----	-------------	---------	-----	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	15MG	A207314	001	Jul 22, 2024	Jul	NEWA
AB		30MG	A207314	002	Jul 22, 2024	Jul	NEWA
AB	NOVAST LABS	15MG	A214732	001	Aug 27, 2024	Aug	NEWA
AB		30MG	A214732	002	Aug 27, 2024	Aug	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

	@ AIPING PHARM INC	5MG	A072854	002	Feb 03, 2006	Jun	CAHN
	@	10MG	A072854	001	Nov 19, 1991	Jun	CAHN
AB	GRAVITI PHARMS	5MG	A218936	001	Sep 12, 2024	Sep	NEWA
AB		7.5MG	A218936	002	Sep 12, 2024	Sep	NEWA
AB		10MG	A218936	003	Sep 12, 2024	Sep	NEWA

CYCLOPHOSPHAMIDE

CAPSULE; ORAL
CYCLOPHOSPHAMIDE

AB	KANCHAN HLTHCARE	25MG	A209872	001	May 07, 2018	Aug	CAHN
AB		50MG	A209872	002	May 07, 2018	Aug	CAHN
AB	NEXTSOURCE	25MG	A218282	001	Dec 03, 2024	Nov	NEWA
AB		50MG	A218282	002	Dec 03, 2024	Nov	NEWA

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

>A>	AP	EPIC PHARMA LLC	500MG/VIAL	A218644	001	Dec 19, 2024	Dec	NEWA
>A>	AP		1GM/VIAL	A218644	002	Dec 19, 2024	Dec	NEWA
>A>	AP		2GM/VIAL	A218644	003	Dec 19, 2024	Dec	NEWA
>A>	AP	HAINAN POLY	500MG/VIAL	A218632	001	Dec 26, 2024	Dec	NEWA
>A>	AP		1GM/VIAL	A218632	002	Dec 26, 2024	Dec	NEWA
>A>	AP		2GM/VIAL	A218632	003	Dec 26, 2024	Dec	NEWA
	AP	HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN
	AP		1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN
	AP		2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN

SOLUTION; INTRAVENOUS
CYCLOPHOSPHAMIDE

	+	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun	CAHN
	+		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun	CAHN
	+		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun	CAHN
	+	BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Oct	CMFD
	+	@	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN

SOLUTION; INTRAVENOUS
CYCLOPHOSPHAMIDE

	+		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Oct	CMFD
	+	@	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN
AP	+	DR REDDYS	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Oct	CFTG
	+		500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jun	CAHN
AP	+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Oct	CFTG
	+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jun	CAHN
	+		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021	Jun	CAHN
AP		NEXUS	500MG/2.5ML (200MG/ML)	A216783	001	Oct 29, 2024	Oct	NFTG
AP			1GM/5ML (200MG/ML)	A216783	002	Oct 29, 2024	Oct	NFTG

CYCLOSERINE

CAPSULE; ORAL
SEROMYCIN

!	SANALUZ	250MG		A060593	001		Sep	CAHN
---	---------	-------	--	---------	-----	--	-----	------

CYCLOSPORINE

EMULSION; OPHTHALMIC
CYCLOSPORINE

AB		DEVA HOLDING AS	0.05%	A209811	001	May 21, 2024	May	NEWA
AB		SAPTALIS PHARMS	0.05%	A211943	001	Jul 05, 2024	Jun	NEWA
AB		TEVA PHARMS USA INC	0.05%	A203880	001	Dec 14, 2023	Oct	CMFD
	@		0.05%	A203880	001	Dec 14, 2023	Jun	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HYDROCHLORIDE

	@	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC
	@	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC
AA	!	RISING	2MG/5ML	A040668	001	Jun 28, 2006	Sep	CAHN

TABLET; ORAL
CYPROHEPTADINE HYDROCHLORIDE

@	CHARTWELL RX	4MG		A086808	001		Aug	CAHN
---	--------------	-----	--	---------	-----	--	-----	------

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS
ELCYS

+	@	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC
---	---	--------------	-----------------------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL
DABIGATRAN ETEXILATE MESYLATE

AB		ALEMBIC	EQ 75MG BASE	A215233	001	Jun 14, 2024	Jun	NEWA
AB			EQ 110MG BASE	A215233	003	Aug 12, 2024	Aug	NEWA
AB			EQ 150MG BASE	A215233	002	Jun 14, 2024	Jun	NEWA
AB		ALKEM LABS LTD	EQ 110MG BASE	A208040	003	Sep 11, 2024	Aug	NEWA
>A>	AB	BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024	Dec	NEWA
>A>	AB		EQ 110MG BASE	A207922	003	Dec 19, 2024	Dec	NEWA
>A>	AB		EQ 150MG BASE	A207922	002	Dec 19, 2024	Dec	NEWA
AB		HETERO LABS LTD III	EQ 110MG BASE	A207961	003	Aug 13, 2024	Aug	NEWA
AB		MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
AB			EQ 110MG BASE	A213879	003	Aug 12, 2024	Aug	NEWA
AB			EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

+	@	RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC
AP	!	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS
SYNERCID

+	@	KING PHARMS	350MG/VIAL; 150MG/VIAL	N050748	001	Sep 21, 1999	Sep	DISC
---	---	-------------	------------------------	---------	-----	--------------	-----	------

DANICOPAN

TABLET; ORAL
VOYDEYA

	+	ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
	+	!	100MG	N218037	002	Mar 29, 2024	Mar	NEWA

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

	@	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Aug	CAHN
--	---	---------------	------	---------	-----	--------------	-----	------

DAPSONE

GEL; TOPICAL
DAPSONE

AB		ACRUX DDS	7.5%	A213636	001	Aug 26, 2024	Aug	NEWA
	@	PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
	@		7.5%	A212657	001	Nov 01, 2023	Jan	DISC
AB		TARO	5%	A209506	001	Oct 16, 2017	Jun	CAHN
AB		TRUPHARMA	5%	A213907	001	Jun 06, 2023	Sep	CAHN
AB			7.5%	A213636	001	Aug 26, 2024	Sep	CAHN
AB		ZYDUS	7.5%	A214019	001	May 08, 2024	Apr	NEWA
AB		ZYDUS LIFESCIENCES	7.5%	A214019	001	May 08, 2024	May	CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS
DAPTOMYCIN

AP		BIOCON PHARMA	500MG/VIAL	A217215	001	Aug 29, 2024	Aug	NEWA
AP		FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jul	NEWA
>A>	+	!	350MG/VIAL	N209949	001	Oct 20, 2017	Dec	CAHN
>A>	+	!	350MG/VIAL	N217415	001	Jan 30, 2023	Dec	CAHN
>A>	+	!	500MG/VIAL	N217415	002	Jan 30, 2023	Dec	CAHN
	+	!	350MG/VIAL	N217630	001	Nov 21, 2024	Nov	NEWA
	+	!	500MG/VIAL	N217630	002	Nov 21, 2024	Nov	NEWA
>D>	+	!	350MG/VIAL	N209949	001	Oct 20, 2017	Dec	CAHN
>D>	+	!	350MG/VIAL	N217415	001	Jan 30, 2023	Dec	CAHN
>D>	+	!	500MG/VIAL	N217415	002	Jan 30, 2023	Dec	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

	@	ENDO OPERATIONS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	May	CAHN
	@		EQ 15MG BASE	A091190	002	Mar 13, 2015	May	CAHN

DARUNAVIR

TABLET; ORAL
DARUNAVIR

AB		ZYDUS LIFESCIENCES	600MG	A214085	001	Dec 13, 2023	May	CAHN
AB			800MG	A214085	002	Dec 13, 2023	May	CAHN

DASATINIB

TABLET; ORAL
DASATINIB

AB		APOTEX	20MG	A202103	001	Jun 10, 2016	Aug	CMFD
AB			50MG	A202103	002	Jun 10, 2016	Aug	CMFD
AB			70MG	A202103	003	Jun 10, 2016	Aug	CMFD
AB			80MG	A203180	001	Nov 23, 2021	Aug	CMFD
AB			100MG	A202103	004	Jun 10, 2016	Aug	CMFD
AB			140MG	A203180	002	Nov 23, 2021	Aug	CMFD
		SPRYCEL						
AB	+	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	Aug	CTEC
AB	+		50MG	N021986	002	Jun 28, 2006	Aug	CTEC
AB	+		70MG	N021986	003	Jun 28, 2006	Aug	CTEC
AB	+		80MG	N021986	005	Oct 28, 2010	Aug	CTEC
AB	+	!	100MG	N021986	004	May 30, 2008	Aug	CTEC
AB	+		140MG	N021986	006	Oct 28, 2010	Aug	CTEC

DECITABINE

INJECTABLE; INTRAVENOUS
DECITABINE

AP HETERO LABS LTD VI 50MG/VIAL A215355 001 May 10, 2024 May NEWA

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB GLENMARK SPECLT 125MG A209433 001 Jan 06, 2020 May CAHN
 AB 250MG A209433 002 Jan 06, 2020 May CAHN
 AB 500MG A209433 003 Jan 06, 2020 May CAHN
 AB TEVA PHARMS USA 125MG A207124 001 Sep 23, 2022 Jul CMFD
 AB 250MG A207124 002 Sep 23, 2022 Jul CMFD
 AB 500MG A207124 003 Sep 23, 2022 Jul CMFD
 AB TORRENT 125MG A209426 001 Nov 05, 2024 Oct NEWA
 AB 250MG A209426 002 Nov 05, 2024 Oct NEWA
 AB 500MG A209426 003 Nov 05, 2024 Oct NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

>A> AP HIKMA 500MG/VIAL A078086 001 May 30, 2007 Dec CAHN
 >A> AP 2GM/VIAL A078086 002 May 30, 2007 Dec CAHN
 >D> AP WEST-WARD PHARMS INT 500MG/VIAL A078086 001 May 30, 2007 Dec CAHN
 >D> AP 2GM/VIAL A078086 002 May 30, 2007 Dec CAHN

DEFLAZACORT

SUSPENSION; ORAL
DEFLAZACORT

AB TRIS PHARMA INC 22.75MG/ML A217813 001 Apr 25, 2024 Apr NFTG
 EMFLAZA
 AB +! PTC THERAP 22.75MG/ML N208685 001 Feb 09, 2017 Apr CFTG
 TABLET; ORAL
 DEFLAZACORT
 AB AUROBINDO PHARMA LTD 6MG A217123 001 Feb 09, 2024 Feb NFTG
 AB 18MG A217123 002 Feb 09, 2024 Feb NFTG
 AB 30MG A217123 003 Feb 09, 2024 Feb NFTG
 AB 36MG A217123 004 Feb 09, 2024 Feb NFTG
 AB UPSHER SMITH LABS 6MG A216720 001 Nov 05, 2024 Oct NEWA
 AB 18MG A216720 002 Nov 05, 2024 Oct NEWA
 AB 30MG A216720 003 Nov 05, 2024 Oct NEWA
 AB 36MG A216720 004 Nov 05, 2024 Oct NEWA
 EMFLAZA
 AB + PTC THERAP 6MG N208684 001 Feb 09, 2017 Feb CFTG
 AB + 18MG N208684 002 Feb 09, 2017 Feb CFTG
 AB + 30MG N208684 003 Feb 09, 2017 Feb CFTG
 AB +! 36MG N208684 004 Feb 09, 2017 Feb CFTG

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS
DEOXYCHOLIC ACID

AP WILSHIRE PHARMS INC 20MG/2ML (10MG/ML) A212296 001 Apr 02, 2021 Jul CAHN
 KYBELLA
 AP +! ABBVIE 20MG/2ML (10MG/ML) N206333 001 Apr 29, 2015 Jan CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB CHARTWELL RX 10MG A072103 002 May 24, 1988 Mar CAHN
 AB 25MG A072103 003 May 24, 1988 Mar CAHN
 AB 50MG A072103 004 May 24, 1988 Mar CAHN
 AB 75MG A072103 005 Jun 20, 1988 Mar CAHN
 AB 100MG A072103 001 Jun 20, 1988 Mar CAHN
 AB 150MG A072103 006 Jun 20, 1988 Mar CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

@ CHARTWELL RX 5MG A078364 001 Dec 03, 2010 Jan CAHN

DESMOPRESSIN ACETATE

	INJECTABLE; INJECTION							
	DESMOPRESSIN ACETATE							
	@ SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Oct	DISC	
	TABLET; ORAL							
	DESMOPRESSIN ACETATE							
	@ ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005	Feb	DISC	
	@	0.2MG	A076470	002	Jul 01, 2005	Feb	DISC	
AB	AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar	NEWA	
AB		0.2MG	A213095	002	Mar 21, 2024	Mar	NEWA	

DESOGESTREL; ETHINYL ESTRADIOL

	TABLET; ORAL-28							
	DESOGESTREL AND ETHINYL ESTRADIOL							
AB	NAARI PTE LTD	0.15MG; 0.03MG	A207067	001	Sep 13, 2018	Apr	CMFD	
	@ XIROMED	0.15MG; 0.03MG	A202085	001	May 20, 2015	Apr	CAHN	
	EMOQUETTE							
	@ ENDO OPERATIONS	0.15MG; 0.03MG	A076675	001	Feb 25, 2011	May	CAHN	
	KIMIDESS							
	@ ENDO OPERATIONS	0.15MG, N/A; 0.02MG, 0.01MG	A076681	001	Apr 30, 2015	Aug	DISC	
AB		0.15MG, N/A; 0.02MG, 0.01MG	A076681	001	Apr 30, 2015	May	CAHN	

DESONIDE

	OINTMENT; TOPICAL							
	DESONIDE							
	@ HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar	DISC	

DESOXIMETASONE

	CREAM; TOPICAL							
	DESOXIMETASONE							
	@ COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar	DISC	
	OINTMENT; TOPICAL							
	DESOXIMETASONE							
	@ COSETTE	0.25%	A206740	001	Dec 23, 2016	Apr	DISC	

DESVENLAFAXINE SUCCINATE

	TABLET, EXTENDED RELEASE; ORAL							
	DESVENLAFAXINE SUCCINATE							
	@ NORVIUM BIOSCIENCE	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	CAHN	
	@	EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	CAHN	

DEURUXOLITINIB PHOSPHATE

	TABLET; ORAL							
	LEQSELVI							
	+! SUN PHARM INDS INC	EQ 8MG BASE	N217900	001	Jul 25, 2024	Jul	NEWA	

DEUTETRABENAZINE

	TABLET; ORAL							
	AUSTEDO							
>D>	+ TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Dec	CFTG	
>A> AB	+	6MG	N208082	001	Apr 03, 2017	Dec	CFTG	
>D>	+	9MG	N208082	002	Apr 03, 2017	Dec	CFTG	
>A> AB	+	9MG	N208082	002	Apr 03, 2017	Dec	CFTG	
>D>	+!	12MG	N208082	003	Apr 03, 2017	Dec	CFTG	
>A> AB	+!	12MG	N208082	003	Apr 03, 2017	Dec	CFTG	
>A>	DEUTETRABENAZINE							
>A> AB	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Dec	NFTG	
>A> AB		9MG	A215971	002	Dec 26, 2024	Dec	NFTG	
>A> AB		12MG	A215971	003	Dec 26, 2024	Dec	NFTG	
	TABLET, EXTENDED RELEASE; ORAL							
	AUSTEDO XR							
	+ TEVA	18MG	N216354	008	Jul 01, 2024	Jul	NEWA	
	+	30MG	N216354	004	May 29, 2024	May	NEWA	
	+	36MG	N216354	005	May 29, 2024	May	NEWA	
	+	42MG	N216354	006	May 29, 2024	May	NEWA	
	+	48MG	N216354	007	May 29, 2024	Oct	CRLD	
		48MG	N216354	007	May 29, 2024	May	NEWA	

>A> DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM

>A> TABLET; ORAL

>A> ALYFTREK

>A>	+	VERTEX PHARMS INC	50MG;20MG;EQ 4MG BASE	N218730	001	Dec 20, 2024	Dec	NEWA
>A>	+	!	125MG;50MG;EQ 10MG BASE	N218730	002	Dec 20, 2024	Dec	NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	!	KANCHAN HLTHCARE	0.5MG/5ML	A084754	001		Aug	CAHN
AA		RISING	0.5MG/5ML	A090891	001	Jul 12, 2011	Sep	CAHN

TABLET; ORAL

DEXAMETHASONE

	@	ABRAXEOLUS	0.25MG	A088149	001	Apr 28, 1983	Sep	CAHN
AB		COREPHARMA	0.5MG	A218372	001	Sep 17, 2024	Sep	NEWA
AB			0.75MG	A218372	002	Sep 17, 2024	Sep	NEWA
AB			1MG	A218372	003	Sep 17, 2024	Sep	NEWA
AB			1.5MG	A218372	004	Sep 17, 2024	Sep	NEWA
AB			2MG	A218372	005	Sep 17, 2024	Sep	NEWA
AB			4MG	A218372	006	Sep 17, 2024	Sep	NEWA
AB			6MG	A218372	007	Sep 17, 2024	Sep	NEWA
	@	KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	May	DISC
BP			1.5MG	A088237	001	Apr 28, 1983	Apr	CAHN
	@	PANGEA	0.25MG	A088149	001	Apr 28, 1983	Nov	CAHN
	@		0.25MG	A088149	001	Apr 28, 1983	Jan	CAHN
AB		ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar	CAHN
AB			0.75MG	A216282	002	Feb 07, 2024	Mar	CAHN
AB			1MG	A216284	001	May 09, 2024	May	CAHN
AB			1.5MG	A216282	003	Feb 07, 2024	Mar	CAHN
AB			2MG	A216283	001	Feb 07, 2024	Mar	CAHN
AB			4MG	A216282	004	Feb 07, 2024	Mar	CAHN
AB			6MG	A216282	005	Feb 07, 2024	Mar	CAHN
AB		ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA
AB			0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
AB			1MG	A216284	001	May 09, 2024	May	NEWA
AB			1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
AB			2MG	A216283	001	Feb 07, 2024	Jan	NEWA
AB			4MG	A216282	004	Feb 07, 2024	Jan	NEWA
AB			6MG	A216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@	GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214890	002	Jul 28, 2023	Jul	CMS1
	@		EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
AP		HIKMA	EQ 4MG PHOSPHATE/ML	A084282	001		Jun	CAHN
	@		EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul	DISC
AP	!		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Jun	CAHN
AP		MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar	NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+	@ PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar	DISC
	!	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CTEC
AA	!		2MG/5ML	A202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXLANSOPRAZOLE

AB		MYLAN	30MG	A205205	001	Jan 19, 2024	Jan	NEWA
AB			60MG	A205205	002	Jan 19, 2024	Jan	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

	@	WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791	003	May 08, 2020	Jul	CAHN
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212791	001	Dec 04, 2019	Jul	CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG)	A212791	002	Dec 04, 2019	Jul	CAHN

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE BASE/ML)		SOLUTION; INTRAVENOUS DEXMEDETOMIDINE HYDROCHLORIDE	
AP	+! HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628 002 Oct 21, 2015 Sep CFTG
AP	+	EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628 001 Oct 21, 2015 Sep CFTG
AP	SOMERSET	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	A218112 002 Sep 24, 2024 Sep NFTG
AP		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	A218112 001 Sep 24, 2024 Sep NFTG

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL DEXEDRINE SPANSULE		TABLET; ORAL DEXTROAMPHETAMINE SULFATE	
AB	+ IMPAX LABS INC	5MG	N017078 001 Aug CTNA
AB	+	10MG	N017078 002 Aug CTNA
AB	+!	15MG	N017078 003 Aug CTNA
	@ NORVIUM BIOSCIENCE	5MG	A206735 001 Jan 27, 2016 Jun CAHN
	@	10MG	A206735 002 Jan 27, 2016 Jun CAHN
	@	15MG	A206735 003 Jan 27, 2016 Jun CAHN
AA	AZURITY	2.5MG	A090533 001 Oct 25, 2011 Mar CAHN
AA		5MG	A090533 002 Oct 25, 2011 Mar CAHN
AA		7.5MG	A090533 003 Oct 25, 2011 Mar CAHN
AA		10MG	A090533 004 Oct 25, 2011 Mar CAHN
AA		15MG	A090533 005 Oct 25, 2011 Mar CAHN
AA		20MG	A090533 006 Oct 25, 2011 Mar CAHN
AA		30MG	A090533 007 Oct 25, 2011 Mar CAHN
	@ TRIS PHARMA INC	5MG	A206095 001 Aug 18, 2022 Jan DISC
	@	10MG	A206095 002 Aug 18, 2022 Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE		
AA	+ ANI PHARMS 15MG/5ML; 6.25MG/5ML	N011265 002 Apr 02, 1984 Sep CMFD

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE		
AB	HETERO LABS LTD III 20MG; 10MG	A218426 001 Aug 28, 2024 Aug NEWA

DEXTROSE

INJECTABLE; INJECTION DEXTROSE 5%		
	@ AM REGENT 50MG/ML	A217263 001 Apr 08, 2024 Nov DISC
AP		A217263 001 Apr 08, 2024 Apr CTNA
AP		A217263 001 Apr 08, 2024 Mar NEWA

DIAZEPAM

FILM; BUCCAL LIBERVANT		INJECTABLE; INJECTION DIAZEPAM	
	+ AQUESTIVE 5MG	N218623 001 Apr 26, 2024 Apr NEWA	
	+ 7.5MG	N218623 002 Apr 26, 2024 Apr NEWA	
	+ 10MG	N218623 003 Apr 26, 2024 Apr NEWA	
	+ 12.5MG	N218623 004 Apr 26, 2024 Apr NEWA	
	+! 15MG	N218623 005 Apr 26, 2024 Apr NEWA	
AP	ALEMBIC 10MG/2ML (5MG/ML)	A218450 001 Apr 25, 2024 Apr NEWA	
AP	DR REDDYS 10MG/2ML (5MG/ML)	A218422 001 Jul 18, 2024 Jul NEWA	
	@ HIKMA 5MG/ML (5MG/ML)	A070311 002 Dec 16, 1985 Jan NEWA	
	@ 10MG/2ML (5MG/ML)	A070311 003 Dec 16, 1985 Jan NEWA	
AP		A070311 001 Dec 16, 1985 Jan CPOT	
>A> AP	LONG GROVE PHARMS 10MG/2ML (5MG/ML)	A217178 001 Dec 31, 2024 Dec NEWA	
TABLET; ORAL DIAZEPAM			
	@ ENDO OPERATIONS 2MG	A070228 002 Sep 26, 1985 May CAHN	
	@ 5MG	A070228 003 Sep 26, 1985 May CAHN	

TABLET;ORAL							
DIAZEPAM							
	@		10MG	A070228	001	Sep 26, 1985	May CAHN
AB		NUVO PHARM	2MG	A070464	002	Sep 10, 2024	Aug NEWA
AB			5MG	A070464	003	Sep 10, 2024	Aug NEWA
<u>DICHLORPHENAMIDE</u>							
TABLET;ORAL							
ORMALVI							
AB		TORRENT	50MG	A215924	001	Dec 29, 2022	Feb CTNA
<u>DICLOFENAC POTASSIUM</u>							
FOR SOLUTION;ORAL							
DICLOFENAC POTASSIUM							
AB		ENDO OPERATIONS	50MG	A202964	001	May 02, 2016	May CAHN
AB		TARO	50MG	A218011	001	Jun 14, 2024	Jun NEWA
TABLET;ORAL							
CATAFLAM							
AB		AMICI PHARMA	25MG	A076561	002	Jul 21, 2021	Oct CAHN
AB			50MG	A076561	001	Mar 18, 2004	Oct CAHN
<u>DICLOFENAC SODIUM</u>							
SOLUTION;TOPICAL							
DICLOFENAC SODIUM							
AB	!	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Mar CHRS
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>							
TABLET, DELAYED RELEASE;ORAL							
DICLOFENAC SODIUM AND MISOPROSTOL							
	@	SANDOZ	50MG;0.2MG	A200158	001	May 09, 2013	Jul DISC
	@		75MG;0.2MG	A200158	002	May 09, 2013	Jul DISC
<u>DICLOXACILLIN SODIUM</u>							
CAPSULE;ORAL							
DICLOXACILLIN SODIUM							
	@	CHARTWELL RX	EQ 125MG BASE	A061454	002		Jul CAHN
	@		EQ 250MG BASE	A061454	001		Jul CAHN
	@		EQ 500MG BASE	A061454	003		Jul CAHN
<u>DICYCLOMINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
DICYCLOMINE HYDROCHLORIDE							
AB		ANNORA PHARMA	10MG	A218018	001	Jul 01, 2024	Jun NEWA
INJECTABLE;INJECTION							
BENTYL							
	+	@ ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Apr DISC
DICYCLOMINE HYDROCHLORIDE							
AP	!	FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Apr CHRS
AP		SOMERSET THERAPS LLC	10MG/ML	A214332	001	Nov 01, 2024	Oct NEWA
AP			10MG/ML	A214333	001	Nov 01, 2024	Oct NEWA
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)							
AP	!	HIKMA	10MG/ML	A040465	001	Jun 30, 2003	Aug CHRS
SYRUP;ORAL							
DICYCLOMINE HYDROCHLORIDE							
AA	!	ENDO OPERATIONS	10MG/5ML	A040169	001	Mar 24, 2005	Apr CAHN
TABLET;ORAL							
DICYCLOMINE HYDROCHLORIDE							
AB		ANNORA PHARMA	20MG	A217566	001	May 07, 2024	Apr NEWA
AB		RISING	20MG	A218952	001	Nov 15, 2024	Nov NEWA
<u>DIFLORASONE DIACETATE</u>							
CREAM;TOPICAL							
DIFLORASONE DIACETATE							
	@	ANI PHARMS	0.05%	A076263	001	Dec 20, 2002	Sep DISC
OINTMENT;TOPICAL							
DIFLORASONE DIACETATE							
	@	SAPTALIS PHARMS	0.05%	A206572	001	Jul 24, 2015	Jun CAHN
	@	SCIEGEN PHARMS INC	0.05%	A206572	001	Jul 24, 2015	Aug CAHN

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

HERITAGE PHARMA	250MG	A202845	002	Aug 16, 2024	Aug	NEWA
	375MG	A202845	003	Aug 16, 2024	Aug	NFTG

DIFLUPREDNATE

EMULSION; OPHTHALMIC
DIFLUPREDNATE

>A> AB	CAPLIN	0.05%	A219441	001	Dec 13, 2024	Dec	NEWA
AB	EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May	NEWA

DIGOXIN

ELIXIR; ORAL
DIGOXIN

AA	AMICI PHARMA	0.05MG/ML	A215209	001	Mar 11, 2022	Oct	CAHN
AA	VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN

INJECTABLE; INJECTION
DIGOXIN

AP	HIKMA	0.25MG/ML	A083391	001		Jun	CAHN
----	-------	-----------	---------	-----	--	-----	------

TABLET; ORAL

DIGOXIN

>D> AB	IMPAX LABS	0.125MG	A078556	001	Jul 20, 2009	Dec	DISC
>A>	@	0.125MG	A078556	001	Jul 20, 2009	Dec	DISC
>D> AB		0.25MG	A078556	002	Jul 20, 2009	Dec	DISC
>A>	@	0.25MG	A078556	002	Jul 20, 2009	Dec	DISC

LANOXIN

>A> AB	+	ADVANZ PHARMA	0.0625MG	N020405	001	Sep 30, 1997	Dec	CAHN
>A> AB	+		0.125MG	N020405	002	Sep 30, 1997	Dec	CAHN
>A>	+	@	0.1875MG	N020405	003	Sep 30, 1997	Dec	CAHN
>A> AB	+	!	0.25MG	N020405	004	Sep 30, 1997	Dec	CAHN
>A>	@		0.375MG	N020405	005	Sep 30, 1997	Dec	CAHN
>A>	@		0.5MG	N020405	006	Sep 30, 1997	Dec	CAHN
>D> AB	+	CONCORDIA	0.0625MG	N020405	001	Sep 30, 1997	Dec	CAHN
>D> AB	+		0.125MG	N020405	002	Sep 30, 1997	Dec	CAHN
>D>	+	@	0.1875MG	N020405	003	Sep 30, 1997	Dec	CAHN
>D> AB	+	!	0.25MG	N020405	004	Sep 30, 1997	Dec	CAHN
>D>	@		0.375MG	N020405	005	Sep 30, 1997	Dec	CAHN
>D>	@		0.5MG	N020405	006	Sep 30, 1997	Dec	CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION
DIHYDROERGOTAMINE MESYLATE

>A> AP	BAXTER HLTHCARE CORP	1MG/ML	A216747	001	Jan 07, 2025	Dec	NEWA
AP	CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Sep	NEWA

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

@	AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC
+	!	IMPEL PHARMS	N213436	001	Sep 02, 2021	Jun	CAHN
+	!	JN BIDCO	N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

AB3	ALEMBIC	120MG	A216968	001	Nov 08, 2024	Nov	NEWA
AB2		120MG	A218587	001	Oct 18, 2024	Oct	NEWA
AB3		180MG	A216968	002	Nov 08, 2024	Nov	NEWA
AB2		180MG	A218587	002	Oct 18, 2024	Oct	NEWA
AB3		240MG	A216968	003	Nov 08, 2024	Nov	NEWA
AB2		240MG	A218587	003	Oct 18, 2024	Oct	NEWA
AB3		300MG	A216968	004	Nov 08, 2024	Nov	NEWA
AB3		360MG	A216968	005	Nov 08, 2024	Nov	NEWA
AB4	CHARTWELL RX	120MG	A091022	001	Sep 28, 2012	Nov	CAHN
AB4		180MG	A091022	002	Sep 28, 2012	Nov	CAHN
AB4		240MG	A091022	003	Sep 28, 2012	Nov	CAHN
AB4		300MG	A091022	004	Sep 28, 2012	Nov	CAHN
AB4		360MG	A091022	005	Sep 28, 2012	Nov	CAHN
AB4		420MG	A091022	006	Sep 28, 2012	Nov	CAHN
AB3	ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN
AB3		180MG	A074984	002	Dec 20, 1999	Apr	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB3		240MG	A074984	003	Dec 20, 1999	Apr	CAHN
AB3		300MG	A074984	004	Dec 20, 1999	Apr	CAHN
	@	360MG	A209766	001	May 30, 2018	May	CAHN
	@ SUN PHARM	120MG	A090421	001	Nov 15, 2010	Nov	DISC
	@	180MG	A090421	002	Nov 15, 2010	Nov	DISC
	@	240MG	A090421	003	Nov 15, 2010	Nov	DISC
	@	300MG	A090421	004	Nov 15, 2010	Nov	DISC
	@	360MG	A090421	005	Nov 15, 2010	Nov	DISC
	@	360MG	A090492	005	Oct 28, 2011	Feb	DISC
AB2	UTOPIC PHARMS	120MG	A216304	001	Aug 08, 2022	Sep	CAHN
AB2		180MG	A216304	002	Aug 08, 2022	Sep	CAHN
AB2		240MG	A216304	003	Aug 08, 2022	Sep	CAHN
	TAZTIA XT						
	@ ACTAVIS LABS FL INC	120MG	A075401	001	Apr 10, 2003	Jul	DISC
	@	180MG	A075401	002	Apr 10, 2003	Jul	DISC
	@	240MG	A075401	003	Apr 10, 2003	Jul	DISC
	@	300MG	A075401	004	Apr 10, 2003	Jul	DISC
	@	360MG	A075401	005	Apr 10, 2003	Jul	DISC

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP	HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN
	@ HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB	MACLEODS PHARMS LTD	120MG	A210377	001	Jun 26, 2024	Jun	NEWA
AB		240MG	A210377	002	Jun 26, 2024	Jun	NEWA
>A> AB	TORRENT	120MG	A210390	001	Jan 06, 2025	Dec	NEWA
>A> AB		240MG	A210390	002	Jan 06, 2025	Dec	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA
	@ HIKMA	50MG/ML	A083183	001		Jun	CAHN
AP	! MYLAN INSTITUTIONAL	50MG/ML	A040498	001	Jul 12, 2005	May	CHRS

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

	@ CHARTWELL RX	25MG	A040898	001	Apr 23, 2008	Aug	CAHN
	@	50MG	A040898	002	Apr 23, 2008	Aug	CAHN
	@	75MG	A040898	003	Apr 23, 2008	Aug	CAHN
	@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
	@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN
	@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN
AB	! IMPAX LABS	75MG	A040782	003	Jul 18, 2007	May	CHRS
	PERSANTINE						
	+ @ BOEHRINGER INGELHEIM	25MG	N012836	003	Dec 22, 1986	May	DISC
	+ @	50MG	N012836	004	Feb 06, 1987	May	DISC
	+ @	75MG	N012836	005	Feb 06, 1987	May	DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

>A> AB	ALEMBIC	EQ 125MG VALPROIC ACID	A218793	001	Dec 19, 2024	Dec	NEWA
--------	---------	------------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

	@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008	May	CAHN
	@ NORVIUM BIOSCIENCE	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jun	CAHN
	@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jun	CAHN
	@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

	@ ENDO OPERATIONS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009	May	CAHN
	@	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009	May	CAHN
	@ UTOPIC PHARMS	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Sep	CAHN
	@	EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Sep	CAHN

DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

AP SLATE RUN PHARMA EQ 12.5MG BASE/ML A216131 001 Dec 21, 2022 Sep CAHN

DOCETAXELINJECTABLE; INJECTION
DOCETAXEL

AP ACIC PHARMS 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Feb NEWA
 AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Feb NEWA
 AP HERITAGE 80MG/4ML (20MG/ML) A216677 002 Feb 28, 2024 Sep CAHN
 AP 160MG/8ML (20MG/ML) A216677 003 Nov 26, 2024 Nov NEWA
 AP 20MG/ML (20MG/ML) A216677 001 Feb 28, 2024 Sep CAHN
 @ NORVIUM BIOSCIENCE 20MG/ML (20MG/ML) A203892 001 May 11, 2023 Jun CAHN
 @ 80MG/4ML (20MG/ML) A203892 002 May 11, 2023 Jun CAHN
 >D> AP SUN PHARM 20MG/ML (20MG/ML) N022534 003 Jan 08, 2019 Dec DISC
 >A> @ 20MG/ML (20MG/ML) N022534 003 Jan 08, 2019 Dec DISC
 >D> AP 80MG/4ML (20MG/ML) N022534 004 Jan 08, 2019 Dec DISC
 >A> @ 80MG/4ML (20MG/ML) N022534 004 Jan 08, 2019 Dec DISC
 >D> AP 160MG/8ML (20MG/ML) N022534 005 Jan 08, 2019 Dec DISC
 >A> @ 160MG/8ML (20MG/ML) N022534 005 Jan 08, 2019 Dec DISC

SOLUTION; INTRAVENOUS
BEIZRAY

+! ZHUHAI 80MG/4ML (20MG/ML) N218711 001 Oct 23, 2024 Oct NEWA
 DOCIVYX
 +! AVYXA HOLDINGS 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Apr CMFD
 + @ 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Apr CTNA
 + @ 20MG/2ML (10MG/ML) N215813 001 Nov 22, 2022 Jan CAHN
 +! 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Apr CMFD
 + @ 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Apr CTNA
 + @ 80MG/8ML (10MG/ML) N215813 002 Nov 22, 2022 Jan CAHN
 +! 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Apr CMFD
 + @ 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Apr CTNA
 + @ 160MG/16ML (10MG/ML) N215813 003 Nov 22, 2022 Jan CAHN

DOLASETRON MESYLATETABLET; ORAL
ANZEMET

+ @ VALIDUS PHARMS 50MG N020623 001 Sep 11, 1997 Jun DISC

DONEPEZIL HYDROCHLORIDESYSTEM; TRANSDERMAL
ADLARITY

+ CORIUM 5MG/DAY N212304 001 Mar 11, 2022 Jun CAHN
 +! 10MG/DAY N212304 002 Mar 11, 2022 Jun CAHN

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

@ ENDO OPERATIONS 23MG A202542 001 Jul 24, 2013 May CAHN
 @ SUN PHARM INDS 5MG A090493 001 May 31, 2011 May DISC
 @ 10MG A090493 002 May 31, 2011 May DISC

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB ! MACLEODS PHARMS LTD 10MG A201787 002 Dec 14, 2012 Mar CHRS
 @ SANDOZ 5MG A091198 001 May 10, 2011 Mar DISC
 @ 10MG A091198 002 May 10, 2011 Mar DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

>D> @ AMNEAL PHARMS 10MG; 14MG A208328 001 Jan 27, 2017 Dec CMFD
 >A> AB 10MG; 14MG A208328 001 Jan 27, 2017 Dec CMFD
 >D> @ 10MG; 28MG A208328 002 Jan 27, 2017 Dec CMFD
 >A> AB 10MG; 28MG A208328 002 Jan 27, 2017 Dec CMFD
 NAMZARIC
 >D> + ABBVIE 10MG; 14MG N206439 001 Dec 23, 2014 Dec CTEC
 >A> AB + 10MG; 14MG N206439 001 Dec 23, 2014 Dec CTEC
 >D> +! 10MG; 28MG N206439 002 Dec 23, 2014 Dec CTEC
 >A> AB +! 10MG; 28MG N206439 002 Dec 23, 2014 Dec CTEC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE
@ HIKMA

EQ 2% BASE

A 077846 001 Oct 28, 2008 Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
@ HIKMA

EQ 2% BASE;EQ 0.5% BASE

A 077847 001 Oct 28, 2008 Mar DISC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB AUROBINDO PHARMA USA EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 4MG BASE
AB EQ 8MG BASE

A 075509 001 Oct 19, 2000 Mar CMFD
A 075509 002 Oct 19, 2000 Mar CMFD
A 075509 003 Oct 19, 2000 Mar CMFD
A 075509 004 Oct 19, 2000 Mar CMFD

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

AB ADAPTIS EQ 150MG BASE
AB AIPING PHARM INC EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 75MG BASE
AB EQ 100MG BASE
@ ENDO OPERATIONS EQ 10MG BASE
@ EQ 25MG BASE
@ EQ 50MG BASE
@ EQ 75MG BASE
@ EQ 100MG BASE
AB ! EQ 150MG BASE
AB LEADING EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 50MG BASE
AB EQ 75MG BASE
AB EQ 100MG BASE
AB VELZEN PHARMA PVT EQ 150MG BASE

A 213796 001 Apr 19, 2022 Sep CAHN
A 213474 001 Jul 28, 2020 Sep CAHN
A 213474 002 Jul 28, 2020 Sep CAHN
A 213474 003 Jul 28, 2020 Sep CAHN
A 213474 004 Jul 28, 2020 Sep CAHN
A 213474 005 Jul 28, 2020 Sep CAHN
A 071422 002 Nov 09, 1987 Apr CAHN
A 071422 003 Nov 09, 1987 Apr CAHN
A 071422 004 Nov 09, 1987 Apr CAHN
A 071422 005 Nov 09, 1987 Apr CAHN
A 071422 001 Nov 09, 1987 Apr CAHN
A 071422 006 Nov 09, 1987 Apr CAHN
A 211619 001 Mar 09, 2021 Aug CAHN
A 211619 002 Mar 09, 2021 Aug CAHN
A 211619 003 Mar 09, 2021 Aug CAHN
A 211619 004 Mar 09, 2021 Aug CAHN
A 211619 005 Mar 09, 2021 Aug CAHN
A 211618 001 Mar 01, 2021 Aug CAHN

TABLET;ORAL

DOXEPIIN HYDROCHLORIDE

>D> AB AJANTA PHARMA LTD EQ 3MG BASE
>A> @ EQ 3MG BASE
AB EQ 3MG BASE
>D> AB EQ 6MG BASE
>A> @ EQ 6MG BASE
AB EQ 6MG BASE
@ AUROBINDO PHARMA LTD EQ 3MG BASE
AB EQ 3MG BASE
@ EQ 6MG BASE
AB EQ 6MG BASE
AB ZYDUS LIFESCIENCES EQ 3MG BASE
@ EQ 3MG BASE
AB EQ 6MG BASE
@ EQ 6MG BASE

A 218564 001 Jul 01, 2024 Dec DISC
A 218564 001 Jul 01, 2024 Dec DISC
A 218564 001 Jul 01, 2024 Jun NEWA
A 218564 002 Jul 01, 2024 Dec DISC
A 218564 002 Jul 01, 2024 Dec DISC
A 218564 002 Jul 01, 2024 Jun NEWA
A 216041 001 Jul 25, 2024 Aug DISC
A 216041 001 Jul 25, 2024 Jul NEWA
A 216041 002 Jul 25, 2024 Aug DISC
A 216041 002 Jul 25, 2024 Jul NEWA
A 202761 001 Aug 16, 2023 Sep CMFD
A 202761 001 Aug 16, 2023 Jun CAHN
A 202761 002 Aug 16, 2023 Sep CMFD
A 202761 002 Aug 16, 2023 Jun CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

@ AMNEAL 2MCG/ML (2MCG/ML)
@ 4MCG/2ML (2MCG/ML)
@ 4MCG/2ML (2MCG/ML)
AP 4MCG/2ML (2MCG/ML)

A 208974 001 May 24, 2017 Jan DISC
A 208974 002 May 24, 2017 Jan DISC
A 208975 001 May 24, 2017 Jul DISC
A 208975 001 May 24, 2017 Jan CMFD

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

+ @ PFIZER 150MG/75ML

N 050629 003 Mar 28, 2011 Oct DISC

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB FORDOZ 20MG/10ML (2MG/ML)

A 215178 001 Jul 16, 2024 Jul NEWA

INJECTABLE, LIPOSOMAL; INJECTION

AB	DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)	50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Jul NEWA
AB	LUPIN	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Sep CAHN
AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Sep CAHN

DOXYCYCLINE

CAPSULE; ORAL						
DOXYCYCLINE						
AB	ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun NEWA
AB	APOTEX	40MG	A217170	001	Jul 11, 2024	Jul NEWA
	@ COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr DISC
	@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr DISC
	@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr DISC
AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar NFTG
AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar NFTG
ORACEA						
AB	+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar CFTG
FOR SUSPENSION; ORAL						
DOXYCYCLINE						
AB	! LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun CHRS
VIBRAMYCIN						
	+ @ PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun DISC
TABLET; ORAL						
DOXYCYCLINE						
	@ SOMERSET THERAPS LLC	EQ 50MG BASE	A065377	001	Nov 07, 2006	Sep CAHN
	@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Sep CAHN
	@	EQ 100MG BASE	A065377	003	Nov 07, 2006	Sep CAHN
	@	EQ 150MG BASE	A065427	001	Jun 07, 2007	Sep CAHN

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL						
VIBRAMYCIN						
	+ @ PFIZER	EQ 50MG BASE/5ML	N050480	001		Sep DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL						
ACTICLATE CAP						
	+ @ CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan CAHN
INJECTABLE; INJECTION						
DOXYCYCLINE HYCLATE						
AP	ACIC PHARMS	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Jul NEWA
AP	AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Nov NEWA
AP	ENDO OPERATIONS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Oct CMFD
AP	HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jun NEWA
AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jun NEWA
AP	HERITAGE	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Sep CAHN
AP	KINDOS	EQ 100MG BASE/VIAL	A218053	001	Oct 28, 2024	Oct NEWA
AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar NEWA
AP	SLATE RUN PHARMA	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Sep CAHN
AP		EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Sep CAHN
TABLET; ORAL						
ACTICLATE						
AB	+ CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan CAHN
AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan CAHN
DOXYCYCLINE HYCLATE						
AB	EPIC PHARMA LLC	EQ 50MG BASE	A062269	003	Oct 05, 1983	Oct CAHN
AB	!	EQ 100MG BASE	A062269	002	Nov 08, 1982	Oct CAHN
	@ NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May DISC
AB		EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr NEWA
	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Aug CAHN
	@ TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr DISC
AB		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr NEWA
	@	EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr DISC
AB		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL						
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE						
AB	ENDO OPERATIONS	10MG; 10MG	A208518	001	Dec 06, 2017	Apr CAHN

DRONABINOL

CAPSULE;ORAL

DRONABINOL

@	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
@		5MG	A079217	002	Jun 20, 2014	Mar	DISC
@		10MG	A079217	003	Jun 20, 2014	Mar	DISC
@	SVC PHARMA	2.5MG	A078292	001	Jun 27, 2008	Aug	DISC
@		5MG	A078292	002	Jun 27, 2008	Aug	DISC
@		10MG	A078292	003	Jun 27, 2008	Aug	DISC

SOLUTION;ORAL

SYNDROS

+	@	BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017	Aug	DISC
---	---	--------------------	--------	---------	-----	--------------	-----	------

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

DRONEDARONE HYDROCHLORIDE

AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG	
AB	+	!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

>D>	!	AM REGENT	2.5MG/ML	A072123	001	Oct 24, 1988	Dec	CTEC
>A>	AP	!		A072123	001	Oct 24, 1988	Dec	CTEC
>D>	@	HIKMA	2.5MG/ML	A208197	001	Dec 14, 2017	Dec	CMFD
>A>	AP			A208197	001	Dec 14, 2017	Dec	CMFD

DROSPIRENONE

TABLET;ORAL

SLYND

>D>	AB	+	!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	Dec	CTEC
>A>					4MG	N211367	001	May 23, 2019	Dec	CTEC
	AB				4MG	N211367	001	May 23, 2019	Sep	CFTG

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		ADAPTIS	100MG	A215265	001	Nov 01, 2021	Oct	CAHN
AB			200MG	A215265	002	Nov 01, 2021	Oct	CAHN
AB			300MG	A215265	003	Nov 01, 2021	Oct	CAHN
AB		SOMERSET THERAPS LLC	100MG	A214543	001	May 05, 2021	Sep	CAHN
AB			200MG	A214543	002	May 05, 2021	Sep	CAHN
AB			300MG	A214543	003	May 05, 2021	Sep	CAHN
	@	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr	DISC
	@		200MG	A213661	002	Feb 18, 2021	Apr	DISC
	@		300MG	A213661	003	Feb 18, 2021	Apr	DISC
AB		YAMPA	100MG	A215265	001	Nov 01, 2021	Sep	CAHN
AB			200MG	A215265	002	Nov 01, 2021	Sep	CAHN
AB			300MG	A215265	003	Nov 01, 2021	Sep	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+		SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CMFD
+			EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CMFD
+			EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CMFD
+	!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CMFD

DULOXETINE HYDROCHLORIDE

@	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
@		EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
@		EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
@	ENDO OPERATIONS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May	CAHN
@		EQ 30MG BASE	A090780	002	Oct 28, 2015	May	CAHN
@		EQ 60MG BASE	A090780	003	Oct 28, 2015	May	CAHN
@	SUN PHARM	EQ 20MG BASE	A090745	001	Dec 11, 2013	Nov	DISC
@		EQ 30MG BASE	A090745	002	Dec 11, 2013	Nov	DISC
@		EQ 60MG BASE	A090745	003	Dec 11, 2013	Nov	DISC

DUTASTERIDE

CAPSULE;ORAL		AVODART	
AB	+! WAYLIS THERAP	0.5MG	N021319 001 Nov 20, 2001 Mar CAHN
DUTASTERIDE		CHARTWELL	
AB		0.5MG	A200899 001 Nov 20, 2015 Mar CAHN
	@ NORVIUM BIOSCIENCE	0.5MG	A203241 001 Jun 14, 2016 Jun CAHN
	@ VINTAGE	0.5MG	A202421 001 Nov 20, 2015 Feb DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL		DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE	
AB	AUROBINDO PHARMA	0.5MG;0.4MG	A213300 001 Jul 18, 2024 Jul NEWA
AB	ENDO OPERATIONS	0.5MG;0.4MG	A202509 001 Feb 26, 2014 Apr CAHN
JALYN		WAYLIS THERAP	
AB	+! WAYLIS THERAP	0.5MG;0.4MG	N022460 001 Jun 14, 2010 Apr CAHN

DYPHYLLINE

TABLET;ORAL		LUFYLLIN	
	@ NORVIUM BIOSCIENCE	200MG	A084566 001 Jul CAHN
	@	400MG	A084566 002 Jul CAHN

EDARAVONE

SOLUTION;INTRAVENOUS		EDARAVONE	
AP	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917 001 May 06, 2024 Apr NEWA
AP	GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199 001 May 06, 2024 Apr NFTG
AP		60MG/100ML (0.6MG/ML)	A216199 002 May 06, 2024 Apr NFTG
AP	HIKMA	30MG/100ML (0.3MG/ML)	A215508 001 May 06, 2024 Apr NFTG
AP	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354 001 May 06, 2024 Apr NEWA
>A> AP	SANDOZ	30MG/100ML (0.3MG/ML)	A216902 001 Dec 23, 2024 Dec NEWA
AP	XGEN PHARMS	30MG/100ML (0.3MG/ML)	A217565 001 Oct 31, 2024 Oct NEWA
AP		60MG/100ML (0.6MG/ML)	A217565 002 Oct 31, 2024 Oct NEWA
RADICAVA		MITSUBISHI TANABE	
AP	+! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176 001 May 05, 2017 Apr CFTG
AP	+!	60MG/100ML (0.6MG/ML)	N209176 002 Nov 15, 2018 Apr CFTG

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION		ENLON	
	@ NORVIUM BIOSCIENCE	10MG/ML	A088873 001 Aug 06, 1985 Jul CAHN

EFAVIRENZ

TABLET;ORAL		EFAVIRENZ	
AB	MACLEODS PHARMS LTD	600MG	A091579 001 May 10, 2024 May NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL		ATRIPLA	
	+ @ GILEAD SCIENCES	600MG;200MG;300MG	N021937 001 Jul 12, 2006 Sep DISC
	EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE		
AB	! AUROBINDO PHARMA	600MG;200MG;300MG	A203041 001 Sep 04, 2018 Sep CHRS
	EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE		
	@ STRIDES PHARMA	600MG;200MG;300MG	A201802 001 Oct 03, 2023 Mar DISC
	EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE		
	@ MYLAN	600MG;200MG;300MG	A209061 001 Sep 05, 2024 Sep DISC
AB		600MG;200MG;300MG	A209061 001 Sep 05, 2024 Aug NEWA

EFINACONAZOLE

SOLUTION;TOPICAL		EFINACONAZOLE	
AB	UMEDICA	10%	A211969 001 Jun 21, 2021 Aug CAHN
	@ ZYDUS LIFESCIENCES	10%	A212178 001 Jul 15, 2022 May CAHN

ELACESTRANT HYDROCHLORIDE

TABLET;ORAL
ORSERDU

	+	STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Nov	CAIN
	+	!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Nov	CAIN

ELAFIBRANOR

TABLET;ORAL
IQIRVO

	+	!	IPSEN	80MG	N218860	001	Jun 10, 2024	Jun	NEWA
--	---	---	-------	------	---------	-----	--------------	-----	------

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL
ELETRIPTAN HYDROBROMIDE

>D>	AB		AJANTA PHARMA LTD	EQ 20MG BASE	A205186	001	Aug 29, 2017	Dec	CAHN
>D>	AB			EQ 40MG BASE	A205186	002	Aug 29, 2017	Dec	CAHN
>A>	AB		CHARTWELL RX	EQ 20MG BASE	A205186	001	Aug 29, 2017	Dec	CAHN
>A>	AB			EQ 40MG BASE	A205186	002	Aug 29, 2017	Dec	CAHN

ELIGLUSTAT TARTRATE

CAPSULE;ORAL
ELIGLUSTAT TARTRATE

AB			APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jun	NEWA
AB			CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Nov	NEWA

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL
ELTROMBOPAG OLAMINE

AB			ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG
AB				EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG
			PROMACTA KIT						
AB	+		NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG
AB	+		!	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
DESCOVY

	+		GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	Sep	CTEC
AB	+			120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG
>D>		+	!	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Dec	CTEC
>A>	AB		+	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Dec	CTEC
			+	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Sep	CTEC
AB			+	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

	@		APOTEX	120MG;EQ 15MG BASE	A214053	001	May 17, 2024	Sep	DISC
AB				120MG;EQ 15MG BASE	A214053	001	May 17, 2024	May	NFTG
	@			200MG;EQ 25MG BASE	A214053	002	May 17, 2024	Sep	DISC
AB				200MG;EQ 25MG BASE	A214053	002	May 17, 2024	May	NFTG
>A>	AB		LUPIN LTD	200MG;EQ 25MG BASE	A213926	001	Dec 13, 2024	Dec	NEWA

ENALAPRIL MALEATE

FOR SOLUTION;ORAL
EPANED KIT

	+	@	AZURITY	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN
--	---	---	---------	--------	---------	-----	--------------	-----	------

SOLUTION;ORAL
ENALAPRIL MALEATE

AB			AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD
----	--	--	--------	--------	---------	-----	--------------	-----	------

TABLET;ORAL
ENALAPRIL MALEATE

AB			AIPING PHARM INC	2.5MG	A075178	002	Mar 23, 2001	Oct	CMFD
AB				5MG	A075178	001	Mar 23, 2001	Oct	CMFD
AB				10MG	A075178	003	Mar 23, 2001	Oct	CMFD
AB				20MG	A075178	004	Mar 23, 2001	Oct	CMFD
AB			UNIQUE PHARM	2.5MG	A218531	001	Sep 19, 2024	Sep	NEWA
AB				5MG	A218531	002	Sep 19, 2024	Sep	NEWA
AB				10MG	A218531	003	Sep 19, 2024	Sep	NEWA
AB				20MG	A218531	004	Sep 19, 2024	Sep	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ COSETTE 5MG; 12.5MG A075727 001 Sep 18, 2001 Apr DISC
 @ 10MG; 25MG A075727 002 Sep 18, 2001 Apr DISC

>A> ENSARTINIB HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> ENSACOVE

>A> + XCOVERY EQ 25MG BASE N218171 001 Dec 18, 2024 Dec NEWA
 >A> +! EQ 100MG BASE N218171 002 Dec 18, 2024 Dec NEWA

ENSIFENTRINE

SUSPENSION; INHALATION

OHTUVAYRE

+! VERONA PHARMA 3MG/2.5ML N217389 001 Jun 26, 2024 Jun NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

>A> AB CONBA USA 0.5MG A216857 001 Dec 23, 2024 Dec NEWA
 >A> AB 1MG A216857 002 Dec 23, 2024 Dec NEWA
 @ PRINSTON INC 0.5MG A208782 001 Oct 10, 2017 Sep DISC
 @ 1MG A208782 002 Oct 10, 2017 Sep DISC
 @ SWISS PHARM 0.5MG A212106 001 Aug 10, 2020 Jul CAHN
 @ 1MG A212106 002 Aug 10, 2020 Jul CAHN
 @ VITRUVIAS 0.5MG A212106 001 Aug 10, 2020 Jun DISC
 @ 1MG A212106 002 Aug 10, 2020 Jun DISC
 AB YUNG SHIN PHARM 0.5MG A208195 001 Nov 10, 2021 Jun CMFD
 AB 1MG A208195 002 Nov 10, 2021 Jun CMFD

ENZALUTAMIDE

CAPSULE; ORAL

ENZALUTAMIDE

AB ZYDUS PHARMS 40MG A209667 001 Sep 26, 2024 Sep NEWA
 XTANDI
 AB +! ASTELLAS 40MG N203415 001 Aug 31, 2012 Sep CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

+ @ DR REDDYS LABS SA 23.5MG/5ML (4.7MG/ML) N213536 001 Jun 14, 2021 May DISC

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

AP +! EXELA PHARMA 25MG/5ML (5MG/ML) N208289 002 Aug 02, 2021 Oct CFTG
 EPHEDRINE SULFATE
 AP CAPLIN 50MG/ML (50MG/ML) A219050 001 Jul 18, 2024 Jul NEWA
 +! ENDO OPERATIONS 25MG/5ML (5MG/ML) N213994 002 Apr 22, 2022 Apr CAHN
 +! 50MG/10ML (5MG/ML) N213994 001 Oct 16, 2020 Apr CAHN
 AP HIKMA 25MG/5ML (5MG/ML) A217721 001 Oct 11, 2024 Oct NFTG

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

@ BRECKENRIDGE 0.05% A090870 001 Mar 14, 2011 Oct DISC

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

EPINEPHRINE

AP AM REGENT EQ 30MG BASE/30ML (EQ 1MG BASE/ML) A217192 001 Sep 06, 2024 Aug NEWA
 +! BPI LABS 1MG/ML (1MG/ML) N205029 005 Mar 04, 2024 Apr NEWA
 +! 30MG/30ML (1MG/ML) N205029 004 Feb 14, 2024 Feb NEWA

SOLUTION; INTRAVENOUS

EPINEPHRINE

+ @ BPI LABS 1MG/ML (1MG/ML) N205029 003 May 12, 2023 Jun DISC

SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

AP +! BPI LABS 1MG/ML (1MG/ML) N205029 001 Jul 29, 2014 Nov CFTG
 AP FRESENIUS KABI USA 1MG/ML (1MG/ML) A213708 001 Nov 20, 2024 Nov NFTG

	SPRAY;NASAL								
	NEFFY								
	+! ARS PHARMS OPERATION	2MG/SPRAY		N214697	001	Aug 09, 2024		Aug	NEWA
	<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	XYLOCAINE W/ EPINEPHRINE								
	+ @ FRESINIUS KABI USA	0.01MG/ML;2%		N006488	003			Feb	CRLD
	<u>EPIRUBICIN HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	EPIRUBICIN HYDROCHLORIDE								
	@ NORVIUM BIOSCIENCE	50MG/25ML (2MG/ML)		A065371	001	Nov 28, 2007		Jul	CAHN
	@	200MG/100ML (2MG/ML)		A065371	002	Nov 28, 2007		Jul	CAHN
	<u>EPLERENONE</u>								
	TABLET;ORAL								
	EPLERENONE								
AB	ADAPTIS	25MG		A212765	001	Aug 10, 2020		Nov	CAHN
AB		50MG		A212765	002	Aug 10, 2020		Nov	CAHN
	@ PRASCO	25MG		A203896	001	Feb 02, 2017		Mar	DISC
	@	50MG		A203896	002	Feb 02, 2017		Mar	DISC
AB	SLATE RUN PHARMA	25MG		A212765	001	Aug 10, 2020		Feb	CAHN
AB		50MG		A212765	002	Aug 10, 2020		Feb	CAHN
	<u>EPLONTERSEN SODIUM</u>								
	SOLUTION;SUBCUTANEOUS								
	WAINUA (AUTOINJECTOR)								
	+! ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)		N217388	001	Dec 21, 2023		Feb	CTNA
	+!	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)		N217388	001	Dec 21, 2023		Jan	CAHN
	<u>EPOPROSTENOL SODIUM</u>								
	INJECTABLE;INJECTION								
	EPOPROSTENOL SODIUM								
AP1	MEITHEAL	EQ 0.5MG BASE/VIAL		A078396	001	Apr 23, 2008		Jan	CAHN
AP1		EQ 1.5MG BASE/VIAL		A078396	002	Apr 23, 2008		Jan	CAHN
AP2	MYLAN	EQ 0.5MG BASE/VIAL		A213913	001	Jun 12, 2024		May	NEWA
AP2		EQ 1.5MG BASE/VIAL		A213913	002	Jun 12, 2024		May	NEWA
	<u>EPTIFIBATIDE</u>								
	INJECTABLE;INJECTION								
	EPTIFIBATIDE								
	@ ACCORD HLTHCARE	2MG/ML		A205557	001	Nov 06, 2017		May	DISC
	@	75MG/100ML		A205557	002	Nov 06, 2017		May	DISC
AP	HONG KONG	2MG/ML		A213599	001	May 09, 2024		May	NEWA
AP		75MG/100ML		A213599	002	May 09, 2024		May	NEWA
	<u>ERGOCALCIFEROL</u>								
	CAPSULE;ORAL								
	DRISDOL								
AA	+ ESJAY PHARMA	50,000 IU		N003444	001			Oct	CAHN
	<u>ERGOLOID MESYLATES</u>								
	TABLET;ORAL								
	ERGOLOID MESYLATES								
	@ SUN PHARM INDUSTRIES	1MG		A081113	001	Oct 31, 1991		Jul	DISC
	<u>ERGOTAMINE TARTRATE</u>								
	TABLET;SUBLINGUAL								
	ERGOMAR								
	! PANGEA	2MG		A087693	001	Feb 24, 1983		Nov	CAHN
	!	2MG		A087693	001	Feb 24, 1983		Feb	CAHN
	! PHARMOBEDIENT	2MG		A087693	001	Feb 24, 1983		Sep	CAHN
	<u>ERIBULIN MESYLATE</u>								
	SOLUTION;INTRAVENOUS								
	ERIBULIN MESYLATE								
AP	BAXTER HLTHCARE CORP	1MG/2ML (0.5MG/ML)		A217250	001	Oct 01, 2024		Sep	NEWA
AP	GLAND PHARMA LTD	1MG/2ML (0.5MG/ML)		A218047	001	Apr 05, 2024		Mar	NFTG
AP	JIANGXI QINGFENG	1MG/2ML (0.5MG/ML)		A218281	001	Jun 28, 2024		Jun	NEWA

SOLUTION; INTRAVENOUS
ERIBULIN MESYLATE

AP	LONG GROVE PHARMS	1MG/2ML (0.5MG/ML)	A214850	001	Jul 18, 2024	Jul	NEWA
AP	HALAVEN						
AP	+! EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

AB	ERLOTINIB HYDROCHLORIDE						
AB	CHARTWELL RX	EQ 25MG BASE	A203843	001	Sep 13, 2024	Sep	CAHN
AB		EQ 150MG BASE	A203843	002	Sep 13, 2024	Sep	CAHN
AB	HETERO LABS LTD V	EQ 25MG BASE	A209267	001	May 24, 2024	May	NEWA
AB		EQ 100MG BASE	A209267	002	May 24, 2024	May	NEWA
AB		EQ 150MG BASE	A209267	003	May 24, 2024	May	NEWA
AB	HIKMA	EQ 25MG BASE	A203843	001	Sep 13, 2024	Sep	NEWA
AB		EQ 150MG BASE	A203843	002	Sep 13, 2024	Sep	NEWA
AB	@ NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Apr	DISC
AB	@	EQ 150MG BASE	A208488	003	Nov 05, 2019	Aug	DISC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

AP	ERTAPENEM SODIUM						
AP	QILU	EQ 1GM BASE/VIAL	A218067	001	Oct 31, 2024	Oct	NEWA
AP	QILU ANTIBIOTICS	EQ 1GM BASE/VIAL	A218067	001	Oct 31, 2024	Nov	CAHN
AP	@ SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Jan	DISC

ERTUGLIFLOZIN

TABLET; ORAL

AB	ERTUGLIFLOZIN						
AB	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Sep	NEWA
AB		15MG	A217071	002	Sep 17, 2024	Sep	NEWA
AB	STEGLATRO						
AB	+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Sep	CTEC
AB	+!	15MG	N209803	002	Dec 19, 2017	Sep	CTEC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

AB	ERYTHROMYCIN						
AB	AZURITY	250MG	A062746	001	Dec 22, 1986	Mar	CAHN
AB	CARNEGIE	250MG	A062746	001	Dec 22, 1986	Nov	CAHN
AT	ERYTHROMYCIN						
AT	! BAUSCH AND LOMB	0.5%	A064067	001	Jul 29, 1994	Mar	CHRS
AT	@ PADAGIS US	0.5%	A062447	001	Sep 26, 1983	Mar	DISC

TABLET; ORAL

>D>	ERYTHROMYCIN						
>A>	AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Dec	DISC
>D>	@	250MG	A209720	001	Mar 09, 2018	Dec	DISC
>D>		500MG	A209720	002	Mar 09, 2018	Dec	DISC
>A>	@	500MG	A209720	002	Mar 09, 2018	Dec	DISC
AB	AZURITY	250MG	A061621	001		Mar	CAHN
AB		500MG	A061621	002		Mar	CAHN
AB	CARNEGIE	250MG	A061621	001		Nov	CAHN
AB		500MG	A061621	002		Nov	CAHN

TABLET, DELAYED RELEASE; ORAL

AB	ERY-TAB						
AB	AZURITY	250MG	A062298	001		Mar	CAHN
AB		333MG	A062298	003	Mar 29, 1982	Mar	CAHN
AB	!	500MG	A062298	002		Mar	CAHN
AB	CARNEGIE	250MG	A062298	001		Nov	CAHN
AB		333MG	A062298	003	Mar 29, 1982	Nov	CAHN
AB	!	500MG	A062298	002		Nov	CAHN
AB	ERYTHROMYCIN						
AB	TORRENT	333MG	A211975	003	Aug 13, 2024	Aug	NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

AB	E.E.S.						
AB	+ CARNEGIE	EQ 200MG BASE/5ML	N050207	001		Nov	CAHN
AB	ERYPED						
AB	+ CARNEGIE	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Nov	CAHN
AB	+!	EQ 400MG BASE/5ML	N050207	002		Nov	CAHN

GRANULE;ORAL									
ERYTHROMYCIN ETHYLSUCCINATE									
	@ ENDO OPERATIONS	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May	CAHN		
	@	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May	CAHN		
TABLET;ORAL									
E.E.S. 400									
	@ AZURITY	EQ 400MG BASE	A061905	001		Mar	CAHN		
BX	!	EQ 400MG BASE	A061905	002	Aug 12, 1982	Mar	CAHN		
	@ CARNEGIE	EQ 400MG BASE	A061905	001		Nov	CAHN		
BX	!	EQ 400MG BASE	A061905	002	Aug 12, 1982	Nov	CAHN		
ERYTHROMYCIN ETHYLSUCCINATE									
BX	!	AZURITY	EQ 400MG BASE	A061904	001		Mar	CAHN	
BX	!	CARNEGIE	EQ 400MG BASE	A061904	001		Nov	CAHN	
<u>ERYTHROMYCIN LACTOBIONATE</u>									
INJECTABLE;INJECTION									
ERYTHROMYCIN LACTOBIONATE									
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A216761	001	Nov 19, 2024	Nov	NEWA		
<u>ERYTHROMYCIN STEARATE</u>									
TABLET;ORAL									
ERYTHROCIN STEARATE									
	@ AZURITY	EQ 125MG BASE	A060359	002		Mar	CAHN		
	!	EQ 250MG BASE	A060359	001		Mar	CAHN		
	@	EQ 500MG BASE	A060359	003		Mar	CAHN		
<u>ESCITALOPRAM OXALATE</u>									
TABLET;ORAL									
ESCITALOPRAM OXALATE									
	@ AIPING PHARM INC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Nov	CAHN		
	@	EQ 10MG BASE	A077512	002	Sep 12, 2012	Nov	CAHN		
	@	EQ 20MG BASE	A077512	003	Sep 12, 2012	Nov	CAHN		
	@ ANIMA	EQ 5MG BASE	A077512	001	Sep 12, 2012	Sep	CAHN		
	@	EQ 10MG BASE	A077512	002	Sep 12, 2012	Sep	CAHN		
	@	EQ 20MG BASE	A077512	003	Sep 12, 2012	Sep	CAHN		
	@ ESJAY PHARMA	EQ 5MG BASE	A077550	001	May 14, 2015	Nov	CAHN		
	@	EQ 10MG BASE	A077550	002	May 14, 2015	Nov	CAHN		
	@	EQ 20MG BASE	A077550	003	May 14, 2015	Nov	CAHN		
	@ PHARM ASSOC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Mar	DISC		
	@	EQ 10MG BASE	A077512	002	Sep 12, 2012	Mar	DISC		
	@	EQ 20MG BASE	A077512	003	Sep 12, 2012	Mar	DISC		
<u>ESLICARBAZEPINE ACETATE</u>									
TABLET;ORAL									
ESLICARBAZEPINE ACETATE									
	@ APOTEX	200MG	A211236	001	Dec 07, 2023	Apr	DISC		
	@	400MG	A211236	002	Dec 07, 2023	Apr	DISC		
	@	600MG	A211236	003	Dec 07, 2023	Apr	DISC		
	@	800MG	A211236	004	Dec 07, 2023	Apr	DISC		
	@ LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Sep	DISC		
AB		200MG	A211246	001	Mar 27, 2024	Mar	NEWA		
	@	400MG	A211246	002	Mar 27, 2024	Sep	DISC		
AB		400MG	A211246	002	Mar 27, 2024	Mar	NEWA		
	@	600MG	A211246	003	Mar 27, 2024	Sep	DISC		
AB		600MG	A211246	003	Mar 27, 2024	Mar	NEWA		
	@	800MG	A211246	004	Mar 27, 2024	Sep	DISC		
AB		800MG	A211246	004	Mar 27, 2024	Mar	NEWA		
	@ TORRENT	200MG	A211227	001	Feb 27, 2024	Mar	DISC		
AB		200MG	A211227	001	Feb 27, 2024	Feb	NEWA		
	@	400MG	A211227	002	Feb 27, 2024	Mar	DISC		
AB		400MG	A211227	002	Feb 27, 2024	Feb	NEWA		
	@	600MG	A211227	003	Feb 27, 2024	Mar	DISC		
AB		600MG	A211227	003	Feb 27, 2024	Feb	NEWA		
	@	800MG	A211227	004	Feb 27, 2024	Mar	DISC		
AB		800MG	A211227	004	Feb 27, 2024	Feb	NEWA		
<u>ESOMEPRAZOLE MAGNESIUM</u>									
CAPSULE, DELAYED REL PELLETS;ORAL									
ESOMEPRAZOLE MAGNESIUM									
	@ GLENMARK SPECLT	EQ 20MG BASE	A209495	001	May 10, 2019	Sep	DISC		
	@	EQ 40MG BASE	A209495	002	May 10, 2019	Sep	DISC		
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Oct	NEWA		
AB		EQ 40MG BASE	A208511	002	Oct 23, 2024	Oct	NEWA		

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

@ SUN PHARM EQ 20MG BASE A209735 001 Apr 30, 2018 Nov DISC
 @ EQ 40MG BASE A209735 002 Apr 30, 2018 Nov DISC

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A> AB CIPLA EQ 2.5MG BASE/PACKET A217714 001 Jan 07, 2025 Dec NFTG
 >A> AB EQ 5MG BASE/PACKET A217714 002 Jan 07, 2025 Dec NFTG
 NEXIUM
 >D> + ASTRAZENECA EQ 2.5MG BASE/PACKET N021957 003 Dec 15, 2011 Dec CFTG
 >A> AB + EQ 2.5MG BASE/PACKET N021957 003 Dec 15, 2011 Dec CFTG
 >D> + EQ 5MG BASE/PACKET N021957 004 Dec 15, 2011 Dec CFTG
 >A> AB + EQ 5MG BASE/PACKET N021957 004 Dec 15, 2011 Dec CFTG

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

@ ACCORD HLTHCARE EQ 40MG BASE/VIAL A205379 001 Sep 25, 2015 May DISC
 ! GLAND PHARMA LTD EQ 20MG BASE/VIAL A203349 001 Apr 01, 2020 May CHRS
 AP ! HAINAN POLY EQ 40MG BASE/VIAL A215732 001 Feb 10, 2022 Aug CHRS
 AP ! SLATE RUN PHARMA EQ 40MG BASE/VIAL A215732 001 Feb 10, 2022 Sep CAHN
 @ SUN PHARM EQ 40MG BASE/VIAL A200882 002 Mar 18, 2013 May DISC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB2 + BAYER HLTHCARE 0.06MG/24HR N020375 006 May 27, 2003 Sep CTEC
 ESTRADIOL
 AB2 MYLAN TECHNOLOGIES 0.06MG/24HR A075182 005 Jul 20, 2006 Oct CTEC
 AB2 ZYDUS PHARMS 0.025MG/24HR A202985 001 Mar 29, 2023 Sep CMFD
 AB2 0.0375MG/24HR A202985 002 Mar 29, 2023 Sep CMFD
 AB2 0.05MG/24HR A202985 003 Mar 29, 2023 Sep CMFD
 AB2 0.06MG/24HR A202985 004 Mar 29, 2023 Sep CMFD
 AB2 0.075MG/24HR A202985 005 Mar 29, 2023 Sep CMFD
 AB2 0.1MG/24HR A202985 006 Mar 29, 2023 Sep CMFD

GEL;TRANSDERMAL

DIVIGEL

AB +! VERTICAL PHARMS 0.1% (0.25GM/PACKET) N022038 001 Jun 04, 2007 Jul CPOT
 AB +! 0.1% (0.5GM/PACKET) N022038 002 Jun 04, 2007 Jul NEWA
 AB +! 0.1% (1GM/PACKET) N022038 003 Jun 04, 2007 Jul NEWA
 AB +! 0.1% (0.75GM/PACKET) N022038 004 Aug 17, 2018 Jul NEWA
 AB +! 0.1% (1.25GM/PACKET) N022038 005 Dec 12, 2019 Jul NEWA

ESTRADIOL

AB AMNEAL 0.1% (0.25GM/PACKET) A216055 001 Jul 12, 2024 Jul NEWA
 AB 0.1% (0.5GM/PACKET) A216055 002 Jul 12, 2024 Jul NEWA
 AB 0.1% (0.75GM/PACKET) A216055 003 Jul 12, 2024 Jul NEWA
 AB 0.1% (1GM/PACKET) A216055 004 Jul 12, 2024 Jul NEWA
 AB 0.1% (1.25GM/PACKET) A216055 005 Jul 12, 2024 Jul NEWA
 AB CHEMO RESEARCH SL 0.1% (0.25GM/PACKET) A211783 001 Aug 10, 2022 Jul CPOT
 AB 0.1% (0.5GM/PACKET) A211783 002 Aug 10, 2022 Jul NEWA
 AB 0.1% (1GM/PACKET) A211783 003 Aug 10, 2022 Jul NEWA
 AB NOVITIUM PHARMA 0.1% (0.25GM/PACKET) A217610 001 Aug 24, 2023 Jul CPOT
 AB 0.1% (0.5GM/PACKET) A217610 002 Aug 24, 2023 Jul NEWA
 AB 0.1% (0.75GM/PACKET) A217610 003 Aug 24, 2023 Jul NEWA
 AB 0.1% (1GM/PACKET) A217610 004 Aug 24, 2023 Jul NEWA
 AB 0.1% (1.25GM/PACKET) A217610 005 Aug 24, 2023 Jul NEWA
 AB PADAGIS ISRAEL 0.1% (0.25GM/PACKET) A216524 001 Nov 14, 2023 Jul CPOT
 AB 0.1% (0.5GM/PACKET) A216524 002 Nov 14, 2023 Jul NEWA
 AB 0.1% (0.75GM/PACKET) A216524 003 Nov 14, 2023 Jul NEWA
 AB 0.1% (1GM/PACKET) A216524 004 Nov 14, 2023 Jul NEWA
 AB 0.1% (1.25GM/PACKET) A216524 005 Nov 14, 2023 Jul NEWA
 AB QUAGEN 0.1% (0.25GM/PACKET) A217863 001 Jul 12, 2024 Sep CAHN
 AB 0.1% (0.5GM/PACKET) A217863 002 Jul 12, 2024 Sep CAHN
 AB 0.1% (0.75GM/PACKET) A217863 003 Jul 12, 2024 Sep CAHN
 AB 0.1% (1GM/PACKET) A217863 004 Jul 12, 2024 Sep CAHN
 AB 0.1% (1.25GM/PACKET) A217863 005 Jul 12, 2024 Sep CAHN
 AB SOLARIS PHARMA CORP 0.1% (0.25GM/PACKET) A217863 001 Jul 12, 2024 Jul NEWA
 AB 0.1% (0.5GM/PACKET) A217863 002 Jul 12, 2024 Jul NEWA
 AB 0.1% (0.75GM/PACKET) A217863 003 Jul 12, 2024 Jul NEWA
 AB 0.1% (1GM/PACKET) A217863 004 Jul 12, 2024 Jul NEWA
 AB 0.1% (1.25GM/PACKET) A217863 005 Jul 12, 2024 Jul NEWA

GEL, METERED; TRANSDERMAL							
ESTRADIOL							
AB	NOVITIUM PHARMA	0.06% (1.25GM/ACTIVATION)	A217882	001	Oct 23, 2024	Oct	NEWA
AB	SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr	NFTG
ESTROGEL							
AB	+! ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr	CFTG
TABLET; VAGINAL							
ESTRADIOL							
AB	AUROBINDO PHARMA	10MCG	A216550	001	Aug 02, 2024	Jul	NEWA
<u>ESTRADIOL ACETATE</u>							
INSERT, EXTENDED RELEASE; VAGINAL							
FEMRING							
+	MILLICENT PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Nov	CAHN
+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Nov	CAHN
<u>ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE</u>							
INJECTABLE; INTRAMUSCULAR							
LUNELLE							
+	@ PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb	CRLD
<u>ESTRADIOL VALERATE</u>							
INJECTABLE; INJECTION							
DELESTROGEN							
AO	+!	ENDO OPERATIONS	N009402	002		Apr	CAHN
AO	+!		N009402	004		Apr	CAHN
	+	@	N009402	003		Sep	DISC
AO	+!		N009402	003		Apr	CAHN
ESTRADIOL VALERATE							
AO	!	XIROMED	A216656	003	Apr 28, 2023	Sep	CHRS
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>							
TABLET; ORAL							
ESTRADIOL AND NORETHINDRONE ACETATE							
AB	NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018	Apr	CMFD
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX</u>							
TABLET; ORAL							
MYFEMBREE							
+	!	SUMITOMO PHARMA	N214846	001	May 26, 2021	Sep	CAHN
<u>ESTRADIOL; NORGESTIMATE</u>							
TABLET; ORAL							
ESTRADIOL AND NORGESTIMATE							
	@ BARR	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Aug	DISC
<u>ESTRAMUSTINE PHOSPHATE SODIUM</u>							
CAPSULE; ORAL							
EMCYT							
+	@ PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001		Jun	DISC
<u>ESTROGENS, ESTERIFIED</u>							
TABLET; ORAL							
MENEST							
	@ MONARCH PHARMS	0.3MG	A084951	001		Jul	DISC
	@	0.625MG	A084948	001		Jul	DISC
	@	1.25MG	A084950	001		Jul	DISC
	@	2.5MG	A084949	001		Jul	DISC
<u>ESTROPIPATE</u>							
TABLET; ORAL							
ESTROPIPATE							
	@ NORVIUM BIOSCIENCE	0.75MG	A040359	001	Aug 26, 1999	Oct	CAHN
	@	1.5MG	A040359	002	Aug 26, 1999	Oct	CAHN
	@	3MG	A040359	003	Aug 26, 1999	Oct	CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

>D>	AB	IPCA LABS LTD	1MG	A206222	001	Dec 29, 2023	Dec	DISC
>A>		@	1MG	A206222	001	Dec 29, 2023	Dec	DISC
>D>	AB		2MG	A206222	002	Dec 29, 2023	Dec	DISC
>A>		@	2MG	A206222	002	Dec 29, 2023	Dec	DISC
>D>	AB		3MG	A206222	003	Dec 29, 2023	Dec	DISC
>A>		@	3MG	A206222	003	Dec 29, 2023	Dec	DISC
		LUNESTA						
AB	+	WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr	CAHN
AB	+		2MG	N021476	002	Dec 15, 2004	Apr	CAHN
AB	+	!	3MG	N021476	003	Dec 15, 2004	Apr	CAHN

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM

AP		ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN
AP		STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar	CAHN

ETHACRYNIC ACID

TABLET; ORAL

ETHACRYNIC ACID

AB		ADAPTIS	25MG	A205609	001	Jun 30, 2016	Sep	CAHN
		@ ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May	CAHN
		@ PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr	DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

AB	+	KANCHAN HLTHCARE	100MG	N016320	001		Aug	CAHN
		@	200MG	N016320	002		Aug	CAHN
AB	+	!	400MG	N016320	003		Aug	CAHN
		@	500MG	N016320	004		Aug	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		XIROMED	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN
		MINZOYA						
AB3		LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb	NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL						
		@ XIROMED	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN
		@	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	May	CAHN
		MYZILRA						
AB		ENDO OPERATIONS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A077502	001	Nov 23, 2011	May	CAHN
		ORSYTHIA						
		@ ENDO OPERATIONS	0.02MG; 0.1MG	A077099	001	May 11, 2011	May	CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB		ZYDUS PHARMS	0.035MG/24HR; 0.15MG/24HR	A214594	001	Sep 14, 2023	Nov	CAHN
----	--	--------------	---------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

CYCLAFEM 0.5/35

		@ ENDO OPERATIONS	0.035MG; 0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
		CYCLAFEM 1/35						
		@ ENDO OPERATIONS	0.035MG; 1MG	A076337	001	Nov 12, 2010	May	CAHN
		CYCLAFEM 7/7/7						
		@ ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A076338	001	Nov 16, 2010	May	CAHN
		GILDAGIA						
AB		ENDO OPERATIONS	0.035MG; 0.4MG	A078376	001	Nov 06, 2012	May	CAHN
		NORETHINDRONE AND ETHINYL ESTRADIOL						
		@ XIROMED	0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr	CAHN
		@	0.05MG; 1MG	A203006	001	Aug 05, 2013	Apr	CAHN

TABLET, CHEWABLE;ORAL							
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+!	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Mar CAHN
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
CAPSULE;ORAL							
MERZEE							
AB		WILSHIRE PHARMS INC	0.02MG;1MG	A212706	001	Dec 18, 2020	Jul CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@	AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Feb DISC
TABLET;ORAL							
GILDESS 24 FE							
AB		ENDO OPERATIONS	0.02MG;1MG	A090293	001	Dec 01, 2014	May CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
	@	XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr CAHN
	@		0.005MG;1MG	A207259	001	Dec 27, 2016	Apr CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@	XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	@	XIROMED	0.02MG;1MG	A206120	001	Sep 12, 2017	May CAHN
OSHIH							
	@	AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023	May DISC
TABLET;ORAL-21							
GILDESS 1.5/30							
	@	ENDO OPERATIONS	0.03MG;1.5MG	A077075	002	Jul 24, 2012	May CAHN
GILDESS 1/20							
	@	ENDO OPERATIONS	0.02MG;1MG	A077077	002	Jul 24, 2012	May CAHN
TABLET;ORAL-28							
GILDESS FE 1.5/30							
	@	ENDO OPERATIONS	0.03MG;1.5MG	A077075	001	Apr 28, 2005	May CAHN
GILDESS FE 1/20							
	@	ENDO OPERATIONS	0.02MG;1MG	A077077	001	May 20, 2005	May CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
FEMLYV							
	+!	MILLICENT PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jul NEWA
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>							
TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
	@	XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	May CAHN
	@		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897	001	Jan 27, 2016	May CAHN
PREVIFEM							
AB		ENDO OPERATIONS	0.035MG;0.25MG	A076334	001	Jan 09, 2004	May CAHN
TRI-PREVIFEM							
	@	ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335	001	Mar 26, 2004	May CAHN
<u>ETHOSUXIMIDE</u>							
CAPSULE;ORAL							
ETHOSUXIMIDE							
AB		EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan CAHN
<u>ETODOLAC</u>							
CAPSULE;ORAL							
ETODOLAC							
AB		IPCA LABS LTD	200MG	A205448	001	Aug 01, 2024	Jul NEWA
AB			300MG	A205448	002	Aug 01, 2024	Jul NEWA
TABLET;ORAL							
ETODOLAC							
AB		ABRAXEOLUS	400MG	A074903	001	Apr 11, 1997	Sep CAHN
AB			500MG	A074903	002	Apr 19, 1999	Sep CAHN
AB		ADAPTIS	400MG	A209888	001	Nov 30, 2018	Sep CAHN
AB			500MG	A209888	002	Nov 30, 2018	Sep CAHN
AB		EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018	Jul CMFD
AB			500MG	A209888	002	Nov 30, 2018	Jul CMFD
AB		IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr NEWA
AB			500MG	A204729	002	May 01, 2024	Apr NEWA
AB		PANGEA	400MG	A074903	001	Apr 11, 1997	Nov CAHN

<u>TABLET;ORAL</u>							
ETODOLAC							
AB		400MG		A074903	001	Apr 11, 1997	Jun CAHN
AB		500MG		A074903	002	Apr 19, 1999	Nov CAHN
AB		500MG		A074903	002	Apr 19, 1999	Jun CAHN
AB	UNICHEM	400MG		A210704	001	Dec 16, 2020	Nov CAHN
AB		500MG		A210704	002	Dec 16, 2020	Nov CAHN
<u>TABLET, EXTENDED RELEASE;ORAL</u>							
ETODOLAC							
AB	UNICHEM	400MG		A212263	001	Nov 24, 2020	Nov CAHN
AB		500MG		A212263	002	Nov 24, 2020	Nov CAHN
AB		600MG		A212263	003	Nov 24, 2020	Nov CAHN
<u>ETOMIDATE</u>							
INJECTABLE; INJECTION							
ETOMIDATE							
	@ ENDO OPERATIONS	2MG/ML		A091297	001	Jun 20, 2012	May CAHN
<u>ETOPOSIDE</u>							
CAPSULE;ORAL							
VEPESID							
	+ @ STRIDES SOFTGELS	50MG		N019557	001	Dec 30, 1986	Nov CAHN
	+ @	100MG		N019557	002	Dec 30, 1986	Nov CAHN
<u>EXENATIDE SYNTHETIC</u>							
INJECTABLE; SUBCUTANEOUS							
BYETTA							
AP	+! ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)		N021773	001	Apr 28, 2005	Nov CFTG
AP	+!	600MCG/2.4ML (250MCG/ML)		N021773	002	Apr 28, 2005	Nov CFTG
EXENATIDE SYNTHETIC							
AP	AMNEAL	300MCG/1.2ML (250MCG/ML)		A206697	001	Nov 19, 2024	Nov NFTG
AP		600MCG/2.4ML (250MCG/ML)		A206697	002	Nov 19, 2024	Nov NFTG
<u>EZETIMIBE</u>							
TABLET;ORAL							
EZETIMIBE							
AB	MACLEODS PHARMS LTD	10MG		A211159	001	Apr 29, 2024	Apr NEWA
<u>EZETIMIBE; SIMVASTATIN</u>							
TABLET;ORAL							
EZETIMIBE AND SIMVASTATIN							
AB	AUROBINDO PHARMA USA	10MG;10MG		A200082	001	Dec 17, 2020	Mar CMFD
AB		10MG;20MG		A200082	002	Dec 17, 2020	Mar CMFD
AB		10MG;40MG		A200082	003	Dec 17, 2020	Mar CMFD
AB		10MG;80MG		A200082	004	Dec 17, 2020	Mar CMFD
AB	SCIEGEN PHARMS INC	10MG;10MG		A211663	001	Dec 10, 2024	Nov NEWA
AB		10MG;20MG		A211663	002	Dec 10, 2024	Nov NEWA
AB		10MG;40MG		A211663	003	Dec 10, 2024	Nov NEWA
AB		10MG;80MG		A211663	004	Dec 10, 2024	Nov NEWA
<u>FAMOTIDINE</u>							
FOR SUSPENSION;ORAL							
FAMOTIDINE							
AB	CEROVENE INC	40MG/5ML		A217605	001	Jan 16, 2024	Jan NEWA
AB	EPIC PHARMA LLC	40MG/5ML		A218344	001	Oct 16, 2024	Oct NEWA
AB	UNICHEM	40MG/5ML		A217605	001	Jan 16, 2024	Sep CAHN
TABLET;ORAL							
FAMOTIDINE							
AB	MSN	20MG		A217400	001	Aug 06, 2024	Jul NEWA
AB		40MG		A217400	002	Aug 06, 2024	Jul NEWA
AB	RISING	20MG		A218181	001	Dec 22, 2023	Aug CAHN
AB		40MG		A218181	002	Dec 22, 2023	Aug CAHN
<u>FAMOTIDINE; IBUPROFEN</u>							
TABLET;ORAL							
FAMOTIDINE AND IBUPROFEN							
	@ TORRENT	26.6MG;800MG		A215925	001	Mar 18, 2024	Mar NEWA
IBUPROFEN AND FAMOTIDINE							
AB	! ALKEM LABS LTD	26.6MG;800MG		A211890	001	Aug 03, 2021	Feb CHRS

FEBUXOSTAT

TABLET; ORAL		FEBUXOSTAT					
	@ LUPIN LTD	40MG		A205406	001	Jan 17, 2024	Apr DISC
AB		40MG		A205406	001	Jan 17, 2024	Jan NEWA
	@	80MG		A205406	002	Jan 17, 2024	Apr DISC
AB		80MG		A205406	002	Jan 17, 2024	Jan NEWA
BX	MSN	40MG		A210461	001	Dec 30, 2019	Jun CTEC
BX		80MG		A210461	002	Dec 30, 2019	Jun CTEC

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL		INREBIC					
	+! BRISTOL-MYERS	EQ 100MG BASE		N212327	001	Aug 16, 2019	Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL		FELODIPINE					
AB	ENDO OPERATIONS	2.5MG		A200815	001	Oct 28, 2011	Apr CAHN
AB		5MG		A200815	002	Oct 28, 2011	Apr CAHN
AB		10MG		A200815	003	Oct 28, 2011	Apr CAHN

FENOFIBRATE

CAPSULE; ORAL		FENOFIBRATE (MICRONIZED)					
AB	CHARTWELL	67MG		A211407	001	Jan 31, 2024	Mar CAHN
AB		134MG		A211407	002	Jan 31, 2024	Mar CAHN
AB		200MG		A211407	003	Jan 31, 2024	Mar CAHN
	@ INVAGEN PHARMS	67MG		A207378	001	Mar 28, 2017	Mar DISC
	@	134MG		A207378	002	Mar 28, 2017	Mar DISC
	@	200MG		A207378	003	Mar 28, 2017	Mar DISC
AB	YOUNGTECH PHARMS INC	67MG		A211407	001	Jan 31, 2024	Jan NEWA
AB		134MG		A211407	002	Jan 31, 2024	Jan NEWA
AB		200MG		A211407	003	Jan 31, 2024	Jan NEWA

TABLET; ORAL

FENOFIBRATE							
AB	! AUROBINDO PHARMA	145MG		A205118	002	May 05, 2016	Mar CHRS
BX	CREEKWOOD PHARMS	40MG		A217732	001	Sep 07, 2023	Jun CTEC
BX		120MG		A217732	002	Sep 07, 2023	Jun CTEC
AB	MACLEODS PHARMS LTD	48MG		A210248	001	Nov 13, 2024	Nov NEWA
AB		145MG		A210248	002	Nov 13, 2024	Nov NEWA
AB	! MYLAN PHARMS INC	120MG		A204475	002	Jun 23, 2016	May CHRS
AB	RISING	48MG		A211122	001	Mar 18, 2020	Aug CAHN
AB		54MG		A210606	001	Aug 17, 2018	Aug CAHN
AB		145MG		A211122	002	Mar 18, 2020	Aug CAHN
AB		160MG		A210606	002	Aug 17, 2018	Aug CAHN
	@ SUN PHARM INDS LTD	54MG		A076635	001	Oct 31, 2005	Nov DISC
	@	160MG		A076635	003	Oct 31, 2005	Nov DISC
AB	YICHANG HUMANWELL	54MG		A218548	001	Apr 24, 2024	Apr NEWA
AB		160MG		A218548	002	Apr 24, 2024	Apr NEWA

FENOGLIDE

	+ @ SALIX	40MG		N022118	001	Aug 10, 2007	May DISC
	+ @	120MG		N022118	002	Aug 10, 2007	May DISC
	TRICOR						
	+ @ ABBVIE	48MG		N021656	001	Nov 05, 2004	Aug DISC
	+ @	145MG		N021656	002	Nov 05, 2004	Mar DISC
	TRIGLIDE						
	+ @ SKYEPHARMA AG	160MG		N021350	002	May 07, 2005	Nov DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION		CORLOPAM					
	+ @ HOSPIRA	EQ 10MG BASE/ML		N019922	001	Sep 23, 1997	May DISC
	FENOLDOPAM MESYLATE						
	@ HIKMA	EQ 10MG BASE/ML		A076582	001	Oct 12, 2004	May DISC
	@ SANDOZ	EQ 10MG BASE/ML		A077155	001	Feb 15, 2005	May DISC

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM							
	@ MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	Aug	DISC
		EQ 200MG BASE	A215548	001	May 16, 2023	May	CTEC
	@	EQ 300MG BASE	A215548	002	May 16, 2023	Aug	DISC
	@	EQ 400MG BASE	A215548	003	May 16, 2023	Aug	DISC
	RISING	EQ 200MG BASE	A214475	002	Jul 26, 2024	Sep	NEWA
		EQ 300MG BASE	A214475	003	Jul 26, 2024	Sep	NEWA
	!	EQ 400MG BASE	A214475	001	Jul 18, 2022	Aug	CTEC
AB	!	EQ 400MG BASE	A214475	001	Jul 18, 2022	May	CHRS
NALFON							
	+ @ KEY THERAP	EQ 200MG BASE	N017604	003		May	DISC
AB	+	EQ 200MG BASE	N017604	003		Apr	CAHN
	+ @	EQ 400MG BASE	N017604	004	Jul 21, 2009	May	DISC
AB	+	EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN

TABLET;ORAL

FENOPROFEN CALCIUM							
	@ KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	May	DISC
	!	EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100							
AB	DIFGEN PHARMS	100MCG/HR	A077449	004	Oct 20, 2008	Sep	CAHN
FENTANYL-12							
AB	DIFGEN PHARMS	12.5MCG/HR	A077449	005	Sep 11, 2015	Sep	CAHN
FENTANYL-25							
AB	DIFGEN PHARMS	25MCG/HR	A077449	001	Oct 20, 2008	Sep	CAHN
FENTANYL-37							
AB	DIFGEN PHARMS	37.5MCG/HR	A077449	006	Dec 06, 2017	Sep	CAHN
FENTANYL-50							
AB	DIFGEN PHARMS	50MCG/HR	A077449	002	Oct 20, 2008	Sep	CAHN
FENTANYL-62							
AB	DIFGEN PHARMS	62.5MCG/HR	A077449	007	Dec 06, 2017	Sep	CAHN
FENTANYL-75							
AB	DIFGEN PHARMS	75MCG/HR	A077449	003	Oct 20, 2008	Sep	CAHN
FENTANYL-87							
AB	DIFGEN PHARMS	87.5MCG/HR	A077449	008	Dec 06, 2017	Sep	CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

>D>	AP	HOSPIRA	EQ 0.05MG BASE/ML	A072786	001	Sep 24, 1991	Dec	DISC
>A>		@	EQ 0.05MG BASE/ML	A072786	001	Sep 24, 1991	Dec	DISC

TABLET;BUCCAL, SUBLINGUAL

FENTORA

	+ @ CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Sep	DISC
	+ @	EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Sep	DISC
	+ @	EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Sep	DISC
	+ @	EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Sep	DISC
	+ @	EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Sep	DISC

TROCHE/LOZENGE;TRANSMUCOSAL

ACTIQ

	+ @ CEPHALON	EQ 0.2MG BASE	N020747	001	Nov 04, 1998	Sep	DISC
	+ @	EQ 0.4MG BASE	N020747	002	Nov 04, 1998	Sep	DISC
	+ @	EQ 0.6MG BASE	N020747	003	Nov 04, 1998	Sep	DISC
	+ @	EQ 0.8MG BASE	N020747	004	Nov 04, 1998	Sep	DISC
	+ @	EQ 1.2MG BASE	N020747	005	Nov 04, 1998	Sep	DISC
	+ @	EQ 1.6MG BASE	N020747	006	Nov 04, 1998	Sep	DISC

FERRIC OXYHYDROXIDE

INJECTABLE;INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

>A>	AB	HIKMA	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	Dec	CAHN
>D>	AB	WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	Dec	CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

	@ ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Apr	DISC
	@	8MG	A204504	002	Jan 04, 2023	Apr	DISC

FIDAXOMICIN

TABLET;ORAL
DIFICID

	+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul	CTEC
AB	+!		200MG	N201699	001	May 27, 2011	Jan	CFTG
		FIDAXOMICIN						
	@	ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul	DISC
AB			200MG	A208443	001	Jan 16, 2024	Jan	NEWA

FINASTERIDE

TABLET;ORAL
FINASTERIDE

	@	CIPLA	1MG	A077335	001	Nov 20, 2014	Mar	DISC
--	---	-------	-----	---------	-----	--------------	-----	------

FINASTERIDE; TADALAFIL

CAPSULE;ORAL
ENTADFI

	+ @	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Sep	DISC
AB	+!		5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG
		FINASTERIDE AND TADALAFIL						
		ZYDUS	5MG;5MG	A218232	001	Mar 15, 2024	Mar	NFTG
AB	@	ZYDUS LIFESCIENCES	5MG;5MG	A218232	001	Mar 15, 2024	Sep	DISC
AB			5MG;5MG	A218232	001	Mar 15, 2024	May	CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb	NEWA
AB		BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb	CMFD
	@	SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Nov	DISC

FLORTAUCIPIR F-18

SOLUTION;INTRAVENOUS
TAUVID

	+ @	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun	DISC
	+ @		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun	DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

>D>	AB	HAINAN POLY	200MG/5ML	A215738	001	Sep 21, 2023	Dec	CAHN
>A>	AB	ZHEJIANG POLY PHARM	200MG/5ML	A215738	001	Sep 21, 2023	Dec	CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Jul	CAHN
	@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Jul	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	AP	HIKMA	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Dec	CAHN
>A>	AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Dec	CAHN
>D>	AP	WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Dec	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Dec	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

>A>		@	EXTROVIS	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Dec	CAHN
		@		50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Jun	CAHN
>D>		@	RISING	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	Dec	CAHN
		@		50MG/VIAL	A200648	001	Oct 16, 2012	Feb	CAHN

FLUDEOXYGLUCOSE F-18

	INJECTABLE; INTRAVENOUS						
	FLUDEOXYGLUCOSE F18						
AP	!	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	May CHRS
		@ SOFIE	20-500mCi/ML	A203665	001	Feb 14, 2013	May DISC

FLUDROCORTISONE ACETATE

	TABLET; ORAL						
	FLUDROCORTISONE ACETATE						
		@ CHARTWELL RX	0.1MG	A216013	001	Oct 27, 2022	Sep CAHN
AB		ZYDUS	0.1MG	A219251	001	Oct 16, 2024	Oct NEWA
AB		ZYDUS LIFESCIENCES	0.1MG	A219251	001	Oct 16, 2024	Oct CAHN

FLUNISOLIDE

	AEROSOL, METERED; INHALATION						
	AEROSPAN HFA						
		+ @ NORVIUM BIOSCIENCE	0.078MG/INH	N021247	001	Jan 27, 2006	Oct CAHN

FLUOCINOLONE ACETONIDE

	OIL; TOPICAL						
	FLUOCINOLONE ACETONIDE						
AT		RISING	0.01%	A090982	001	Apr 25, 2016	Sep CAHN
AT			0.01%	A203377	001	Apr 25, 2016	Sep CAHN
AT		TARO	0.01%	A209336	001	May 19, 2016	Jan CAHN
	OIL/DROPS; OTIC						
	FLAC						
AT		ANDA REPOSITORY	0.01%	A210736	001	Apr 11, 2018	Sep CAHN
	FLUOCINOLONE ACETONIDE						
AT		RISING	0.01%	A203378	001	Apr 25, 2016	Sep CAHN
AT		TRUPHARMA	0.01%	A213264	001	Feb 05, 2021	Aug CAHN

FLUOCINONIDE

	CREAM; TOPICAL						
	FLUOCINONIDE						
		@ AMNEAL	0.1%	A211111	001	Jun 04, 2018	Jul DISC
		@ PADAGIS ISRAEL	0.1%	A090256	001	Jan 14, 2014	Jan DISC
		+ @ TARO	0.05%	N019117	001	Jun 26, 1984	Aug CAHN
	GEL; TOPICAL						
	FLUOCINONIDE						
		+ @ ALVOGEN	0.05%	N017373	001		May DISC
		@ COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr DISC
		@ PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan CAHN
	OINTMENT; TOPICAL						
	LIDEX						
		+ @ ALVOGEN	0.05%	N016909	002		Nov DISC
	SOLUTION; TOPICAL						
	FLUOCINONIDE						
		@ COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr DISC

FLUOROURACIL

	CREAM; TOPICAL						
	CARAC						
		+! EXTROVIS	0.5%	N020985	001	Oct 27, 2000	Nov CAHN
		EFUDEX					
AB		+! EXTROVIS	5%	N016831	003		Nov CAHN
		FLUOROURACIL					
>A>		@ EXTROVIS	0.5%	A203122	001	Apr 20, 2015	Dec CAHN
		@	0.5%	A203122	001	Apr 20, 2015	Jun CAHN
>D>		@ RISING	0.5%	A203122	001	Apr 20, 2015	Dec CAHN
	INJECTABLE; INJECTION						
	FLUOROURACIL						
AP		EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr CMFD
AP			1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr CMFD
AP			2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr CMFD
AP			5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr CMFD
AP		KINDOS	2.5GM/50ML (50MG/ML)	A216494	001	Sep 24, 2024	Sep NEWA
	SOLUTION; TOPICAL						
	EFUDEX						
AT		+! EXTROVIS	2%	N016831	001		Nov CAHN
		+ @	5%	N016831	002		Nov CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1	STRIDES PHARMA	EQ 10MG BASE	A076922	001	Dec 16, 2004	Sep	CMFD
AB1		EQ 20MG BASE	A076922	002	Dec 16, 2004	Sep	CMFD
AB		EQ 40MG BASE	A076922	003	Dec 16, 2004	Sep	CMFD
	@ SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Jan	DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

	@ BAJAJ	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	Mar	CAHN
AA	UPSHER SMITH LABS	EQ 20MG BASE/5ML	A216953	001	Nov 15, 2022	Sep	CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

	@ ADAPTIS	EQ 10MG BASE	A211444	001	Sep 13, 2022	Nov	CAHN
	@	EQ 20MG BASE	A211444	002	Sep 13, 2022	Nov	CAHN
AB	ENDO OPERATIONS	EQ 10MG BASE	A203836	001	Aug 19, 2016	Apr	CAHN
AB		EQ 20MG BASE	A203836	002	Aug 19, 2016	Apr	CAHN
AB		EQ 60MG BASE	A209419	001	Nov 16, 2017	Apr	CAHN
AB	STRIDES PHARMA	EQ 10MG BASE	A212684	001	Apr 05, 2024	Mar	NEWA
AB		EQ 20MG BASE	A212684	002	Apr 05, 2024	Mar	NEWA
AB		EQ 60MG BASE	A212683	001	Sep 13, 2024	Sep	NEWA
	@ TEVA	EQ 10MG BASE	A075872	001	Jan 29, 2002	Jan	DISC
	@	EQ 20MG BASE	A075872	002	Jan 04, 2019	Jan	DISC
	@ TEVA PHARMS USA	EQ 60MG BASE	A211051	001	Dec 03, 2018	Jan	DISC
	@ UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jun	DISC
	@	EQ 20MG BASE	A211696	002	Jan 30, 2019	Jun	DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	ENDO OPERATIONS	EQ 25MG BASE;EQ 3MG BASE	A077742	001	Nov 02, 2012	Apr	CAHN
AB		EQ 25MG BASE;EQ 6MG BASE	A077742	002	Nov 02, 2012	Apr	CAHN
AB		EQ 25MG BASE;EQ 12MG BASE	A077742	003	Nov 02, 2012	Apr	CAHN
AB		EQ 50MG BASE;EQ 6MG BASE	A077742	004	Nov 02, 2012	Apr	CAHN
AB		EQ 50MG BASE;EQ 12MG BASE	A077742	005	Nov 02, 2012	Apr	CAHN

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO	ENDO OPERATIONS	25MG/ML	A203732	001	Jul 03, 2014	Apr	CAHN
----	-----------------	---------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	ALEMBIC	1MG	A218173	001	Jul 23, 2024	Jul	NEWA
AB		2.5MG	A218173	002	Jul 23, 2024	Jul	NEWA
AB		5MG	A218173	003	Jul 23, 2024	Jul	NEWA
AB		10MG	A218173	004	Jul 23, 2024	Jul	NEWA
>A>	BRECKENRIDGE	1MG	A216891	001	Nov 15, 2022	Dec	CAHN
>A>		2.5MG	A216891	002	Nov 15, 2022	Dec	CAHN
>A>		5MG	A216891	003	Nov 15, 2022	Dec	CAHN
>A>		10MG	A216891	004	Nov 15, 2022	Dec	CAHN
AB	CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Sep	CAHN
AB		2.5MG	A215141	002	Oct 20, 2021	Sep	CAHN
AB		5MG	A215141	003	Oct 20, 2021	Sep	CAHN
AB		10MG	A215141	004	Oct 20, 2021	Sep	CAHN
AB	RISING	1MG	A218283	001	Jun 07, 2024	May	NEWA
AB		2.5MG	A218283	002	Jun 07, 2024	May	NEWA
AB		5MG	A218283	003	Jun 07, 2024	May	NEWA
AB		10MG	A218283	004	Jun 07, 2024	May	NEWA
>D>	SANDOZ	1MG	A216891	001	Nov 15, 2022	Dec	CAHN
>D>		2.5MG	A216891	002	Nov 15, 2022	Dec	CAHN
>D>		5MG	A216891	003	Nov 15, 2022	Dec	CAHN
>D>		10MG	A216891	004	Nov 15, 2022	Dec	CAHN
AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb	CAHN
AB		2.5MG	A215141	002	Oct 20, 2021	Feb	CAHN
AB		5MG	A215141	003	Oct 20, 2021	Feb	CAHN
AB		10MG	A215141	004	Oct 20, 2021	Feb	CAHN

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

!	GENUS	100MG	A074431	001	May 31, 1995	Nov	CAHN
@	NATCO PHARMA	50MG	A074358	001	Jun 20, 1994	Aug	CAHN
@		100MG	A074358	002	Jun 20, 1994	Aug	CAHN

FLURPIRIDAZ F-18

SOLUTION; INTRAVENOUS

FLYRCADO

+	GE HLTHCARE	5-55mCi/ML	N215168	001	Sep 27, 2024	Sep	NEWA
---	-------------	------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

+	@ TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Jun	DISC
+	@	0.113MG/INH	N208798	005	Feb 20, 2020	Jun	DISC
+	@	0.232MG/INH	N208798	006	Feb 20, 2020	Jun	DISC

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

@	HIKMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008	Mar	DISC
---	-------	--------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO DIGIHALER

+	@ TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jun	DISC
+	@	0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jun	DISC
+	@	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jun	DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	AJANTA PHARMA LTD	100MG	A219055	001	Oct 17, 2024	Oct	NEWA
AB		150MG	A219055	002	Oct 17, 2024	Oct	NEWA
AB	ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr	CAHN
AB		150MG	A091476	002	Mar 13, 2013	Apr	CAHN

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan	NEWA
AB		50MG	A217917	002	Jan 22, 2024	Jan	NEWA
AB		100MG	A217917	003	Jan 22, 2024	Jan	NEWA

FOLIC ACID

TABLET; ORAL

FOLIC ACID

@	ENDO OPERATIONS	1MG	A040756	001	Jun 04, 2010	May	CAHN
---	-----------------	-----	---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

FONDAPARINUX SODIUM

>A>	AP	BRIGHTGENE	2.5MG/0.5ML	A218312	001	Dec 18, 2024	Dec	NEWA
	AP	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Aug	NEWA
	AP		5MG/0.4ML	A216493	002	Aug 19, 2024	Aug	NEWA
	AP		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Aug	NEWA
	AP		10MG/0.8ML	A216493	004	Aug 19, 2024	Aug	NEWA

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN	LEXENPHARM	0.02MG/2ML	A216426	001	Oct 22, 2024	Oct	NEWA
AN	MICRO LABS	0.02MG/2ML	A218304	001	Jun 26, 2024	Jun	NEWA
AN	RITEDOSE CORP	0.02MG/2ML	A216486	001	Nov 25, 2022	May	CAHN
AN	WILSHIRE PHARMS INC	0.02MG/2ML	A215621	001	Dec 13, 2022	Jul	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

>D>	+	ORGANON LLC	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Dec	CHRS
>A>	+	!	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Dec	CHRS

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB ! MYLAN EQ 700MG BASE A204060 001 Apr 15, 2016 Jan CHRS

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

@ ACCORD HLTHCARE EQ 150MG BASE/VIAL A204025 001 Aug 26, 2020 May DISC

@ GENEYORK PHARMS EQ 150MG BASE/VIAL A211624 001 Sep 05, 2019 Jul CAHN

@ NAVINTA LLC EQ 150MG BASE/VIAL A212957 002 Aug 20, 2020 Oct DISC

FOSCARBIDOPA; FOSLEVODOPA

SOLUTION; SUBCUTANEOUS

VYALEV

+! ABBVIE 120MG/10ML; 2400MG/10ML (12MG/ML; 240MG/ML) N216962 001 Oct 16, 2024 Oct NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP AMNEAL 2.4GM/100ML A216602 001 Mar 01, 2024 Feb NEWA

AP SCIECURE 2.4GM/100ML A213987 001 Nov 29, 2023 Nov CAHN

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

AA AMNEAL EQ 3GM BASE/PACKET A216600 001 Mar 25, 2024 Mar NEWA

>D> AA XIROMED EQ 3GM BASE/PACKET A212548 001 Oct 06, 2020 Dec CHRS

>A> AA ! EQ 3GM BASE/PACKET A212548 001 Oct 06, 2020 Dec CHRS

>D> MONUROL

>D> AA +! ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996 Dec DISC

>A> + @ EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996 Dec DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ NORVIUM BIOSCIENCE EQ 50MG PHENYTOIN NA/ML A078736 001 Jun 08, 2010 Jul CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

AB +! ENDO OPERATIONS EQ 2.5MG BASE N021006 001 Nov 08, 2001 Apr CAHN

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FULVESTRANT

AO @ AVYXA HOLDINGS 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019 Oct CAHN

@ FRESENIUS KABI USA 250MG/5ML (50MG/ML) N210326 001 May 20, 2019 Aug CTEC

@ TEVA PHARMS USA INC 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019 Jun DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>A> AP ASPIRO 10MG/ML A217557 001 Dec 13, 2024 Dec NEWA

AP HIKMA 10MG/ML N018267 001 Aug CMFD

AP SABA ILAC SANAYIVE 10MG/ML A215856 001 Apr 02, 2024 Mar NEWA

TABLET; ORAL

FUROSEMIDE

@ ESJAY PHARMA 20MG N018415 001 Jul 27, 1982 Oct CAHN

@ 40MG N018415 002 Jul 27, 1982 Oct CAHN

@ 80MG N018415 003 Nov 26, 1984 Oct CAHN

@ MYLAN 20MG N018487 001 Sep DISC

@ 40MG N018487 002 Sep DISC

@ 80MG A070082 001 Oct 29, 1986 Sep DISC

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

>D>	AB	IPCA LABS LTD	100MG	A208928	001	Nov 20, 2023	Dec	DISC
>A>	@		100MG	A208928	001	Nov 20, 2023	Dec	DISC
>D>	AB		300MG	A208928	002	Nov 20, 2023	Dec	DISC
>A>	@		300MG	A208928	002	Nov 20, 2023	Dec	DISC
>D>	AB		400MG	A208928	003	Nov 20, 2023	Dec	DISC
>A>	@		400MG	A208928	003	Nov 20, 2023	Dec	DISC
	AB	RISING	100MG	A207099	001	Mar 24, 2017	Aug	CAHN
	AB		300MG	A207099	002	Mar 24, 2017	Aug	CAHN
	AB		400MG	A207099	003	Mar 24, 2017	Aug	CAHN
	@	SUN PHARM INDS LTD	100MG	A077242	001	Aug 24, 2006	May	DISC
	@		300MG	A077242	002	Aug 24, 2006	May	DISC
	@		400MG	A077242	003	Aug 24, 2006	May	DISC

SOLUTION;ORAL

GABAPENTIN

AA		ANNORA PHARMA	250MG/5ML	A217682	001	Jan 17, 2024	Jan	NEWA
----	--	---------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

GABAPENTIN

AB2		ABON PHARMS LLC	600MG	A203643	001	Sep 09, 2024	Sep	CAHN
AB1		ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jan	CTEC
AB1			800MG	A075694	002	Oct 21, 2004	Jan	CTEC
AB1		ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015	Jan	CTEC
AB1			800MG	A206402	002	Dec 23, 2015	Jan	CTEC
AB2		ANNORA PHARMA	300MG	A218075	001	Feb 26, 2024	Feb	NEWA
AB2			600MG	A218075	002	Feb 26, 2024	Feb	NEWA
AB1		APOTEX	100MG	A077894	001	Oct 10, 2006	Jan	CTEC
AB1			300MG	A077894	002	Oct 10, 2006	Jan	CTEC
AB1			400MG	A077894	003	Oct 10, 2006	Jan	CTEC
AB1		ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Jan	CTEC
AB1			800MG	A214957	002	Oct 01, 2021	Jan	CTEC
AB1		AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Jan	CTEC
AB1			800MG	A200651	002	Oct 06, 2011	Jan	CTEC
AB1		CSPC OUYI	600MG	A207057	001	Oct 26, 2017	Jan	CTEC
AB1			800MG	A207057	002	Oct 26, 2017	Jan	CTEC
AB1		GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	Jan	CTEC
AB1			800MG	A077662	002	Aug 18, 2006	Jan	CTEC
AB1		GRANULES	600MG	A217116	001	Mar 28, 2023	Jan	CTEC
AB1			800MG	A217116	002	Mar 28, 2023	Jan	CTEC
AB2		HUMANWELL	300MG	A216252	001	Feb 26, 2024	Feb	NEWA
AB2			600MG	A216252	002	Feb 26, 2024	Feb	NEWA
AB2		INCEPTA PHARMS LTD	600MG	A203643	001	Sep 09, 2024	Aug	NEWA
	@	INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Mar	DISC
AB1			600MG	A202764	001	Oct 16, 2012	Jan	CTEC
	@		800MG	A202764	002	Oct 16, 2012	Mar	DISC
AB1			800MG	A202764	002	Oct 16, 2012	Jan	CTEC
>D>	AB1	IPCA LABS LTD	600MG	A209855	001	May 29, 2024	Dec	DISC
>A>	@		600MG	A209855	001	May 29, 2024	Dec	DISC
	AB1		600MG	A209855	001	May 29, 2024	May	NEWA
>D>	AB1		800MG	A209855	002	May 29, 2024	Dec	DISC
>A>	@		800MG	A209855	002	May 29, 2024	Dec	DISC
	AB1		800MG	A209855	002	May 29, 2024	May	NEWA
	AB1	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan	CTEC
	AB1		300MG	A076017	002	Apr 28, 2004	Jan	CTEC
	AB1		400MG	A076017	003	Apr 28, 2004	Jan	CTEC
	AB1	LAURUS	600MG	A217965	001	Apr 08, 2024	Mar	NEWA
	AB1		800MG	A217965	002	Apr 08, 2024	Mar	NEWA
	AB1	RISING	600MG	A217995	001	Jul 19, 2023	Jan	CTEC
	AB1		800MG	A217995	002	Jul 19, 2023	Jan	CTEC
	AB1	RUBICON	600MG	A077661	004	Sep 13, 2006	Jan	CTEC
	AB1		800MG	A077661	005	Sep 13, 2006	Jan	CTEC
	AB1	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	CTEC
	AB1		800MG	A205101	002	Feb 04, 2016	Jan	CTEC
>A>	AB1	STRIDES PHARMA	100MG	A211313	003	Dec 20, 2024	Dec	NEWA
>A>	AB1		400MG	A211313	004	Dec 20, 2024	Dec	NEWA
	AB1		600MG	A211313	001	Mar 04, 2024	Feb	NEWA
	AB1		800MG	A211313	002	Mar 04, 2024	Feb	NEWA
	@	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Oct	DISC
	AB1		600MG	A077525	001	Aug 24, 2006	Jan	CTEC
	@		800MG	A077525	002	Aug 24, 2006	Oct	DISC
	AB1		800MG	A077525	002	Aug 24, 2006	Jan	CTEC

TABLET; ORAL

GABAPENTIN

AB2	ZYDUS PHARMS	300MG	A203934	001	Jan 24, 2024	Jan NEWA
AB2		600MG	A203934	002	Jan 24, 2024	Jan NEWA
AB1	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan CTEC
AB1		800MG	A078926	002	Feb 11, 2011	Jan CTEC
<u>GRALISE</u>						
AB2	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CTEC
AB2	+	600MG	N022544	002	Jan 28, 2011	Jan CTEC
EX	+	600MG	N022544	002	Jan 28, 2011	Jan CHRS
	+!	900MG	N022544	005	Apr 18, 2023	Jan CHRS
<u>NEURONTIN</u>						
AB1	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan CTEC
AB1	+!	800MG	N020882	002	Oct 09, 1998	Jan CTEC

GADOBUTROL

SOLUTION; INTRAVENOUS

GADOBUTROL

AP	HENGRUI PHARMA	1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jul CMS1
AP		4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jul CMS1
AP		6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jul CMS1
AP		9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jul CMS1

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+	@ GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar CRLD
+	@	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar DISC

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

GADOTERATE MEGLUMINE

AP	HAINAN POLY	1.8845GM/5ML (376.9MG/ML)	A218073	001	Jun 17, 2024	Jun NEWA
AP		3.769GM/10ML (376.9MG/ML)	A218073	002	Jun 17, 2024	Jun NEWA
AP		5.6535GM/15ML (376.9MG/ML)	A218073	003	Jun 17, 2024	Jun NEWA
AP		7.538GM/20ML (376.9MG/ML)	A218073	004	Jun 17, 2024	Jun NEWA
AP		37.69GM/100ML (376.9MG/ML)	A218073	005	Jun 17, 2024	Jun NEWA

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

AP	ENDO OPERATIONS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May CAHN
----	-----------------	--------------------	---------	-----	--------------	----------

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

@	HIKMA	0.5%	A203189	001	Sep 03, 2014	Mar DISC
---	-------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

@	ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr DISC
@		EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr DISC
@		EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr DISC

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	EPIC PHARMA LLC	600MG	A078012	001	Mar 26, 2007	Oct CAHN
----	-----------------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTAK

>A>	@ RENOVA PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Dec CAHN
	@ SAPTALIS PHARMS	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb CAHN
>D>	@ SCIEGEN PHARMS INC	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Dec CAHN

GEPIRONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
EXXUA

+ @	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun	DISC
+ @		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun	DISC
+ @		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun	DISC
+ @		EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun	DISC

GIVINOSTAT HYDROCHLORIDE

SUSPENSION;ORAL
DUVYZAT

+!	ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar	NEWA
----	-----------------	-------------------	---------	-----	--------------	-----	------

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS
GLATIRAMER ACETATE

AP	SYNTHON PHARMS INC	20MG/ML	A203857	001	Sep 25, 2024	Sep	NEWA
AP		40MG/ML	A206873	001	Sep 25, 2024	Sep	NEWA

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

>A>	AB	CHARTWELL RX	2MG;30MG	A201049	001	Jan 04, 2013	Dec	CAHN
>A>	AB		4MG;30MG	A201049	002	Jan 04, 2013	Dec	CAHN
>D>	AB	SANDOZ	2MG;30MG	A201049	001	Jan 04, 2013	Dec	CAHN
>D>	AB		4MG;30MG	A201049	002	Jan 04, 2013	Dec	CAHN

GLIPIZIDE

TABLET;ORAL
GLIPIZIDE

@	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	May	DISC
@		10MG	A074550	002	Sep 11, 1997	May	DISC
@	SANDOZ	5MG	A074305	001	Apr 07, 1995	Jun	DISC
@		10MG	A074305	002	Apr 07, 1995	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL
GLIPIZIDE

	@	ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May	CAHN
	@		10MG	A076159	001	Sep 20, 2013	May	CAHN
AB	!	UNIQUE	10MG	A204720	003	Dec 29, 2016	Nov	CHRS
		GLUCOTROL XL						
	+ @	PFIZER	5MG	N020329	001	Apr 26, 1994	Nov	DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@	ESJAY PHARMA	2.5MG;250MG	A078083	001	Apr 12, 2007	Nov	CAHN
@		2.5MG;500MG	A078083	002	Apr 12, 2007	Nov	CAHN
@		5MG;500MG	A078083	003	Apr 12, 2007	Nov	CAHN

GLUCAGON

INJECTABLE;INJECTION
GLUCAGON

AP	!	AMPHASTAR PHARMS INC	1MG/VIAL	A208086	001	Dec 28, 2020	Nov	CTEC
AP		MYLAN LABS LTD	1MG/VIAL	A204468	001	Dec 12, 2024	Nov	NEWA

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
GLUCAGON

+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019	Apr	CMS1
----	--------------------	------------------	---------	-----	--------------	-----	------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		HERITAGE	1.25MG;250MG	A079009	001	Jun 03, 2009	Feb	CMFD
AB			2.5MG;500MG	A079009	002	Jun 03, 2009	Feb	CMFD
AB			5MG;500MG	A079009	003	Jun 03, 2009	Feb	CMFD

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

GLYCEROL PHENYLBUTYRATE

@ ENDO OPERATIONS 1.1GM/ML A205742 001 Dec 02, 2021 May CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP NIVAGEN PHARMS INC 0.2MG/ML A212591 001 Oct 13, 2021 Feb CAHN
 AP OMNIVIUM PHARMS 0.2MG/ML A212871 001 Nov 29, 2022 Sep CAHN
 AP UMEDICA 0.2MG/ML A212591 001 Oct 13, 2021 Aug CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

+ @ EXELA PHARMA 0.6MG/3ML (0.2MG/ML) N210997 004 Dec 14, 2020 Sep DISC

SOLUTION; ORAL

GLYCOPYRROLATE

>A> AA AUROBINDO PHARMA LTD 1MG/5ML A214847 001 Dec 31, 2024 Dec NEWA
 AA CHARTWELL RX 1MG/5ML A216368 001 Aug 28, 2024 Aug NEWA
 AA GRANULES 1MG/5ML A214735 001 Aug 19, 2024 Aug NEWA
 AA SAPTALIS PHARMS 1MG/5ML A216297 001 Oct 07, 2024 Sep NEWA

TABLET; ORAL

GLYCOPYRROLATE

AA ADAPTIS 1MG A091182 001 Feb 03, 2014 Aug CAHN
 AA 2MG A091182 002 Feb 03, 2014 Aug CAHN
 AA APPCO 1MG A207201 001 Jan 03, 2017 Nov CAHN
 AA 2MG A207201 002 Jan 03, 2017 Nov CAHN
 >D> AA DR REDDYS LABS LTD 1MG A040847 001 Mar 21, 2008 Dec CAHN
 >D> AA 2MG A040847 002 Mar 21, 2008 Dec CAHN
 >A> AA INDICUS PHARMA 1MG A040847 001 Mar 21, 2008 Dec CAHN
 >A> AA 2MG A040847 002 Mar 21, 2008 Dec CAHN
 ! LGM PHARMA 1.5MG A091522 001 Mar 12, 2012 Jul CHRS
 AA QUAGEN 1MG A212696 001 Jul 10, 2024 Jun NEWA
 AA 2MG A212696 002 Jul 10, 2024 Jun NEWA
 AA VELZEN PHARMA PVT 1MG A090195 001 Sep 21, 2012 Aug CAHN
 AA 2MG A090195 002 Sep 21, 2012 Aug CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

PREVDUO

+! AZURITY 0.6MG/3ML (0.2MG/ML); 3MG/3ML (1MG/ML) N216903 001 Feb 23, 2023 Feb CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT NORDIC PHARMA 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML A065187 001 Oct 28, 2005 Jun CAHN

GRANISETRON

INJECTABLE; SUBCUTANEOUS

SUSTOL

+! HERON THERAPS INC 10MG/0.4ML (10MG/0.4ML) N022445 001 Aug 09, 2016 Aug CMS1

GRISEOFULVIN, MICROSIZE

TABLET; ORAL

FULVICIN-U/F

AB CHARTWELL RX 250MG A060569 002 Jan CTEC
 250MG A060569 002 Jan CAIN
 AB 500MG A060569 001 Jan CTEC
 500MG A060569 001 Jan CAIN

GRISEOFULVIN

AB SANDOZ 250MG A091592 001 Aug 07, 2013 Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

FULVICIN P/G

AB CHARTWELL RX 125MG A061996 001 Jan CTEC
 125MG A061996 001 Jan CAIN
 AB 250MG A061996 002 Jan CTEC
 250MG A061996 002 Jan CAIN

TABLET;ORAL

FULVICIN P/G 165

CHARTWELL RX

165MG

A 061996 003 Apr 06, 1982 Jan CAIN

FULVICIN P/G 330

CHARTWELL RX

330MG

A 061996 004 Apr 06, 1982 Jan CAIN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB XIROMED

EQ 1MG BASE

A 218326 001 Feb 23, 2024 Feb NEWA

AB

EQ 2MG BASE

A 218326 002 Feb 23, 2024 Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB UNICHEM

EQ 1MG BASE

A 219033 001 Nov 19, 2024 Nov NEWA

AB

EQ 2MG BASE

A 219033 002 Nov 19, 2024 Nov NEWA

AB

EQ 3MG BASE

A 219033 003 Nov 19, 2024 Nov NEWA

AB

EQ 4MG BASE

A 219033 004 Nov 19, 2024 Nov NEWA

>D> AB

WANBANG BIOPHARMS

EQ 1MG BASE

A 217638 001 Jun 12, 2024 Dec DISC

>A> @

EQ 1MG BASE

A 217638 001 Jun 12, 2024 Dec DISC

AB

EQ 1MG BASE

A 217638 001 Jun 12, 2024 May NEWA

>D> AB

EQ 2MG BASE

A 217638 002 Jun 12, 2024 Dec DISC

>A> @

EQ 2MG BASE

A 217638 002 Jun 12, 2024 Dec DISC

AB

EQ 2MG BASE

A 217638 002 Jun 12, 2024 May NEWA

>D> AB

EQ 3MG BASE

A 217638 003 Jun 12, 2024 Dec DISC

>A> @

EQ 3MG BASE

A 217638 003 Jun 12, 2024 Dec DISC

AB

EQ 3MG BASE

A 217638 003 Jun 12, 2024 May NEWA

>D> AB

EQ 4MG BASE

A 217638 004 Jun 12, 2024 Dec DISC

>A> @

EQ 4MG BASE

A 217638 004 Jun 12, 2024 Dec DISC

AB

EQ 4MG BASE

A 217638 004 Jun 12, 2024 May NEWA

HALCINONIDE

OINTMENT;TOPICAL

HALOG

+ @ SUN PHARM INDS INC

0.1%

N 017824 001 Jan DISC

SOLUTION;TOPICAL

HALCINONIDE

ENCUBE

0.1%

A 217671 001 May 29, 2024 May NFTG

HALOBETASOL PROPIONATE

LOTION;TOPICAL

ULTRAVATE

+ @ MICAL PHARMS

0.05%

N 208183 001 Nov 06, 2015 May CAHN

+ @ SUN PHARM INDUSTRIES

0.05%

N 208183 001 Nov 06, 2015 May DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB AIPING PHARM INC

2MG

A 071130 001 Feb 17, 1987 Oct CAHN

AB

5MG

A 071130 002 Feb 17, 1987 Oct CAHN

AB

10MG

A 071130 003 May 12, 1987 Oct CAHN

AB AUROBINDO PHARMA LTD

0.5MG

A 218789 001 Apr 19, 2024 Apr NEWA

AB

1MG

A 218789 002 Apr 19, 2024 Apr NEWA

AB

2MG

A 218789 003 Apr 19, 2024 Apr NEWA

AB

5MG

A 218789 004 Apr 19, 2024 Apr NEWA

AB

10MG

A 218789 005 Apr 19, 2024 Apr NEWA

AB

20MG

A 218789 006 Apr 19, 2024 Apr NEWA

AB CHARTWELL RX

0.5MG

A 071209 002 Nov 17, 1986 Jan CAHN

AB

1MG

A 071209 003 Nov 17, 1986 Jan CAHN

@

2MG

A 071209 004 Nov 17, 1986 Jan CAHN

AB

5MG

A 071209 001 Nov 17, 1986 Jan CAHN

AB

10MG

A 071210 001 Mar 11, 1988 Jan CAHN

AB

20MG

A 071211 001 Mar 11, 1988 Jan CAHN

AB MANKIND PHARMA

0.5MG

A 216918 001 Apr 11, 2024 Apr NEWA

AB

1MG

A 216918 002 Apr 11, 2024 Apr NEWA

AB

2MG

A 216918 003 Apr 11, 2024 Apr NEWA

AB

5MG

A 216918 004 Apr 11, 2024 Apr NEWA

AB

10MG

A 216918 005 Apr 11, 2024 Apr NEWA

AB

20MG

A 216918 006 Apr 11, 2024 Apr NEWA

AB SCIEGEN PHARMS INC

5MG

A 071130 002 Feb 17, 1987 May CMS1

AB

10MG

A 071130 003 May 12, 1987 May CMS1

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
 HALOPERIDOL DECANOATE
 @ TEVA PHARMS USA EQ 50MG BASE/ML
 @ EQ 100MG BASE/ML

A075393 001 May 11, 1999 Jan DISC
 A075393 002 May 11, 1999 Jan DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
 HALOPERIDOL

AA RUBICON EQ 2MG BASE/ML

A218371 001 Jan 31, 2024 Jan NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION
 HEPARIN SODIUM

@ ASPEN GLOBAL INC 1,000 UNITS/ML
 @ 5,000 UNITS/ML
 @ 10,000 UNITS/ML

N000552 008 Jun CAHN
 N000552 009 Jun CAHN
 N000552 010 Jun CAHN

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+! HOSPIRA 5,000 UNITS/100ML
 + 5,000 UNITS/100ML

N018916 006 Jan 31, 1984 Oct CHRS
 N018916 006 Jan 31, 1984 Oct CRLD

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%

+ @ FRESENIUS KABI USA 40 UNITS/ML
 +! 40 UNITS/ML

N017029 021 Aug 24, 2017 Sep DISC
 N017029 021 Aug 24, 2017 Mar NEWA

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

+! FRESENIUS KABI USA 50 UNITS/ML
 +! 100 UNITS/ML

N017029 022 Aug 24, 2017 Mar NEWA
 N017029 023 Aug 24, 2017 Mar NEWA

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

+! FRESENIUS KABI USA 50 UNITS/ML
 +! 100 UNITS/ML

N017029 024 Aug 24, 2017 Mar NEWA
 N017029 025 Aug 24, 2017 Mar NEWA

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+! HOSPIRA 5,000 UNITS/100ML
 + 5,000 UNITS/100ML
 +! 10,000 UNITS/100ML
 + 10,000 UNITS/100ML

N018916 007 Jan 31, 1984 Oct CHRS
 N018916 007 Jan 31, 1984 Oct CRLD
 N018916 008 Jan 31, 1984 Oct CHRS
 N018916 008 Jan 31, 1984 Oct CRLD

LIQUAEMIN LOCK FLUSH

@ ASPEN GLOBAL INC 100 UNITS/ML
 LIQUAEMIN SODIUM

N000552 007 Jun CAHN

@ ASPEN GLOBAL INC 1,000 UNITS/ML
 @ 5,000 UNITS/ML
 @ 10,000 UNITS/ML
 @ 20,000 UNITS/ML
 @ 40,000 UNITS/ML

N000552 004 Jun CAHN
 N000552 003 Jun CAHN
 N000552 005 Jun CAHN
 N000552 001 Jun CAHN
 N000552 002 Jun CAHN

LIQUAEMIN SODIUM PRESERVATIVE FREE

@ ASPEN GLOBAL INC 1,000 UNITS/ML
 @ 5,000 UNITS/ML
 @ 10,000 UNITS/ML

N000552 011 Apr 11, 1986 Jun CAHN
 N000552 012 Apr 11, 1986 Jun CAHN
 N000552 013 Apr 11, 1986 Jun CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS
 SUPPRELIN LA

+! ENDO OPERATIONS 50MG
 VANTAS

N022058 001 May 03, 2007 Apr CAHN

+ @ ENDO OPERATIONS 50MG

N021732 001 Oct 12, 2004 May CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA ! ABHAI LLC 1.5MG/5ML; 5MG/5ML
 @ GENUS 1.5MG/5ML; 5MG/5ML
 @ PAI HOLDINGS PHARM 1.5MG/5ML; 5MG/5ML
 @ SCIEGEN PHARMS INC 1.5MG/5ML; 5MG/5ML

A207487 001 Feb 21, 2017 Mar CHRS
 A040613 001 Feb 08, 2008 Apr CAHN
 A040613 001 Feb 08, 2008 Mar DISC
 A204765 001 Mar 06, 2017 Sep CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 HYDRALAZINE HYDROCHLORIDE

AP ADRASTEIA PHARMA 20MG/ML
 AP ! FRESENIUS KABI USA 20MG/ML
 @ NORVIUM BIOSCIENCE 20MG/ML
 AP RISING 20MG/ML

A203110 001 Jun 29, 2015 Feb CAHN
 A040388 001 Mar 13, 2001 Aug CHRS
 A204680 001 Apr 28, 2016 Jun CAHN
 A040730 001 Apr 21, 2009 Aug CHRS

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA	GLENMARK PHARMS LTD	10MG	A 090527	001	May 29, 2009	Jul	CMS1
AA		25MG	A 090527	002	May 29, 2009	Jul	CMS1
AA		50MG	A 090527	003	May 29, 2009	Jul	CMS1
AA		100MG	A 090527	004	May 29, 2009	Jul	CMS1
	@ INVAGEN PHARMS	10MG	A 090255	001	Dec 15, 2008	Mar	DISC
	@	25MG	A 090255	002	Dec 15, 2008	Mar	DISC
	@	50MG	A 090255	003	Dec 15, 2008	Mar	DISC
	@	100MG	A 090255	004	Dec 15, 2008	Mar	DISC
AA	MACLEODS PHARMS LTD	10MG	A 211010	001	Aug 21, 2024	Aug	NEWA
AA		25MG	A 211010	002	Aug 21, 2024	Aug	NEWA
AA		50MG	A 211010	003	Aug 21, 2024	Aug	NEWA
AA		100MG	A 211010	004	Aug 21, 2024	Aug	NEWA
	@ NORVIUM BIOSCIENCE	10MG	A 090413	001	Dec 08, 2010	Jul	CAHN
	@	25MG	A 090413	002	Dec 08, 2010	Jul	CAHN
	@	50MG	A 090413	003	Dec 08, 2010	Jul	CAHN
	@	100MG	A 090413	004	Dec 08, 2010	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB	I3 PHARMS	37.5MG;20MG	A 215988	001	Jan 17, 2024	Jan	NEWA
----	-----------	-------------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	IPCA LABS LTD	12.5MG	A 079237	001	Apr 02, 2009	Dec	DISC
>A>		@	12.5MG	A 079237	001	Apr 02, 2009	Dec	DISC

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	AB	ACCORD HLTHCARE	12.5MG	A 202556	001	Sep 24, 2012	Nov	CHRS
>D>	AB	IPCA LABS LTD	12.5MG	A 040807	001	Jul 20, 2007	Dec	DISC
>A>		@	12.5MG	A 040807	001	Jul 20, 2007	Dec	DISC
>D>	AB		25MG	A 040807	002	Jul 20, 2007	Dec	DISC
>A>		@	25MG	A 040807	002	Jul 20, 2007	Dec	DISC
>D>	AB		50MG	A 040807	003	Jul 20, 2007	Dec	DISC
>A>		@	50MG	A 040807	003	Jul 20, 2007	Dec	DISC
	AB	+ IVAX SUB TEVA PHARMS	12.5MG	A 083177	003	Sep 19, 2024	Nov	CRLD
	AB		12.5MG	A 083177	003	Sep 19, 2024	Sep	NEWA
		@ PRINSTON INC	25MG	A 040412	001	Mar 29, 2002	Aug	DISC
		@	50MG	A 040412	002	Mar 29, 2002	Aug	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	COREPHARMA	12.5MG;10MG	A 076674	001	Oct 05, 2004	Sep	CMFD
AB		12.5MG;20MG	A 076674	002	Oct 05, 2004	Sep	CMFD
AB		25MG;20MG	A 076674	003	Oct 05, 2004	Sep	CMFD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>A>	AB	CHARTWELL RX	12.5MG;50MG	A 077948	001	Oct 06, 2010	Dec	CAHN
>A>	AB		12.5MG;100MG	A 077948	003	Aug 19, 2010	Dec	CAHN
>A>	AB		25MG;100MG	A 077948	002	Oct 06, 2010	Dec	CAHN
		@ GRANULES	12.5MG;50MG	A 218015	001	Sep 29, 2023	Mar	DISC
		@	12.5MG;100MG	A 218015	002	Sep 29, 2023	Mar	DISC
		@	25MG;100MG	A 218015	003	Sep 29, 2023	Mar	DISC
>D>	AB	IPCA LABS LTD	12.5MG;50MG	A 201682	001	Mar 01, 2013	Dec	DISC
>A>		@	12.5MG;50MG	A 201682	001	Mar 01, 2013	Dec	DISC
>D>	AB		12.5MG;100MG	A 201682	002	Mar 01, 2013	Dec	DISC
>A>		@	12.5MG;100MG	A 201682	002	Mar 01, 2013	Dec	DISC
>D>	AB		25MG;100MG	A 201682	003	Mar 01, 2013	Dec	DISC
>A>		@	25MG;100MG	A 201682	003	Mar 01, 2013	Dec	DISC
>D>	AB	SANDOZ	12.5MG;50MG	A 077948	001	Oct 06, 2010	Dec	CAHN
>D>	AB		12.5MG;100MG	A 077948	003	Aug 19, 2010	Dec	CAHN
>D>	AB		25MG;100MG	A 077948	002	Oct 06, 2010	Dec	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

@	SUN PHARM INDS	25MG;50MG	A 090654	001	Jan 19, 2012	May	DISC
@		25MG;100MG	A 090654	002	Jan 19, 2012	May	DISC
@		50MG;100MG	A 090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

AB	ALKEM LABS LTD	12.5MG;20MG	A 207037	001	Jul 11, 2024	Jul	NEWA
AB		12.5MG;40MG	A 207037	002	Jul 11, 2024	Jul	NEWA
AB		25MG;40MG	A 207037	003	Jul 11, 2024	Jul	NEWA
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE						
@	TEVA PHARMS USA	12.5MG;40MG	A 200532	002	Apr 24, 2017	May	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	CHARTWELL RX	12.5MG;EQ 10MG BASE	A 076374	001	Mar 31, 2004	Oct	CMFD
AB		12.5MG;EQ 20MG BASE	A 076374	002	Mar 31, 2004	Oct	CMFD
AB		25MG;EQ 20MG BASE	A 076374	003	Mar 31, 2004	Oct	CMFD
@	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A 201356	001	Apr 20, 2011	Mar	DISC
@		12.5MG;EQ 20MG BASE	A 201356	002	Apr 20, 2011	Mar	DISC
@		25MG;EQ 20MG BASE	A 201356	003	Apr 20, 2011	Mar	DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>	AB	CHARTWELL RX	50MG;75MG	A 072011	001	Jun 17, 1988	Dec	CAHN
>D>	AB	SANDOZ	50MG;75MG	A 072011	001	Jun 17, 1988	Dec	CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

>D>	AB	ALVOGEN	120MG	A 208269	007	Mar 01, 2021	Dec	CTEC
>A>			120MG	A 208269	007	Mar 01, 2021	Dec	CTEC
		HYSINGLA ER						
>D>	AB	+ PURDUE PHARMA LP	120MG	N 206627	007	Nov 20, 2014	Dec	DISC
>A>		+ @	120MG	N 206627	007	Nov 20, 2014	Dec	DISC

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE

>D>	AB	NOSTRUM LABS INC	5MG;200MG	A 077723	003	Nov 06, 2006	Dec	DISC
>A>		@	5MG;200MG	A 077723	003	Nov 06, 2006	Dec	DISC

HYDROCODONE BITARTRATE AND IBUPROFEN

>D>	AB	AMNEAL PHARMS NY	5MG;200MG	A 076642	002	Mar 18, 2004	Dec	CTEC
>A>			5MG;200MG	A 076642	002	Mar 18, 2004	Dec	CTEC
>D>	AB	NOSTRUM LABS INC	7.5MG;200MG	A 077723	001	Nov 06, 2006	Dec	DISC
>A>		@	7.5MG;200MG	A 077723	001	Nov 06, 2006	Dec	DISC
>D>			10MG;200MG	A 077723	002	Nov 06, 2006	Dec	DISC
>A>		@	10MG;200MG	A 077723	002	Nov 06, 2006	Dec	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A 206661	001	Jan 23, 2019	Sep	CAHN
---	--------------------	------------------	----------	-----	--------------	-----	------

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB	HIBROW HLTHCARE	5MG	A 217160	001	Nov 25, 2024	Nov	NEWA
AB		10MG	A 217160	002	Nov 25, 2024	Nov	NEWA
AB		20MG	A 217160	003	Nov 25, 2024	Nov	NEWA

HYDROCORTISONE ACETATE

CREAM; TOPICAL
MICORT-HC

LEGACY PHARMA 2.5% A040396 001 Feb 27, 2001 Nov CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

CREAM; TOPICAL
PRAMOSONE

LEGACY PHARMA 0.5%;1% A083778 001 Nov CAHN
1%;1% A085368 001 Nov CAHN

LOTION; TOPICAL
PRAMOSONE

LEGACY PHARMA 1%;1% A085980 001 Nov CAHN
2.5%;1% A085979 001 Nov CAHN

HYDROCORTISONE BUTYRATE

LOTION; TOPICAL
HYDROCORTISONE BUTYRATE

AB ! LUPIN LTD 0.1% A210209 001 Aug 17, 2018 Aug CHRS
LOCOID
+ @ BAUSCH 0.1% N022076 001 May 18, 2007 Aug DISC

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL
PANDEL

+ @ ANI PHARMS 0.1% N020453 001 Feb 28, 1997 Oct DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE

AP CIPLA EQ 100MG BASE/VIAL A214050 001 Sep 05, 2024 Aug NFTG
SOLU-CORTEF
AP +! PHARMACIA AND UPJOHN EQ 100MG BASE/VIAL N009866 001 Aug CFTG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID

AP +! FRESENIUS KABI USA 0.2MG/ML N019034 006 Jan 16, 2020 Feb CFTG
AP +! 0.5MG/0.5ML N019034 007 Feb 10, 2017 Feb CFTG
+! 0.5MG/0.5ML N019034 007 Feb 10, 2017 Jan NEWA
AP +! 4MG/ML N019034 005 Apr 30, 2009 Aug CMFD

HYDROMORPHONE HYDROCHLORIDE

AP HIKMA 0.2MG/ML A216899 001 Feb 09, 2024 Feb NFTG
AP 0.5MG/0.5ML A216899 002 Feb 09, 2024 Feb NFTG
AP 1MG/ML A216899 003 Feb 09, 2024 Feb NEWA
AP 2MG/ML A216899 004 Feb 09, 2024 Feb NEWA
AP HOSPIRA INC 4MG/ML N200403 003 Dec 01, 2011 Aug CTEC

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ CHARTWELL 5MG/5ML A207108 001 Apr 22, 2020 Sep CAHN
@ GENUS 5MG/5ML A207108 001 Apr 22, 2020 Jan CAHN
@ GENUS LIFESCIENCES 5MG/5ML A207108 001 Apr 22, 2020 Nov CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ CHARTWELL 2MG A077471 002 Dec 09, 2009 Sep CAHN
@ 4MG A077471 003 Dec 09, 2009 Sep CAHN
@ 8MG A077471 001 Dec 09, 2009 Sep CAHN
@ GENUS 2MG A077471 002 Dec 09, 2009 Jan CAHN
@ 4MG A077471 003 Dec 09, 2009 Jan CAHN
@ 8MG A077471 001 Dec 09, 2009 Jan CAHN
@ GENUS LIFESCIENCES 2MG A077471 002 Dec 09, 2009 Nov CAHN
@ 4MG A077471 003 Dec 09, 2009 Nov CAHN
@ 8MG A077471 001 Dec 09, 2009 Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

HYDROMORPHONE HYDROCHLORIDE

OSMOTICA PHARM US 24MG A205629 005 Oct 30, 2024 Oct NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ALLIED	200MG	A040150	001	Jan 27, 1996	Jun	CAHN
AB	!	APPCO	100MG	A210441	002	Sep 19, 2022	Jun	CHRS
AB		CREEKWOOD PHARMS	200MG	A040150	001	Jan 27, 1996	Jul	CAHN
AB			200MG	A040150	001	Jan 27, 1996	Apr	CMFD
		@	200MG	A040150	001	Jan 27, 1996	Jan	CAHN
AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb	CAHN
AB		TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb	CMFD
		PLAQUENIL						
>A>	AB	+!	ADVANZ PHARMA	200MG	N009768	001		Dec CAHN
>D>	AB	+!	CONCORDIA	200MG	N009768	001		Dec CAHN

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

		+ @	BAUSCH AND LOMB INC	5MG	N018771	001		Jul DISC
--	--	-----	---------------------	-----	---------	-----	--	----------

HYDROXYUREA

CAPSULE; ORAL

DROXIA

		+ @	CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998	Oct DISC
		+ @		300MG	N016295	003	Feb 25, 1998	Oct DISC
		+ @		400MG	N016295	004	Feb 25, 1998	Oct DISC

HYDROXYUREA

AB			QILU	500MG	A218021	001	Mar 06, 2024	Feb NEWA
----	--	--	------	-------	---------	-----	--------------	----------

SOLUTION; ORAL

XROMI

		+!	NOVA LABS LTD	100MG/ML	N216593	001	Apr 04, 2024	Apr NEWA
--	--	----	---------------	----------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA			APOZEAL PHARMS	10MG/5ML	A210634	001	Feb 26, 2019	Jun CMFD
AA			PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Oct CMFD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

		@	INVAGEN PHARMS	10MG	A040812	001	Mar 12, 2008	Mar DISC
		@		25MG	A040812	002	Mar 12, 2008	Mar DISC
		@		50MG	A040812	003	Mar 12, 2008	Mar DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	!		HERITAGE PHARMA	EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jul CHRS
AB			SANDOZ	EQ 50MG HYDROCHLORIDE	A086183	001		Jul CHRS
			VISTARIL					
		+ @	PFIZER	EQ 100MG HYDROCHLORIDE	N011459	006		Jul CRLD

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

AP			CHEMI SPA	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	Nov CAHN
		@	SUN PHARM	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	May DISC

TABLET; ORAL

IBANDRONATE SODIUM

		@	WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May DISC
--	--	---	------------------	---------------	---------	-----	--------------	----------

IBRUTINIB

CAPSULE; ORAL

IBRUTINIB

		@	ZYDUS LIFESCIENCES	70MG	A211344	001	Mar 31, 2021	Sep CAHN
		@		140MG	A211344	002	Mar 31, 2021	Sep CAHN

TABLET; ORAL

IMBRUVICA

		+!	PHARMACYCLICS LLC	420MG	N210563	003	Feb 16, 2018	Jan CHRS
--	--	----	-------------------	-------	---------	-----	--------------	----------

IBUPROFEN

TABLET; ORAL		IBUPROFEN					
AB	DR REDDYS	400MG		A 075682	001	Nov 14, 2001	Nov CAHN
AB		600MG		A 075682	002	Nov 14, 2001	Nov CAHN
AB	!	800MG		A 075682	003	Nov 14, 2001	Nov CAHN
	@ ENDO OPERATIONS	300MG		A 071230	001	Oct 22, 1986	May CAHN
	@	400MG		A 071231	001	Oct 22, 1986	May CAHN
	@	400MG		A 071644	001	Feb 01, 1988	May CAHN
	@	600MG		A 071232	001	Oct 22, 1986	May CAHN
	@	800MG		A 072004	001	Nov 18, 1987	May CAHN
	SHANDONG XINHUA	300MG		A 202413	004	Jul 05, 2024	Jul NEWA

IBUTILIDE FUMARATE

INJECTABLE; INJECTION		IBUTILIDE FUMARATE					
AP	AVET LIFESCIENCES	0.1MG/ML		A 204146	001	Apr 01, 2024	Mar NEWA

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS		ICATIBANT ACETATE					
AP	ALEMBIC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A 213773	001	Jun 14, 2024	Jun NEWA
AP	WILSHIRE PHARMS INC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)		A 211501	001	Sep 01, 2020	Jul CAHN

ICOSAPENT ETHYL

CAPSULE; ORAL		ICOSAPENT ETHYL					
AB	ASCENT PHARMS INC	1GM		A 216811	002	Feb 16, 2024	Feb NEWA
AB	QILU	1GM		A 218899	001	Nov 20, 2024	Nov NEWA
>A>	AB SPRIASO LLC	1GM		A 218994	001	Dec 20, 2024	Dec NEWA
AB	ZYDUS LIFESCIENCES	500MG		A 217656	001	Apr 20, 2023	Apr CAHN
AB		1GM		A 217656	002	Apr 20, 2023	Apr CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION		IDARUBICIN HYDROCHLORIDE					
	@ RISING	1MG/ML		A 200144	001	Oct 11, 2012	Feb CAHN

IFOSFAMIDE

INJECTABLE; INJECTION		IFOSFAMIDE					
>A>	@ EXTROVIS	1GM/20ML (50MG/ML)		A 201689	001	Nov 26, 2012	Dec CAHN
	@	1GM/20ML (50MG/ML)		A 201689	001	Nov 26, 2012	Jun CAHN
>A>	@	3GM/60ML (50MG/ML)		A 201689	002	Nov 26, 2012	Dec CAHN
	@	3GM/60ML (50MG/ML)		A 201689	002	Nov 26, 2012	Jun CAHN
>D>	@ RISING	1GM/20ML (50MG/ML)		A 201689	001	Nov 26, 2012	Dec CAHN
>D>	@	3GM/60ML (50MG/ML)		A 201689	002	Nov 26, 2012	Dec CAHN

ILOPROST

SOLUTION; INHALATION		VENTAVIS					
+	@ ACTELION	10MCG/ML (10MCG/ML)		N 021779	002	Dec 08, 2005	Mar DISC
+	@	20MCG/ML (20MCG/ML)		N 021779	003	Aug 07, 2009	Mar DISC
SOLUTION; INTRAVENOUS		AURLUMYN					
+	! BTG INTL	100MCG/ML (100MCG/ML)		N 217933	001	Feb 13, 2024	Nov CAHN
+	! EICOS SCI	100MCG/ML (100MCG/ML)		N 217933	001	Feb 13, 2024	Feb NEWA

IMATINIB MESYLATE

SOLUTION; ORAL		IMKELDI					
+	! SHORLA ONCOLOGY	EQ 80MG BASE/ML		N 219097	001	Nov 22, 2024	Nov NEWA
TABLET; ORAL		IMATINIB MESYLATE					
	@ ALLIED	EQ 100MG BASE		A 205990	001	Feb 08, 2019	Nov CAHN
	@	EQ 400MG BASE		A 205990	002	Feb 08, 2019	Nov CAHN
	@ ESJAY PHARMA	EQ 100MG BASE		A 205990	001	Feb 08, 2019	Nov CAHN
	@	EQ 400MG BASE		A 205990	002	Feb 08, 2019	Nov CAHN

IMETELSTAT SODIUMPOWDER; INTRAVENOUS
RYTELO

+!	GERON	EQ 47MG BASE/VIAL	N217779	001	Jun 06, 2024	Jun	NEWA
+!		EQ 188MG BASE/VIAL	N217779	002	Jun 06, 2024	Jun	NEWA

IMIPRAMINE HYDROCHLORIDETABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

AB	!	LEADING	50MG	A040903	003	Oct 24, 2012	Apr	CHRS
	+	@ SPECGX LLC	10MG	A087846	002	May 22, 1984	Apr	DISC
	+	@	25MG	A087846	003	May 22, 1984	Apr	DISC
		TOFRANIL						
	+	@ SPECGX LLC	50MG	A087846	001	May 22, 1984	Apr	DISC

INAVOLISIBTABLET; ORAL
ITOVEBI

+	GENENTECH INC	3MG	N219249	001	Oct 10, 2024	Oct	NEWA
+!		9MG	N219249	002	Oct 10, 2024	Oct	NEWA

INDIUM IN-111 CHLORIDEINJECTABLE; INJECTION
INDIUM IN 111 CHLORIDE

+	@ CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Sep	DISC
---	----------	------------	---------	-----	--------------	-----	------

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE; INJECTION
INDIUM IN-111 PENTETREOTIDE KIT

AP		SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Jun	NFTG	
		OCTREOSCAN							
AP	+	!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jun	CFTG

INDOMETHACINCAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

	@	MYLAN	75MG	A202139	001	Mar 20, 2014	Aug	CAHN
--	---	-------	------	---------	-----	--------------	-----	------

SUPPOSITORY; RECTAL
INDOMETHACIN

AB		HIKMA	50MG	A215899	001	Nov 19, 2024	Nov	NEWA
AB		ZYDUS LIFESCIENCES	50MG	A216184	001	Aug 02, 2023	Apr	CAHN

SUSPENSION; ORAL
INDOCIN

AB	+	!	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan	CTEC
			INDOMETHACIN						
AB		NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan	NEWA	

INDOMETHACIN SODIUMINJECTABLE; INJECTION
INDOMETHACIN SODIUM

	@	HIKMA	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Nov	DISC
AP			EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Nov	CAHN
	@	HOSPIRA	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Nov	DISC
	@	NAVINTA LLC	EQ 1MG BASE/VIAL	A206561	001	Jul 19, 2017	Nov	DISC

INOTERSEN SODIUMSOLUTION; SUBCUTANEOUS
TEGSEDI

+	@	AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)	N211172	001	Oct 05, 2018	Sep	DISC
---	---	---------------	--	---------	-----	--------------	-----	------

IOBENGUANE I-131SOLUTION; INTRAVENOUS
AZEDRA

+	@	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb	DISC
---	---	----------------------	----------	---------	-----	--------------	-----	------

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS
ADREVIEW

AP	+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008	Nov CFTG
		IOBENGUANE I-123					
AP		BWXT MEDCL	10mCi/5ML (2mCi/ML)	A213637	001	Dec 09, 2024	Nov NFTG

IOMEPROL

SOLUTION; INTRA-ARTERIAL
IOMERVU

+!	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216016	002	Nov 27, 2024	Nov NEWA
+!		17.5GM IODINE/50ML (350MG IODINE/ML)	N216016	006	Nov 27, 2024	Nov NEWA
+!		20GM IODINE/50ML (400MG IODINE/ML)	N216016	010	Nov 27, 2024	Nov NEWA
+!		25GM IODINE/100ML (250MG IODINE/ML)	N216016	001	Nov 27, 2024	Nov NEWA
+!		30GM IODINE/100ML (300MG IODINE/ML)	N216016	003	Nov 27, 2024	Nov NEWA
+!		35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Nov NEWA
+!		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Nov NEWA
+!		60GM IODINE/150ML (400MG IODINE/ML)	N216016	012	Nov 27, 2024	Nov NEWA
+!		45GM IODINE/150ML (300MG IODINE/ML)	N216016	004	Nov 27, 2024	Nov NEWA
+!		52.5GM IODINE/150ML (350MG IODINE/ML)	N216016	008	Nov 27, 2024	Nov NEWA
+!		60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024	Nov NEWA
+!		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Nov NEWA
+!		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Nov NEWA

SOLUTION; INTRAVENOUS
IOMERVU

+!	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Nov NEWA
+!		17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Nov NEWA
+!		20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Nov NEWA
+!		25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Nov NEWA
+!		30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Nov NEWA
+!		35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Nov NEWA
+!		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Nov NEWA
+!		60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Nov NEWA
+!		45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Nov NEWA
+!		52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Nov NEWA
+!		60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Nov NEWA
+!		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Nov NEWA
+!		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Nov NEWA

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL

AP		HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar NEWA
AP			61%	A217134	003	Apr 09, 2024	Mar NEWA
AP			76%	A217134	004	Apr 09, 2024	Mar NEWA
		ISOVUE-250					
AP	+!	BRACCO	51%	N018735	007	Jul 06, 1992	Mar CTEC
		ISOVUE-300					
AP	+!	BRACCO	61%	N018735	002	Dec 31, 1985	Mar CTEC
		ISOVUE-370					
AP	+!	BRACCO	76%	N018735	003	Dec 31, 1985	Mar CTEC

IPRATROPIUM BROMIDE

	SOLUTION; INHALATION						
	IPRATROPIUM BROMIDE						
	@ NORVIUM BIOSCIENCE	0.02%	A074755	001	Jan 10, 1997	Jul	CAHN
	SPRAY, METERED; NASAL						
	IPRATROPIUM BROMIDE						
AB	RUBICON	0.042MG/SPRAY	A219221	001	Nov 15, 2024	Nov	NEWA

IRBESARTAN

	TABLET; ORAL						
	AVAPRO						
	+ @ SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997	Jul	DISC
	IRBESARTAN						
>A>	@ APPCO	75MG	A200461	001	Sep 27, 2012	Dec	CAHN
>A>	@	150MG	A200461	002	Sep 27, 2012	Dec	CAHN
>A>	@	300MG	A200461	003	Sep 27, 2012	Dec	CAHN
>D>	AB IPCA LABS LTD	75MG	A211056	001	May 22, 2024	Dec	DISC
>A>	@	75MG	A211056	001	May 22, 2024	Dec	DISC
	AB	75MG	A211056	001	May 22, 2024	May	NEWA
>D>	AB	150MG	A211056	002	May 22, 2024	Dec	DISC
>A>	@	150MG	A211056	002	May 22, 2024	Dec	DISC
	AB	150MG	A211056	002	May 22, 2024	May	NEWA
>D>	AB	300MG	A211056	003	May 22, 2024	Dec	DISC
>A>	@	300MG	A211056	003	May 22, 2024	Dec	DISC
	AB	300MG	A211056	003	May 22, 2024	May	NEWA
>D>	@ UPSHER SMITH LABS	75MG	A200461	001	Sep 27, 2012	Dec	CAHN
>D>	@	150MG	A200461	002	Sep 27, 2012	Dec	CAHN
>D>	@	300MG	A200461	003	Sep 27, 2012	Dec	CAHN

IRINOTECAN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	IRINOTECAN HYDROCHLORIDE						
>A>	AP HIKMA	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Dec	CAHN
>A>	AP	100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Dec	CAHN
	@ HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Jul	DISC
	@	100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Jul	DISC
>D>	AP WEST-WARD PHARMS INT	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Dec	CAHN
>D>	AP	100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Dec	CAHN

ISONIAZID

	TABLET; ORAL						
	ISONIAZID						
AA	! GENUS	100MG	A080936	001		Nov	CAHN
AA	!	300MG	A080937	002		Nov	CAHN

ISOPROTERENOL HYDROCHLORIDE

	INJECTABLE; INJECTION						
	ISOPROTERENOL HYDROCHLORIDE						
	@ CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018	Mar	DISC
	@ EUGIA PHARMA	0.2MG/ML	A211864	001	Feb 09, 2021	Jun	DISC
AP	GLAND PHARMA LTD	0.2MG/ML	A217648	001	Oct 03, 2024	Sep	NEWA
AP	SOMERSET THERAPS LLC	0.2MG/ML	A211590	001	Aug 06, 2024	Jul	NEWA

ISOSORBIDE DINITRATE

	CAPSULE, EXTENDED RELEASE; ORAL						
	DILATRATE-SR						
	+ @ ENDO OPERATIONS	40MG	N019790	001	Sep 02, 1988	May	CAHN
	TABLET; ORAL						
	ISOSORBIDE DINITRATE						
AB	ENDO OPERATIONS	40MG	A211290	001	Nov 23, 2021	Apr	CAHN
AB	ZYDUS LIFESCIENCES	5MG	A213057	001	Nov 20, 2019	Aug	CAHN
AB		10MG	A213057	002	Nov 20, 2019	Aug	CAHN
AB		20MG	A213057	003	Nov 20, 2019	Aug	CAHN
AB		30MG	A213057	004	Nov 20, 2019	Aug	CAHN
AB		40MG	A213057	005	Nov 20, 2019	Aug	CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB	GENUS	10MG	A 075037	002	Oct 30, 1998	Nov	CAHN
AB		20MG	A 075037	001	Oct 30, 1998	Nov	CAHN
MONOKET							
AB	+ OMNIVIUM PHARMS	10MG	N 020215	002	Jun 30, 1993	Jan	CAHN
AB	+!	20MG	N 020215	001	Jun 30, 1993	Jan	CAHN
TABLET, EXTENDED RELEASE; ORAL							
ISOSORBIDE MONONITRATE							
AB	CHARTWELL MOLECULAR	120MG	A 075155	003	Aug 04, 2000	Mar	CHRS
AB	! RICONPHARMA LLC	120MG	A 210918	003	Nov 05, 2018	Mar	CHRS
AB	SHANDONG	30MG	A 214115	002	Feb 08, 2024	Feb	NEWA
AB		60MG	A 214115	003	Feb 08, 2024	Feb	NEWA
AB		120MG	A 214115	001	Apr 29, 2022	Mar	CMFD
	@ ZYDUS PHARMS	30MG	A 218255	001	Feb 15, 2024	Aug	DISC
AB		30MG	A 218255	001	Feb 15, 2024	Feb	NEWA
	@	60MG	A 218255	002	Feb 15, 2024	Aug	DISC
AB		60MG	A 218255	002	Feb 15, 2024	Feb	NEWA
	@	120MG	A 218255	003	Feb 15, 2024	Aug	DISC
AB		120MG	A 218255	003	Feb 15, 2024	Feb	NEWA

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS

ISOSULFAN BLUE

AP	AM REGENT	1%	A 210294	001	May 17, 2023	May	CDFR
AP		50MG/5ML (10MG/ML)	A 210294	001	May 17, 2023	May	CPOT
	@ BELOTECA	1%	A 210714	001	Jan 16, 2019	May	CDFR
	@	50MG/5ML (10MG/ML)	A 210714	001	Jan 16, 2019	May	CPOT
	@ EUGIA PHARMA	1%	A 206831	001	Feb 02, 2016	May	CDFR
	@	50MG/5ML (10MG/ML)	A 206831	001	Feb 02, 2016	May	CPOT
	@ FRESENIUS KABI USA	1%	A 211869	001	Sep 08, 2022	May	CDFR
	@	50MG/5ML (10MG/ML)	A 211869	001	Sep 08, 2022	May	CPOT
AP	MEITHEAL	1%	A 213130	001	Nov 03, 2021	May	CDFR
AP		50MG/5ML (10MG/ML)	A 213130	001	Nov 03, 2021	May	CPOT
AP	MSN	1%	A 216090	001	Sep 16, 2022	May	CDFR
AP		50MG/5ML (10MG/ML)	A 216090	001	Sep 16, 2022	May	CPOT
AP	! MYLAN INSTITUTIONAL	1%	A 090874	001	Jul 20, 2010	May	CDFR
AP	!	50MG/5ML (10MG/ML)	A 090874	001	Jul 20, 2010	May	CPOT
	@ SOMERSET THERAPS LLC	1%	A 210558	001	Jul 12, 2019	May	CDFR
	@	50MG/5ML (10MG/ML)	A 210558	001	Jul 12, 2019	May	CPOT
LYMPHAZURIN							
	+ @ COVIDIEN	1%	N 018310	001		May	CDFR
	+ @	50MG/5ML (10MG/ML)	N 018310	001		May	CPOT

ISOTRETINOIN

CAPSULE; ORAL

ISOTRETINOIN

AB2	AUROBINDO PHARMA	10MG	A 218194	001	Jan 29, 2024	Jan	NEWA
AB2		20MG	A 218194	002	Jan 29, 2024	Jan	NEWA
AB2		25MG	A 218194	003	Jan 29, 2024	Jan	NEWA
AB2		30MG	A 218194	004	Jan 29, 2024	Jan	NEWA
AB2		35MG	A 218194	005	Jan 29, 2024	Jan	NEWA
AB2		40MG	A 218194	006	Jan 29, 2024	Jan	NEWA

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

	@ ACCORD HLTHCARE	100MG	A 205991	001	May 26, 2016	May	DISC
	@ RISING	100MG	A 205724	001	Dec 13, 2016	Apr	CAHN

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

IVABRADINE HYDROCHLORIDE

AB	ALEMBIC	EQ 5MG BASE	A 215238	001	Nov 08, 2024	Nov	NEWA
AB		EQ 7.5MG BASE	A 215238	002	Nov 08, 2024	Nov	NEWA
AB	BIONPHARMA	EQ 5MG BASE	A 213276	001	Sep 05, 2024	Aug	NEWA
AB		EQ 7.5MG BASE	A 213276	002	Sep 05, 2024	Aug	NEWA
AB	INGENUS PHARMS LLC	EQ 5MG BASE	A 214051	001	Dec 30, 2021	May	CMFD
AB		EQ 7.5MG BASE	A 214051	002	Dec 30, 2021	May	CMFD

IVERMECTIN

	CREAM; TOPICAL							
	IVERMECTIN							
AB	ZYDUS LIFESCIENCES	1%		A215210	001	Aug 02, 2022	Mar	CAHN
	TABLET; ORAL							
	IVERMECTIN							
AB	SENORES PHARMS	3MG		A218324	001	Oct 16, 2024	Oct	NEWA

KETAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	KETALAR							
AP	+ ENDO OPERATIONS	EQ 50MG BASE/ML		N016812	002		Aug	CHRS
AP	+ ENDO OPERATIONS	EQ 100MG BASE/ML		N016812	003		Aug	CHRS
	KETAMINE HYDROCHLORIDE							
AP	FRESENIUS KABI USA	EQ 10MG BASE/ML		A215808	001	Jan 13, 2023	Sep	CMFD
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML		A215808	002	Jan 13, 2023	Sep	CMFD
AP	! HIKMA	EQ 50MG BASE/ML		A074524	001	Mar 22, 1996	Aug	CHRS
AP	! HIKMA	EQ 100MG BASE/ML		A074524	002	Mar 22, 1996	Aug	CHRS

KETOCONAZOLE

	AEROSOL, FOAM; TOPICAL							
	KETOCONAZOLE							
AB	! XIROMED	2%		A213601	001	May 21, 2021	Feb	CHRS
	CREAM; TOPICAL							
	KETOCONAZOLE							
AB	TRUPHARMA	2%		A215185	001	Nov 17, 2021	Aug	CAHN
	SHAMPOO; TOPICAL							
	KETOCONAZOLE							
AB	COSETTE	2%		A076942	001	Apr 11, 2005	Jul	CAHN
AB	NOVITIUM PHARMA	2%		A218498	001	Sep 16, 2024	Sep	NEWA
	TABLET; ORAL							
	KETOCONAZOLE							
AB	SENORES PHARMS	200MG		A075912	001	Jan 10, 2002	Feb	CAHN

KETOROLAC TROMETHAMINE

	SOLUTION/DROPS; OPHTHALMIC							
	KETOROLAC TROMETHAMINE							
AT	CAPLIN	0.5%		A218204	001	Mar 26, 2024	Mar	NEWA
	@ SUN PHARM	0.5%		A090017	001	Nov 05, 2009	Nov	DISC

L-GLUTAMINE

	FOR SOLUTION; ORAL							
	ENDARI							
AA	+ EMMAUS MEDCL	5GM/PACKET		N208587	001	Jul 07, 2017	Jun	CFTG
	L-GLUTAMINE							
AA	NOVITIUM PHARMA	5GM/PACKET		A215647	001	Jul 08, 2024	Jun	NFTG

LABETALOL HYDROCHLORIDE

	SOLUTION; INTRAVENOUS							
	LABETALOL HYDROCHLORIDE							
	+ @ HIKMA	10MG/2ML (5MG/ML)		N213330	005	Mar 18, 2022	Sep	DISC
	+!	20MG/4ML (5MG/ML)		N213330	006	Aug 19, 2024	Aug	NEWA
	TABLET; ORAL							
	LABETALOL HYDROCHLORIDE							
AB	ANDAS 5 HOLDING	100MG		A075215	001	Jul 29, 1999	Aug	CAHN
AB	ANDAS 5 HOLDING	200MG		A075215	002	Jul 29, 1999	Aug	CAHN
AB	ANDAS 5 HOLDING	300MG		A075215	003	Jul 29, 1999	Aug	CAHN
	APPCO	400MG		A209603	004	Oct 18, 2024	Oct	NEWA
AB	ENDO OPERATIONS	100MG		A200908	001	Jul 10, 2012	Apr	CAHN
AB	!	200MG		A200908	002	Jul 10, 2012	Apr	CAHN
AB	!	300MG		A200908	003	Jul 10, 2012	Apr	CAHN
AB	HIBROW HLTHCARE	100MG		A207863	001	Feb 04, 2019	Sep	CAHN
AB	HIBROW HLTHCARE	200MG		A207863	002	Feb 04, 2019	Sep	CAHN
AB	HIBROW HLTHCARE	300MG		A207863	003	Feb 04, 2019	Sep	CAHN

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP	ACELLA	200MG/20ML (10MG/ML)	A218464	001	Nov 14, 2024	Nov	NEWA
AP	DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar	NEWA
AP	HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb	NEWA
AP	HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar	NEWA
AP	SOMERSET THERAPS LLC	200MG/20ML (10MG/ML)	A214960	001	Oct 09, 2024	Sep	NEWA

SOLUTION; ORAL

LACOSAMIDE

	@ AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
AA		10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
AA	AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA
AA	CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May	NEWA
AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Nov	CAHN

TABLET; ORAL

LACOSAMIDE

	@ AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022	Oct	DISC
	@	100MG	A204857	002	Mar 17, 2022	Oct	DISC
	@	150MG	A204857	003	Mar 17, 2022	Oct	DISC
	@	200MG	A204857	004	Mar 17, 2022	Oct	DISC
AB	KANCHAN HLTHCARE	50MG	A218014	001	Apr 02, 2024	Sep	CAHN
AB		100MG	A218014	002	Apr 02, 2024	Sep	CAHN
AB		150MG	A218014	003	Apr 02, 2024	Sep	CAHN
AB		200MG	A218014	004	Apr 02, 2024	Sep	CAHN
AB	MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May	NEWA
AB		100MG	A208466	002	May 24, 2024	May	NEWA
AB		150MG	A208466	003	May 24, 2024	May	NEWA
AB		200MG	A208466	004	May 24, 2024	May	NEWA
AB	MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar	NEWA
AB		100MG	A218014	002	Apr 02, 2024	Mar	NEWA
AB		150MG	A218014	003	Apr 02, 2024	Mar	NEWA
AB		200MG	A218014	004	Apr 02, 2024	Mar	NEWA
AB	UNICHEM	50MG	A213109	001	Sep 04, 2024	Aug	NEWA
AB		100MG	A213109	002	Sep 04, 2024	Aug	NEWA
AB		150MG	A213109	003	Sep 04, 2024	Aug	NEWA
AB		200MG	A213109	004	Sep 04, 2024	Aug	NEWA
	@ ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May	DISC
	@	100MG	A204947	002	Dec 15, 2023	May	DISC
	@	150MG	A204947	003	Dec 15, 2023	May	DISC
	@	200MG	A204947	004	Dec 15, 2023	May	DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

AA	APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018	Jul	CMFD
	@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	! PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS
>A> AA	TARO	10GM/15ML	A218858	001	Dec 13, 2024	Dec	NEWA

SOLUTION; ORAL, RECTAL
GENERLAC

AA	CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun	CAHN
AA	APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul	CMFD
	@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC

LAMIVUDINE

SOLUTION; ORAL

EPIVIR-HBV

+ @ GLAXOSMITHKLINE 5MG/ML

N021004	001	Dec 08, 1998	Apr	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

EPIVIR-HBV

+ @ GLAXOSMITHKLINE 100MG

N021003	001	Dec 08, 1998	Apr	DISC
---------	-----	--------------	-----	------

LAMIVUDINE

AB	! APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
	@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
	@	300MG	A078545	002	Mar 05, 2019	Jan	DISC
	@ NATCO	150MG	A204528	001	Mar 04, 2016	Jun	CAHN
	@	300MG	A204528	002	Mar 04, 2016	Jun	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	EPIC PHARMA LLC	150MG;300MG	A206375	001	Apr 10, 2018	Sep	CAHN
AB	! HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS
	@ NATCO	150MG;300MG	A204005	001	Aug 28, 2014	Jun	CAHN
	@ NORVIUM BIOSCIENCE	150MG;300MG	A079079	001	Aug 12, 2019	Jul	CAHN

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 04, 2012	Jul	CMS1
AB		25MG	A090169	001	May 12, 2012	Mar	CAHN
AB		100MG	A090169	002	May 04, 2012	Jul	CMS1
AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
AB		150MG	A090169	003	May 04, 2012	Jul	CMS1
AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
AB		200MG	A090169	004	May 04, 2012	Jul	CMS1
AB		200MG	A090169	004	May 12, 2012	Mar	CAHN
AB	IPCA LABS	25MG	A204499	001	Sep 26, 2024	Sep	NEWA
AB		100MG	A204499	002	Sep 26, 2024	Sep	NEWA
AB		150MG	A204499	003	Sep 26, 2024	Sep	NEWA
AB		200MG	A204499	004	Sep 26, 2024	Sep	NEWA
	@ NORVIUM BIOSCIENCE	25MG	A078443	001	Feb 11, 2009	Jul	CAHN
	@	100MG	A078443	002	Feb 11, 2009	Jul	CAHN
	@	150MG	A078443	003	Feb 11, 2009	Jul	CAHN
	@	200MG	A078443	004	Feb 11, 2009	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB	ALEMBIC	200MG	A211821	001	Oct 01, 2024	Sep	NEWA
AB		250MG	A211821	002	Oct 01, 2024	Sep	NEWA
AB		300MG	A211821	003	Oct 01, 2024	Sep	NEWA
	@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC
	@	50MG	A201374	002	Dec 26, 2012	Feb	DISC
	@	100MG	A201374	003	Dec 26, 2012	Feb	DISC
	@	200MG	A201374	004	Dec 26, 2012	Feb	DISC
	@	250MG	A201374	005	Dec 26, 2012	Feb	DISC
	@	300MG	A201374	006	Dec 26, 2012	Feb	DISC
	@ ENDO OPERATIONS	25MG	A201374	001	Dec 26, 2012	May	CAHN
AB		25MG	A201791	001	Jan 18, 2013	Apr	CAHN
	@	50MG	A201374	002	Dec 26, 2012	May	CAHN
AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
	@	100MG	A201374	003	Dec 26, 2012	May	CAHN
AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
	@	200MG	A201374	004	Dec 26, 2012	May	CAHN
AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
	@	250MG	A201374	005	Dec 26, 2012	May	CAHN
AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
	@	300MG	A201374	006	Dec 26, 2012	May	CAHN
AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN
AB	SCIEGEN PHARMS INC	25MG	A202498	001	Jan 04, 2013	Nov	CAHN
AB		50MG	A202498	002	Jan 04, 2013	Nov	CAHN
AB		100MG	A202498	003	Jan 04, 2013	Nov	CAHN
AB		200MG	A202498	004	Jan 04, 2013	Nov	CAHN
AB		300MG	A202498	005	Jan 04, 2013	Nov	CAHN

TABLET, FOR SUSPENSION;ORAL

LAMOTRIGINE

>A>	@ CHARTWELL RX	5MG	A078409	002	Jan 22, 2009	Dec	CAHN
>A>	@	25MG	A078409	003	Jan 22, 2009	Dec	CAHN
>D>	@ SANDOZ	5MG	A078409	002	Jan 22, 2009	Dec	CAHN
>D>	@	25MG	A078409	003	Jan 22, 2009	Dec	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB	ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN
AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN
AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN
AB	IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Oct	CMFD
AB		50MG	A200828	002	Jul 15, 2013	Oct	CMFD
AB		100MG	A200828	003	Jul 15, 2013	Oct	CMFD
AB		200MG	A200828	004	Jul 15, 2013	Oct	CMFD

LANDIOLOL HYDROCHLORIDEPOWDER; INTRAVENOUS
RABIPLYK

+! AOP ORPHAN EQ 280MG BASE/VIAL N217202 001 Nov 22, 2024 Nov NEWA

LANREOTIDE ACETATESOLUTION; SUBCUTANEOUS
LANREOTIDE ACETATE

AB	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	A217193	001	May 21, 2024	May	NFTG
AB		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	A217193	002	May 21, 2024	May	NFTG
AB		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG
	SOMATULINE DEPOT						
AB	+! IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
AB	+!	EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
AB	+!	EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS; ORAL
LANSOPRAZOLE

	@ ALLIED	15MG	A203964	001	Oct 17, 2018	Nov	CAHN
	@	30MG	A203964	002	Oct 17, 2018	Nov	CAHN
	@ ESJAY PHARMA	15MG	A203964	001	Oct 17, 2018	Nov	CAHN
	@	30MG	A203964	002	Oct 17, 2018	Nov	CAHN
AB	MACLEODS PHARMS LTD	15MG	A208671	001	Nov 04, 2024	Oct	NEWA
AB		30MG	A208671	002	Nov 04, 2024	Oct	NEWA
	@ SANDOZ	15MG	A090331	001	Apr 23, 2010	Sep	DISC
	@	30MG	A090331	002	Apr 23, 2010	Sep	DISC
	@ SUN PHARM	15MG	A202637	001	Sep 13, 2013	May	DISC
	@	30MG	A091509	001	Sep 13, 2013	May	DISC

LAPATINIB DITOSYLATETABLET; ORAL
LAPATINIB DITOSYLATE

AB TEVA PHARMS USA INC EQ 250MG BASE A217968 001 Aug 16, 2024 Aug NEWA

LATANOPROSTEMULSION; OPHTHALMIC
XELPROS

+ @ SUN PHARM 0.005% N206185 001 Sep 12, 2018 Sep DISC

SOLUTION/DROPS; OPHTHALMIC
LATANOPROST

AT	GLAND	0.005%	A218257	001	Nov 26, 2024	Nov	NEWA
>D>	AT	RYAN LABS	A202077	001	Feb 11, 2013	Dec	DISC
>A>	@	0.005%	A202077	001	Feb 11, 2013	Dec	DISC
AT		0.005%	A202077	001	Feb 11, 2013	Sep	CAHN

LAZERTINIB MESYLATETABLET; ORAL
LAZCLUZE

+	JANSSEN BIOTECH	EQ 80MG BASE	N219008	001	Aug 19, 2024	Aug	NEWA
+!		EQ 240MG BASE	N219008	002	Aug 19, 2024	Aug	NEWA

LEFAMULIN ACETATESOLUTION; INTRAVENOUS
XENLETA

>A>	+!	HONG KONG	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Dec	CAHN
>D>	+!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Dec	CAHN
	+!		EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Apr	CMFD

TABLET; ORAL
XENLETA

>A>	+!	HONG KONG	EQ 600MG BASE	N211672	001	Aug 19, 2019	Dec	CAHN
>D>	+!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019	Dec	CAHN

LENALIDOMIDE

CAPSULE; ORAL
LENALIDOMIDE

AB	NOVUGEN	2.5MG	A217281	001	Sep 11, 2024	Aug	NEWA
AB		5MG	A217281	002	Sep 11, 2024	Aug	NEWA
AB		10MG	A217281	003	Sep 11, 2024	Aug	NEWA
AB		15MG	A217281	004	Sep 11, 2024	Aug	NEWA
AB		20MG	A217281	005	Sep 11, 2024	Aug	NEWA
AB		25MG	A217281	006	Sep 11, 2024	Aug	NEWA
	@ QILU	2.5MG	A217265	001	Feb 22, 2024	Jul	DISC
AB		2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
	@	5MG	A217265	002	Feb 22, 2024	Jul	DISC
AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA
	@	10MG	A217265	003	Feb 22, 2024	Jul	DISC
AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
	@	15MG	A217265	004	Feb 22, 2024	Jul	DISC
AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
	@	20MG	A217265	005	Feb 22, 2024	Jul	DISC
AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
	@	25MG	A217265	006	Feb 22, 2024	Jul	DISC
AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LETERMOVIR

PELLETS; ORAL
PREVYMIS

+	MSD	20MG/PACKET	N219104	001	Aug 30, 2024	Aug	NEWA
+	!	120MG/PACKET	N219104	002	Aug 30, 2024	Aug	NEWA

LETROZOLE

TABLET; ORAL
LETROZOLE

>D>	AB	RYAN LABS	2.5MG	A091191	001	Jun 03, 2011	Dec	DISC
>A>		@	2.5MG	A091191	001	Jun 03, 2011	Dec	DISC
	AB		2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

>A>	AP	HAINAN POLY	EQ 350MG BASE/VIAL	A217021	005	Dec 19, 2024	Dec	NEWA
	AP	MEITHEAL	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jun	CAHN
	AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jun	CAHN
	AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jun	CAHN
	AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jun	CAHN
	AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jun	CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

	@	ABIC	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	A089352	001	Jun 01, 1988	Sep	CPOT
	@		EQ 3MG BASE/ML	A089352	001	Jun 01, 1988	Sep	CDFR
	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Sep	CDFR
	!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Sep	CDFR
	!		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A207241	001	Mar 14, 2018	Sep	CPOT
	!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A207226	001	Jul 27, 2018	Sep	CPOT
	+	@ HOSPIRA	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	N008107	001		Sep	CPOT
	+	@	EQ 3MG BASE/ML	N008107	001		Sep	CDFR
		@ NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep	CDFR
		@	EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Sep	CPOT

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CDFR
	@		EQ 300MG BASE/30ML (EQ 10MG BASE/ML)	A040347	001	Apr 25, 2000	Sep	CPOT
	@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040347	002	Apr 25, 2000	Sep	NEWA
	@	HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997	Sep	CDFR
	@		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A040147	001	Jun 25, 1997	Sep	CPOT
	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A040147	002	Jun 25, 1997	Sep	NEWA
	@	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999	Sep	CDFR
	@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040332	001	Jun 28, 1999	Sep	CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
WELLCOVORIN

@	GLAXOSMITHKLINE	EQ 5MG BASE/ML (EQ 5MG BASE/ML)	A087439	001	Oct 19, 1982	Sep CPOT
@		EQ 5MG BASE/ML	A087439	001	Oct 19, 1982	Sep CDFR
@		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A087439	002	Oct 19, 1982	Sep NEWA

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

AP	AMNEAL	1MG/0.2ML	A215336	001	Oct 28, 2022	Jul CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A215336	001	Oct 28, 2022	Jul CPOT
AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	Jul CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A212963	001	Jun 06, 2022	Jul CPOT
	@ GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Jul CDFR
	@	14MG/2.8ML (1MG/0.2ML)	A075721	001	Nov 29, 2001	Jul CPOT
AP	MEITHEAL	1MG/0.2ML	A075471	001	Oct 25, 2000	Jul CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A075471	001	Oct 25, 2000	Jul CPOT
AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jul CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Jul CPOT
AP	! SANDOZ	1MG/0.2ML	A074728	001	Aug 04, 1998	Jul CDFR
AP	!	14MG/2.8ML (1MG/0.2ML)	A074728	001	Aug 04, 1998	Jul CPOT
AP	SUN PHARM	1MG/0.2ML	A078885	001	Mar 09, 2009	Jul CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A078885	001	Mar 09, 2009	Jul CPOT
AP	UBI	14MG/2.8ML (1MG/0.2ML)	A217957	001	Oct 17, 2024	Oct NEWA
	LUPRON					
+	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CDFR
+	@	14MG/2.8ML (1MG/0.2ML)	N019010	001	Apr 09, 1985	Jul CPOT

LEVACETYLLUCINE

FOR SUSPENSION;ORAL
AQNEURSA

+	!	INTRABIO	1GM/PACKET	N219132	001	Sep 24, 2024	Sep NEWA
---	---	----------	------------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Oct NEWA
AN		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Oct NEWA
AN		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Oct NEWA
AN	! MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr CHRS
	@ NORVIUM BIOSCIENCE	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Jul CAHN
	@	EQ 0.021% BASE	A077800	002	Mar 15, 2013	Jul CAHN
	@	EQ 0.042% BASE	A077800	003	Mar 15, 2013	Jul CAHN
	@ SUN PHARM	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May DISC
	@	EQ 0.021% BASE	A207820	002	Nov 05, 2018	May DISC
	@	EQ 0.042% BASE	A207820	003	Nov 05, 2018	May DISC
AN	! TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr CHRS
AN	!	EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr CHRS
AN	!	EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr CHRS

LEVAMLODIPINE MALEATE

TABLET;ORAL
CONJUPRI

+	@	CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Sep DISC
+			EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar CMFD
+	@		EQ 5MG BASE	N212895	003	Dec 19, 2019	Sep DISC
+	!		EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar CMFD

LEVETIRACETAM

INJECTABLE;INTRAVENOUS
LEVETIRACETAM

AP	ADRASTEIA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb CAHN
	@ SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May DISC
AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul CAHN
	LEVETIRACETAM IN SODIUM CHLORIDE					
AP	B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb NEWA
AP		1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb NEWA
AP		1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb NEWA
AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb CTNA
AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb CTNA
AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb CTNA
	@ FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar DISC
	@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar DISC

INJECTABLE; INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

	@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP	HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA

SOLUTION; ORAL

LEVETIRACETAM

>D>	AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	Dec	DISC
>A>		@	100MG/ML	A079120	001	Jan 16, 2009	Dec	DISC
		@ HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
		@ STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	May	DISC

TABLET; ORAL

LEVETIRACETAM

	@	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	May	DISC
	@		500MG	A090843	002	Feb 14, 2011	May	DISC
	@		750MG	A090843	003	Feb 14, 2011	May	DISC
	@		1GM	A090843	004	Feb 14, 2011	May	DISC
	@	GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
	@		500MG	A217878	002	Jun 13, 2023	Mar	DISC
	@		750MG	A217878	003	Jun 13, 2023	Mar	DISC
	@		1GM	A217878	004	Jun 13, 2023	Mar	DISC
AB		INGENUS PHARMS LLC	250MG	A079042	001	Jan 15, 2009	Sep	CAHN
AB			500MG	A079042	002	Jan 15, 2009	Sep	CAHN
AB			750MG	A079042	003	Jan 15, 2009	Sep	CAHN
AB			1GM	A079042	004	Jan 15, 2009	Sep	CAHN
	@	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
	@		500MG	A078234	002	Jan 15, 2009	Mar	DISC
	@		750MG	A078234	003	Jan 15, 2009	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@	ADAPTIS	500MG	A202167	001	Sep 04, 2015	Sep	CAHN
	@		750MG	A202167	002	Sep 04, 2015	Sep	CAHN
	@	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
	@		750MG	A091360	002	Oct 04, 2011	Feb	DISC
	@	ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
	@		750MG	A091360	002	Oct 04, 2011	May	CAHN
	@	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Sep	DISC
	@		750MG	A201464	002	May 25, 2012	Sep	DISC
	@	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Aug	DISC
	@		750MG	A202533	002	Jul 20, 2012	Aug	DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@	CHARTWELL RX	0.5%	A074850	001	Oct 28, 1996	Jul	CAHN
--	---	--------------	------	---------	-----	--------------	-----	------

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

	+	@	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
	+	@		EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
	+	@		EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD

LEVOCARNITINE

SOLUTION; ORAL

LEVOCARNITINE

	@	HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
AA		RISING	1GM/10ML	A076851	001	Aug 10, 2004	Sep	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>D>	AB	IPCA LABS LTD	5MG	A204626	001	May 06, 2024	Dec	DISC
>A>		@	5MG	A204626	001	May 06, 2024	Dec	DISC
	AB		5MG	A204626	001	May 06, 2024	Apr	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

	@ NORVIUM BIOSCIENCE	EQ 500MG/20ML (EQ 25MG/ML)	A 200560	001	Jun 20, 2011	Jun	CAHN
	@	EQ 750MG/30ML (EQ 25MG/ML)	A 200560	002	Jun 20, 2011	Jun	CAHN
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	AP	BAXTER HLTHCARE CORP	EQ 250MG/50ML (EQ 5MG/ML)	A 091397	001	Aug 08, 2013	Dec DISC
>A>		@	EQ 250MG/50ML (EQ 5MG/ML)	A 091397	001	Aug 08, 2013	Dec DISC
>D>	AP		EQ 500MG/100ML (EQ 5MG/ML)	A 091397	002	Aug 08, 2013	Dec DISC
>A>		@	EQ 500MG/100ML (EQ 5MG/ML)	A 091397	002	Aug 08, 2013	Dec DISC
>D>	AP		EQ 750MG/150ML (EQ 5MG/ML)	A 091397	003	Aug 08, 2013	Dec DISC
>A>		@	EQ 750MG/150ML (EQ 5MG/ML)	A 091397	003	Aug 08, 2013	Dec DISC
		@ KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A 216164	001	Jan 29, 2024	Jul DISC
AP		@	EQ 250MG/50ML (EQ 5MG/ML)	A 216164	001	Jan 29, 2024	Jan NEWA
		@	EQ 500MG/100ML (EQ 5MG/ML)	A 216164	002	Jan 29, 2024	Jul DISC
AP		@	EQ 500MG/100ML (EQ 5MG/ML)	A 216164	002	Jan 29, 2024	Jan NEWA
		@	EQ 750MG/150ML (EQ 5MG/ML)	A 216164	003	Jan 29, 2024	Jul DISC
AP		@	EQ 750MG/150ML (EQ 5MG/ML)	A 216164	003	Jan 29, 2024	Jan NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

>D>	!	RISING	0.5%	A 077700	001	Dec 20, 2010	Dec CTEC
>A>	AT	!	0.5%	A 077700	001	Dec 20, 2010	Dec CTEC
>D>		@ RUBICON	0.5%	A 078282	001	Dec 20, 2010	Dec CMFD
>A>	AT		0.5%	A 078282	001	Dec 20, 2010	Dec CMFD

TABLET; ORAL

LEVOFLOXACIN

	@ ANDA REPOSITORY	250MG	A 090367	001	Jun 20, 2011	Sep	CAHN
	@	500MG	A 090367	002	Jun 20, 2011	Sep	CAHN
	@	750MG	A 090367	003	Jun 20, 2011	Sep	CAHN
	@ CELLTRION	250MG	A 090367	001	Jun 20, 2011	Apr	DISC
	@	500MG	A 090367	002	Jun 20, 2011	Apr	DISC
	@	750MG	A 090367	003	Jun 20, 2011	Apr	DISC
	@ SANDOZ	250MG	A 077438	001	Jun 20, 2011	Nov	DISC
	@	500MG	A 077438	002	Jun 20, 2011	Nov	DISC
	@	750MG	A 077438	003	Jun 20, 2011	Nov	DISC

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

+	@ ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N 020140	001	Mar 07, 2008	May	DISC
+	!	EQ 50MG BASE/VIAL	N 020140	001	Mar 07, 2008	Mar	CTEC
	LEVOLEUCOVORIN CALCIUM						
	@ MEITHEAL	EQ 50MG BASE/VIAL	A 211003	001	Aug 22, 2019	Mar	DISC

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

	@ NORVIUM BIOSCIENCE	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A 203576	001	Oct 20, 2015	Jun	CAHN
	@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A 203576	002	Oct 20, 2015	Jun	CAHN
	@ PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A 213797	001	Nov 02, 2021	Jul	CAHN

LEVONORGESTREL

SYSTEM; INTRAUTERINE

KYLEENA

+	!	BAYER HLTHCARE	19.5MG	N 208224	001	Sep 16, 2016	Jun CDFR
		LILETTA					
+	!	MEDICINES360	52MG	N 206229	001	Feb 26, 2015	Jun CDFR
		MIRENA					
+	!	BAYER HLTHCARE	52MG	N 021225	001	Dec 06, 2000	Jun CDFR
		SKYLA					
+	!	BAYER HLTHCARE	13.5MG	N 203159	001	Jan 09, 2013	Jun CDFR

TABLET; ORAL

LEVONORGESTREL

	@ XIROMED	0.75MG	A 202740	001	Sep 02, 2016	May	CAHN
--	-----------	--------	----------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

	@ ENDO OPERATIONS	200MCG/VIAL	A205366	001	Dec 07, 2015	May CAHN
AP	XIROMED	100MCG/VIAL	A217495	001	Nov 29, 2024	Nov NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jul NEWA
AB2		0.15MG	A216414	002	Jul 16, 2024	Jul NEWA
AB2		0.175MG	A216414	003	Jul 16, 2024	Jul NEWA
AB2		0.2MG	A216414	004	Jul 16, 2024	Jul NEWA
AB2		0.3MG	A216414	005	Jul 16, 2024	Jul NEWA
AB1,	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.05MG	A211417	002	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.075MG	A211417	003	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.088MG	A211417	004	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.1MG	A211417	005	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.112MG	A211417	006	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.125MG	A211417	007	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.137MG	A211417	008	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.15MG	A211417	009	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.175MG	A211417	010	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.2MG	A211417	011	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.3MG	A211417	012	Dec 21, 2022	Sep CTEC
AB2						
AB1,	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.05MG	A207588	002	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.075MG	A207588	003	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.088MG	A207588	004	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.1MG	A207588	005	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.112MG	A207588	006	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.125MG	A207588	007	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.137MG	A207588	008	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.15MG	A207588	009	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.175MG	A207588	010	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						

TABLET; ORAL

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
AB1, AB2, AB3, AB4	LEVOTHYROXINE SODIUM	0.2MG	A207588 011	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4	LEVOTHYROXINE SODIUM	0.3MG	A207588 012	May 10, 2022	Feb	CTEC

LIDOCAINE

OINTMENT; TOPICAL

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
AT	AUROBINDO PHARMA LTD	5%	A217117 001	Jun 18, 2024	Jun	NEWA
	@ COSETTE	5%	A211019 001	Dec 12, 2018	Apr	DISC
	@ GENEYORK PHARMS	5%	A212486 001	Oct 17, 2019	Jul	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
AP	FRESENIUS KABI USA	1%	A088586 002		Apr	CMS1
AP		2%	A088586 003		Apr	CMS1
AP	+ INTL MEDICATION	1%	A083173 001		Aug	CRLD
>A>	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ EXTROVIS	2%	A090665 001	Sep 27, 2010	Dec	CAHN
	@	2%	A090665 001	Sep 27, 2010	Jun	CAHN
AP	HIKMA	1%	A084625 001		Jun	CAHN
AP		2%	A084625 002		Jun	CAHN
>D>	@ RISING	2%	A090665 001	Sep 27, 2010	Dec	CAHN

SOLUTION; ORAL

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
AT	LIDOCAINE HYDROCHLORIDE VISCOUS					
	PAI HOLDINGS PHARM	2%	A218138 001	Feb 20, 2024	Feb	NEWA
AT	SOLUTION; TOPICAL					
	LIDOCAINE HYDROCHLORIDE					
	THE J MOLNER	4%	A218411 001	Apr 29, 2024	Apr	NEWA

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
	LIDOCAINE AND PRILOCAINE					
	@ HIKMA	2.5%; 2.5%	A076290 001	Sep 25, 2003	Mar	DISC
AB	PAI HOLDINGS PHARM	2.5%; 2.5%	A205887 001	Jun 29, 2018	Jun	CMFD
	@ RHODES PHARMS	2.5%; 2.5%	A213253 001	Sep 21, 2020	Sep	DISC
AB		2.5%; 2.5%	A213253 001	Sep 21, 2020	Jun	CMFD
>A>	ZYDUS LIFESCIENCES	2.5%; 2.5%	A219120 001	Dec 17, 2024	Dec	NEWA

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
	PLIAGLIS					
	+ @ CRESCITA THERAP	7%; 7%	N021717 001	Jun 29, 2006	Jul	CAHN

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
	LIFITEGRAST					
	@ EUGIA PHARMA	5%	A215063 001	Nov 07, 2023	May	DISC
	@ INGENUS PHARMS LLC	5%	A215058 001	Oct 03, 2024	Nov	DISC
AB		5%	A215058 001	Oct 03, 2024	Sep	NFTG
	@ MICRO LABS	5%	A215081 001	Aug 04, 2023	May	DISC
	XIIDRA					
	+! BAUSCH AND LOMB INC	5%	N208073 001	Jul 11, 2016	Nov	CTEC
AB	+!	5%	N208073 001	Jul 11, 2016	Sep	CFTG
	+!	5%	N208073 001	Jul 11, 2016	May	CTEC
AB	+!	5%	N208073 001	Jul 11, 2016	Jan	CAHN

LINAGLIPTIN

TABLET; ORAL

Product Code	Manufacturer	Strength	NDA Number	Approval Date	Expiration Date	Agency
AB	LINAGLIPTIN					
	INVAGEN PHARMS	5MG	A208423 001	Sep 03, 2024	Aug	NEWA

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LINCOMYCIN HYDROCHLORIDE

AP	ARTHUR GRP	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul CAHN
AP	GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May CMFD
	@ SLAYBACK	EQ 300MG BASE/ML	A063180	001	Apr 16, 1991	Sep CAHN

LINEZOLID

TABLET; ORAL
LINEZOLID

AB	MACLEODS PHARMS LTD	600MG	A210378	001	Oct 10, 2024	Oct NEWA
----	---------------------	-------	---------	-----	--------------	----------

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION
TRIOSTAT

+ @ ENDO OPERATIONS EQ 0.01MG BASE/ML

N020105	001	Dec 31, 1991	May CAHN
---------	-----	--------------	----------

TABLET; ORAL

LIOTHYRONINE SODIUM

AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar CAHN
AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb CAHN
AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan NEWA
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan NEWA
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan NEWA
	@ NORVIUM BIOSCIENCE	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul CAHN
	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul CAHN
	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul CAHN
AB	ZYDUS LIFESCIENCES	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Aug CAHN
AB		EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Aug CAHN
AB		EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Aug CAHN

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

>A> LIRAGLUTIDE

>A> AP	HIKMA	18MG/3ML (6MG/ML)	A215503	001	Dec 23, 2024	Dec NFTG
	SAXENDA					
	+! NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Mar CAIN
	VICTOZA					
>D>	+! NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Dec CFTG
>A> AP	+!	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Dec CFTG
	+!	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Oct CMFD
	@	10MG	A202802	001	Aug 25, 2023	Feb DISC
AB		20MG	A202802	002	Aug 25, 2023	Oct CMFD
	@	20MG	A202802	002	Aug 25, 2023	Feb DISC
AB		30MG	A202802	003	Aug 25, 2023	Oct CMFD
	@	30MG	A202802	003	Aug 25, 2023	Feb DISC
AB		40MG	A202802	004	Aug 25, 2023	Oct CMFD
	@	40MG	A202802	004	Aug 25, 2023	Feb DISC
AB		50MG	A202802	005	Aug 25, 2023	Oct CMFD
	@	50MG	A202802	005	Aug 25, 2023	Feb DISC
AB		60MG	A202802	006	Aug 25, 2023	Oct CMFD
	@	60MG	A202802	006	Aug 25, 2023	Feb DISC
AB		70MG	A202802	007	Aug 25, 2023	Oct CMFD
	@	70MG	A202802	007	Aug 25, 2023	Feb DISC
AB	ELITE LABS INC	10MG	A218604	001	Nov 15, 2024	Nov NEWA
AB		20MG	A218604	002	Nov 15, 2024	Nov NEWA
AB		30MG	A218604	003	Nov 15, 2024	Nov NEWA
AB		40MG	A218604	004	Nov 15, 2024	Nov NEWA
AB		50MG	A218604	005	Nov 15, 2024	Nov NEWA
AB		60MG	A218604	006	Nov 15, 2024	Nov NEWA
AB		70MG	A218604	007	Nov 15, 2024	Nov NEWA
AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan NEWA
>A> AB	SANDOZ	10MG	A202836	007	Dec 26, 2024	Dec NEWA
	@	20MG	A202836	001	Jul 26, 2024	Aug DISC

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		20MG	A202836	001	Jul 26, 2024	Jul	NEWA
	@	30MG	A202836	002	Jul 26, 2024	Aug	DISC
AB		30MG	A202836	002	Jul 26, 2024	Jul	NEWA
	@	40MG	A202836	003	Jul 26, 2024	Aug	DISC
AB		40MG	A202836	003	Jul 26, 2024	Jul	NEWA
	@	50MG	A202836	004	Jul 26, 2024	Aug	DISC
AB		50MG	A202836	004	Jul 26, 2024	Jul	NEWA
	@	60MG	A202836	005	Jul 26, 2024	Aug	DISC
AB		60MG	A202836	005	Jul 26, 2024	Jul	NEWA
	@	70MG	A202836	006	Jul 26, 2024	Aug	DISC
AB		70MG	A202836	006	Jul 26, 2024	Jul	NEWA

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

>A>	AB	GRANULES	10MG	A219258	001	Dec 16, 2024	Dec	NEWA
>A>	AB		20MG	A219258	002	Dec 16, 2024	Dec	NEWA
>A>	AB		30MG	A219258	003	Dec 16, 2024	Dec	NEWA
>A>	AB		40MG	A219258	004	Dec 16, 2024	Dec	NEWA
>A>	AB		50MG	A219258	005	Dec 16, 2024	Dec	NEWA
>A>	AB		60MG	A219258	006	Dec 16, 2024	Dec	NEWA
AB		MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB			20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB			30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB			40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB			50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB			60MG	A218306	006	Feb 02, 2024	Jan	NEWA
>A>	AB	SPECGX LLC	10MG	A218850	001	Dec 17, 2024	Dec	NEWA
>A>	AB		20MG	A218850	002	Dec 17, 2024	Dec	NEWA
>A>	AB		30MG	A218850	003	Dec 17, 2024	Dec	NEWA
>A>	AB		40MG	A218850	004	Dec 17, 2024	Dec	NEWA
>A>	AB		50MG	A218850	005	Dec 17, 2024	Dec	NEWA
>A>	AB		60MG	A218850	006	Dec 17, 2024	Dec	NEWA
AB		TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug	CMFD
	@		10MG	A215415	001	Aug 25, 2023	Feb	DISC
AB			20MG	A215415	002	Aug 25, 2023	Aug	CMFD
	@		20MG	A215415	002	Aug 25, 2023	Feb	DISC
AB			30MG	A215415	003	Aug 25, 2023	Aug	CMFD
	@		30MG	A215415	003	Aug 25, 2023	Feb	DISC
AB			40MG	A215415	004	Aug 25, 2023	Aug	CMFD
	@		40MG	A215415	004	Aug 25, 2023	Feb	DISC
AB			50MG	A215415	005	Aug 25, 2023	Aug	CMFD
	@		50MG	A215415	005	Aug 25, 2023	Feb	DISC
AB			60MG	A215415	006	Aug 25, 2023	Aug	CMFD
	@		60MG	A215415	006	Aug 25, 2023	Feb	DISC

LISINAPRIL

TABLET;ORAL

LISINAPRIL

	@	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC
	@		5MG	A202554	002	Jul 30, 2013	May	DISC
	@		10MG	A202554	003	Jul 30, 2013	May	DISC
	@		20MG	A202554	004	Jul 30, 2013	May	DISC
	@		30MG	A202554	005	Jul 30, 2013	May	DISC
	@		40MG	A202554	006	Jul 30, 2013	May	DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	!	@ PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

AB		INDOCO	EQ 0.18MG BASE	A218613	001	Aug 20, 2024	Aug	NFTG
AB	+	! USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Aug	CFTG

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan CAHN
+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan CAHN
+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan CAHN
+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan CAHN
+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan CAHN
+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan CAHN

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+	@ LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb CAHN
+		10MG	N017588	001		Feb CAHN
+	!	40MG	N017588	002		May CHRS
+		40MG	N017588	002		Feb CAHN
+		100MG	N017588	003		May CHRS
+	!	100MG	N017588	003		Feb CAHN

LONAFARNIB

CAPSULE;ORAL

ZOKINVY

+	SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May CAHN
+	!	75MG	N213969	002	Nov 20, 2020	May CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	MACLEODS PHARMS LTD	100MG;25MG	A204739	001	Jul 25, 2024	Jul NEWA
AB		200MG;50MG	A204739	002	Jul 25, 2024	Jul NEWA
AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan NEWA

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

@ HIKMA

2MG/ML

A200169 001 Jan 30, 2012 Mar DISC

INJECTABLE;INJECTION

LORAZEPAM

@ ENDO OPERATIONS

2MG/ML

A074793 001 Mar 16, 2000 Apr CAHN

@

4MG/ML

A074793 002 Mar 16, 2000 Apr CAHN

AP FRESENIUS KABI USA

2MG/ML

A217598 001 Nov 18, 2024 Nov NEWA

TABLET;ORAL

LORAZEPAM

AB ANI PHARMS

0.5MG

A077396 001 Dec 13, 2006 Nov CMFD

AB

1MG

A077396 002 Dec 13, 2006 Nov CMFD

AB

2MG

A077396 003 Dec 13, 2006 Nov CMFD

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

@ AIPING PHARM INC

25MG

A090544 001 Oct 06, 2010 Feb CAHN

@

50MG

A090544 002 Oct 06, 2010 Feb CAHN

@

100MG

A090544 003 Oct 06, 2010 Feb CAHN

AB APOTEX

25MG

A218551 001 Jun 04, 2024 May NEWA

AB

50MG

A218551 002 Jun 04, 2024 May NEWA

AB

100MG

A218551 003 Jun 04, 2024 May NEWA

AB CHARTWELL RX

25MG

A077424 001 Oct 06, 2010 Jan CAHN

AB

50MG

A077424 002 Oct 06, 2010 Jan CAHN

AB

100MG

A077424 003 Oct 06, 2010 Jan CAHN

>D> AB IPCA LABS LTD

25MG

A200290 001 Aug 30, 2013 Dec DISC

>A>

@

25MG

A200290 001 Aug 30, 2013 Dec DISC

>D> AB

50MG

A200290 002 Aug 30, 2013 Dec DISC

>A>

@

50MG

A200290 002 Aug 30, 2013 Dec DISC

>D> AB

100MG

A200290 003 Aug 30, 2013 Dec DISC

>A>

@

100MG

A200290 003 Aug 30, 2013 Dec DISC

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

	@ HIKMA	0.5%	A213956	001	Nov 29, 2023	Oct	DISC
AB		0.5%	A213956	001	Nov 29, 2023	Apr	CAHN

SUSPENSION/DROPS;OPHTHALMIC

LOTEPREDNOL ETABONATE

>A>	AB	AMNEAL	0.2%	A216345	001	Dec 13, 2024	Dec	NEWA
	AB	LUPIN LTD	0.5%	A215719	001	Apr 24, 2024	Apr	NEWA
	AB	PADAGIS US	0.2%	A215203	001	Jul 10, 2024	Jun	NEWA

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

>A>	AB	ASCENT PHARMS INC	8MCG	A218640	001	Jan 02, 2025	Dec	NEWA
>A>	AB		24MCG	A218640	002	Jan 02, 2025	Dec	NEWA
		@ ENDO OPERATIONS	8MCG	A201442	001	Jun 27, 2022	Apr	CAHN
		@	24MCG	A201442	002	Jun 27, 2022	Apr	CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		ADAPTIS	20MG	A212091	001	Dec 28, 2020	Nov	CAHN
AB			40MG	A212091	002	Dec 28, 2020	Nov	CAHN
AB			60MG	A212091	003	Dec 28, 2020	Nov	CAHN
AB			80MG	A212091	004	Dec 28, 2020	Nov	CAHN
AB			120MG	A212091	005	Dec 28, 2020	Nov	CAHN
AB		ANNORA PHARMA	20MG	A218174	001	Aug 21, 2024	Aug	NEWA
AB			40MG	A218174	002	Aug 21, 2024	Aug	NEWA
AB			60MG	A218174	003	Aug 21, 2024	Aug	NEWA
AB			80MG	A218174	004	Aug 21, 2024	Aug	NEWA
AB			120MG	A218174	005	Aug 21, 2024	Aug	NEWA
AB		HERITAGE PHARMA AVET	20MG	A208058	001	Sep 04, 2019	Oct	CAHN
AB			40MG	A208058	002	Sep 04, 2019	Oct	CAHN
AB			60MG	A208058	003	Sep 04, 2019	Oct	CAHN
AB			80MG	A208058	004	Sep 04, 2019	Oct	CAHN
AB			120MG	A208058	005	Feb 28, 2023	Oct	CAHN
AB		JUBILANT GENERICS	20MG	A210388	001	Dec 06, 2024	Nov	NEWA
AB			40MG	A210388	002	Dec 06, 2024	Nov	NEWA
AB			60MG	A210388	003	Dec 06, 2024	Nov	NEWA
AB			80MG	A210388	004	Dec 06, 2024	Nov	NEWA
AB			120MG	A210388	005	Dec 06, 2024	Nov	NEWA
AB		SLATE RUN PHARMA	20MG	A212091	001	Dec 28, 2020	Feb	CAHN
AB			40MG	A212091	002	Dec 28, 2020	Feb	CAHN
AB			60MG	A212091	003	Dec 28, 2020	Feb	CAHN
AB			80MG	A212091	004	Dec 28, 2020	Feb	CAHN
AB			120MG	A212091	005	Dec 28, 2020	Feb	CAHN

MACITENTAN

TABLET;ORAL

MACITENTAN

	@ APOTEX	10MG	A211195	001	Jan 09, 2024	Apr	DISC
	@ TORRENT	10MG	A211107	001	Aug 05, 2024	Aug	DISC
AB		10MG	A211107	001	Aug 05, 2024	Jul	NFTG
	@ ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	May	CAHN
	OPSUMIT						
	+! ACTELION	10MG	N204410	001	Oct 18, 2013	Aug	CTEC
AB	+!	10MG	N204410	001	Oct 18, 2013	Jul	CFTG
	+!	10MG	N204410	001	Oct 18, 2013	Apr	CTEC

MACITENTAN; TADALAFIL

TABLET;ORAL

OPSYNVI

+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024	Mar	NEWA
+	!	10MG;40MG	N218490	002	Mar 22, 2024	Mar	NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL
MAFENIDE ACETATE
@ ENDO OPERATIONS 5%

A201511 001 Feb 12, 2013 May CAHN

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE
@ EXELA PHARMA 5GM/10ML (500MG/ML)

A206039 001 Dec 18, 2014 Aug DISC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar	NEWA
	SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE						
AA	ANNORA PHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A212903	001	Oct 18, 2024	Oct	NEWA
AA	BIONPHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A204135	001	Jun 24, 2024	Jun	NEWA
AA	LANNETT CO INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Jul	NEWA
AA	PAI HOLDINGS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Sep	CAHN
AA	TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Jun	CMS1

MANNITOL

INJECTABLE;INJECTION
OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	20GM/100ML	N013684	007		Jul	CHRS
AP	+		20GM/100ML	N013684	007		Jul	CRLD

POWDER;INHALATION
ARIDOL KIT

+	!	PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May	CAHN
		BRONCHITOL						
+	!	PHARMAXIS EUROPE	40MG	N202049	001	Oct 30, 2020	Aug	CAHN

MARALIXIBAT CHLORIDE

SOLUTION;ORAL
LIVMARLI

+	!	MIRUM	EQ 19MG BASE/ML	N214662	002	Jul 24, 2024	Jul	NEWA
---	---	-------	-----------------	---------	-----	--------------	-----	------

MAVORIXAFOR

CAPSULE;ORAL
XOLREMDI

+	!	X4 PHARMS	100MG	N218709	001	Apr 26, 2024	Apr	NEWA
---	---	-----------	-------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
MECLIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
AA	!		50MG	A201451	003	Feb 23, 2011	Feb	CMFD
		@ CHARTWELL RX	12.5MG	A205136	001	Feb 22, 2019	Sep	CAHN
		@	25MG	A205136	002	Feb 22, 2019	Sep	CAHN
		@	50MG	A205136	003	Feb 22, 2019	Sep	CAHN
		@ INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
		@	25MG	A200432	002	Feb 17, 2022	Mar	DISC
		@	50MG	A200432	003	Feb 17, 2022	Mar	DISC
		@ WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	Jul	DISC
		@	25MG	A205136	002	Feb 22, 2019	Jul	DISC
		@	50MG	A205136	003	Feb 22, 2019	Jul	DISC

TABLET, CHEWABLE;ORAL
MECLIZINE HYDROCHLORIDE

@		INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar	DISC
---	--	----------------	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION
MEDROXYPROGESTERONE ACETATE

AB		HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
----	--	-----------	----------	---------	-----	--------------	-----	------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

>A>	@ CHARTWELL RX	250MG	A 076175	001	Feb 20, 2002	Dec	CAHN
>D>	@ SANDOZ	250MG	A 076175	001	Feb 20, 2002	Dec	CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB	+!	ENDO OPERATIONS	125MG/ML	N 021778	001	Jul 05, 2005	May	CAHN
		MEGESTROL ACETATE						
		@ CHARTWELL	125MG/ML	A 204688	001	Dec 01, 2017	Mar	CAHN
		@ HIKMA	40MG/ML	A 203960	001	Jun 09, 2017	Mar	DISC
AB		NOVITIUM PHARMA	40MG/ML	A 077404	001	Feb 16, 2006	May	CMFD

MELOXICAM

TABLET; ORAL

MELOXICAM

AB		AIPING PHARM INC	7.5MG	A 077920	001	Jul 19, 2006	Jun	CAHN
AB			15MG	A 077920	002	Jul 19, 2006	Jun	CAHN
AB		SCIEGEN PHARMS INC	7.5MG	A 077920	001	Jul 19, 2006	Apr	CMFD
AB			15MG	A 077920	002	Jul 19, 2006	Apr	CMFD
AB	!	ZYDUS PHARMS USA	15MG	A 077921	002	Jul 19, 2006	Jan	CTEC

MELPHALAN

TABLET; ORAL

MELPHALAN

@ ALVOGEN

2MG

A 207809 001 Mar 22, 2017 May DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP		AVET LIFESCIENCES	EQ 50MG BASE/VIAL	A 206523	001	Oct 29, 2024	Oct	NEWA
		@ ENDO OPERATIONS	EQ 50MG BASE/VIAL	A 204773	001	Aug 22, 2016	May	CAHN
AP		HETERO LABS	EQ 50MG BASE/VIAL	A 215024	001	May 23, 2024	May	NEWA
		SOLUTION; INTRAVENOUS						
		IVRA						
	+!	APOTEX	EQ 90MG BASE/ML (EQ 90MG BASE/ML)	N 217110	001	Aug 18, 2023	Jul	CTNA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

@ ENDO OPERATIONS

7MG

A 205784 001 Jun 09, 2017 Apr CAHN

@

14MG

A 205784 002 Jun 09, 2017 Apr CAHN

@

21MG

A 205784 003 Jun 09, 2017 Apr CAHN

@

28MG

A 205784 004 Jun 09, 2017 Apr CAHN

AB		XIAMEN LP PHARM CO	21MG	A 213985	004	Feb 06, 2024	Jan	NEWA
AB	!	ZYDUS PHARMS	28MG	A 203293	004	Aug 03, 2017	Jul	CHRS
		NAMENDA XR						
	+	@ ABBVIE	14MG	N 022525	002	Jun 21, 2010	Jul	DISC
	+	@	21MG	N 022525	003	Jun 21, 2010	Jul	DISC
	+	@	28MG	N 022525	004	Jun 21, 2010	Jul	DISC

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

@ SCIEGEN PHARMS INC

2MG/ML

A 205446 001 Dec 07, 2015 Sep CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB	ACME LABS	5MG	A 209527	001	May 07, 2018	Dec	CAHN
	AB		5MG	A 209527	001	May 07, 2018	Aug	CAHN
>D>	AB		10MG	A 209527	002	May 07, 2018	Dec	CAHN
	AB		10MG	A 209527	002	May 07, 2018	Aug	CAHN
		@ ALLIED	5MG	A 090073	001	Sep 04, 2015	Nov	DISC
	AB		5MG	A 090073	001	Sep 04, 2015	Jul	CAHN
		@	10MG	A 090073	002	Sep 04, 2015	Nov	DISC
	AB		10MG	A 090073	002	Sep 04, 2015	Jul	CAHN
>A>	AB	RENATA	5MG	A 209527	001	May 07, 2018	Dec	CAHN
	AB		5MG	A 209527	001	May 07, 2018	Jan	CAHN
>A>	AB		10MG	A 209527	002	May 07, 2018	Dec	CAHN
	AB		10MG	A 209527	002	May 07, 2018	Jan	CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@ QUAGEN	25MG/ML	N005010	007		Sep CAHN
@	50MG/ML	N005010	002		Sep CAHN
@	75MG/ML	N005010	009		Sep CAHN
@	100MG/ML	N005010	003		Sep CAHN

SYRUP; ORAL

DEMEROL

@ QUAGEN	50MG/5ML	N005010	005		Sep CAHN
----------	----------	---------	-----	--	----------

TABLET; ORAL

DEMEROL

+ @ QUAGEN	50MG	N005010	001		Sep CAHN
+ @	100MG	N005010	004		Sep CAHN

MEPERIDINE HYDROCHLORIDE

AA	!	EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999	Feb CTEC
	!		50MG	A040331	001	May 28, 1999	Feb CHRS
AA		GENUS	50MG	A040893	001	Jun 24, 2009	Feb CMFD
	@		50MG	A040893	001	Jun 24, 2009	Jan CAHN
	@		75MG	A040893	002	Jun 24, 2009	Jan CAHN
	@		100MG	A040893	003	Jun 24, 2009	Jan CAHN
	@		150MG	A040893	004	Jun 24, 2009	Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		QILU	500MG/VIAL	A216424	001	Jul 22, 2024	Jul NEWA	
AP			1GM/VIAL	A216424	002	Jul 22, 2024	Jul NEWA	
>D>		MERREM						
>D>	AP	+	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Dec CTNA
>D>	AP	+		1GM/VIAL	N050706	001	Jun 21, 1996	Dec CTNA
>A>		MERREM IV						
>A>	AP	+	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Dec CTNA
>A>	AP	+		1GM/VIAL	N050706	001	Jun 21, 1996	Dec CTNA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

>D>	AB	+	ABBVIE	400MG	N204412	001	Feb 01, 2013	Dec DISC
>A>		+	@	400MG	N204412	001	Feb 01, 2013	Dec DISC

MESALAMINE

>D>	AB		TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	Dec CHRS
>A>		!		400MG	A207873	001	May 09, 2019	Dec CTEC
>A>	AB	!		400MG	A207873	001	May 09, 2019	Dec CHRS

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

AB		NOVAST LABS	375MG	A218410	001	Aug 22, 2024	Aug NEWA
----	--	-------------	-------	---------	-----	--------------	----------

SUPPOSITORY; RECTAL

MESALAMINE

AB		RISING	1GM	A207448	001	Apr 19, 2019	Sep CAHN
----	--	--------	-----	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

MESALAMINE

AB		ANNORA PHARMA	1.2GM	A216334	001	Feb 05, 2024	Jan NEWA
AB		TEVA PHARMS INC	800MG	A213191	001	Aug 22, 2024	Aug NEWA
AB	!	ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	Aug CTEC

MESNA

INJECTABLE; INTRAVENOUS

MESNA

@ RISING	100MG/ML	A203364	001	Jul 18, 2014	Feb CAHN
----------	----------	---------	-----	--------------	----------

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

!	CHARTWELL	10MG/5ML	A073632	001	Jul 22, 1992	Sep CAHN
!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Jan CAHN
!	GENUS LIFESCIENCES	10MG/5ML	A073632	001	Jul 22, 1992	Nov CAHN

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
 METARAMINOL BITARTRATE
 AZURITY

EQ 10MG BASE/ML

A211304 001 Aug 24, 2021 Jul CAHN

METAXALONE

TABLET; ORAL
 METAXALONE

BX @ RISING 800MG
 800MG

A208774 001 Sep 24, 2018 Nov DISC
 A208774 001 Sep 24, 2018 Sep CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
 METFORMIN HYDROCHLORIDE
 @ AMNEAL PHARMS NY 500MG
 @ 850MG
 @ 1GM

A077880 001 Jun 05, 2006 Jul DISC
 A077880 002 Jun 05, 2006 Jul DISC
 A077880 003 Jun 05, 2006 Jul DISC

TABLET, EXTENDED RELEASE; ORAL
 METFORMIN HYDROCHLORIDE

AB2 AUROBINDO PHARMA 500MG
 AB2 1GM
 AB1 HARMAN FINOCHEM 500MG
 AB 750MG
 >D> AB3 MACLEODS PHARMS LTD 1GM
 >A> @ 1GM
 AB3 1GM
 @ UTOPIC PHARMS 500MG
 @ 1GM

A209694 001 Oct 18, 2024 Oct NEWA
 A209694 002 Oct 18, 2024 Oct NEWA
 A218673 001 Jul 05, 2024 Jun NEWA
 A218673 002 Jul 05, 2024 Jun NEWA
 A211163 001 Mar 13, 2024 Dec DISC
 A211163 001 Mar 13, 2024 Dec DISC
 A211163 001 Mar 13, 2024 Mar NEWA
 A213394 001 Aug 03, 2021 Sep CAHN
 A213394 002 Aug 03, 2021 Sep CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
 @ CHARTWELL RX 500MG; EQ 15MG BASE
 @ 850MG; EQ 15MG BASE

A091273 001 Apr 16, 2013 Jan CAHN
 A091273 002 Apr 16, 2013 Jan CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET, EXTENDED RELEASE; ORAL
 ZITUVIMET XR
 + ZYDUS 500MG; 50MG
 + 1GM; 50MG
 +! 1GM; 100MG
 + ZYDUS LIFESCIENCES 500MG; 50MG
 + 1GM; 50MG
 +! 1GM; 100MG

N216778 001 Jul 18, 2024 Jul NEWA
 N216778 002 Jul 18, 2024 Jul NEWA
 N216778 003 Jul 18, 2024 Jul NEWA
 N216778 001 Jul 18, 2024 Aug CAHN
 N216778 002 Jul 18, 2024 Aug CAHN
 N216778 003 Jul 18, 2024 Aug CAHN

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
 METHADONE HYDROCHLORIDE
 VISTAPHARM LLC 10MG/ML
 INJECTABLE; INJECTION
 METHADONE HYDROCHLORIDE

AA
 >A> AP BRECKENRIDGE 10MG/ML
 >A> AP PYRAMID PHARM 10MG/ML

A040088 001 Nov 30, 1994 Apr CAHN
 A218252 001 Dec 16, 2024 Dec CAHN
 A218252 001 Dec 16, 2024 Dec NEWA

SOLUTION; ORAL
 METHADONE HYDROCHLORIDE

AA @ VISTAPHARM LLC 5MG/5ML
 5MG/5ML
 @ 10MG/5ML
 AA 10MG/5ML

A090707 001 Jun 30, 2010 Jun DISC
 A090707 001 Jun 30, 2010 Apr CAHN
 A090707 002 Jun 30, 2010 Jun DISC
 A090707 002 Jun 30, 2010 Apr CAHN

TABLET; ORAL
 METHADONE HYDROCHLORIDE

AA ELITE LABS INC 5MG
 @ 5MG
 AA 10MG
 @ 10MG
 AA HIKMA 5MG
 AA 10MG
 @ VISTAPHARM LLC 5MG
 AA 10MG
 AA 10MG

A210484 001 Aug 02, 2018 Aug CMFD
 A210484 001 Aug 02, 2018 Jun CAHN
 A210484 002 Aug 02, 2018 Aug CMFD
 A210484 002 Aug 02, 2018 Jun CAHN
 A088108 001 Mar 08, 1983 Nov CAHN
 A088109 001 Mar 08, 1983 Nov CAHN
 A040241 001 May 29, 1998 Apr CAHN
 A040241 002 May 29, 1998 Apr CAHN
 A204166 001 Mar 16, 2020 Apr CAHN

METHAZOLAMIDE

TABLET; ORAL							
METHAZOLAMIDE							
AB		CHARTWELL RX	25MG	A 040036	001	Jun 30, 1993	Nov CAHN
AB			50MG	A 040036	002	Jun 30, 1993	Nov CAHN

METHENAMINE HIPPURATE

TABLET; ORAL							
HIPREX							
AB	+	ESJAY PHARMA	1GM	N 017681	001		Oct CAHN
AB		JUBILANT CADISTA	1GM	A 217675	001	Dec 01, 2023	Apr CAHN

METHOCARBAMOL

SOLUTION; IM-IV							
METHOCARBAMOL							
		@ NAVINTA LLC	1GM/10ML (100MG/ML)	A 206071	001	Nov 24, 2017	Oct DISC
		@ NORVIUM BIOSCIENCE	1GM/10ML (100MG/ML)	A 204404	001	Dec 05, 2014	Jul CAHN
TABLET; ORAL							
METHOCARBAMOL							
		@ AIPING PHARM INC	500MG	A 084616	001		Nov CAHN
		@	750MG	A 084615	001		Nov CAHN
AA		ALLIED	500MG	A 212623	001	Apr 30, 2021	Aug CAHN
AA			750MG	A 212623	002	Apr 30, 2021	Aug CAHN
AA		DBL PHARMS	500MG	A 203550	001	Feb 08, 2017	Feb CAHN
AA			750MG	A 203550	002	Feb 08, 2017	Feb CAHN
AA		HANGZHOU BINJIANG	500MG	A 200958	001	Oct 21, 2011	Mar CAHN
AA			750MG	A 200958	002	Oct 21, 2011	Mar CAHN
AB	!		1GM	A 200958	003	Dec 06, 2021	Mar CAHN
AA		HLTHCARE	500MG	A 203550	001	Feb 08, 2017	Sep CAHN
AA			750MG	A 203550	002	Feb 08, 2017	Sep CAHN
ROBAXIN							
	+	@ ENDO OPERATIONS	500MG	N 011011	004		May CAHN
ROBAXIN-750							
	+	@ ENDO OPERATIONS	750MG	N 011011	006		May CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION							
BREVITAL SODIUM							
AP	+	ENDO OPERATIONS	500MG/VIAL	N 011559	001		Sep CFTG
METHOHEXITAL SODIUM							
AP		STERISCIENCE	500MG/VIAL	A 215488	001	Oct 03, 2024	Sep NFTG
AP		STERISCIENCE SPECILTS	500MG/VIAL	A 215488	001	Oct 03, 2024	Oct CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION							
METHOTREXATE SODIUM PRESERVATIVE FREE							
>A>		@ EXTROVIS	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Dec CAHN
		@	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Jun CAHN
AP	!	HIKMA	EQ 1GM BASE/VIAL	A 040632	001	Aug 12, 2005	Nov CTEC
>D>		@ RISING	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Dec CAHN
TABLET; ORAL							
METHOTREXATE SODIUM							
AB		ALEMBIC	EQ 2.5MG BASE	A 217552	001	Jun 03, 2024	May NEWA
		@ AMNEAL PHARMS	EQ 2.5MG BASE	A 210040	001	Dec 22, 2017	Sep DISC
AB		ELITE LABS INC	EQ 2.5MG BASE	A 216453	001	May 16, 2024	May NEWA
		@ LOTUS PHARM CO LTD	EQ 2.5MG BASE	A 209787	001	Apr 23, 2021	Apr DISC

METHOXSALLEN

INJECTABLE; INJECTION							
UVADEX							
>D>	+	MALLINCKRODT HOSP	0.02MG/ML	N 020969	001	Feb 25, 1999	Dec CAHN
>A>	+	THERAKOS DEVELOPMENT	0.02MG/ML	N 020969	001	Feb 25, 1999	Dec CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL							
METHSCOPOLAMINE BROMIDE							
AA		AACE PHARMS	2.5MG	A 216786	001	Feb 01, 2024	Jan NEWA
AA			5MG	A 216786	002	Feb 01, 2024	Jan NEWA
AA		NE RX PHARMA	2.5MG	A 216786	001	Feb 01, 2024	May CAHN
AA			5MG	A 216786	002	Feb 01, 2024	May CAHN

TABLET;ORAL
METHSCOPOLAMINE BROMIDE

AA	UNICHEM	2.5MG	A200602	001	Sep 24, 2012	Nov	CAHN
AA	!	5MG	A200602	002	Sep 24, 2012	Nov	CAHN

METHYLDOPA

TABLET;ORAL
METHYLDOPA

	@ CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Feb	DISC
		250MG	N018934	001	Jun 29, 1984	Jan	CMFD
	@	500MG	N018934	002	Jun 29, 1984	Feb	DISC
	!	500MG	N018934	002	Jun 29, 1984	Jan	CMFD
	RISING	250MG	A070076	002	Apr 18, 1985	Nov	CMFD
	!	500MG	A070076	001	Apr 18, 1985	Nov	CMFD

METHYLENE BLUE

SOLUTION;INTRAVENOUS
METHYLENE BLUE

AP	NEXUS	50MG/10ML (5MG/ML)	A217561	001	Nov 21, 2024	Nov	NEWA	
>A>	AP	RK PHARMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Dec	NEWA
AP	STERISCIENCE	50MG/10ML (5MG/ML)	A216955	001	Nov 22, 2024	Nov	NEWA	
AP	ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN	
AP		50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN	

METHYLERGONOVINE MALEATE

INJECTABLE;INJECTION

>D>		METHERGINE						
>D>	AP	+! EDISON THERAPS LLC	0.2MG/ML	N006035	004		Dec	DISC
>A>		+ @	0.2MG/ML	N006035	004		Dec	DISC
		METHYLERGONOVINE MALEATE						
>D>	AP	AM REGENT	0.2MG/ML	A090193	001	Nov 24, 2008	Dec	CHRS
>A>	AP	!	0.2MG/ML	A090193	001	Nov 24, 2008	Dec	CHRS

TABLET;ORAL
METHYLERGONOVINE MALEATE

AB	TRUPHARMA	0.2MG	A212233	001	May 01, 2020	Sep	CAHN
----	-----------	-------	---------	-----	--------------	-----	------

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS
METHYLNALTREXONE BROMIDE

AP	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Aug	NFTG
AP		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Aug	NFTG
		RELISTOR					
AP	+! SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Aug	CFTG
AP	+!	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Aug	CFTG

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

	+ @ NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Sep	DISC
	+	34.6MG	N205489	004	Aug 19, 2024	Aug	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
JORNAY PM

	+ IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018	Oct	CAHN
	+	40MG	N209311	002	Aug 08, 2018	Oct	CAHN
	+	60MG	N209311	003	Aug 08, 2018	Oct	CAHN
	+	80MG	N209311	004	Aug 08, 2018	Oct	CAHN
	+!	100MG	N209311	005	Aug 08, 2018	Oct	CAHN

METHYLPHENIDATE HYDROCHLORIDE

	@ TEVA PHARMS	40MG	A078873	001	Jul 19, 2012	Nov	DISC
	@	50MG	A078873	002	Jul 19, 2012	Nov	DISC
	@	60MG	A078873	003	Jul 19, 2012	Nov	DISC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	@ ALLIED	5MG/5ML	A201466	001	Nov 12, 2013	Dec	CAHN
>A>	@	10MG/5ML	A201466	002	Nov 12, 2013	Dec	CAHN
AA	ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020	Sep	CAHN
AA		10MG/5ML	A210764	002	Apr 10, 2020	Sep	CAHN
>D>	@ BRECKENRIDGE	5MG/5ML	A201466	001	Nov 12, 2013	Dec	CAHN
	@	5MG/5ML	A201466	001	Nov 12, 2013	Mar	DISC
>D>	@	10MG/5ML	A201466	002	Nov 12, 2013	Dec	CAHN

SOLUTION;ORAL								
METHYLPHENIDATE HYDROCHLORIDE								
	@	10MG/5ML	A201466	002	Nov 12, 2013	Mar	DISC	
TABLET;ORAL								
METHYLPHENIDATE HYDROCHLORIDE								
AB	CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD	
AB		10MG	A208737	002	Feb 01, 2019	Mar	CMFD	
AB		20MG	A208737	003	Feb 01, 2019	Mar	CMFD	
<u>METHYLPREDNISOLONE</u>								
TABLET;ORAL								
METHYLPREDNISOLONE								
AB	ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN	
	@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC	
<u>METHYLPREDNISOLONE ACETATE</u>								
INJECTABLE;INJECTION								
METHYLPREDNISOLONE ACETATE								
AB	ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN	
AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN	
AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN	
AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN	
	@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC	
	@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC	
AB	WILSHIRE PHARMS INC	40MG/ML	A214870	002	May 10, 2023	Jul	CAHN	
AB		80MG/ML	A214870	001	Jan 03, 2023	Jul	CAHN	
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>								
SOLUTION;ORAL								
METOCLOPRAMIDE HYDROCHLORIDE								
AA	! GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN	
TABLET;ORAL								
METOCLOPRAMIDE HYDROCHLORIDE								
AB	AIPING PHARM INC	EQ 5MG BASE	A072215	002	Nov 05, 2024	Oct	NEWA	
AB		EQ 10MG BASE	A072215	001	Jan 30, 1990	Oct	CMFD	
<u>METOLAZONE</u>								
TABLET;ORAL								
METOLAZONE								
AB	CHEMISTRY HLTH	2.5MG	A218606	001	Apr 17, 2024	Sep	CAHN	
AB		5MG	A218606	002	Apr 17, 2024	Sep	CAHN	
AB		10MG	A218606	003	Apr 17, 2024	Sep	CAHN	
AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA	
AB		5MG	A218606	002	Apr 17, 2024	Apr	NEWA	
AB		10MG	A218606	003	Apr 17, 2024	Apr	NEWA	
AB	MICRO LABS	2.5MG	A217563	001	Nov 06, 2024	Oct	NEWA	
AB		5MG	A217563	002	Nov 06, 2024	Oct	NEWA	
AB		10MG	A217563	003	Nov 06, 2024	Oct	NEWA	
AB	UNICHEM	2.5MG	A214799	001	Mar 30, 2021	Nov	CAHN	
AB		5MG	A214799	002	Mar 30, 2021	Nov	CAHN	
AB		10MG	A214799	003	Mar 30, 2021	Nov	CAHN	
<u>METOPROLOL SUCCINATE</u>								
TABLET, EXTENDED RELEASE;ORAL								
METOPROLOL SUCCINATE								
	@ GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar	DISC	
	@	EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar	DISC	
	@	EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar	DISC	
	@	EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar	DISC	
AB	SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May	NEWA	
AB	ZHEJIANG JUTAI PHARM	EQ 50MG TARTRATE	A214110	001	Jul 26, 2024	Jul	NEWA	
AB		EQ 100MG TARTRATE	A214110	002	Jul 26, 2024	Jul	NEWA	
AB		EQ 200MG TARTRATE	A214110	003	Jul 26, 2024	Jul	NEWA	
<u>METRONIDAZOLE</u>								
GEL;TOPICAL								
METROGEL								
	+ @ GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May	DISC	
METRONIDAZOLE								
AB	AUROBINDO PHARMA LTD	1%	A218941	001	Oct 15, 2024	Oct	NEWA	
AB	! COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CHRS	

GEL;VAGINAL									
METRONIDAZOLE									
AB	ENCUBE	1.3%		A216795	001	Mar 18, 2024	Mar	NFTG	
>A>	AB	SAPTALIS PHARMS	0.75%	A216750	001	Dec 31, 2024	Dec	NEWA	
NUVESSA									
AB	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar	CFTG	
TABLET;ORAL									
METRONIDAZOLE									
AB	APPCO	250MG		A205245	001	Sep 23, 2015	Oct	CAHN	
AB		500MG		A205245	002	Sep 23, 2015	Oct	CAHN	
	@	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC	
	@		500MG	A207309	002	May 16, 2016	Mar	DISC	
		INNOGENIX	125MG	A070772	003	Oct 29, 2024	Oct	NEWA	
<u>METYROSINE</u>									
CAPSULE;ORAL									
METYROSINE									
AB	LEADING	250MG		A215541	001	Sep 17, 2024	Sep	NEWA	
<u>MEXILETINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
MEXILETINE HYDROCHLORIDE									
AB	LEADING	150MG		A215876	001	Feb 27, 2023	Aug	CAHN	
AB		200MG		A215876	002	Feb 27, 2023	Aug	CAHN	
AB		250MG		A215876	003	Feb 27, 2023	Aug	CAHN	
AB	RISING	150MG		A215315	001	Aug 26, 2022	Oct	CAHN	
AB		200MG		A215315	002	Aug 26, 2022	Oct	CAHN	
AB		250MG		A215315	003	Aug 26, 2022	Oct	CAHN	
AB	ZENARA	150MG		A215315	001	Aug 26, 2022	Apr	CAHN	
AB		200MG		A215315	002	Aug 26, 2022	Apr	CAHN	
AB		250MG		A215315	003	Aug 26, 2022	Apr	CAHN	
<u>MICAFUNGIN SODIUM</u>									
INJECTABLE;INTRAVENOUS									
MICAFUNGIN SODIUM									
	@	APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul	DISC	
	@		EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul	DISC	
AP		BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May	NEWA	
AP			EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May	NEWA	
<u>MIDAZOLAM</u>									
SOLUTION;INTRAVENOUS									
MIDAZOLAM IN 0.8% SODIUM CHLORIDE									
+ @	EXELA PHARMA	100MG/100ML (1MG/ML)		N215868	002	Jul 20, 2022	Nov	DISC	
MIDAZOLAM IN 0.9% SODIUM CHLORIDE									
AP	GLAND PHARMA LTD	50MG/50ML (1MG/ML)		A218993	001	Aug 12, 2024	Aug	NEWA	
AP		100MG/100ML (1MG/ML)		A218993	002	Aug 12, 2024	Aug	NEWA	
<u>MIDAZOLAM HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
MIDAZOLAM HYDROCHLORIDE									
	@	ENDO OPERATIONS	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Sep	CAHN	
	@		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Sep	CAHN	
	@		EQ 5MG BASE/ML	A078141	002	May 30, 2008	Sep	CAHN	
	@		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Sep	CAHN	
	@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan	DISC	
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE									
AP		STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Aug	CAHN	
AP			EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Aug	CAHN	
MIDOZALAM HYDROCHLORIDE									
AP		STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Aug	CAHN	
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Aug	CAHN	
SOLUTION;INTRAMUSCULAR									
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)									
>D>	+ @	RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Dec	CMFD	
>A>	+!		EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Dec	CMFD	
SYRUP;ORAL									
MIDAZOLAM HYDROCHLORIDE									
	@	PAI HOLDINGS	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Jul	CAHN	

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr	CAHN
AB		5MG	A207169	002	Oct 29, 2018	Apr	CAHN
AB		10MG	A207169	003	Oct 29, 2018	Apr	CAHN

MIDOSTAURIN

CAPSULE; ORAL

MIDOSTAURIN

AB	DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun	NEWA
AB	LUPIN	25MG	A216015	001	May 10, 2024	May	NEWA
	@ TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Oct	DISC
AB		25MG	A216076	001	Apr 29, 2024	Apr	NFTG
	RYDAPT						
AB	+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr	CFTG

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

	@ BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Oct	DISC
--	----------------	-------	---------	-----	--------------	-----	------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

>A>	@ FIRST TIME US	12.5MG	A205071	001	Jan 27, 2016	Dec	CAHN
>A>	@	25MG	A205071	002	Jan 27, 2016	Dec	CAHN
>A>	@	50MG	A205071	003	Jan 27, 2016	Dec	CAHN
>A>	@	100MG	A205071	004	Jan 27, 2016	Dec	CAHN
AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Sep	NFTG
AB		25MG	A205147	002	Oct 03, 2024	Sep	NFTG
AB		50MG	A205147	003	Oct 03, 2024	Sep	NFTG
AB		100MG	A205147	004	Oct 03, 2024	Sep	NFTG
>D>	@ ORYZA	12.5MG	A205071	001	Jan 27, 2016	Dec	CAHN
	@	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
>D>	@	25MG	A205071	002	Jan 27, 2016	Dec	CAHN
	@	25MG	A205071	002	Jan 27, 2016	Sep	CAHN
>D>	@	50MG	A205071	003	Jan 27, 2016	Dec	CAHN
	@	50MG	A205071	003	Jan 27, 2016	Sep	CAHN
>D>	@	100MG	A205071	004	Jan 27, 2016	Dec	CAHN
	@	100MG	A205071	004	Jan 27, 2016	Sep	CAHN
	SAVELLA						
AB	+ ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Sep	CFTG
AB	+	25MG	N022256	002	Jan 14, 2009	Sep	CFTG
AB	+!	50MG	N022256	003	Jan 14, 2009	Sep	CFTG
AB	+	100MG	N022256	004	Jan 14, 2009	Sep	CFTG

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	HIKMA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Dec	CAHN
>A>	AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Dec	CAHN
>D>	AP	WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Dec	CAHN
>D>	AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Dec	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMROSI

>D>	+!	DR REDDYS	40MG	N219015	001	Nov 01, 2024	Dec	CAHN
	+!		40MG	N219015	001	Nov 01, 2024	Nov	NEWA
>A>	+!	JOURNEY	40MG	N219015	001	Nov 01, 2024	Dec	CAHN

INJECTABLE; INJECTION

MINOCIN

AP	+!	REMPLEX	EQ 100MG BASE/VIAL	N050444	001		Oct	CFTG
		MINOCYCLINE HYDROCHLORIDE						
AP		NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Oct	NFTG

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	CHARTWELL RX	EQ 50MG BASE	A065436	001	Dec 26, 2007	Dec	CAHN
>A>	AB		EQ 75MG BASE	A065436	002	Dec 26, 2007	Dec	CAHN
>A>	AB		EQ 100MG BASE	A065436	003	Dec 26, 2007	Dec	CAHN
>D>	AB	DR REDDYS LABS LTD	EQ 50MG BASE	A065436	001	Dec 26, 2007	Dec	CAHN
>D>	AB		EQ 75MG BASE	A065436	002	Dec 26, 2007	Dec	CAHN
>D>	AB		EQ 100MG BASE	A065436	003	Dec 26, 2007	Dec	CAHN
>A>	AB	INDICUS PHARMA	EQ 50MG BASE	A065436	001	Dec 26, 2007	Dec	CAHN
>A>	AB		EQ 75MG BASE	A065436	002	Dec 26, 2007	Dec	CAHN
>A>	AB		EQ 100MG BASE	A065436	003	Dec 26, 2007	Dec	CAHN
		@ SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jul	DISC
		@	EQ 75MG BASE	A090217	002	Jan 29, 2016	Jul	DISC
		@	EQ 100MG BASE	A090217	003	Jan 29, 2016	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	!	ALKEM LABS LTD	EQ 115MG BASE	A204453	007	Mar 16, 2018	Jul	CHRS
AB	!		EQ 135MG BASE	A204453	005	Sep 28, 2016	Jul	CHRS
AB		SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Jul	CHRS
AB		SUN PHARM	EQ 45MG BASE	A204394	001	Dec 30, 2015	Aug	CAHN
AB			EQ 55MG BASE	A204394	002	Oct 07, 2022	Aug	CAHN
AB			EQ 65MG BASE	A204394	003	Oct 07, 2022	Aug	CAHN
AB			EQ 80MG BASE	A204394	004	Dec 30, 2015	Aug	CAHN
AB			EQ 105MG BASE	A204394	005	Dec 30, 2015	Aug	CAHN
AB			EQ 115MG BASE	A204394	006	Oct 07, 2022	Aug	CAHN
AB			EQ 135MG BASE	A204394	007	Dec 30, 2015	Aug	CAHN
		@ SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
		@	EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
		@	EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
		@	EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
		@	EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
		@	EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
		@	EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
		@ ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
		@	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
		@	EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
		@	EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
		@	EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
		@	EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
		@	EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
		@	EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC
		MINOLIRA						
		@ EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017	Jul	DISC
		@	EQ 135MG BASE	N209269	002	May 08, 2017	Jul	DISC
		SOLODYN						
		+ @ BAUSCH	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun	DISC
		+ @	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun	DISC
		+ @	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun	DISC
		+ @	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun	DISC
		+ @	EQ 115MG BASE	N050808	005	Jul 23, 2009	Jun	DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		ENDO OPERATIONS	2.5MG	A071826	001	Nov 14, 1988	Apr	CAHN
AB			10MG	A071839	001	Nov 14, 1988	Apr	CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB		ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb	NEWA
AB			50MG	A215948	002	Feb 12, 2024	Feb	NEWA
>A>	AB	APOTEX	25MG	A209434	001	Jan 02, 2025	Dec	NEWA
>A>	AB		50MG	A209434	002	Jan 02, 2025	Dec	NEWA
AB		ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar	CMFD
AB			50MG	A209488	002	Sep 29, 2022	Mar	CMFD

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Feb	CAHN
AB			30MG	A076219	002	Jun 19, 2003	Feb	CAHN
AB			45MG	A076219	003	Jun 19, 2003	Feb	CAHN

TABLET;ORAL

MIRTAZAPINE									
AB	CHARTWELL RX	15MG	A076219	001	Jun 19, 2003	Jun	CAHN		
AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN		
AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN		

MISOPROSTOL

TABLET;ORAL									
MISOPROSTOL									
AB	ACQ PHARMA	0.1MG	A210201	001	Jul 02, 2019	Oct	CMFD		
AB		0.2MG	A210201	002	Jul 02, 2019	Oct	CMFD		

MITOMYCIN

INJECTABLE;INJECTION									
MITOMYCIN									
AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar	NEWA		
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar	NEWA		
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar	NEWA		

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION									
MITOXANTRONE HYDROCHLORIDE									
	@ RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAHN		

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION									
ASMANEX HFA									
>D>	+ ORGANON LLC	0.05MG/INH	N205641	003	Aug 12, 2019	Dec	CHRS		
>A>	+!	0.05MG/INH	N205641	003	Aug 12, 2019	Dec	CHRS		
>D>	+!	0.10MG/INH	N205641	001	Apr 25, 2014	Dec	CHRS		
>A>	+!	0.10MG/INH	N205641	001	Apr 25, 2014	Dec	CHRS		
LOTION;TOPICAL									
MOMETASONE FUROATE									
>D>	@ COSETTE	0.1%	A077678	001	Nov 21, 2007	Apr	DISC		
>A>	@ ENCUBE	0.1%	A076499	001	Nov 21, 2007	Dec	CMFD		
>A>	AB	0.1%	A076499	001	Nov 21, 2007	Dec	CMFD		
OINTMENT;TOPICAL									
MOMETASONE FUROATE									
AB	TORRENT	0.1%	A207899	001	Jul 13, 2018	Nov	CMFD		
SPRAY, METERED;NASAL									
MOMETASONE FUROATE									
AB	AUROBINDO PHARMA	0.05MG/SPRAY	A215878	001	Mar 18, 2024	Mar	NEWA		

MONTELUKAST SODIUM

GRANULE;ORAL									
MONTELUKAST SODIUM									
	@ TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan	DISC		
TABLET;ORAL									
MONTELUKAST SODIUM									
AB	RISING	EQ 10MG BASE	A209012	001	Apr 24, 2017	Aug	CAHN		
	@ SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Jul	DISC		
TABLET, CHEWABLE;ORAL									
MONTELUKAST SODIUM									
	@ SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Sep	DISC		
	@	EQ 5MG BASE	A091414	002	Aug 03, 2012	Sep	DISC		

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL									
MORPHINE SULFATE									
	UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013	Sep	CHRS		
SOLUTION;INTRAMUSCULAR, INTRAVENOUS									
MORPHINE SULFATE									
+	@ FRESENIUS KABI USA	5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013	Sep	DISC		
+	@	8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013	Sep	DISC		
SOLUTION;ORAL									
MORPHINE SULFATE									
	@ HIKMA	100MG/5ML	A208809	001	Jul 06, 2017	Mar	DISC		
	@ PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Aug	DISC		
	@	100MG/5ML	A206573	001	Nov 14, 2016	Aug	DISC		
AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD		
AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD		

SOLUTION;ORAL
MORPHINE SULFATE

AA 100MG/5ML A211454 003 Feb 12, 2021 Jan CMFD

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1 ADAPTIS EQ 0.5% BASE A202525 001 Mar 06, 2015 Aug CAHN
 @ MYLAN EQ 0.5% BASE A206447 001 Mar 30, 2020 Nov DISC
 AT1 SOMERSET THERAPS LLC EQ 0.5% BASE A209698 001 Nov 14, 2024 Nov NEWA
 VIGAMOX
 AT1 +! HARROW EYE EQ 0.5% BASE N021598 001 Apr 15, 2003 Jan CAHN
 TABLET;ORAL
 MOXIFLOXACIN HYDROCHLORIDE
 @ NATCO EQ 400MG BASE A204635 001 Aug 31, 2015 Jun CAHN

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL
MYCOPHENOLATE MOFETIL

AB HETERO LABS LTD V 250MG A207022 001 Oct 22, 2024 Oct NEWA
 AB WUXI 250MG A214079 001 Nov 07, 2024 Nov NEWA

FOR SUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB AUROBINDO PHARMA LTD 200MG/ML A218227 001 Sep 26, 2024 Sep NEWA
 AB RISING 200MG/ML A213955 001 Sep 11, 2023 Nov CAHN

SUSPENSION;ORAL
MYHIBBIN

+! AZURITY 200MG/ML N216482 001 May 01, 2024 May NEWA

TABLET;ORAL
MYCOPHENOLATE MOFETIL

@ AMNEAL 500MG A090606 001 Jul 16, 2010 Feb DISC
 AB AUROBINDO PHARMA 500MG A217937 001 Feb 20, 2024 Feb NEWA
 AB HETERO LABS LTD V 500MG A208119 001 Oct 22, 2024 Oct NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP ENDO OPERATIONS 500MG/VIAL A203575 001 Oct 28, 2016 Apr CAHN
 AP STERISCIENCE SPECLTS 500MG/VIAL A216390 001 Dec 23, 2022 Aug CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC SODIUM

AB AUROBINDO PHARMA LTD EQ 180MG BASE A218603 001 Feb 27, 2024 Feb NEWA
 AB EQ 360MG BASE A218603 002 Feb 27, 2024 Feb NEWA
 AB BIOCON PHARMA EQ 180MG BASE A217031 001 Nov 29, 2023 Jun CAHN
 AB EQ 360MG BASE A217031 002 Nov 29, 2023 Jun CAHN
 AB NOVUGEN EQ 180MG BASE A216637 001 May 29, 2024 May NEWA
 AB EQ 360MG BASE A216637 002 May 29, 2024 May NEWA
 AB SKG PHARMA EQ 180MG BASE A217031 001 Nov 29, 2023 Apr CAHN
 AB EQ 360MG BASE A217031 002 Nov 29, 2023 Apr CAHN
 AB WANBANG BIOPHARMS EQ 180MG BASE A216637 001 May 29, 2024 Jun CAHN
 AB EQ 360MG BASE A216637 002 May 29, 2024 Jun CAHN

NABILONE

CAPSULE;ORAL
CESAMET

+ @ BAUSCH 1MG N018677 001 Dec 26, 1985 Aug DISC

NABUMETONE

TABLET;ORAL
NABUMETONE

>A> AB NOVITIUM PHARMA 500MG A219118 001 Jan 07, 2025 Dec NEWA
 >A> AB 750MG A219118 002 Jan 07, 2025 Dec NEWA

NADOLOL

TABLET;ORAL
NADOLOL

AB ! INVAGEN PHARMS 80MG A203455 003 Dec 18, 2015 Aug CHRS

NAFTIFINE HYDROCHLORIDE

	CREAM; TOPICAL							
	NAFTIN							
	+ @	LEGACY PHARMA	1%	N019599	001	Feb 29, 1988	Nov CAHN	
AB	+	!	2%	N019599	002	Jan 13, 2012	Nov CAHN	
	GEL; TOPICAL							
	NAFTIN							
AB	+	!	LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Nov CAHN
AB	+	!		2%	N204286	001	Jun 27, 2013	Nov CAHN

NALBUPHINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	NALBUPHINE HYDROCHLORIDE						
AP		SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Sep NEWA
AP			10MG/ML	A216050	001	Sep 19, 2024	Sep NEWA
AP			20MG/ML	A216049	002	Sep 19, 2024	Sep NEWA
AP			20MG/ML	A216050	002	Sep 19, 2024	Sep NEWA
	NUBAIN						
	+ @	ENDO OPERATIONS	10MG/ML	N018024	001		May CAHN
	+ @		20MG/ML	N018024	002	May 27, 1982	May CAHN

NALMEFENE HYDROCHLORIDE

	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
	NALMEFENE HYDROCHLORIDE							
	!	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Jun CMFD	
	@		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May DISC	
AP	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Jun CMFD	
	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May DISC	
AP	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jun CTEC	
	!		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May CTEC	
	SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
	ZURNAI (AUTOINJECTOR)							
	+	!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Aug NEWA

NALOXONE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	NALOXONE HYDROCHLORIDE							
	@	EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019	Jun DISC	
AP		FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024	Mar NEWA	
AP			1MG/ML	A213573	002	Apr 02, 2024	Mar NEWA	
AP		HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024	Mar NEWA	
AP		MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb NEWA	
	SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
	ZIMHI							
	+	!	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May CAHN
	SPRAY; NASAL							
	REZENOPY							
	+	!	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Apr NEWA
	SPRAY, METERED; NASAL							
	REXTOVY							
	+	!	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Apr CMFD

NALTREXONE

	FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
	NALTREXONE							
	@	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan DISC	
	VIVITROL							
	+	!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan CTEC

NAPROXEN

	TABLET; ORAL						
	NAPROXEN						
AB		ADAPTIS	250MG	A091416	001	Feb 14, 2011	Sep CAHN
AB			375MG	A091416	002	Feb 14, 2011	Sep CAHN
AB			500MG	A091416	003	Feb 14, 2011	Sep CAHN
	@	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar DISC
	@		375MG	A091305	002	Aug 24, 2011	Mar DISC
	@		500MG	A091305	003	Aug 24, 2011	Mar DISC

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May	NEWA
AB		500MG	A218497	002	Jun 12, 2024	May	NEWA
AB	TRUPHARMA	375MG	A216908	001	May 31, 2023	Sep	CAHN
AB		500MG	A216908	002	May 31, 2023	Sep	CAHN

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

>D>	AB	AMNEAL PHARMS NY	EQ 250MG BASE	A078432	001	Apr 25, 2007	Dec	DISC
>A>		@	EQ 250MG BASE	A078432	001	Apr 25, 2007	Dec	DISC
>D>	AB		EQ 500MG BASE	A078432	002	Apr 25, 2007	Dec	DISC
>A>		@	EQ 500MG BASE	A078432	002	Apr 25, 2007	Dec	DISC

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

	@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC
--	---	--------------------	---------------	---------	-----	--------------	-----	------

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

	@	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC
AB			EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA
	@		EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC
AB			EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA
	@	CHARTWELL RX	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Nov	CAHN
	@		EQ 5MG BASE	A213349	002	Mar 31, 2022	Nov	CAHN
	@		EQ 10MG BASE	A213349	003	Mar 31, 2022	Nov	CAHN
	@		EQ 20MG BASE	A213349	004	Mar 31, 2022	Nov	CAHN
AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun	CMFD
AB			EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD
AB			EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD
AB			EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD
AB		MSN	EQ 2.5MG BASE	A217397	001	Oct 01, 2024	Sep	NEWA
AB			EQ 5MG BASE	A217397	002	Oct 01, 2024	Sep	NEWA
AB			EQ 10MG BASE	A217397	003	Oct 01, 2024	Sep	NEWA
AB			EQ 20MG BASE	A217397	004	Oct 01, 2024	Sep	NEWA
AB		UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Aug	CMFD
AB			EQ 5MG BASE	A213830	002	Mar 15, 2022	Aug	CMFD
AB			EQ 10MG BASE	A213830	003	Mar 15, 2022	Aug	CMFD
AB			EQ 20MG BASE	A213830	004	Mar 15, 2022	Aug	CMFD

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	@	CHARTWELL RX	50MG	A076302	001	Sep 16, 2003	Jun	CAHN
	@		100MG	A076302	002	Sep 16, 2003	Jun	CAHN
	@		150MG	A076302	003	Sep 16, 2003	Jun	CAHN
	@		200MG	A076302	004	Sep 16, 2003	Jun	CAHN
	@		250MG	A076302	005	Sep 16, 2003	Jun	CAHN

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

AP	ALEMBIC	250MG/50ML (5MG/ML)	A218554	001	Aug 01, 2024	Jul	NEWA
AP	MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN
AP	MSN	250MG/50ML (5MG/ML)	A216948	001	Sep 13, 2024	Sep	NEWA
AP	XGEN PHARMS	250MG/50ML (5MG/ML)	A216510	001	Sep 05, 2024	Aug	NEWA

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA	ADRASTEIA PHARMA	500MG	A065220	001	Jul 28, 2006	Sep	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

+	!	EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	Nov	CMFD
+	@		5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE								
AP	ADAPTIS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Aug	CAHN	
AP		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Aug	CAHN	
AP	ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN	
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN	
	@ EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC	
	@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC	
AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN	
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN	
AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug	CAHN	
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug	CAHN	

NESIRITIDE

FOR SOLUTION;INTRAVENOUS
NATRECOR

	+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar	CAIN	
--	---------------	------------	---------	-----	--------------	-----	------	--

NEVIRAPINE

SUSPENSION;ORAL
NEVIRAPINE

AA	! AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	Jun	CHRS	
	VIRAMUNE							
	+ @ BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	Jun	DISC	
	TABLET;ORAL							
	NEVIRAPINE							
	@ NORVIUM BIOSCIENCE	200MG	A078864	001	May 22, 2012	Jul	CAHN	
	TABLET, EXTENDED RELEASE;ORAL							
	NEVIRAPINE							
AB	! MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Jun	CHRS	
	VIRAMUNE XR							
	+ @ BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Jun	DISC	
	+ @	400MG	N201152	001	Mar 25, 2011	Jun	DISC	

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	HIBROW HLTHCARE	500MG	A213090	001	Aug 25, 2023	Jul	CAHN	
AB		750MG	A213090	002	Aug 25, 2023	Jul	CAHN	
AB		1GM	A213090	003	Aug 25, 2023	Jul	CAHN	

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL
NICARDIPINE HYDROCHLORIDE

AB	SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA	
AB		30MG	A218202	002	Apr 10, 2024	Mar	NEWA	

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Oct	NEWA	
AP	CHENGDU SHUODE	25MG/10ML (2.5MG/ML)	A217548	001	Sep 06, 2024	Aug	NEWA	
>A>	@ HIKMA	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Dec	CAHN	
AP	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD	
>D>	@ WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Dec	CAHN	
AP	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Aug	CMFD	

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+! CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CFTG	
	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
AP	+! CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CFTG	
	NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE							
AP	INFORLIFE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr	NFTG	
	NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE							
AP	INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr	NFTG	
	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE							
AP	CIPLA	20MG/200ML (0.1MG/ML)	A215592	001	Sep 24, 2024	Sep	NFTG	
AP		40MG/200ML (0.2MG/ML)	A215592	002	Sep 24, 2024	Sep	NFTG	
AP	+! HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Sep	CFTG	
AP	+!	40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Sep	CFTG	

NICOTINE

INHALANT;ORAL

NICOTROL

+ @	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997	Sep	DISC
-----	--------	---------------	---------	-----	--------------	-----	------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

	@	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Aug	DISC
AB		VELZEN PHARMA PVT	10MG	A073250	001	Oct 08, 1991	Aug	CAHN
AB			20MG	A074045	001	Apr 30, 1992	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

	@	ENDO OPERATIONS	30MG	A077899	001	Dec 13, 2006	May	CAHN
	@		60MG	A077899	002	Dec 13, 2006	May	CAHN
	@		90MG	A077899	003	May 25, 2012	May	CAHN
	@	SWISS PHARM	30MG	A216019	001	Nov 18, 2022	Jul	CAHN
	@		60MG	A216019	002	Nov 18, 2022	Jul	CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

	@	APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	DISC
	@		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	DISC
	@		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	DISC
		TASIGNA						
+		NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
+			EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
+	!		EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NILOTINIB TARTRATE

TABLET;ORAL

DANZITEN

+		AZURITY	EQ 71MG BASE	N219293	001	Nov 07, 2024	Nov	NEWA
+	!		EQ 95MG BASE	N219293	002	Nov 07, 2024	Nov	NEWA

NILUTAMIDE

TABLET;ORAL

NILANDRON

>A>		@	ADVANSZ PHARMA	50MG	N020169	001	Sep 19, 1996	Dec	CAHN
>A>	AB	+	!	150MG	N020169	002	Apr 30, 1999	Dec	CAHN
>D>		@	CONCORDIA	50MG	N020169	001	Sep 19, 1996	Dec	CAHN
>D>	AB	+	!	150MG	N020169	002	Apr 30, 1999	Dec	CAHN

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

!		ANNORA PHARMA	3MG/ML	A216937	001	Jul 09, 2024	Nov	CHRS
			3MG/ML	A216937	001	Jul 09, 2024	Jun	NFTG

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	@	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
---	---	-----------------	---------------	---------	-----	--------------	-----	------

NIRMATRELVIR; RITONAVIR

TABLET;ORAL

PAXLOVID (COPACKAGED)

+	!	PFIZER	150MG;100MG	N217188	001	May 25, 2023	Jul	CHRS
---	---	--------	-------------	---------	-----	--------------	-----	------

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL

OGSIVEO

+		SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr	CHRS
+			EQ 100MG BASE	N217677	002	Apr 04, 2024	Apr	NEWA
+	!		EQ 150MG BASE	N217677	003	Apr 04, 2024	Apr	NEWA

NISOLDIPINE

	TABLET, EXTENDED RELEASE;ORAL						
	NISOLDIPINE						
	@ AMTA	8.5MG	A216606	001	Apr 10, 2023	Sep	DISC
AB		8.5MG	A216606	001	Apr 10, 2023	Jun	CMFD

NITAZOXANIDE

	FOR SUSPENSION;ORAL						
	ALINIA						
	+ @ ROMARK	100MG/5ML	N021498	001	Nov 22, 2002	Sep	DISC
	TABLET;ORAL						
	ALINIA						
	+ @ ROMARK	500MG	N021497	001	Jul 21, 2004	Sep	DISC
	NITAZOXANIDE						
	! RISING	500MG	A213820	001	Nov 27, 2020	Sep	CTEC
AB	!	500MG	A213820	001	Nov 27, 2020	Sep	CHRS

NITRIC OXIDE

	GAS;INHALATION						
	INOMAX						
	+! MALLINCKRODT HOSP	4880PPM	N020845	004	Jan 17, 2023	May	NEWA
	NOXIVENT						
	! LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	May	CHRS

NITROFURANTOIN

	SUSPENSION;ORAL						
	NITROFURANTOIN						
AB	BIOCON PHARMA	25MG/5ML	A218346	001	Oct 28, 2024	Nov	CAHN
AB	CARNEGIE	25MG/5ML	A218346	001	Oct 28, 2024	Oct	NEWA

NITROFURANTOIN, MACROCRYSTALLINE

	CAPSULE;ORAL						
	NITROFURANTOIN						
	@ ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb	DISC
	@	50MG	A091095	002	Jun 18, 2015	Feb	DISC
	@	100MG	A091095	003	Jun 18, 2015	Feb	DISC
AB	AUROBINDO PHARMA USA	25MG	A077025	002	Oct 02, 2024	Sep	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

	CAPSULE;ORAL						
	NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
AB	MICRO LABS	75MG;25MG	A217073	001	Nov 03, 2023	Sep	CAHN
AB	OMSAV PHARMA	75MG;25MG	A217073	001	Nov 03, 2023	Nov	CAHN

NITROGLYCERIN

	OINTMENT;INTRA-ANAL						
	NITROGLYCERIN						
AB	ACRUX DDS	0.4%	A212222	001	Nov 29, 2024	Nov	NEWA
AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb	NFTG
>A> AB	ENCUBE	0.4%	A216452	001	Dec 16, 2024	Dec	NEWA
	RECTIV						
AB	+! ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb	CFTG
	TABLET;SUBLINGUAL						
	NITROGLYCERIN						
AB	VIWIT PHARM	0.3MG	A218583	001	Oct 15, 2024	Oct	NEWA
AB		0.4MG	A218583	002	Oct 15, 2024	Oct	NEWA
AB		0.6MG	A218583	003	Oct 15, 2024	Oct	NEWA

NIZATIDINE

	CAPSULE;ORAL						
	NIZATIDINE						
	@ NORVIUM BIOSCIENCE	150MG	A075806	001	Jul 05, 2002	Aug	CAHN
	@	300MG	A075806	002	Jul 05, 2002	Aug	CAHN

NOREPINEPHRINE BITARTRATE

	INJECTABLE;INJECTION						
	NOREPINEPHRINE BITARTRATE						
AP	DDREG PHARMA	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	NEWA
AP	RISING	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	CAHN
	@ SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Oct	DISC

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

	@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN	
	@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN	
	@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN	
	@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN	
>D>	AB	TEVA	EQ 75MG BASE	A074132	004	Mar 27, 1995	Dec	CHRS	
>A>	AB	!	EQ 75MG BASE	A074132	004	Mar 27, 1995	Dec	CHRS	
>D>		PAMELOR							
>D>	AB	+	SPECGX LLC	EQ 10MG BASE	N018013	001		Dec	DISC
>A>		+	@	EQ 10MG BASE	N018013	001		Dec	DISC
>D>	AB	+		EQ 25MG BASE	N018013	002		Dec	DISC
>A>		+	@	EQ 25MG BASE	N018013	002		Dec	DISC
>D>	AB	+		EQ 50MG BASE	N018013	004		Dec	DISC
>A>		+	@	EQ 50MG BASE	N018013	004		Dec	DISC
>D>	AB	+!		EQ 75MG BASE	N018013	003		Dec	DISC
>A>		+	@	EQ 75MG BASE	N018013	003		Dec	DISC

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

AT		TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Nov	CMFD
		POWDER;TOPICAL						
		NYSTATIN						
AT		ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
		SUSPENSION;ORAL						
		NYSTATIN						
AA	!	LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Jul	CHRS
AA	!	MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Nov	CAHN
		@ MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Sep	DISC
		@ PAI HOLDINGS	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Jul	CAHN
>D>		@ VISTAPHARM	100,000 UNITS/ML	A064142	001	Jun 25, 1998	Dec	CAHN
>D>		@	100,000 UNITS/ML	A064142	002	Mar 07, 2011	Dec	CAHN
>A>		@ VISTAPHARM LLC	100,000 UNITS/ML	A064142	001	Jun 25, 1998	Dec	CAHN
>A>		@	100,000 UNITS/ML	A064142	002	Mar 07, 2011	Dec	CAHN
AA		WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS

TABLET;ORAL

NYSTATIN

	@	SUN PHARM INDUSTRIES	500,000 UNITS	A062838	001	Dec 22, 1988	Aug	DISC
--	---	----------------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

	@	COSETTE	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Apr	DISC
--	---	---------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

MYKACET

	@	COSETTE	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	Apr	DISC
--	---	---------	-----------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

	@	SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Oct	DISC
AP			EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA
AB		TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC
AB			EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC
AB			EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC
		SANDOSTATIN LAR						
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC
AB	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC
AB	+!		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC

SOLUTION;SUBCUTANEOUS
BYNFEZIA PEN

+!	SUN PHARM	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	N213224	001	Sep 27, 2024	Nov CPOT
+!		7MG/2.8ML (2.5MG/ML)	N213224	001	Sep 27, 2024	Sep NEWA

ODEVIXIBAT

CAPSULE;ORAL
BYLVAY

+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan CAHN
+!		1.2MG	N215498	004	Jul 20, 2021	Jan CAHN

CAPSULE, PELLETS;ORAL
BYLVAY

+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan CAHN
+!		0.6MG	N215498	003	Jul 20, 2021	Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb NEWA
AT	CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr NEWA
AT	SOMERSET	0.3%	A213597	001	Aug 01, 2024	Jul NEWA

SOLUTION/DROPS;OTIC
OFLOXACIN

	@ HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar DISC
AT	SOMERSET THERAPS LLC	0.3%	A216328	001	Oct 15, 2024	Oct NEWA

TABLET;ORAL

OFLOXACIN

	@ CHARTWELL RX	200MG	A076093	001	Sep 02, 2003	Sep CAHN
	@	300MG	A076093	002	Sep 02, 2003	Sep CAHN
AB	@	400MG	A076093	003	Sep 02, 2003	Sep CAHN

OLANZAPINE

TABLET;ORAL

OLANZAPINE

	@ NATCO PHARMA	2.5MG	A076866	001	Apr 23, 2012	Aug CAHN
	@	5MG	A076866	002	Apr 23, 2012	Aug CAHN
	@	7.5MG	A076866	003	Apr 23, 2012	Aug CAHN
	@	10MG	A076866	004	Apr 23, 2012	Aug CAHN
	@	15MG	A076866	005	Apr 23, 2012	Aug CAHN
	@	20MG	A076866	006	Apr 23, 2012	Aug CAHN
	@ SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	May DISC
	@	5MG	A091038	002	Apr 23, 2012	May DISC
	@	7.5MG	A091038	003	Apr 23, 2012	May DISC
	@	10MG	A091038	004	Apr 23, 2012	May DISC
	@	15MG	A091038	005	Apr 23, 2012	May DISC
	@	20MG	A091038	006	Apr 23, 2012	May DISC

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

	@ SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May DISC
	@	10MG	A090881	002	Feb 28, 2012	May DISC
	@	15MG	A090881	003	Feb 28, 2012	May DISC
	@	20MG	A090881	004	Feb 28, 2012	May DISC

>A> OLEZARSEN SODIUM

>A> SOLUTION;SUBCUTANEOUS

>A> TRYNGOLZA (AUTOINJECTOR)

>A>	+!	IONIS PHARMS INC	EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)	N218614	001	Dec 19, 2024	Dec NEWA
-----	----	------------------	--	---------	-----	--------------	----------

OLICERIDINE

SOLUTION;INTRAVENOUS

OLINVYK

>D>	+!	TREVENA	30MG/30ML (1MG/ML)	N210730	003	Oct 30, 2020	Dec DISC
>A>	+ @		30MG/30ML (1MG/ML)	N210730	003	Oct 30, 2020	Dec DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan NEWA
AB		20MG	A206227	002	Jan 25, 2024	Jan NEWA
AB		40MG	A206227	003	Jan 25, 2024	Jan NEWA

TABLET;ORAL

OLMESARTAN MEDOXOMIL							
AB	CADILA PHARMS LTD	5MG	A210682	001	Nov 08, 2024	Nov	NEWA
AB		20MG	A210682	002	Nov 08, 2024	Nov	NEWA
AB		40MG	A210682	003	Nov 08, 2024	Nov	NEWA
AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN
AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN
AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN
AB	HETERO LABS LTD V	5MG	A205499	001	Oct 31, 2024	Oct	NEWA
AB		20MG	A205499	002	Oct 31, 2024	Oct	NEWA
AB		40MG	A205499	003	Oct 31, 2024	Oct	NEWA
AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	CMFD
AB		20MG	A208659	002	May 18, 2020	May	CMFD
AB		40MG	A208659	003	May 18, 2020	May	CMFD

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

@	HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC
---	-------	---------------	---------	-----	--------------	-----	------

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS
SYNRIBO

+	@	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun	DISC
---	---	------------------	------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN
AB	WILSHIRE PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

>A>	AB	XIROMED	40MG	A212977	003	Dec 27, 2024	Dec	NEWA
-----	----	---------	------	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS	
		ZEGERID							
	+	@	SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
	+	@		40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS	
		ZEGERID							
	+	@	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
	+	@		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC
OMLONTI

>A>		+	@	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022	Dec	CAHN
>D>		+	@	VISIOX PHARMA	0.002%	N215092	001	Sep 22, 2022	Dec	CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

>D>	AB	IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	Dec	DISC	
>A>		@		A209389	001	Oct 30, 2023	Dec	DISC	
>D>	AB		8MG	A209389	002	Oct 30, 2023	Dec	DISC	
>A>		@		A209389	002	Oct 30, 2023	Dec	DISC	
		@	MYLAN	4MG	A078139	001	Jun 25, 2007	Jun	DISC
		@		8MG	A078139	002	Jun 25, 2007	Jun	DISC
		@	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan	DISC
		@		8MG	A078602	002	Feb 24, 2011	Jan	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ ACCORD HLTHCARE EQ 2MG BASE/ML A206845 001 Mar 10, 2016 May DISC

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

@ PHARM ASSOC EQ 4MG BASE/5ML A078127 001 Jun 25, 2007 Feb DISC

@ TARO EQ 4MG BASE/5ML A077009 001 Nov 30, 2007 May DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ CHARTWELL RX EQ 4MG BASE A077517 001 Jun 25, 2007 Jun CAHN

@ EQ 8MG BASE A077517 002 Jun 25, 2007 Jun CAHN

@ EQ 24MG BASE A077517 003 Jun 25, 2007 Jun CAHN

>D> AB IPCA LABS LTD EQ 4MG BASE A203761 001 Jan 23, 2014 Dec DISC

>A> @ EQ 4MG BASE A203761 001 Jan 23, 2014 Dec DISC

>D> AB EQ 8MG BASE A203761 002 Jan 23, 2014 Dec DISC

>A> @ EQ 8MG BASE A203761 002 Jan 23, 2014 Dec DISC

@ SUN PHARM INDS (IN) EQ 4MG BASE A077050 001 Jun 25, 2007 Nov DISC

@ EQ 8MG BASE A077050 002 Jun 25, 2007 Nov DISC

OPICAPONE

CAPSULE; ORAL

ONGENTYS

+ AMNEAL 25MG N212489 001 Apr 24, 2020 Apr CAHN

+! 50MG N212489 002 Apr 24, 2020 Apr CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB @ STEVENS J 100MG A040368 001 Jun 23, 2000 Jun CAHN

UNICHEM 100MG A091158 001 Jul 27, 2012 Nov CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB CEDIPROF INC EQ 30MG BASE A217451 001 Dec 03, 2024 Nov NEWA

AB EQ 45MG BASE A217451 002 Dec 03, 2024 Nov NEWA

AB EQ 75MG BASE A217451 003 Dec 03, 2024 Nov NEWA

AB LAURUS EQ 30MG BASE A218565 001 May 01, 2024 Apr NEWA

AB EQ 45MG BASE A218565 002 May 01, 2024 Apr NEWA

AB EQ 75MG BASE A218565 003 May 01, 2024 Apr NEWA

AB NANJING DAOQUN EQ 30MG BASE A217133 001 Oct 30, 2024 Oct NEWA

AB EQ 75MG BASE A217133 002 Oct 30, 2024 Oct NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB AUROBINDO PHARMA LTD EQ 6MG BASE/ML A218131 001 May 10, 2024 May NEWA

AB INVAGEN PHARMS EQ 6MG BASE/ML A212858 001 Aug 30, 2021 Sep CAHN

@ LEADING EQ 6MG BASE/ML A214949 001 Feb 28, 2022 Aug CAHN

AB ORYZA EQ 6MG BASE/ML A217303 001 Jul 02, 2024 Jun NEWA

OSPEMIFENE

TABLET; ORAL

OSPEMIFENE

AB HETERO LABS LTD V 60MG A215574 001 Feb 13, 2024 Feb NFTG

AB +! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Feb CFTG

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP ! FRESENIUS KABI USA EQ 1GM BASE/VIAL A206198 001 Jul 20, 2020 Oct CHRS

AP ! EQ 2GM BASE/VIAL A206198 002 Jul 20, 2020 Oct CHRS

@ SAGENT PHARMS EQ 1GM BASE/VIAL A091246 001 Mar 30, 2012 Oct DISC

@ EQ 2GM BASE/VIAL A091246 002 Mar 30, 2012 Oct DISC

@ STERISCIENCE SPECLTS EQ 1GM BASE/VIAL A091486 001 Aug 25, 2014 Aug CAHN

AP EQ 2GM BASE/VIAL A091486 002 Aug 25, 2014 Aug CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS		ELOXATIN							
+ @	SANOFI AVENTIS US	50MG/10ML (5MG/ML)		N021759	001	Jan 31, 2005	Jun	DISC	
+ @		100MG/20ML (5MG/ML)		N021759	002	Jan 31, 2005	Jun	DISC	
OXALIPLATIN									
@	ACTAVIS TOTOWA	50MG/VIAL		A078803	001	Aug 08, 2012	Sep	DISC	
@		100MG/VIAL		A078803	002	Aug 08, 2012	Sep	DISC	
@	EUGIA PHARMA	50MG/10ML (5MG/ML)		A205529	001	Sep 06, 2017	Nov	DISC	
@		100MG/20ML (5MG/ML)		A205529	002	Sep 06, 2017	Nov	DISC	
AP	! GLAND	50MG/10ML (5MG/ML)		A207325	001	Feb 10, 2017	Jun	CHRS	
AP	!	100MG/20ML (5MG/ML)		A207325	002	Feb 10, 2017	Jun	CHRS	
AP	KINDOS	50MG/10ML (5MG/ML)		A217348	001	Jan 11, 2024	Jan	NEWA	
AP		100MG/20ML (5MG/ML)		A217348	002	Jan 11, 2024	Jan	NEWA	
AP	MEITHEAL	50MG/10ML (5MG/ML)		A217348	001	Jan 11, 2024	Jun	CAHN	
AP		100MG/20ML (5MG/ML)		A217348	002	Jan 11, 2024	Jun	CAHN	
@	NORVIUM BIOSCIENCE	50MG/VIAL		A200979	001	Aug 08, 2012	Jul	CAHN	
@		100MG/VIAL		A200979	002	Aug 08, 2012	Jul	CAHN	

OXAPROZIN

TABLET; ORAL		OXAPROZIN							
AB	ABRAXEOLUS	600MG		A075845	001	Jan 31, 2001	Sep	CAHN	
AB	PANGEA	600MG		A075845	001	Jan 31, 2001	Nov	CAHN	
AB		600MG		A075845	001	Jan 31, 2001	Jun	CAHN	
@	TEVA	600MG		A075849	001	Jul 03, 2002	Jan	DISC	

OXAZEPAM

CAPSULE; ORAL		OXAZEPAM							
AB	TRUPHARMA	10MG		A071026	002	Aug 10, 1987	Sep	CAHN	
AB		15MG		A071026	003	Aug 10, 1987	Sep	CAHN	
AB		30MG		A071026	001	Aug 10, 1987	Sep	CAHN	

OXCARBAZEPINE

SUSPENSION; ORAL		OXCARBAZEPINE							
AB	ALKEM LABS LTD	300MG/5ML		A213183	001	Mar 18, 2023	Mar	NEWA	
AB	BIOCON PHARMA	300MG/5ML		A218278	001	Mar 01, 2024	Apr	CAHN	
AB	CARNEGIE	300MG/5ML		A218278	001	Mar 01, 2024	Feb	NEWA	
AB	KANCHAN HLTHCARE	300MG/5ML		A217782	001	Feb 14, 2024	Sep	CAHN	
AB	MEDLEY PHARMS	300MG/5ML		A217782	001	Feb 14, 2024	Feb	NEWA	
AB	RISING	300MG/5ML		A218278	001	Mar 01, 2024	Mar	CAHN	
TABLET; ORAL		OXCARBAZEPINE							
AB	ANI PHARMS	150MG		A078005	001	Dec 11, 2007	Jul	CMFD	
AB		300MG		A078005	002	Dec 11, 2007	Jul	CMFD	
AB		600MG		A078005	003	Dec 11, 2007	Jul	CMFD	
AB	RUBICON	150MG		A207717	001	Mar 05, 2024	Feb	NEWA	
AB		300MG		A207717	002	Mar 05, 2024	Feb	NEWA	
AB		600MG		A207717	003	Mar 05, 2024	Feb	NEWA	
@	ZYDUS	150MG		A211747	001	Jul 03, 2023	Jan	DISC	
@		300MG		A211747	002	Jul 03, 2023	Jan	DISC	
@		600MG		A211747	003	Jul 03, 2023	Jan	DISC	
TABLET, EXTENDED RELEASE; ORAL		OXCARBAZEPINE							
@	AJANTA PHARMA LTD	150MG		A217659	001	Feb 22, 2024	Aug	DISC	
AB		150MG		A217659	001	Feb 22, 2024	Feb	NEWA	
@		300MG		A217659	002	Feb 22, 2024	Aug	DISC	
AB		300MG		A217659	002	Feb 22, 2024	Feb	NEWA	
@		600MG		A217659	003	Feb 22, 2024	Aug	DISC	
AB		600MG		A217659	003	Feb 22, 2024	Feb	NEWA	
AB	APOTEX	150MG		A213369	001	Jul 13, 2023	Aug	CMFD	
AB		300MG		A213369	002	Jul 13, 2023	Aug	CMFD	
AB		600MG		A213369	003	Jul 13, 2023	Aug	CMFD	
>D>	AB	RICONPHARMA LLC	150MG	A215796	001	Nov 22, 2024	Dec	DISC	
>A>	@		150MG	A215796	001	Nov 22, 2024	Dec	DISC	
AB		150MG		A215796	001	Nov 22, 2024	Nov	NEWA	
>D>	AB		300MG	A215796	002	Nov 22, 2024	Dec	DISC	
>A>	@		300MG	A215796	002	Nov 22, 2024	Dec	DISC	
AB		300MG		A215796	002	Nov 22, 2024	Nov	NEWA	
>D>	AB		600MG	A215796	003	Nov 22, 2024	Dec	DISC	

TABLET, EXTENDED RELEASE;ORAL							
OXCARBAZEPINE							
>A>	@	600MG	A215796	003	Nov 22, 2024	Dec	DISC
AB		600MG	A215796	003	Nov 22, 2024	Nov	NEWA
OXTELLAR XR							
AB	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb	CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Feb	CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Feb	CTEC
<u>OXYBUTYNIN CHLORIDE</u>							
SYRUP;ORAL							
OXYBUTYNIN CHLORIDE							
	@ PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	Feb	DISC
TABLET;ORAL							
OXYBUTYNIN CHLORIDE							
	@ EYWA	5MG	A211062	001	Feb 06, 2019	Mar	DISC
	@ HIBROW HLTHCARE	5MG	A211062	001	Feb 06, 2019	Jul	CAHN
AB	TRUPHARMA	5MG	A210125	001	Sep 06, 2018	Sep	CAHN
<u>OXYCODONE HYDROCHLORIDE</u>							
SOLUTION;ORAL							
OXYCODONE HYDROCHLORIDE							
	@ HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar	DISC
	@	100MG/5ML	A208795	001	Aug 07, 2017	Mar	DISC
	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar	CAHN
TABLET;ORAL							
OXYCODONE HYDROCHLORIDE							
AB	STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009	Aug	CMFD
AB		10MG	A077712	004	Apr 13, 2015	Aug	CMFD
AB		15MG	A077712	001	Jan 31, 2007	Aug	CMFD
AB		20MG	A077712	005	Apr 13, 2015	Aug	CMFD
AB		30MG	A077712	002	Jan 31, 2007	Aug	CMFD
	@ SUN PHARM INDS INC	5MG	A090659	001	Apr 10, 2009	Jun	DISC
	@	10MG	A090659	005	Nov 06, 2012	Jun	DISC
	@	15MG	A090659	002	Apr 10, 2009	Jun	DISC
	@	20MG	A090659	004	Nov 06, 2012	Jun	DISC
	@	30MG	A090659	003	Apr 10, 2009	Jun	DISC
ROXYBOND							
	PROTEGA PHARMS	10MG	N209777	004	Sep 05, 2024	Sep	NEWA
<u>OXYMETHOLONE</u>							
TABLET;ORAL							
ANADROL-50							
	+ @ NORVIUM BIOSCIENCE	50MG	N016848	001		Jun	CAHN
<u>OXYMORPHONE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
OPANA ER							
	+ @ ENDO OPERATIONS	5MG	N021610	001	Jun 22, 2006	May	CAHN
	+ @	7.5MG	N021610	005	Feb 29, 2008	May	CAHN
	+ @	10MG	N021610	002	Jun 22, 2006	May	CAHN
	+ @	15MG	N021610	006	Feb 29, 2008	May	CAHN
	+ @	20MG	N021610	003	Jun 22, 2006	May	CAHN
	+ @	30MG	N021610	007	Feb 29, 2008	May	CAHN
	+ @	40MG	N021610	004	Jun 22, 2006	May	CAHN
<u>OZANIMOD HYDROCHLORIDE</u>							
CAPSULE;ORAL							
ZEPOSIA							
	+ BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan	CAHN
	+	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan	CAHN
	+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan	CAHN
<u>OZENOXACIN</u>							
CREAM;TOPICAL							
XEPI							
	+ @ FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017	Oct	DISC

PACLITAXEL

POWDER; INTRAVENOUS
ABRAXANE

AB	+	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan	CTEC
		PACLITAXEL						
AB	+	AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr	CTEC
AB		HENGRUI PHARMA	100MG/VIAL	A212700	001	Oct 08, 2024	Sep	NEWA
AB	+	TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan	CMFD

PACRITINIB CITRATE

CAPSULE; ORAL
VONJO

	+	SOBI	EQ 100MG BASE	N208712	001	Feb 28, 2022	Nov	CAHN
--	---	------	---------------	---------	-----	--------------	-----	------

PALBOCICLIB

TABLET; ORAL
IBRANCE

	+	PFIZER	75MG	N212436	001	Nov 01, 2019	Nov	CTEC
AB	+		75MG	N212436	001	Nov 01, 2019	May	CFTG
	+		75MG	N212436	001	Nov 01, 2019	Jan	CTEC
	+		100MG	N212436	002	Nov 01, 2019	Nov	CTEC
AB	+		100MG	N212436	002	Nov 01, 2019	May	CFTG
	+		100MG	N212436	002	Nov 01, 2019	Jan	CTEC
	+		125MG	N212436	003	Nov 01, 2019	Nov	CTEC
AB	+		125MG	N212436	003	Nov 01, 2019	May	CFTG
	+		125MG	N212436	003	Nov 01, 2019	Jan	CTEC
		PALBOCICLIB						
	@	SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	Nov	DISC
AB			75MG	A215570	001	Jun 05, 2024	May	NFTG
	@		100MG	A215570	002	Jun 05, 2024	Nov	DISC
AB			100MG	A215570	002	Jun 05, 2024	May	NFTG
	@		125MG	A215570	003	Jun 05, 2024	Nov	DISC
AB			125MG	A215570	003	Jun 05, 2024	May	NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

	@	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul	DISC
	@		3MG	A202645	002	Aug 03, 2015	Jul	DISC
	@		6MG	A202645	003	Aug 03, 2015	Jul	DISC
	@		9MG	A202645	004	Aug 03, 2015	Jul	DISC
AB		AJANTA PHARMA LTD	1.5MG	A218514	001	Jun 26, 2024	Jun	NEWA
>D>	AB		3MG	A218514	002	Jun 26, 2024	Dec	DISC
>A>		@	3MG	A218514	002	Jun 26, 2024	Dec	DISC
AB			3MG	A218514	002	Jun 26, 2024	Jun	NEWA
>D>	AB		6MG	A218514	003	Jun 26, 2024	Dec	DISC
>A>		@	6MG	A218514	003	Jun 26, 2024	Dec	DISC
AB			6MG	A218514	003	Jun 26, 2024	Jun	NEWA
>D>	AB		9MG	A218514	004	Jun 26, 2024	Dec	DISC
>A>		@	9MG	A218514	004	Jun 26, 2024	Dec	DISC
AB			9MG	A218514	004	Jun 26, 2024	Jun	NEWA
AB		ALEMBIC	1.5MG	A218330	001	Sep 26, 2024	Sep	NEWA
AB			3MG	A218330	002	Sep 26, 2024	Sep	NEWA
AB			6MG	A218330	003	Sep 26, 2024	Sep	NEWA
AB			9MG	A218330	004	Sep 26, 2024	Sep	NEWA
BX		LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun	CTEC
BX			3MG	A208643	002	Jun 29, 2022	Jun	CTEC
BX			6MG	A208643	003	Jun 29, 2022	Jun	CTEC
BX			9MG	A208643	004	Jun 29, 2022	Jun	CTEC
AB		ZYDUS PHARMS	1.5MG	A217445	001	Oct 08, 2024	Sep	NEWA
AB			3MG	A217445	002	Oct 08, 2024	Sep	NEWA
AB			6MG	A217445	003	Oct 08, 2024	Sep	NEWA
AB			9MG	A217445	004	Oct 08, 2024	Sep	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ERZOFRI

	+	LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Aug	CHRS
	+		39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Jul	NEWA
	+		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Aug	CHRS
	+		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Jul	NEWA
	+		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Aug	CHRS

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ERZOFRI

	+		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Jul	NEWA
	+!		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Aug	CHRS
	+		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Jul	NEWA
	+!		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Aug	CHRS
	+		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Jul	NEWA
	+!		351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024	Jul	NEWA

INVEGA SUSTENNA

AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
AB	+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC

INVEGA TRINZA

	+!	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	Aug	CHRS
	+!		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	Aug	CHRS
	+!		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	Aug	CHRS

PALIPERIDONE PALMITATE

AB		TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
AB			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
AB			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
AB			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
AB			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		MEITHEAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun	CAHN
----	--	----------	--	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

POSFREA

	+	@ AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CTNA
	+	@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CRLD
		@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
	+!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CTNA
	+!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CMFD
		@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN

PALOPEGTERIPARATIDE

SOLUTION; SUBCUTANEOUS

YORVIPATH

	+!	ASCENDIS PHARMA BONE	EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	N216490	001	Aug 09, 2024	Aug	NEWA
	+		EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	Aug	NEWA
	+		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	Aug	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

	!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
	@	HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989	May	DISC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

AP		HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
>D>	AP	SANDOZ	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Dec	DISC
>A>		@	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Dec	DISC
		@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

POWDER; INTRAVENOUS

PANTOPRAZOLE SODIUM

AP		FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Jul	NEWA
AP	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CFTG

SOLUTION;INTRAVENOUS

PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
+!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
+!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

	@ MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Oct	DISC
AB		EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA

PARICALCITOL

SOLUTION;INTRAVENOUS

PARICALCITOL

	@ HOSPIRA	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	May	DISC
	@	0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	May	DISC
	@	0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	May	DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

!	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Nov	CHRS
		EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Nov	CTEC
	PAXIL						
+ @	APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Nov	DISC

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB	+!	LEGACY PHARMA	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Nov	CAHN
----	----	---------------	---------------	---------	-----	--------------	-----	------

PATIROMER SORBITE X CALCIUM

POWDER;ORAL

VELTASSA

+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Aug	CMFD
+ @		EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
+!		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS
+ @		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

PAZOPANIB HYDROCHLORIDE

AB		EUGIA PHARMA	EQ 200MG BASE	A219034	001	Dec 04, 2024	Nov	NEWA
AB		NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA

PEGULICIANINE ACETATE

POWDER;INTRAVENOUS

LUMISIGHT

+!	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA
----	----------	-------------------	---------	-----	--------------	-----	------

PEMETREXED DIPOTASSIUM

POWDER;INTRAVENOUS

AXTLE

>A>	+!	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Dec	CTNA
>A>	+!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Dec	CTNA
>D>		PEMETREXED						
>D>	+!	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Dec	CTNA
	+!		EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Jun	NEWA
>D>	+!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Dec	CTNA
	+!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Jun	NEWA

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

AP		HETERO LABS LTD VI	EQ 100MG BASE/VIAL	A215460	001	Jun 14, 2024	Jun	NEWA
AP			EQ 500MG BASE/VIAL	A215460	002	Jun 14, 2024	Jun	NEWA
AP		RELIANCE LIFE	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	Jun	CAHN
AP			EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	Jun	CAHN

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+ @ ENDO OPERATIONS 10MG N018976 001 Dec 30, 1987 May CAHN
 + @ 20MG N018976 004 Jan 05, 1989 May CAHN

PENCICLOVIR

CREAM; TOPICAL

PENCICLOVIR

AB PADAGIS ISRAEL 1% A212368 001 Sep 27, 2024 Sep NEWA

PENICILLAMINE

CAPSULE; ORAL

LUXZYLA

@ ANI PHARMS 250MG A209921 001 May 07, 2019 Aug CTNA
 AB 250MG A209921 001 May 07, 2019 Aug CTNA

PENICILLAMINE

AB ENDO OPERATIONS 250MG A211231 001 Dec 23, 2019 Apr CAHN

TABLET; ORAL

PENICILLAMINE

AB ENDO OPERATIONS 250MG A211196 001 Dec 23, 2019 Apr CAHN

PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN V POTASSIUM

AB ! AUROBINDO PHARMA EQ 500MG BASE A065435 002 Apr 29, 2008 Jan CHRS
 @ SANDOZ EQ 250MG BASE A064071 001 Nov 30, 1995 Jan DISC
 @ EQ 500MG BASE A064071 002 Nov 30, 1995 Jan DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB ANI PHARMS 400MG A074878 001 Jul 09, 1997 Jan CMFD
 AB RISING 400MG A074425 001 Jul 08, 1997 Jun CMFD

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

@ DR REDDYS LABS EU 5% A209732 001 Aug 01, 2023 Jan DISC

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB ENDO OPERATIONS 2MG A040226 001 Dec 31, 1998 Apr CAHN
 AB 4MG A040226 002 Dec 31, 1998 Apr CAHN
 AB 8MG A040226 003 Dec 31, 1998 Apr CAHN
 AB 16MG A040226 004 Dec 31, 1998 Apr CAHN
 AB MACLEODS PHARMS LTD 2MG A212545 001 May 06, 2024 Apr NEWA
 AB 4MG A212545 002 May 06, 2024 Apr NEWA
 AB 8MG A212545 003 May 06, 2024 Apr NEWA
 AB 16MG A212545 004 May 06, 2024 Apr NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLIN

>A> AB + ADVANZ PHARMA 10MG N008708 001 Dec CAHN
 >D> AB + CONCORDIA 10MG N008708 001 Dec CAHN
 PHENOXYBENZAMINE HYDROCHLORIDE
 AB ! ENDO OPERATIONS 10MG A204522 001 Jan 24, 2017 May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

+ @ TEVA 37.5MG A088023 001 Aug 02, 1983 Feb DISC
 PHENTERMINE HYDROCHLORIDE
 >D> AA ELITE LABS INC 37.5MG A040228 001 Jun 19, 1997 Dec DISC
 >A> @ 37.5MG A040228 001 Jun 19, 1997 Dec DISC
 @ INVAGEN PHARMS 15MG A202858 001 Feb 14, 2014 Mar DISC
 @ 30MG A202858 002 Feb 14, 2014 Mar DISC
 @ 30MG A204414 001 May 05, 2014 Mar DISC
 @ 37.5MG A202846 001 Feb 05, 2014 Mar DISC

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE						
AA	! NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb CHRS
TABLET;ORAL						
PHENTERMINE HYDROCHLORIDE						
AA	AUROBINDO PHARMA LTD	37.5MG	A203068	001	Aug 06, 2014	Sep CAHN
	@ INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Mar DISC

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL						
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE						
AB	ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A204982	001	Jun 25, 2024	Jun NFTG
AB		EQ 7.5MG BASE;46MG	A204982	002	Jun 25, 2024	Jun NFTG
AB		EQ 11.25MG BASE;69MG	A204982	003	Jun 25, 2024	Jun NFTG
AB		EQ 15MG BASE;92MG	A204982	004	Jun 25, 2024	Jun NFTG
QSYMIA						
AB	+ VIVUS LLC	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun CFTG
	+	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	May CAHN
AB	+	EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun CFTG
	+	EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	May CAHN
AB	+	EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun CFTG
	+	EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	May CAHN
AB	+!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun CFTG
	+!	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	May CAHN

PHENTOLAMINE MESYLATE

SOLUTION;OPHTHALMIC						
RYZUMVI						
	+! FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan CAHN

PHENYLBUZAZONE

CAPSULE;ORAL						
PHENYLBUZAZONE						
	@ CHARTWELL RX	100MG	A087774	001	Jun 16, 1982	Aug CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS						
PHENYLEPHRINE HYDROCHLORIDE						
	@ ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May DISC
	@	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May DISC
	@	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May DISC
AP1	ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May NEWA
AP1		50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May NEWA
AP1		100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May NEWA
	@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr CAHN
AP1		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr CAHN
AP1		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr CAHN
	@ HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Sep DISC
AP1		10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar NEWA
	@	50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Sep DISC
AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar NEWA
	@	100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Sep DISC
AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar NEWA
SOLUTION/DROPS;OPHTHALMIC						
PHENYLEPHRINE HYDROCHLORIDE						
AT	CAPLIN	2.5%	A215183	001	May 23, 2024	May NEWA
AT		10%	A215183	002	May 23, 2024	May NEWA
>A>	AT	GLAND PHARMA LTD	A218129	001	Dec 18, 2024	Dec NEWA
>A>	AT		A218129	002	Dec 18, 2024	Dec NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL						
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE						
AA	! GENUS	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Apr CAHN
	@ HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar DISC

PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

SPRAY, METERED;OPHTHALMIC						
MYDCOMBI						
	+ @ EYENOVIA	2.5%;1%	N215352	001	May 05, 2023	Nov DISC

PHENYTOIN

	SUSPENSION;ORAL							
	PHENYTOIN							
	@ PAI HOLDINGS PHARM	125MG/5ML	A 040420	001	Apr 19, 2002	Feb	DISC	
	TABLET, CHEWABLE;ORAL							
	PHENYTOIN							
AB	TARO	50MG	A 200565	001	Apr 17, 2014	Apr	CAHN	

PHENYTOIN SODIUM

	CAPSULE;ORAL							
	EXTENDED PHENYTOIN SODIUM							
	@ SUN PHARM INDS	200MG EXTENDED	A 040731	001	Jun 30, 2008	Nov	DISC	
	@	300MG EXTENDED	A 040731	002	Jun 30, 2008	Nov	DISC	
	PHENYTEK							
	MYLAN	200MG EXTENDED	A 040298	002	Dec 06, 2001	Nov	CTEC	
	!	300MG EXTENDED	A 040298	003	Dec 06, 2001	Nov	CTEC	
	INJECTABLE;INJECTION							
	PHENYTOIN SODIUM							
AP	+! HIKMA	50MG/ML	A 084307	001		Jun	CAHN	

PHYTONADIONE

	INJECTABLE;INJECTION							
	PHYTONADIONE							
>A>	AB	CIPLA	1MG/0.5ML	A 214966	001	Jan 03, 2025	Dec	NEWA
	AB1	GLAND PHARMA LTD	10MG/ML	A 217386	001	Dec 10, 2024	Nov	NEWA
>D>	BP	+! INTL MEDICATION	1MG/0.5ML	A 083722	001		Dec	CTEC
>A>	AB	+!	1MG/0.5ML	A 083722	001		Dec	CTEC
	TABLET;ORAL							
	PHYTONADIONE							
>A>	AB	HIKMA	5MG	A 212112	001	Dec 19, 2024	Dec	NEWA
	AB	! ZYDUS LIFESCIENCES	5MG	A 210189	001	Feb 20, 2019	Jul	CAHN

PILOCARPINE HYDROCHLORIDE

	TABLET;ORAL							
	SALAGEN							
>A>	AB	+ ADVANZ PHARMA	5MG	N 020237	001	Mar 22, 1994	Dec	CAHN
>A>	AB	+!	7.5MG	N 020237	002	Apr 18, 2003	Dec	CAHN
>D>	AB	+ CONCORDIA	5MG	N 020237	001	Mar 22, 1994	Dec	CAHN
>D>	AB	+!	7.5MG	N 020237	002	Apr 18, 2003	Dec	CAHN

PIMAVANSERIN TARTRATE

	CAPSULE;ORAL							
	NUPLAZID							
	+! ACADIA PHARMS INC	EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jul	CTEC	
AB	+!	EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jan	CFTG	
	PIMAVANSERIN							
	@ MSN	EQ 34MG BASE	A 214925	001	Jan 16, 2024	Feb	DISC	
AB		EQ 34MG BASE	A 214925	001	Jan 16, 2024	Jan	NEWA	
	@ ZYDUS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jul	DISC	
AB		EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	CAHN	
AB	ZYDUS PHARMS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	NEWA	
	TABLET;ORAL							
	NUPLAZID							
	+! ACADIA PHARMS INC	EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jul	CTEC	
AB	+!	EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jan	CFTG	
	PIMAVANSERIN							
	@ ZYDUS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jul	DISC	
AB		EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	CAHN	
AB	ZYDUS PHARMS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	NEWA	

PIMOZIDE

	TABLET;ORAL							
	PIMOZIDE							
	ENDO OPERATIONS	1MG	A 204521	001	Sep 28, 2015	Apr	CAHN	
	!	2MG	A 204521	002	Sep 28, 2015	Apr	CAHN	

PINDOLOL

TABLET;ORAL

AB	UNICHEM	5MG	A211712	001	Aug 01, 2019	Nov	CAHN
AB		10MG	A211712	002	Aug 01, 2019	Nov	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

AB	COREPHARMA	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jul	CAHN
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jul	CAHN
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jul	CAHN
	@ NORVIUM BIOSCIENCE	EQ 15MG BASE	A076801	001	Aug 17, 2012	Sep	CAHN
	@	EQ 30MG BASE	A076801	002	Aug 17, 2012	Sep	CAHN
	@	EQ 45MG BASE	A076801	003	Aug 17, 2012	Sep	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

AP	STERISCIENCE SPECLTS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug	CAHN
	@ EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Apr	DISC
	@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Apr	DISC

PIRFENIDONE

CAPSULE;ORAL

>A>	AB	MACLEODS PHARMS LTD	267MG	A212748	001	Dec 18, 2024	Dec	NEWA
-----	----	---------------------	-------	---------	-----	--------------	-----	------

PIROXICAM

CAPSULE;ORAL

	@	FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar	DISC
	@		20MG	A207938	002	Sep 09, 2016	Mar	DISC

PITAVASTATIN CALCIUM

TABLET;ORAL

AB	AMNEAL PHARMS NY	EQ 1MG BASE	A205961	001	Aug 20, 2024	Aug	NEWA
AB		EQ 2MG BASE	A205961	002	Aug 20, 2024	Aug	NEWA
AB		EQ 4MG BASE	A205961	003	Aug 20, 2024	Aug	NEWA
AB	HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr	NEWA
AB		EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr	NEWA
AB		EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr	NEWA

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

>D>	+ @	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Dec	CMFD
>A>	+	!	EQ 185MG BASE	N216483	001	Apr 24, 2024	Dec	CMFD
	+	@	EQ 185MG BASE	N216483	001	Apr 24, 2024	Aug	DISC
	+	!	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr	NEWA

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

AP	GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr	NEWA
AP	MEITHEAL	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun	CAHN
	@ ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

>A>	@	EXTROVIS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Dec	CAHN
	@		420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Jun	CAHN

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA	NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019	001	May 27, 2009	Jun	CMFD
>D>	@ RISING	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010	Dec	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@	NORVIUM BIOSCIENCE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jul	CAHN
@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul	CAHN
@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul	CAHN
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul	CAHN
@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul	CAHN

COLYTE WITH FLAVOR PACKS

@	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
@	NORVIUM BIOSCIENCE	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CAHN

COLYTE-FLAVORED

@	NORVIUM BIOSCIENCE	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul	CAHN
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul	CAHN

PEG 3350 AND ELECTROLYTES

>A>	@ EXTROVIS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Dec	CAHN
	@	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Jun	CAHN
	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC
>D>	@ RISING	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Dec	CAHN

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP	ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	------------------	----------------------------	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SOMERSET THERAPS LLC	10,000 UNITS/ML;EQ 1MG BASE/ML	A211572	001	Aug 05, 2024	Jul	NEWA
----	----------------------	--------------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

AB	APOTEX	1MG	A210164	001	Jun 11, 2024	May	NEWA
AB		2MG	A210164	002	Jun 11, 2024	May	NEWA
AB		3MG	A210164	003	Jun 11, 2024	May	NEWA
AB		4MG	A210164	004	Jun 11, 2024	May	NEWA
AB	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Sep	NEWA
AB		2MG	A210236	002	Sep 26, 2024	Sep	NEWA
AB		3MG	A210236	003	Sep 26, 2024	Sep	NEWA
AB		4MG	A210236	004	Sep 26, 2024	Sep	NEWA

POMALYST

AB	+ BRISTOL	1MG	N204026	001	Feb 08, 2013	May	CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	May	CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	May	CTEC
AB	+	4MG	N204026	004	Feb 08, 2013	May	CTEC

PONESIMOD

TABLET; ORAL
PONVORY

+!	VANDA PHARMS INC	2MG	N213498	001	Mar 18, 2021	May	CAHN
+		3MG	N213498	002	Mar 18, 2021	May	CAHN
+		4MG	N213498	003	Mar 18, 2021	May	CAHN
+		5MG	N213498	004	Mar 18, 2021	May	CAHN
+		6MG	N213498	005	Mar 18, 2021	May	CAHN
+		7MG	N213498	006	Mar 18, 2021	May	CAHN
+		8MG	N213498	007	Mar 18, 2021	May	CAHN
+		9MG	N213498	008	Mar 18, 2021	May	CAHN
+		10MG	N213498	009	Mar 18, 2021	May	CAHN
+		20MG	N213498	010	Mar 18, 2021	May	CAHN

POSACONAZOLE

SOLUTION; INTRAVENOUS
POSACONAZOLE

>A>	AP	ASPIRO	300MG/16.7ML (18MG/ML)	A219057	001	Dec 23, 2024	Dec	NEWA	
		TABLET, DELAYED RELEASE; ORAL POSACONAZOLE							
	AB	!	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Aug	CHRS
	AB		AUROBINDO PHARMA	100MG	A217119	001	Jul 18, 2024	Jul	NEWA

POTASSIUM ACETATE

INJECTABLE; INJECTION
POTASSIUM ACETATE

AP		FRESENIUS KABI USA	2MEQ/ML	A217515	001	Nov 27, 2024	Nov	NEWA
----	--	--------------------	---------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

		@	ANCHEN PHARMS	8MEQ	A202886	001	Dec 26, 2013	Feb	DISC
		@		10MEQ	A202886	002	Dec 26, 2013	Feb	DISC
		@	ENDO OPERATIONS	8MEQ	A202886	001	Dec 26, 2013	May	CAHN
		@		10MEQ	A202886	002	Dec 26, 2013	May	CAHN
		@	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Sep	DISC

FOR SOLUTION; ORAL

			POKONZA						
	+		GENUS	10MEQ	N208019	002	Aug 25, 2023	Jun	CAHN
			POTASSIUM CHLORIDE						
AA	+		GENUS	20MEQ	N208019	001	Aug 19, 2015	Jun	CAHN
	+	!		40MEQ	N208019	003	Aug 25, 2023	Jun	CAHN

SOLUTION; ORAL

AA			STRIDES PHARMA	20MEQ/15ML	A211665	002	Jan 16, 2024	Jan	NEWA
----	--	--	----------------	------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

			POTASSIUM CHLORIDE						
		@	CHARTWELL RX	10MEQ	A206630	001	Mar 29, 2019	May	CAHN
		@		15MEQ	A206630	002	Mar 29, 2019	May	CAHN
		@		20MEQ	A206630	003	Mar 29, 2019	May	CAHN
AB2			MACLEODS PHARMS LTD	8MEQ	A212987	001	Sep 06, 2024	Aug	NEWA
AB2				10MEQ	A212987	002	Sep 06, 2024	Aug	NEWA
AB1				10MEQ	A216269	001	May 09, 2024	May	NEWA
AB1				15MEQ	A216269	002	May 09, 2024	May	NEWA
AB1				20MEQ	A216269	003	May 09, 2024	May	NEWA
		!	RUBICON	15MEQ	A215725	003	Aug 22, 2024	Aug	NEWA
AB2			TWI PHARMS	8MEQ	A218979	001	Oct 28, 2024	Oct	NEWA
AB2				10MEQ	A218979	002	Oct 28, 2024	Oct	NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

AB			HIBROW HLTHCARE	5MEQ	A214426	001	Feb 19, 2021	Jul	CAHN
AB				10MEQ	A214426	002	Feb 19, 2021	Jul	CAHN
AB				15MEQ	A214426	003	Feb 19, 2021	Jul	CAHN
		@	TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb	DISC
AB				5MEQ	A213986	001	Feb 06, 2024	Jan	NEWA
		@		10MEQ	A213986	002	Feb 06, 2024	Feb	DISC
AB				10MEQ	A213986	002	Feb 06, 2024	Jan	NEWA
		@		15MEQ	A213986	003	Feb 06, 2024	Feb	DISC
AB				15MEQ	A213986	003	Feb 06, 2024	Jan	NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

	+ @ CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Oct	DISC
AP	SOMERSET THERAPS LLC	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	A217726	001	Jul 11, 2024	Jun	NEWA
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	A217726	002	Jul 11, 2024	Jun	NEWA
	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
	+! AMNEAL	1.18GM/250ML (4.72MG/ML);1.12GM/250ML	N218343	001	Jul 26, 2024	Jul	NEWA

PRALSETINIB

CAPSULE;ORAL

GAVRETO

	+! BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb	CAHN
	+! RIGEL PHARMS	100MG	N213721	001	Sep 04, 2020	Jun	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	GLENMARK PHARMS LTD	0.125MG	A090781	001	Oct 08, 2010	Mar	CAHN
AB	!	0.25MG	A090781	002	Oct 08, 2010	Mar	CAHN
AB		0.5MG	A090781	003	Oct 08, 2010	Mar	CAHN
AB		0.75MG	A090781	006	Sep 11, 2015	Mar	CAHN
AB		1MG	A090781	004	Oct 08, 2010	Mar	CAHN
AB		1.5MG	A090781	005	Oct 08, 2010	Mar	CAHN
	@ NATCO	0.125MG	A077854	001	Oct 08, 2010	Aug	CAHN
	@	0.25MG	A077854	002	Oct 08, 2010	Aug	CAHN
	@	0.5MG	A077854	003	Oct 08, 2010	Aug	CAHN
	@	1MG	A077854	004	Oct 08, 2010	Aug	CAHN
	@	1.5MG	A077854	005	Oct 08, 2010	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

	+ @ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Aug	DISC
	+ @	0.75MG	N022421	002	Feb 19, 2010	Aug	DISC
	+ @	1.5MG	N022421	003	Feb 19, 2010	Aug	DISC
	+ @	2.25MG	N022421	006	Jun 17, 2011	Aug	DISC
	+ @	3MG	N022421	004	Feb 19, 2010	Aug	DISC
	+ @	3.75MG	N022421	007	Jun 17, 2011	Aug	DISC
	+ @	4.5MG	N022421	005	Feb 19, 2010	Aug	DISC

PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	CHARTWELL RX	0.375MG	A202353	001	Dec 04, 2014	Dec	CAHN
>A>	AB		0.75MG	A202353	002	Dec 04, 2014	Dec	CAHN
>A>	AB		1.5MG	A202353	003	Dec 04, 2014	Dec	CAHN
>A>	AB		3MG	A202353	004	Dec 04, 2014	Dec	CAHN
>A>	AB		4.5MG	A202353	005	Dec 04, 2014	Dec	CAHN
	AB	! DR REDDYS	0.375MG	A203354	001	Aug 07, 2015	Aug	CHRS
		@ ENDO OPERATIONS	0.375MG	A202206	001	Feb 06, 2014	May	CAHN
		@	0.75MG	A202206	002	Feb 06, 2014	May	CAHN
		@	1.5MG	A202206	003	Feb 06, 2014	May	CAHN
		@	2.25MG	A202206	004	Feb 06, 2014	May	CAHN
		@	3MG	A202206	005	Feb 06, 2014	May	CAHN
		@	3.75MG	A202206	006	Feb 06, 2014	May	CAHN
		@	4.5MG	A202206	007	Feb 06, 2014	May	CAHN
>D>	AB	SANDOZ	0.375MG	A202353	001	Dec 04, 2014	Dec	CAHN
>D>	AB		0.75MG	A202353	002	Dec 04, 2014	Dec	CAHN
>D>	AB		1.5MG	A202353	003	Dec 04, 2014	Dec	CAHN
>D>	AB		3MG	A202353	004	Dec 04, 2014	Dec	CAHN
>D>	AB		4.5MG	A202353	005	Dec 04, 2014	Dec	CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A>	AB	AUROBINDO PHARMA USA	10MG	A076056	001	Apr 24, 2006	Dec	CAHN
>A>	AB		20MG	A076056	002	Apr 24, 2006	Dec	CAHN
>A>	AB		40MG	A076056	003	Apr 24, 2006	Dec	CAHN
>A>	AB	!	80MG	A077793	001	Jan 15, 2008	Dec	CAHN
>D>	AB	TEVA	10MG	A076056	001	Apr 24, 2006	Dec	CAHN
>D>	AB		20MG	A076056	002	Apr 24, 2006	Dec	CAHN
>D>	AB		40MG	A076056	003	Apr 24, 2006	Dec	CAHN
>D>	AB	!	80MG	A077793	001	Jan 15, 2008	Dec	CAHN

PRAZIQUANTEL

TABLET;ORAL		BILTRICIDE							
	+ @ BAYER HLTHCARE	600MG		N018714	001	Dec 29, 1982	Sep	DISC	
AB	+	600MG		N018714	001	Dec 29, 1982	Jun	CHRS	
PRAZIQUANTEL									
	! ENDO OPERATIONS	600MG		A208820	001	Nov 27, 2017	Sep	CTEC	
AB	!	600MG		A208820	001	Nov 27, 2017	Jun	CHRS	
AB		600MG		A208820	001	Nov 27, 2017	Apr	CAHN	

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL		PRAZOSIN HYDROCHLORIDE							
	@ LANNETT CO INC	EQ 1MG BASE		A214083	001	Jan 03, 2024	Jul	DISC	
	@	EQ 2MG BASE		A214083	002	Jan 03, 2024	Jul	DISC	
	@	EQ 5MG BASE		A214083	003	Jan 03, 2024	Jul	DISC	
AB	MSN	EQ 1MG BASE		A216727	001	Sep 17, 2024	Sep	NEWA	
AB		EQ 2MG BASE		A216727	002	Sep 17, 2024	Sep	NEWA	
AB		EQ 5MG BASE		A216727	003	Sep 17, 2024	Sep	NEWA	

PREDNISOLONE

SYRUP;ORAL		PREDNISOLONE							
	@ HIKMA	15MG/5ML		A040401	001	Feb 27, 2003	Mar	DISC	
	@ PHARM ASSOC	15MG/5ML		A040399	001	Mar 05, 2003	Feb	DISC	
TABLET;ORAL		PREDNISOLONE							
	+ @ HEATHER	5MG		A080326	001		Oct	CRLD	
AB	ZHEJIANG XIANJU	5MG		A218083	001	May 02, 2024	Apr	NEWA	

PREDNISOLONE ACETATE

SUSPENSION;ORAL		FLO-PRED							
	@ TARO	EQ 5MG BASE/5ML		N022067	001	Jan 17, 2008	Aug	CAHN	
	@	EQ 15MG BASE/5ML		N022067	002	Jan 17, 2008	Aug	CAHN	
SUSPENSION/DROPS;OPHTHALMIC		PREDNISOLONE ACETATE							
AB	LUPIN LTD	1%		A216935	001	Aug 02, 2024	Jul	NFTG	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL		PREDNISOLONE SODIUM PHOSPHATE							
	@ ENDO OPERATIONS	EQ 15MG BASE/5ML		A079010	001	May 26, 2009	May	CAHN	
	@ HIKMA	EQ 5MG BASE/5ML		A075183	001	Mar 26, 2003	Mar	DISC	
	@ PHARM ASSOC	EQ 30MG BASE/5ML		A204962	001	Mar 11, 2020	Mar	DISC	
	@ PHARMOBEDIENT	EQ 15MG BASE/5ML		A076895	001	Oct 04, 2004	Sep	CAHN	
TABLET, ORALLY DISINTEGRATING;ORAL		ORAPRED ODT							
>A>	+ ADVANZ PHARMA	EQ 10MG BASE		N021959	001	Jun 01, 2006	Dec	CAHN	
>A>	+	EQ 15MG BASE		N021959	002	Jun 01, 2006	Dec	CAHN	
>A>	+!	EQ 30MG BASE		N021959	003	Jun 01, 2006	Dec	CAHN	
>D>	+ CONCORDIA PHARMS INC	EQ 10MG BASE		N021959	001	Jun 01, 2006	Dec	CAHN	
>D>	+	EQ 15MG BASE		N021959	002	Jun 01, 2006	Dec	CAHN	
>D>	+!	EQ 30MG BASE		N021959	003	Jun 01, 2006	Dec	CAHN	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC		SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE							
	@ GENUS	EQ 0.23% PHOSPHATE;10%		A073630	001	May 27, 1993	Aug	CAHN	

PREDNISONE

SOLUTION;ORAL		PREDNISONE INTENSOL							
	+! HIKMA	5MG/ML		A088810	001	Feb 20, 1985	Jan	CRLD	
TABLET;ORAL		PREDNISONE							
>D>	@ ALLIED	5MG		A212629	001	Dec 05, 2023	Dec	CMFD	
>A>	AB	5MG		A212629	001	Dec 05, 2023	Dec	CMFD	
	@	5MG		A212629	001	Dec 05, 2023	Aug	CAHN	
>D>	@	10MG		A212629	002	Dec 05, 2023	Dec	CMFD	
>A>	AB	10MG		A212629	002	Dec 05, 2023	Dec	CMFD	

TABLET;ORAL

PREDNISONE

	@	10MG	A212629	002	Dec 05, 2023	Aug	CAHN
>D>	@	20MG	A212629	003	Dec 05, 2023	Dec	CMFD
>A>	AB	20MG	A212629	003	Dec 05, 2023	Dec	CMFD
	@	20MG	A212629	003	Dec 05, 2023	Aug	CAHN
BX	CHARTWELL MOLECULAR	20MG	A084275	001		Jul	CMFD
AB	ENDO OPERATIONS	1MG	A040584	001	Dec 21, 2004	Apr	CAHN
AB		2.5MG	A040581	001	Dec 21, 2004	Apr	CAHN
AB		5MG	A040256	001	Jul 12, 2002	Apr	CAHN
AB		10MG	A040256	002	Jul 12, 2002	Apr	CAHN
AB		20MG	A040392	001	Feb 12, 2003	Apr	CAHN
	@ GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Feb	DISC
	@	2.5MG	A210525	004	Dec 07, 2018	Feb	DISC
	@	5MG	A210525	005	Dec 07, 2018	Feb	DISC
	@	10MG	A210525	001	Dec 04, 2018	Feb	DISC
	@	20MG	A210525	002	Dec 04, 2018	Feb	DISC
	@	50MG	A210525	003	Dec 04, 2018	Feb	DISC
	@ GRANULATION TECH	5MG	A212629	001	Dec 05, 2023	Jul	DISC
	@	10MG	A212629	002	Dec 05, 2023	Jul	DISC
	@	20MG	A212629	003	Dec 05, 2023	Jul	DISC
AB	STRIDES PHARMA	2.5MG	A208412	004	Nov 20, 2020	Jun	CMS1
AB		5MG	A208412	005	Nov 20, 2020	Jun	CMS1

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

	@ ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Oct	DISC
		1MG	A204867	001	Apr 25, 2017	Oct	CTEC
	@	2MG	A204867	002	Apr 25, 2017	Oct	DISC
		2MG	A204867	002	Apr 25, 2017	Oct	CTEC
	@	5MG	A204867	003	Apr 25, 2017	Oct	DISC
!		5MG	A204867	003	Apr 25, 2017	Oct	CHRS
		5MG	A204867	003	Apr 25, 2017	Oct	CTEC
	RAYOS						
+	@ HORIZON	1MG	N202020	001	Jul 26, 2012	Oct	DISC
+	@	2MG	N202020	002	Jul 26, 2012	Oct	DISC
+	@	5MG	N202020	003	Jul 26, 2012	Oct	DISC

PREGABALIN

CAPSULE;ORAL

PREGABALIN

>D>	AB	ACME LABS	50MG	A210585	001	Dec 26, 2019	Dec	CAHN
	AB		50MG	A210585	001	Dec 26, 2019	Aug	CAHN
>D>	AB		75MG	A210585	002	Dec 26, 2019	Dec	CAHN
	AB		75MG	A210585	002	Dec 26, 2019	Aug	CAHN
>D>	AB		100MG	A210585	003	Dec 26, 2019	Dec	CAHN
	AB		100MG	A210585	003	Dec 26, 2019	Aug	CAHN
>D>	AB		150MG	A210585	004	Dec 26, 2019	Dec	CAHN
	AB		150MG	A210585	004	Dec 26, 2019	Aug	CAHN
>D>	AB		200MG	A210585	005	Dec 26, 2019	Dec	CAHN
	AB		200MG	A210585	005	Dec 26, 2019	Aug	CAHN
>D>	AB		300MG	A210585	006	Dec 26, 2019	Dec	CAHN
	AB		300MG	A210585	006	Dec 26, 2019	Aug	CAHN
	AB	ADAPTIS	25MG	A208113	001	May 17, 2024	Aug	CAHN
	AB		50MG	A208113	002	May 17, 2024	Aug	CAHN
	AB		75MG	A208113	004	May 17, 2024	Aug	CAHN
	AB		100MG	A208113	005	May 17, 2024	Aug	CAHN
	AB		150MG	A208113	003	May 17, 2024	Aug	CAHN
	AB		200MG	A208113	006	May 17, 2024	Aug	CAHN
	AB		225MG	A208113	007	May 17, 2024	Aug	CAHN
	AB		300MG	A208113	008	May 17, 2024	Aug	CAHN
	@ CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC	
	@	50MG	A206452	002	Jul 12, 2023	Jan	DISC	
	@	75MG	A206452	003	Jul 12, 2023	Jan	DISC	
	@	100MG	A206452	004	Jul 12, 2023	Jan	DISC	
	@	150MG	A206452	005	Jul 12, 2023	Jan	DISC	
	@	200MG	A206452	006	Jul 12, 2023	Jan	DISC	
	@	225MG	A206452	007	Jul 12, 2023	Jan	DISC	
	@	300MG	A206452	008	Jul 12, 2023	Jan	DISC	
AB	CHANGZHOU PHARM	25MG	A214322	008	Sep 26, 2024	Sep	NEWA	
	@ CIPLA	25MG	A212280	001	Jan 10, 2020	May	DISC	
	@	50MG	A212280	002	Jan 10, 2020	May	DISC	
	@	75MG	A212280	003	Jan 10, 2020	May	DISC	
	@	100MG	A212280	004	Jan 10, 2020	May	DISC	

CAPSULE;ORAL		PREGABALIN							
	@	150MG	A212280	005	Jan 10, 2020	May	DISC		
	@	200MG	A212280	006	Jan 10, 2020	May	DISC		
	@	225MG	A212280	007	Jan 10, 2020	May	DISC		
	@	300MG	A212280	008	Jan 10, 2020	May	DISC		
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Oct	CAHN		
AB		50MG	A212988	002	Mar 08, 2022	Oct	CAHN		
AB		75MG	A212988	003	Mar 08, 2022	Oct	CAHN		
AB		100MG	A212988	004	Mar 08, 2022	Oct	CAHN		
AB		150MG	A212988	005	Mar 08, 2022	Oct	CAHN		
AB		200MG	A212988	006	Mar 08, 2022	Oct	CAHN		
AB		225MG	A212988	007	Mar 08, 2022	Oct	CAHN		
AB		300MG	A212988	008	Mar 08, 2022	Oct	CAHN		
AB	INDOCO	25MG	A208113	001	May 17, 2024	May	NEWA		
AB		50MG	A208113	002	May 17, 2024	May	NEWA		
AB		75MG	A208113	004	May 17, 2024	May	NEWA		
AB		100MG	A208113	005	May 17, 2024	May	NEWA		
AB		150MG	A208113	003	May 17, 2024	May	NEWA		
AB		200MG	A208113	006	May 17, 2024	May	NEWA		
AB		225MG	A208113	007	May 17, 2024	May	NEWA		
AB		300MG	A208113	008	May 17, 2024	May	NEWA		
AB	MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024	Nov	NEWA		
AB		50MG	A205924	002	Nov 12, 2024	Nov	NEWA		
AB		75MG	A205924	003	Nov 12, 2024	Nov	NEWA		
AB		100MG	A205924	004	Nov 12, 2024	Nov	NEWA		
AB		150MG	A205924	005	Nov 12, 2024	Nov	NEWA		
AB		200MG	A205924	006	Nov 12, 2024	Nov	NEWA		
AB		225MG	A205924	007	Nov 12, 2024	Nov	NEWA		
AB		300MG	A205924	008	Nov 12, 2024	Nov	NEWA		
>A>	RENATA	50MG	A210585	001	Dec 26, 2019	Dec	CAHN		
>A>		75MG	A210585	002	Dec 26, 2019	Dec	CAHN		
>A>		100MG	A210585	003	Dec 26, 2019	Dec	CAHN		
>A>		150MG	A210585	004	Dec 26, 2019	Dec	CAHN		
>A>		200MG	A210585	005	Dec 26, 2019	Dec	CAHN		
>A>		300MG	A210585	006	Dec 26, 2019	Dec	CAHN		
AB	RK PHARMA	25MG	A212988	001	Mar 08, 2022	Aug	CAHN		
AB		50MG	A212988	002	Mar 08, 2022	Aug	CAHN		
AB		75MG	A212988	003	Mar 08, 2022	Aug	CAHN		
AB		100MG	A212988	004	Mar 08, 2022	Aug	CAHN		
AB		150MG	A212988	005	Mar 08, 2022	Aug	CAHN		
AB		200MG	A212988	006	Mar 08, 2022	Aug	CAHN		
AB		225MG	A212988	007	Mar 08, 2022	Aug	CAHN		
AB		300MG	A212988	008	Mar 08, 2022	Aug	CAHN		
AB	@ STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jul	DISC		
AB		25MG	A209883	001	Jan 24, 2024	Jan	NEWA		
	@	50MG	A209883	002	Jan 24, 2024	Jul	DISC		
AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA		
	@	75MG	A209883	003	Jan 24, 2024	Jul	DISC		
AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA		
	@	100MG	A209883	004	Jan 24, 2024	Jul	DISC		
AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA		
	@	150MG	A209883	005	Jan 24, 2024	Jul	DISC		
AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA		
	@	200MG	A209883	006	Jan 24, 2024	Jul	DISC		
AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA		
	@	225MG	A209883	007	Jan 24, 2024	Jul	DISC		
AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA		
	@	300MG	A209883	008	Jan 24, 2024	Jul	DISC		
AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA		
	@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC		
	@	50MG	A091157	002	Nov 29, 2019	Jan	DISC		
	@	75MG	A091157	003	Nov 29, 2019	Jan	DISC		
	@	100MG	A091157	004	Nov 29, 2019	Jan	DISC		
	@	150MG	A091157	005	Nov 29, 2019	Jan	DISC		
	@	200MG	A091157	006	Nov 29, 2019	Jan	DISC		
	@	225MG	A091157	007	Nov 29, 2019	Jan	DISC		
	@	300MG	A091157	008	Nov 29, 2019	Jan	DISC		
	@ TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Aug	DISC		
	@	50MG	A091219	002	Jul 19, 2019	Aug	DISC		
	@	75MG	A091224	001	Jul 19, 2019	Aug	DISC		
	@	100MG	A091224	002	Jul 19, 2019	Aug	DISC		
	@	150MG	A091224	003	Jul 19, 2019	Aug	DISC		
	@	200MG	A091224	004	Jul 19, 2019	Aug	DISC		

		CAPSULE;ORAL							
		PREGABALIN							
		@	225MG		A091224	005	Jul 19, 2019	Aug	DISC
		@	300MG		A091224	006	Jul 19, 2019	Aug	DISC
		SOLUTION;ORAL							
		PREGABALIN							
AA		ANDA REPOSITORY	20MG/ML		A212604	001	Feb 18, 2022	Sep	CAHN
		TABLET, EXTENDED RELEASE;ORAL							
		PREGABALIN							
		@ NORVIUM BIOSCIENCE	330MG		A211431	001	Jul 02, 2021	Jun	CAHN
>D>	AB	SUN PHARM	82.5MG		A211889	001	Apr 13, 2021	Dec	DISC
>A>		@	82.5MG		A211889	001	Apr 13, 2021	Dec	DISC
>D>	AB		165MG		A211889	002	Apr 13, 2021	Dec	DISC
>A>		@	165MG		A211889	002	Apr 13, 2021	Dec	DISC
>D>	AB		330MG		A211889	003	Apr 13, 2021	Dec	DISC
>A>		@	330MG		A211889	003	Apr 13, 2021	Dec	DISC
		<u>PRIMAQUINE PHOSPHATE</u>							
		TABLET;ORAL							
		PRIMAQUINE PHOSPHATE							
AB		UNICHEM	EQ 15MG BASE		A204476	001	Feb 25, 2014	Nov	CAHN
		<u>PRIMIDONE</u>							
		SUSPENSION;ORAL							
		MYSOLINE							
		+ @ FHITA	250MG/5ML		N010401	001		Jan	CAHN
		TABLET;ORAL							
		PRIMIDONE							
AB		CARNEGIE	50MG		A218366	001	Jan 23, 2024	Jan	NEWA
AB			250MG		A218366	002	Jan 23, 2024	Jan	NEWA
		<u>PROBENECID; SULOPENEM ETZADROXIL</u>							
		TABLET;ORAL							
		ORLYNVAH							
		+! ITERUM THERAP	500MG;500MG		N213972	001	Oct 25, 2024	Oct	NEWA
		<u>PROCAINAMIDE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		PROCAINAMIDE HYDROCHLORIDE							
AP		GLAND PHARMA LTD	100MG/ML		A218135	001	Jul 22, 2024	Jul	NEWA
AP			500MG/ML		A218135	002	Jul 22, 2024	Jul	NEWA
		@ HIKMA	100MG/ML		A089029	001	Apr 17, 1986	Jun	CAHN
		<u>PROCHLORPERAZINE EDISYLATE</u>							
		INJECTABLE;INJECTION							
		PROCHLORPERAZINE EDISYLATE							
		@ HIKMA	EQ 5MG BASE/ML		A213630	001	Nov 22, 2022	Jul	DISC
AP		SOMERSET THERAPS LLC	EQ 5MG BASE/ML		A212257	001	Sep 13, 2024	Sep	NEWA
		<u>PROCHLORPERAZINE MALEATE</u>							
		TABLET;ORAL							
		PROCHLORPERAZINE MALEATE							
AB		AJANTA PHARMA LTD	EQ 5MG BASE		A218515	001	May 09, 2024	Apr	NEWA
AB			EQ 10MG BASE		A218515	002	May 09, 2024	Apr	NEWA
AB		LEADING	EQ 5MG BASE		A218912	001	Sep 30, 2024	Sep	NEWA
AB			EQ 10MG BASE		A218912	002	Sep 30, 2024	Sep	NEWA
		<u>PROGESTERONE</u>							
		GEL;VAGINAL							
		CRINONE							
>A>		+! ABBVIE	4%		N020701	001	Jul 31, 1997	Dec	CAHN
>A>		+!	8%		N020701	002	Jul 31, 1997	Dec	CAHN
>D>		+! ALLERGAN	4%		N020701	001	Jul 31, 1997	Dec	CAHN
>D>		+!	8%		N020701	002	Jul 31, 1997	Dec	CAHN
		INJECTABLE;INJECTION							
		PROGESTERONE							
		@ ACCORD HLTHCARE	50MG/ML		A217707	001	Nov 21, 2023	Jul	DISC

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	HIKMA	25MG/ML	A 083312	001			Jun	CAHN
AP	+		50MG/ML	A 083312	002			Jun	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPAFENONE HYDROCHLORIDE

AB		SINOTHERAPEUTICS INC	225MG	A 210339	001	Jan 04, 2019	May	CTEC	
AB			325MG	A 210339	002	Jan 04, 2019	May	CTEC	
AB			425MG	A 210339	003	Jan 04, 2019	May	CTEC	
		@ TWI PHARMS	225MG	A 212928	001	Jun 18, 2020	Aug	DISC	
AB			225MG	A 212928	001	Jun 18, 2020	Mar	CAHN	
		@	325MG	A 212928	002	Jun 18, 2020	Aug	DISC	
AB			325MG	A 212928	002	Jun 18, 2020	Mar	CAHN	
		@	425MG	A 212928	003	Jun 18, 2020	Aug	DISC	
AB			425MG	A 212928	003	Jun 18, 2020	Mar	CAHN	
		TABLET; ORAL							
		PROPAFENONE HYDROCHLORIDE							
		@ SUN PHARM INDUSTRIES	150MG	A 075998	001	Nov 29, 2001	Jul	DISC	
		@	225MG	A 075998	002	Nov 29, 2001	Jul	DISC	
		@	300MG	A 075998	003	Nov 29, 2001	Jul	DISC	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	0.5%	A 215816	001	Aug 09, 2024	Aug	NEWA
----	--	----------------------	------	----------	-----	--------------	-----	------

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB		AMNEAL	10MG/ML	A 217525	001	Aug 15, 2024	Aug	NEWA
AB		ASPIRO	10MG/ML	A 217013	001	Jun 20, 2024	Jun	NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

>A>		@ EXTROVIS	60MG	A 078022	001	Feb 15, 2007	Dec	CAHN
		@	60MG	A 078022	001	Feb 15, 2007	Jul	CAHN
>A>		@	80MG	A 078022	002	Feb 15, 2007	Dec	CAHN
		@	80MG	A 078022	002	Feb 15, 2007	Jul	CAHN
>A>		@	120MG	A 078022	003	Feb 15, 2007	Dec	CAHN
		@	120MG	A 078022	003	Feb 15, 2007	Jul	CAHN
>A>		@	160MG	A 078022	004	Feb 15, 2007	Dec	CAHN
		@	160MG	A 078022	004	Feb 15, 2007	Jul	CAHN
		@ LUPIN LTD	60MG	A 204349	001	Jan 12, 2024	Apr	DISC
AB			60MG	A 204349	001	Jan 12, 2024	Jan	NEWA
		@	80MG	A 204349	002	Jan 12, 2024	Apr	DISC
AB			80MG	A 204349	002	Jan 12, 2024	Jan	NEWA
		@	120MG	A 204349	003	Jan 12, 2024	Apr	DISC
AB			120MG	A 204349	003	Jan 12, 2024	Jan	NEWA
		@	160MG	A 204349	004	Jan 12, 2024	Apr	DISC
AB			160MG	A 204349	004	Jan 12, 2024	Jan	NEWA
>D>		@ RISING	60MG	A 078022	001	Feb 15, 2007	Dec	CAHN
>D>		@	80MG	A 078022	002	Feb 15, 2007	Dec	CAHN
>D>		@	120MG	A 078022	003	Feb 15, 2007	Dec	CAHN
>D>		@	160MG	A 078022	004	Feb 15, 2007	Dec	CAHN

SOLUTION; ORAL

HEMANGEOL

+! PIERRE FABRE 4.28MG/ML

N 205410 001 Mar 14, 2014 May CAHN

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

		@ AIPING PHARM INC	90MG	A 071288	001	Oct 22, 1986	Jul	CAHN
AB		ENDO OPERATIONS	10MG	A 070221	002	Aug 01, 1986	Apr	CAHN
AB			20MG	A 070221	003	Aug 01, 1986	Apr	CAHN
AB			40MG	A 070221	004	Aug 01, 1986	Apr	CAHN
AB			60MG	A 070221	005	Sep 24, 1986	Apr	CAHN
AB			80MG	A 070221	001	Apr 14, 1986	Apr	CAHN

PROPYLTHIOURACIL

TABLET;ORAL
 PROPYLTHIOURACIL
 AB +! ENDO OPERATIONS 50MG N006188 001 Apr CAHN

PRUCALOPRIDE SUCCINATE

TABLET;ORAL
 MOTEGRITY
 >D> + TAKEDA PHARMS USA EQ 1MG BASE N210166 001 Dec 14, 2018 Dec CFTG
 >A> AB + EQ 1MG BASE N210166 001 Dec 14, 2018 Dec CFTG
 >D> +! EQ 2MG BASE N210166 002 Dec 14, 2018 Dec CFTG
 >A> AB +! EQ 2MG BASE N210166 002 Dec 14, 2018 Dec CFTG
 >A> PRUCALOPRIDE SUCCINATE
 >A> AB NOVITIUM PHARMA EQ 1MG BASE A218492 001 Dec 26, 2024 Dec NFTG
 >A> AB EQ 2MG BASE A218492 002 Dec 26, 2024 Dec NFTG

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL
 CORPHED
 @ CHARTWELL RX 60MG;2.5MG A088602 001 Apr 11, 1985 Aug CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL
 PYRIDOSTIGMINE BROMIDE
 AB ANI PHARMS 60MG A040512 001 Oct 08, 2003 Jan CMFD
 AB MLV 30MG A211181 002 May 14, 2019 Mar CAHN
 AB 60MG A211181 001 Jul 20, 2018 Mar CAHN
 TABLET, EXTENDED RELEASE;ORAL
 PYRIDOSTIGMINE BROMIDE
 @ AMNEAL 105MG N217604 001 Oct 04, 2024 Oct DISC
 105MG N217604 001 Oct 04, 2024 Oct NEWA

PYRIMETHAMINE

TABLET;ORAL
 PYRIMETHAMINE
 AB SANALUZ 25MG A207127 001 Feb 28, 2020 Sep CAHN

QUETIAPINE FUMARATE

TABLET;ORAL
 QUETIAPINE FUMARATE
 @ CHARTWELL RX EQ 25MG BASE A078679 001 Dec 14, 2012 Nov CAHN
 @ EQ 50MG BASE A078679 002 Dec 14, 2012 Nov CAHN
 @ EQ 100MG BASE A078679 003 Dec 14, 2012 Nov CAHN
 @ EQ 150MG BASE A078679 004 Dec 14, 2012 Nov CAHN
 @ EQ 200MG BASE A078679 005 Dec 14, 2012 Nov CAHN
 @ EQ 300MG BASE A078679 006 Dec 14, 2012 Nov CAHN
 @ EQ 400MG BASE A078679 007 Dec 14, 2012 Nov CAHN
 >D> AB IPCA LABS LTD EQ 25MG BASE A205983 001 May 20, 2024 Dec DISC
 >A> @ EQ 25MG BASE A205983 001 May 20, 2024 Dec DISC
 AB EQ 25MG BASE A205983 001 May 20, 2024 May NEWA
 >D> AB EQ 50MG BASE A205983 002 May 20, 2024 Dec DISC
 >A> @ EQ 50MG BASE A205983 002 May 20, 2024 Dec DISC
 AB EQ 50MG BASE A205983 002 May 20, 2024 May NEWA
 >D> AB EQ 100MG BASE A205983 003 May 20, 2024 Dec DISC
 >A> @ EQ 100MG BASE A205983 003 May 20, 2024 Dec DISC
 AB EQ 100MG BASE A205983 003 May 20, 2024 May NEWA
 >D> AB EQ 200MG BASE A205983 004 May 20, 2024 Dec DISC
 >A> @ EQ 200MG BASE A205983 004 May 20, 2024 Dec DISC
 AB EQ 200MG BASE A205983 004 May 20, 2024 May NEWA
 >D> AB EQ 300MG BASE A205983 005 May 20, 2024 Dec DISC
 >A> @ EQ 300MG BASE A205983 005 May 20, 2024 Dec DISC
 AB EQ 300MG BASE A205983 005 May 20, 2024 May NEWA
 >D> AB EQ 400MG BASE A205983 006 May 20, 2024 Dec DISC
 >A> @ EQ 400MG BASE A205983 006 May 20, 2024 Dec DISC
 AB EQ 400MG BASE A205983 006 May 20, 2024 May NEWA
 @ SANDOZ EQ 25MG BASE A078679 001 Dec 14, 2012 Sep DISC
 @ EQ 50MG BASE A078679 002 Dec 14, 2012 Sep DISC
 @ EQ 100MG BASE A078679 003 Dec 14, 2012 Sep DISC
 @ EQ 150MG BASE A078679 004 Dec 14, 2012 Sep DISC
 @ EQ 200MG BASE A078679 005 Dec 14, 2012 Sep DISC
 @ EQ 300MG BASE A078679 006 Dec 14, 2012 Sep DISC
 @ EQ 400MG BASE A078679 007 Dec 14, 2012 Sep DISC

TABLET;ORAL

QUETIAPINE FUMARATE

AB	SCIEGEN PHARMS INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Sep	CAHN
AB		EQ 50MG BASE	A090960	002	Mar 27, 2012	Sep	CAHN
AB		EQ 100MG BASE	A090960	003	Mar 27, 2012	Sep	CAHN
AB		EQ 200MG BASE	A090960	004	Mar 27, 2012	Sep	CAHN
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012	Sep	CAHN
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

	@ ENDO OPERATIONS	EQ 50MG BASE	A090482	001	May 09, 2017	May	CAHN
	@	EQ 150MG BASE	A090482	002	May 09, 2017	May	CAHN
	@	EQ 150MG BASE	A090757	001	Dec 01, 2017	May	CAHN
	@	EQ 200MG BASE	A090482	003	May 09, 2017	May	CAHN
	@	EQ 200MG BASE	A090757	002	Dec 01, 2017	May	CAHN
	@	EQ 300MG BASE	A090482	004	May 09, 2017	May	CAHN
	@	EQ 300MG BASE	A090757	003	Dec 01, 2017	May	CAHN
	@	EQ 400MG BASE	A090482	005	May 09, 2017	May	CAHN
	@	EQ 400MG BASE	A090757	004	Dec 01, 2017	May	CAHN
AB	GRAVITI PHARMS	EQ 50MG BASE	A211144	001	Nov 26, 2024	Nov	NEWA
AB		EQ 150MG BASE	A211144	002	Nov 26, 2024	Nov	NEWA
AB		EQ 200MG BASE	A211144	003	Nov 26, 2024	Nov	NEWA
AB		EQ 300MG BASE	A211144	004	Nov 26, 2024	Nov	NEWA
AB		EQ 400MG BASE	A211144	005	Nov 26, 2024	Nov	NEWA
	@ PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
	@	EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
	@	EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
	@	EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
	@	EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC
	@ PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Nov	DISC
	@	EQ 150MG BASE	A206260	002	May 09, 2017	Nov	DISC
	@	EQ 200MG BASE	A206260	003	May 09, 2017	Nov	DISC
	@	EQ 300MG BASE	A206260	004	May 09, 2017	Nov	DISC
	@	EQ 400MG BASE	A206260	005	May 09, 2017	Nov	DISC
AB	PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB	CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jul	CMFD
AB		EQ 10MG BASE	A076803	002	Mar 02, 2005	Jul	CMFD
AB		EQ 20MG BASE	A076803	003	Mar 02, 2005	Jul	CMFD
AB		EQ 40MG BASE	A076803	004	Mar 02, 2005	Jul	CMFD
	@ INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar	DISC
	@	EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar	DISC
	@	EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar	DISC
	@	EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar	DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

AB	HIBROW HLTHCARE	324MG	A212589	001	Sep 17, 2021	Sep	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	@ CHARTWELL RX	300MG	A089839	001	Sep 29, 1988	Jul	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

	+ @ SUN PHARM INDUSTRIES	324MG	N021799	001	Aug 12, 2005	Aug	DISC
AB	! NOVAST LABS	324MG	A204372	001	Jul 22, 2015	Aug	CHRS

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

	+ @ WAYLIS THERAP	10MG	N020973	001	May 29, 2002	Apr	CAHN
AB	+!	20MG	N020973	002	Aug 19, 1999	Apr	CAHN

RALTEGRAVIR POTASSIUM

TABLET; ORAL
ISENTRESS

>D>	+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Dec	CFTG
>A>	AB	+!	EQ 400MG BASE	N022145	001	Oct 12, 2007	Dec	CFTG
>A>		RALTEGRAVIR POTASSIUM						
>A>	AB	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Dec	NFTG

RAMELTEON

TABLET; ORAL
RAMELTEON

AB		ANDAS 5 HOLDING	8MG	A215435	001	Aug 24, 2022	Aug	CAHN
----	--	-----------------	-----	---------	-----	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

@	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	May	DISC
@		2.5MG	A202392	002	Apr 15, 2014	May	DISC
@		5MG	A202392	003	Apr 15, 2014	May	DISC
@		10MG	A202392	004	Apr 15, 2014	May	DISC

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

@	LANNETT CO INC	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010	Mar	DISC
@	PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Mar	DISC

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

@	ENDO OPERATIONS	EQ 150MG BASE	A075180	001	Jan 28, 1999	May	CAHN
@		EQ 300MG BASE	A075180	002	Jan 28, 1999	May	CAHN
@	PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb	DISC
@		EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb	DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE; ORAL
ASPRUZYO SPRINKLE

+	@	SPIL	500MG	N216018	001	Feb 28, 2022	Aug	DISC
+	@		1GM	N216018	002	Feb 28, 2022	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL
RANOLAZINE

AB		ALLIED	500MG	A213517	001	Apr 27, 2022	Sep	CAHN
AB			1GM	A213517	002	Apr 27, 2022	Sep	CAHN
AB		I3 PHARMS	500MG	A213517	001	Apr 27, 2022	Nov	CAHN
AB			1GM	A213517	002	Apr 27, 2022	Nov	CAHN
	@	PIRAMAL	500MG	A213085	001	Jul 25, 2023	Jan	DISC
	@		1GM	A213085	002	Jul 25, 2023	Jan	DISC

RASAGILINE MESYLATE

TABLET; ORAL
RASAGILINE MESYLATE

AB		MACLEODS PHARMS LTD	EQ 0.5MG BASE	A208866	001	Jun 28, 2024	Jun	NEWA
AB			EQ 1MG BASE	A208866	002	Jun 28, 2024	Jun	NEWA
	@	RYAN LABS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Sep	CAHN
	@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Sep	CAHN
AB		SKG PHARMA	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Mar	NEWA
AB			EQ 1MG BASE	A218163	002	Apr 09, 2024	Mar	NEWA

REGADENOSON

SOLUTION; INTRAVENOUS
REGADENOSON

AP		GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Jul	NEWA
AP		INDIES PHARMA	0.4MG/5ML (0.08MG/ML)	A218054	001	Aug 22, 2024	Aug	NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
REMIFENTANIL HYDROCHLORIDE

AP		NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
AP			EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
AP			EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

<u>REPOTRECTINIB</u>									
CAPSULE;ORAL									
AUGTYRO									
	+	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	NEWA	
<u>RESMETIROM</u>									
TABLET;ORAL									
REZDIFFRA									
	+	MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA	
	+		80MG	N217785	002	Mar 14, 2024	Mar	NEWA	
	+	!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA	
<u>RETAPAMULIN</u>									
OINTMENT;TOPICAL									
ALTABAX									
	+	@ ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC	
<u>REVUMENIB CITRATE</u>									
TABLET;ORAL									
REVUFORJ									
	+	SYNDAX	EQ 25MG BASE	N218944	001	Nov 15, 2024	Nov	NEWA	
	+		EQ 110MG BASE	N218944	002	Nov 15, 2024	Nov	NEWA	
	+	!	EQ 160MG BASE	N218944	003	Nov 15, 2024	Nov	NEWA	
<u>REZAFUNGIN ACETATE</u>									
POWDER;INTRAVENOUS									
REZZAYO									
	+	!	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
<u>RIFAMPIN</u>									
CAPSULE;ORAL									
RIFAMPIN									
	@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC	
	@		300MG	A065028	002	Mar 14, 2001	Mar	DISC	
<u>RIFAMYCIN SODIUM</u>									
TABLET, DELAYED RELEASE;ORAL									
AEMCOLO									
	+	@ COSMO TECHNOLOGIES	EQ 194MG BASE	N210910	001	Nov 16, 2018	Nov	CAHN	
	+	@ REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct	DISC	
<u>RILPIVIRINE HYDROCHLORIDE</u>									
TABLET, FOR SUSPENSION;ORAL									
EDURANT PED									
	+	@ JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Aug	DISC	
	+	!	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA	
<u>RILUZOLE</u>									
FILM;ORAL									
EXSERVAN									
	+	@ AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Sep	DISC	
SUSPENSION;ORAL									
RILUZOLE									
AB		ALKEM LABS LTD	50MG/10ML	A216035	001	Aug 22, 2024	Aug	NFTG	
AB	+	!	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Aug	CFTG
TABLET;ORAL									
RILUTEK									
	+	@ COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC	
RILUZOLE									
AB	!	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS	
	@	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Oct	DISC	
<u>RISEDRONATE SODIUM</u>									
TABLET;ORAL									
RISEDRONATE SODIUM									
BX		AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Jun	CTEC	

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RISVAN

+ @ LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024	Oct	DISC
+	75MG	N214835	001	Mar 29, 2024	Mar	NEWA
+ @	100MG	N214835	002	Mar 29, 2024	Oct	DISC
+!	100MG	N214835	002	Mar 29, 2024	Mar	NEWA

RYKINDO

+ SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Sep	CHRS
+	37.5MG	N212849	003	Jan 13, 2023	Sep	CHRS
+	50MG	N212849	004	Jan 13, 2023	Sep	CHRS

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

AB + JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CMS1
AB +!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CMS1
AB +	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CMS1
AB +	50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CMS1

RISPERIDONE

AB TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CMS1
AB	25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CMS1
AB	37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CMS1
AB	50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CMS1

SOLUTION;ORAL

RISPERIDONE

@ HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar	DISC
@ PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb	DISC
@ SCIEGEN PHARMS INC	1MG/ML	A078909	001	Jul 29, 2009	Sep	CAHN

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

UZEDY

>D> + TEVA	50MG/0.14ML (50MG/0.14ML)	N213586	001	Apr 28, 2023	Dec	CHRS
>A> +!	50MG/0.14ML (50MG/0.14ML)	N213586	001	Apr 28, 2023	Dec	CHRS
>D> +	75MG/0.21ML (75MG/0.21ML)	N213586	002	Apr 28, 2023	Dec	CHRS
>A> +!	75MG/0.21ML (75MG/0.21ML)	N213586	002	Apr 28, 2023	Dec	CHRS
>D> +	100MG/0.28ML (100MG/0.28ML)	N213586	003	Apr 28, 2023	Dec	CHRS
>A> +!	100MG/0.28ML (100MG/0.28ML)	N213586	003	Apr 28, 2023	Dec	CHRS
>D> +	125MG/0.35ML (125MG/0.35ML)	N213586	004	Apr 28, 2023	Dec	CHRS
>A> +!	125MG/0.35ML (125MG/0.35ML)	N213586	004	Apr 28, 2023	Dec	CHRS
>D> +	150MG/0.42ML (150MG/0.42ML)	N213586	005	Apr 28, 2023	Dec	CHRS
>A> +!	150MG/0.42ML (150MG/0.42ML)	N213586	005	Apr 28, 2023	Dec	CHRS
>D> +	200MG/0.56ML (200MG/0.56ML)	N213586	006	Apr 28, 2023	Dec	CHRS
>A> +!	200MG/0.56ML (200MG/0.56ML)	N213586	006	Apr 28, 2023	Dec	CHRS

TABLET;ORAL

RISPERIDONE

AB ALLIED	0.25MG	A078871	001	Oct 09, 2008	Jul	CAHN
AB	0.5MG	A078871	002	Oct 09, 2008	Jul	CAHN
AB	1MG	A078871	003	Oct 09, 2008	Jul	CAHN
AB	2MG	A078871	004	Oct 09, 2008	Jul	CAHN
AB	3MG	A078871	005	Oct 09, 2008	Jul	CAHN
AB	4MG	A078871	006	Oct 09, 2008	Jul	CAHN
AB ESJAY PHARMA	0.25MG	A078871	001	Oct 09, 2008	Oct	CAHN
AB	0.5MG	A078871	002	Oct 09, 2008	Oct	CAHN
AB	1MG	A078871	003	Oct 09, 2008	Oct	CAHN
AB	2MG	A078871	004	Oct 09, 2008	Oct	CAHN
AB	3MG	A078871	005	Oct 09, 2008	Oct	CAHN
AB	4MG	A078871	006	Oct 09, 2008	Oct	CAHN
AB IPCA LABS LTD	0.25MG	A205104	001	Jun 26, 2024	Jun	NEWA
AB	0.5MG	A205104	002	Jun 26, 2024	Jun	NEWA
AB	1MG	A205104	003	Jun 26, 2024	Jun	NEWA
AB	2MG	A205104	004	Jun 26, 2024	Jun	NEWA
AB	3MG	A205104	005	Jun 26, 2024	Jun	NEWA
AB	4MG	A205104	006	Jun 26, 2024	Jun	NEWA
AB NOVITIUM PHARMA	0.25MG	A078871	001	Oct 09, 2008	Aug	CAHN
AB	0.5MG	A078871	002	Oct 09, 2008	Aug	CAHN
AB	1MG	A078871	003	Oct 09, 2008	Aug	CAHN
AB	2MG	A078871	004	Oct 09, 2008	Aug	CAHN
AB	3MG	A078871	005	Oct 09, 2008	Aug	CAHN
AB	4MG	A078871	006	Oct 09, 2008	Aug	CAHN
AB RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB	0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
AB	1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB	2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB	3MG	A078707	005	Dec 29, 2008	Feb	CAHN

TABLET;ORAL
RISPERIDONE

AB		4MG	A078707	006	Dec 29, 2008	Feb	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	RISPERIDONE						
	ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr	CAHN
AB		0.5MG	A077494	002	Apr 30, 2009	Apr	CAHN
AB		1MG	A077494	003	Oct 26, 2009	Apr	CAHN
AB		2MG	A077494	004	Apr 30, 2009	Apr	CAHN
AB		3MG	A077494	005	Apr 30, 2009	Apr	CAHN
AB		4MG	A077494	006	Apr 30, 2009	Apr	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

	@ SUN PHARM	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Oct	DISC
	@	EQ 3MG BASE	A077131	002	Oct 22, 2007	Oct	DISC
	@	EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Oct	DISC
	@	EQ 6MG BASE	A077131	004	Oct 22, 2007	Oct	DISC
	SOLUTION;ORAL						
	EXELON						
	+ @ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr	CRLD

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

	+ @ GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023	Jun	DISC
--	------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

RIZATRIPTAN BENZOATE

	@ GLENMARK PHARMS LTD	EQ 5MG BASE	A201967	001	Dec 31, 2012	Aug	DISC
	@	EQ 10MG BASE	A201967	002	Dec 31, 2012	Aug	DISC
	@ INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr	DISC
	@	EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr	DISC
	@ NATCO PHARMA LTD	EQ 5MG BASE	A200482	001	Dec 31, 2012	Aug	DISC
	@	EQ 10MG BASE	A200482	002	Dec 31, 2012	Aug	DISC
	TABLET, ORALLY DISINTEGRATING;ORAL						
	RIZATRIPTAN BENZOATE						
	@ CHARTWELL RX	EQ 5MG BASE	A078739	001	Jul 01, 2013	Nov	CAHN
	@	EQ 10MG BASE	A078739	002	Jul 01, 2013	Nov	CAHN
	@ GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	Aug	DISC
	@	EQ 10MG BASE	A201914	002	Jul 01, 2013	Aug	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>D>	AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Dec	CHRS	
>A>	AP	!	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Dec	CHRS	
>D>	AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Dec	CHRS	
>A>	AP	!	100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Dec	CHRS	
		@ HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	Jul	DISC	
>D>	AP	!	SANDOZ	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Dec	CHRS
>A>	AP			50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Dec	CHRS
>D>	AP	!		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Dec	CHRS
>A>	AP			100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Dec	CHRS
	AP	SHANDONG	50MG/5ML (10MG/ML)	A215684	001	Jul 12, 2024	Jul	NEWA	
	AP		100MG/10ML (10MG/ML)	A215684	002	Jul 12, 2024	Jul	NEWA	
	AP	STERISCIENCE	50MG/5ML (10MG/ML)	A217092	001	Jul 22, 2024	Jul	NEWA	

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

	+!	ARCUTIS	0.15%	N215985	002	Jul 09, 2024	Jul	NEWA
--	----	---------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

ROFLUMILAST

	@ BRECKENRIDGE	250MCG	A208236	002	Oct 19, 2023	Jul	DISC
AB	TORRENT	250MCG	A208272	002	Oct 18, 2024	Oct	NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	200MG/100ML (2MG/ML)	A212808	005	May 23, 2024	May	NEWA
AP		400MG/200ML (2MG/ML)	A212808	006	May 23, 2024	May	NEWA
AP	HIKMA	200MG/100ML (2MG/ML)	A211907	001	Aug 15, 2024	Aug	NEWA
AP		400MG/200ML (2MG/ML)	A211907	002	Aug 15, 2024	Aug	NEWA
AP		500MG/100ML (5MG/ML)	A211907	003	Aug 15, 2024	Aug	NEWA
	@ HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	May	DISC
	@	40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	May	DISC
	@	100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	May	DISC
	@	150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	May	DISC
	@	150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	May	DISC
	@	200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	May	DISC
AP	KINDOS	20MG/10ML (2MG/ML)	A218713	001	Jul 30, 2024	Jul	NEWA
AP		40MG/20ML (2MG/ML)	A218713	002	Jul 30, 2024	Jul	NEWA
AP		100MG/20ML (5MG/ML)	A218713	003	Jul 30, 2024	Jul	NEWA
AP		100MG/10ML (10MG/ML)	A218713	004	Jul 30, 2024	Jul	NEWA
AP		150MG/30ML (5MG/ML)	A218713	005	Jul 30, 2024	Jul	NEWA
AP		150MG/20ML (7.5MG/ML)	A218713	006	Jul 30, 2024	Jul	NEWA
AP		200MG/20ML (10MG/ML)	A218713	007	Jul 30, 2024	Jul	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Oct	NEWA
AB		EQ 10MG BASE	A207296	002	Nov 06, 2024	Oct	NEWA
AB		EQ 20MG BASE	A207296	003	Nov 06, 2024	Oct	NEWA
AB		EQ 40MG BASE	A207296	004	Nov 06, 2024	Oct	NEWA
	@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan	DISC
	@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan	DISC
	@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan	DISC
	@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan	DISC
	@ SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Oct	DISC
	@	EQ 10MG BASE	A079169	002	Jul 19, 2016	Oct	DISC
	@	EQ 20MG BASE	A079169	003	Jul 19, 2016	Oct	DISC
>D>	AB	EQ 40MG BASE	A079169	004	Jul 19, 2016	Dec	DISC
>A>	@	EQ 40MG BASE	A079169	004	Jul 19, 2016	Dec	DISC

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+	PHARMAAND	EQ 200MG BASE	N209115	001	Dec 19, 2016	Jul	CAHN
+		EQ 250MG BASE	N209115	003	May 01, 2017	Jul	CAHN
+	!	EQ 300MG BASE	N209115	002	Dec 19, 2016	Jul	CAHN

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL

ENTRESTO SPRINKLE

+	NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
+	!	15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL

ENTRESTO

AB	+	NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
AB	+		49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
AB	+	!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG

SACUBITRIL AND VALSARTAN

AB	ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
AB	ALKEM LABS LTD	24MG; 26MG	A213764	001	Sep 16, 2024	Sep	NEWA
AB		49MG; 51MG	A213764	002	Sep 16, 2024	Sep	NEWA
AB		97MG; 103MG	A213764	003	Sep 16, 2024	Sep	NEWA
AB	BIOCON PHARMA	24MG; 26MG	A213680	001	Aug 30, 2024	Aug	NEWA
AB		49MG; 51MG	A213680	002	Aug 30, 2024	Aug	NEWA
AB		97MG; 103MG	A213680	003	Aug 30, 2024	Aug	NEWA
AB	CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
AB	LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213676	003	May 28, 2024	May	NFTG

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB	MACLEODS PHARMS LTD	24MG;26MG	A213728	001	Oct 16, 2024	Oct	NEWA
AB		49MG;51MG	A213728	002	Oct 16, 2024	Oct	NEWA
AB		97MG;103MG	A213728	003	Oct 16, 2024	Oct	NEWA
AB	MSN	24MG;26MG	A213748	001	Jul 24, 2024	Jul	NEWA
AB		49MG;51MG	A213748	002	Jul 24, 2024	Jul	NEWA
AB		97MG;103MG	A213748	003	Jul 24, 2024	Jul	NEWA
AB	TORRENT	24MG;26MG	A213604	001	Aug 22, 2024	Oct	CMFD
	@	24MG;26MG	A213604	001	Aug 22, 2024	Sep	DISC
AB		24MG;26MG	A213604	001	Aug 22, 2024	Aug	NEWA
AB		49MG;51MG	A213604	002	Aug 22, 2024	Oct	CMFD
	@	49MG;51MG	A213604	002	Aug 22, 2024	Sep	DISC
AB		49MG;51MG	A213604	002	Aug 22, 2024	Aug	NEWA
AB		97MG;103MG	A213604	003	Aug 22, 2024	Oct	CMFD
	@	97MG;103MG	A213604	003	Aug 22, 2024	Sep	DISC
AB		97MG;103MG	A213604	003	Aug 22, 2024	Aug	NEWA
AB	ZYDUS PHARMS	24MG;26MG	A213719	001	Jul 09, 2024	Jun	NEWA
AB		49MG;51MG	A213719	002	Jul 09, 2024	Jun	NEWA
AB		97MG;103MG	A213719	003	Jul 09, 2024	Jun	NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

>A>	AB	MSN	EQ 50MG BASE	A215978	001	Dec 31, 2024	Dec	NEWA
>A>	AB		EQ 100MG BASE	A215978	002	Dec 31, 2024	Dec	NEWA
	AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
	AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
		XADAGO						
AB	+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
AB	+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

SAXAGLIPTIN

@ AMNEAL

@

EQ 2.5MG BASE

EQ 5MG BASE

A205941 001 Jul 31, 2023 Feb DISC

A205941 002 Jul 31, 2023 Feb DISC

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
AB	ZYDUS PHARMS	1MG/72HR	A217893	001	Aug 29, 2024	Aug	NEWA

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

+! EVOFEM INC

2GM/PACKET

N209363 001 Sep 15, 2017 Sep CAHN

SELADELPAR LYSINE

CAPSULE;ORAL

LIVDELZI

+! CYMABAY

+! GILEAD SCIENCES INC

EQ 10MG BASE

EQ 10MG BASE

N217899 001 Aug 14, 2024 Aug NEWA

N217899 001 Aug 14, 2024 Sep CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

+ @ NORVIUM BIOSCIENCE

5MG

N020647 001 May 15, 1996 Aug CAHN

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ ESJAY PHARMA

I3 PHARMS

@ KENTON

MLV

+ @ NORVIUM BIOSCIENCE

5MG

5MG

5MG

5MG

5MG

A074866 001 Nov 26, 1997 Nov CAHN

A074672 001 Apr 01, 1997 Nov CAHN

A074912 001 Apr 30, 1998 May CAHN

A074672 001 Apr 01, 1997 Sep CAHN

N019334 001 Jun 05, 1989 Aug CAHN

AB

AB

SELEXIPAG

TABLET;ORAL

SELEXIPAG

@	ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May	CAHN
@		0.4MG	A214302	002	Dec 21, 2022	May	CAHN
@		0.6MG	A214302	003	Dec 21, 2022	May	CAHN
@		0.8MG	A214302	004	Dec 21, 2022	May	CAHN
@		1MG	A214302	005	Dec 21, 2022	May	CAHN
@		1.2MG	A214302	006	Dec 21, 2022	May	CAHN
@		1.4MG	A214302	007	Dec 21, 2022	May	CAHN
@		1.6MG	A214302	008	Dec 21, 2022	May	CAHN

SELPERCATINIB

TABLET;ORAL

RETEVMO

+	LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr	NEWA
+		80MG	N218160	002	Apr 10, 2024	Apr	NEWA
+		120MG	N218160	003	Apr 10, 2024	Apr	NEWA
+	!	160MG	N218160	004	Apr 10, 2024	Apr	NEWA

SEMAGLUTIDE

TABLET;ORAL

RYBELSUS

>A>	+	NOVO	1.5MG	N213051	004	Dec 09, 2024	Dec	NEWA
>D>	+		3MG	N213051	001	Sep 20, 2019	Dec	CHRS
>A>	+	!	3MG	N213051	001	Sep 20, 2019	Dec	CHRS
>A>	+		4MG	N213051	005	Dec 09, 2024	Dec	NEWA
>D>	+		7MG	N213051	002	Sep 20, 2019	Dec	CHRS
>A>	+	!	7MG	N213051	002	Sep 20, 2019	Dec	CHRS
>A>	+	!	9MG	N213051	006	Dec 09, 2024	Dec	NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	May	CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	May	CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jul	NEWA
AB		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jul	NEWA
AB	MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr	NEWA
AB		2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr	NEWA

TABLET;ORAL

SEVELAMER CARBONATE

AB	@ ANXIN	800MG	A212970	001	Apr 09, 2020	Apr	DISC
AB	SHANDONG XINHUA	800MG	A215998	001	Oct 24, 2024	Oct	NEWA
AB	@ SINOTHERAPEUTICS INC	800MG	A212970	001	Apr 09, 2020	Aug	CAHN
AB	STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May	NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB	@ GRANULES	EQ 10MG BASE/ML	A214556	001	Dec 01, 2023	Nov	DISC
AB	INVAGEN PHARMS	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Sep	CAHN
AB	SOMERSET THERAPS LLC	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Sep	CAHN

SUSPENSION;ORAL

LIQREV

+	@ CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023	Jul	DISC
---	---------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SILDENAFIL CITRATE

>A>	AB	JUBILANT GENERICS	EQ 25MG BASE	A201156	001	Dec 20, 2024	Dec	NEWA
>A>	AB		EQ 50MG BASE	A201156	002	Dec 20, 2024	Dec	NEWA
>A>	AB		EQ 100MG BASE	A201156	003	Dec 20, 2024	Dec	NEWA
		@ MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC
	BX	UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	CTEC
	BX		EQ 50MG BASE	A209302	001	Aug 25, 2020	Jun	CTEC
	BX		EQ 100MG BASE	A209302	002	Aug 25, 2020	Jun	CTEC

SILODOSIN

		CAPSULE; ORAL							
		RAPAFLO							
AB	+	ABBVIE	4MG	N022206	001	Oct 08, 2008	Oct	CAHN	
AB	+		8MG	N022206	002	Oct 08, 2008	Oct	CAHN	
		SILODOSIN							
AB		CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar	CAHN	
AB			8MG	A204726	002	Mar 31, 2017	Mar	CAHN	

SILVER SULFADIAZINE

		CREAM; TOPICAL							
		SSD							
AB	+	DR REDDYS	1%	N018578	001	Feb 25, 1982	Nov	CAHN	
AB	+	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD	
AB	!		1%	N018578	001	Feb 25, 1982	Jan	CHRS	
		SSD AF							
	@	DR REDDYS	1%	N018578	003	Jul 11, 1990	Nov	CAHN	

SIMVASTATIN

		SUSPENSION; ORAL							
		FLOLIPID							
	+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN	
	+		40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN	
		TABLET; ORAL							
		SIMVASTATIN							
AB		YILING	10MG	A211394	001	Nov 27, 2024	Nov	NEWA	
AB			20MG	A211394	002	Nov 27, 2024	Nov	NEWA	
AB			40MG	A211394	003	Nov 27, 2024	Nov	NEWA	
AB			80MG	A211394	004	Nov 27, 2024	Nov	NEWA	

SINCALIDE

		INJECTABLE; INJECTION							
		KINEVAC							
AP	+	BRACCO	0.005MG/VIAL	N017697	001		May	CTEC	
		POWDER; INTRAVENOUS							
		KINEVAC							
AP	+	BRACCO	0.005MG/VIAL	N017697	001		May	CDFR	
		SINCALIDE							
AP	+	MAIA PHARMS INC	0.005MG/VIAL	N210850	001	Nov 22, 2022	May	CTEC	

SIROLIMUS

		SOLUTION; ORAL							
		SIROLIMUS							
AA		HETERO LABS LTD V	1MG/ML	A215080	001	Sep 16, 2024	Sep	NEWA	

SODIUM ACETATE

		INJECTABLE; INJECTION							
		SODIUM ACETATE							
AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CPOT	
AP		MILLA PHARMS	400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CPOT	
		SOLUTION; INTRAVENOUS							
		SODIUM ACETATE							
AP	!	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CDFR	
AP		HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar	NEWA	
AP			100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar	NEWA	
AP			200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar	NEWA	
AP	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar	CDFR	
AP	+		40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar	CPOT	
AP	+		100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar	CMS1	
AP	+		200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar	CMS1	
AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar	CDFR	
AP			40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar	CMS1	
AP			100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar	CPOT	
AP			200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar	CMS1	
AP			400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CDFR	

SODIUM BENZOATE; SODIUM PHENYLACETATE

	SOLUTION; INTRAVENOUS						
	AMMONUL						
	+ @ BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	DISC
	SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP	! AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CHRS

SODIUM BICARBONATE

	INJECTABLE; INJECTION						
	SODIUM BICARBONATE						
AP	LONG GROVE PHARMS	1MEQ/ML	A216042	001	Feb 27, 2024	Jun	CAHN
AP	NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb	NEWA
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
	@	1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM CHLORIDE

	INJECTABLE; INJECTION						
	SODIUM CHLORIDE 0.9%						
>D>	+ @ MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Dec	CMFD
>A>	+	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Dec	CMFD
>D>	+ @	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Dec	CMFD
>A>	+	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Dec	CMFD
>D>	+ @	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Dec	CMFD
>A>	+	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Dec	CMFD
>D>	+ @	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Dec	CMFD
>A>	+	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Dec	CMFD
>D>	+ @	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Dec	CMFD
>A>	+	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Dec	CMFD
	SOLUTION; INJECTION						
	SODIUM CHLORIDE 0.9%						
	@ HIKMA	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Mar	DISC
	SOLUTION; IRRIGATION						
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AT	FRESENIUS KABI USA	900MG/100ML	A213688	001	Jun 24, 2024	Jun	NEWA

SODIUM FLUORIDE F-18

	INJECTABLE; INTRAVENOUS						
	SODIUM FLUORIDE F-18						
AP	! PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan	CHRS

SODIUM NITROPRUSSIDE

	INJECTABLE; INJECTION						
	SODIUM NITROPRUSSIDE						
AP	SLATE RUN PHARMA	25MG/ML	A214199	001	Aug 25, 2020	Sep	CAHN
	SOLUTION; INTRAVENOUS						
	SODIUM NITROPRUSSIDE						
	SLATE RUN PHARMA	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Sep	CAHN
AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Sep	CAHN
AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Sep	CAHN

SODIUM PHENYLBUTYRATE

	FOR SUSPENSION; ORAL						
	OLPRUVA						
>D>	+ ACER	5GM/PACKET	N214860	004	Dec 22, 2022	Dec	CHRS
>A>	+	5GM/PACKET	N214860	004	Dec 22, 2022	Dec	CHRS
>D>	+	6.67GM/PACKET	N214860	006	Dec 22, 2022	Dec	CHRS
>A>	+	6.67GM/PACKET	N214860	006	Dec 22, 2022	Dec	CHRS
	POWDER; ORAL						
	SODIUM PHENYLBUTYRATE						
AB	ENDO OPERATIONS	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN
	TABLET; ORAL						
	SODIUM PHENYLBUTYRATE						
AB	ENDO OPERATIONS	500MG	A204395	001	Apr 15, 2016	Apr	CAHN

SODIUM PHENYLBUTYRATE; TAURURSODIOL

	FOR SUSPENSION; ORAL						
	RELYVRIO						
	+ @ AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022	Oct	DISC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION							
SODIUM PHOSPHATES							
AP	AM REAGENT	142MG/ML; 276MG/ML	A218314	001	Jun 21, 2024	Jun	NEWA
SOLUTION; INTRAVENOUS							
SODIUM PHOSPHATES							
AP	AM REAGENT	142MG/ML; 276MG/ML	A218314	001	Jun 21, 2024	Sep	CDFR
AP		1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A218314	001	Jun 21, 2024	Sep	CPOT
AP	! FRESENIUS KABI USA	142MG/ML; 276MG/ML	A209997	001	Mar 30, 2022	Sep	CDFR
AP	!	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A209997	001	Mar 30, 2022	Sep	CPOT
SODIUM PHOSPHATES IN PLASTIC CONTAINER							
AP	+! HOSPIRA	142MG/ML; 276MG/ML	N018892	001	May 10, 1983	Sep	CDFR
AP	+!	4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	N018892	001	May 10, 1983	Sep	CPOT

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SOLUTION; INTRAVENOUS							
SODIUM PHOSPHATES							
AP	AM REAGENT	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A218314	001	Jun 21, 2024	Sep	CAIN
AP		4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	A218314	002	Jun 21, 2024	Sep	NEWA
AP		13.4GM/50ML; 13.8GM/50ML (268MG/ML; 276MG/ML)	A218314	003	Jun 21, 2024	Sep	NEWA
AP	! FRESENIUS KABI USA	1.34GM/5ML; 1.38GM/5ML (268MG/ML; 276MG/ML)	A209997	001	Mar 30, 2022	Sep	CAIN
AP		4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	A209997	002	Mar 30, 2022	Sep	NEWA
AP	!	13.4GM/50ML; 13.8GM/50ML (268MG/ML; 276MG/ML)	A209997	003	Mar 30, 2022	Sep	NEWA
SODIUM PHOSPHATES IN PLASTIC CONTAINER							
AP	+! HOSPIRA	4.02GM/15ML; 4.14GM/15ML (268MG/ML; 276MG/ML)	N018892	001	May 10, 1983	Sep	CAIN

SOFPIRONIUM BROMIDE

GEL, METERED; TOPICAL							
SOFDRA							
	+! BOTANIX SB	EQ 12.45% BASE (EQ 72MG BASE/ACTUATION)	N217347	001	Jun 18, 2024	Jun	NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL							
SOLIFENACIN SUCCINATE							
AB	JUBILANT GENERICS	5MG	A205484	001	Oct 02, 2024	Sep	NEWA
AB		10MG	A205484	002	Oct 02, 2024	Sep	NEWA
AB	MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb	NEWA
AB		10MG	A204374	002	Feb 20, 2024	Feb	NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL							
SOTALOL HYDROCHLORIDE							
	@ ESJAY PHARMA	80MG	A075237	001	May 01, 2000	Nov	CAHN
	@	120MG	A075237	002	May 01, 2000	Nov	CAHN
	@	160MG	A075237	003	May 01, 2000	Nov	CAHN
	@	240MG	A075237	004	May 01, 2000	Nov	CAHN
	@ RISING	80MG	A075725	001	Dec 19, 2000	Feb	CAHN
	@	120MG	A075725	002	Dec 19, 2000	Feb	CAHN
	@	160MG	A075725	003	Dec 19, 2000	Feb	CAHN
	@	240MG	A075725	004	Dec 19, 2000	Feb	CAHN

SOTORASIB

TABLET; ORAL							
LUMAKRAS							
	+ AMGEN INC	240MG	N214665	003	Jun 26, 2024	Jul	NEWA

SOYBEAN OIL

INJECTABLE; INJECTION							
NUTRILIPID 10%							
	+ @ B BRAUN	10%	N019531	001	May 28, 1993	Jul	DISC

SPINOSADSUSPENSION;TOPICAL
NATROBA

+! CIPHER 0.9% N022408 001 Jan 18, 2011 Aug CAHN

STERILE WATER FOR INJECTIONLIQUID;N/A
STERILE WATER FOR INJECTION

AP AM REGENT 100% (5ML) A217341 003 Feb 09, 2024 Feb NEWA

STERILE WATER FOR IRRIGATIONLIQUID;IRRIGATION
STERILE WATER FOR IRRIGATION

AT FRESENIUS KABI USA 100% A216123 001 Aug 12, 2024 Aug NFTG

SUCCINYLCHOLINE CHLORIDEINJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE

	@ ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	May	DISC
AP	ADAPTIS	20MG/ML	A214308	001	May 22, 2020	Aug	CAHN
AP	BAXTER HLTHCARE CORP	20MG/ML	A218878	001	Sep 24, 2024	Sep	NEWA
	@ EUGIA PHARMA	20MG/ML	A217808	001	Oct 16, 2023	Apr	DISC
AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Jan	CAHN
AP	UMEDICA	20MG/ML	A211625	001	May 19, 2020	Aug	CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
SUCCINYLCHOLINE CHLORIDE

AP	DR REDDYS	100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan	NEWA
AP	+! HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan	CFTG
AP	STERISCIENCE	100MG/5ML (20MG/ML)	A217873	001	Jul 09, 2024	Jun	NEWA

SUCRALFATESUSPENSION;ORAL
SUCRALFATE

AB	ABON PHARMS LLC	1GM/10ML	A216726	001	Mar 21, 2024	Mar	NEWA
AB	COSETTE	1GM/10ML	A217126	001	Nov 13, 2024	Nov	NEWA
>D>	AB	HIKMA	A212769	001	Jul 23, 2024	Dec	DISC
>A>	@	1GM/10ML	A212769	001	Jul 23, 2024	Dec	DISC
AB		1GM/10ML	A212769	001	Jul 23, 2024	Jul	NEWA
AB	PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan	NEWA
AB	STRIDES PHARMA	1GM/10ML	A216474	001	May 21, 2024	May	NEWA
AB	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Apr	CAHN

SUFENTANIL CITRATETABLET;SUBLINGUAL
DSUVIA

+ @ VERTICAL PHARMS EQ 0.03MG BASE N209128 001 Nov 02, 2018 Nov DISC

SUGAMMADEX SODIUMSOLUTION;INTRAVENOUS
SUGAMMADEX SODIUM

	@ ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar	DISC
	@	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar	DISC

SULFACETAMIDE SODIUMSOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

AT	! BAUSCH AND LOMB	10%	A040066	001	Dec 28, 1994	Oct	CHRS
>A>	AT	CHARTWELL RX	A089560	001	Oct 18, 1988	Dec	CAHN
>A>	@	RENOVA PHARMS	A040215	001	May 25, 1999	Dec	CAHN
>D>	AT	SANDOZ	A089560	001	Oct 18, 1988	Dec	CAHN
	@	SAPTALIS PHARMS	A040215	001	May 25, 1999	Aug	CAHN
>D>	@	SCIEGEN PHARMS INC	A040215	001	May 25, 1999	Dec	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIMSUSPENSION;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	! AUROBINDO PHARMA	200MG/5ML;40MG/5ML	A091348	001	Jun 08, 2010	Mar	CHRS
	@	HIKMA	A074650	001	Dec 29, 1997	Mar	DISC

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ AIPING PHARM INC 400MG;80MG A070889 001 Nov 13, 1986 Nov CAHN
 @ 800MG;160MG A070890 001 Nov 13, 1986 Nov CAHN

SULFANILAMIDE

CREAM;VAGINAL

AVC
 + @ NORVIUM BIOSCIENCE 15% N006530 003 Jan 27, 1987 Jun CAHN
 SUPPOSITORY;VAGINAL
 AVC
 @ NORVIUM BIOSCIENCE 1.05GM N006530 004 Jan 27, 1987 Jun CAHN

SUMATRIPTAN

SPRAY;NASAL

SUMATRIPTAN
 AB ADAPTIS 20MG/SPRAY A208967 001 Feb 17, 2021 Sep CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP CAPLIN EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A213998 001 Jul 13, 2021 Jun CAHN
 @ ENDO OPERATIONS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077332 001 Oct 09, 2009 May CAHN
 @ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077871 001 Jul 09, 2009 May CAHN
 AP ! EUGIA PHARMA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A202758 001 Apr 23, 2013 Jan CHRS
 >A> AP HIKMA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079123 001 Feb 06, 2009 Dec CAHN
 @ PAR PHARM EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077332 001 Oct 09, 2009 Feb DISC
 >D> AP STERISCIENCE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A215651 001 Nov 21, 2024 Dec CAHN
 AP EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A215651 001 Nov 21, 2024 Nov NEWA
 >A> AP STERISCIENCE SPECLTS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A215651 001 Nov 21, 2024 Dec CAHN
 @ SUN PHARM EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090358 001 Jun 21, 2011 Nov DISC
 >D> AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079123 001 Feb 06, 2009 Dec CAHN
 SUMAVEL DOSEPRO
 + @ ENDO OPERATIONS EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013 May CAHN
 + @ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N022239 001 Jul 15, 2009 May CAHN

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>A> AB VKT PHARMA EQ 25MG BASE A219036 001 Dec 31, 2024 Dec NEWA
 >A> AB EQ 50MG BASE A219036 002 Dec 31, 2024 Dec NEWA
 >A> AB EQ 100MG BASE A219036 003 Dec 31, 2024 Dec NEWA

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB EUGIA PHARMA EQ 12.5MG BASE A218615 001 Mar 14, 2024 Mar NEWA
 AB EQ 25MG BASE A218615 002 Mar 14, 2024 Mar NEWA
 AB EQ 37.5MG BASE A218615 003 Mar 14, 2024 Mar NEWA
 AB EQ 50MG BASE A218615 004 Mar 14, 2024 Mar NEWA
 AB NOVUGEN EQ 12.5MG BASE A218012 001 Aug 21, 2023 May CMFD
 @ EQ 12.5MG BASE A218012 001 Aug 21, 2023 Feb DISC
 AB EQ 25MG BASE A218012 002 Aug 21, 2023 May CMFD
 @ EQ 25MG BASE A218012 002 Aug 21, 2023 Feb DISC
 AB EQ 37.5MG BASE A218012 003 Aug 21, 2023 May CMFD
 @ EQ 37.5MG BASE A218012 003 Aug 21, 2023 Feb DISC
 AB EQ 50MG BASE A218012 004 Aug 21, 2023 May CMFD
 @ EQ 50MG BASE A218012 004 Aug 21, 2023 Feb DISC
 AB WANBANG BIOPHARMS EQ 12.5MG BASE A218012 001 Aug 21, 2023 Aug CAHN
 AB EQ 25MG BASE A218012 002 Aug 21, 2023 Aug CAHN
 AB EQ 37.5MG BASE A218012 003 Aug 21, 2023 Aug CAHN
 AB EQ 50MG BASE A218012 004 Aug 21, 2023 Aug CAHN

TACROLIMUS

CAPSULE;ORAL		TACROLIMUS					
AB	CONCORD BIOTECH LTD	EQ 0.5MG BASE	A213112	001	Nov 10, 2020	Nov	CMFD
CAPSULE, EXTENDED RELEASE;ORAL		ASTAGRAF XL					
AB	+ ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG
AB	+	EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG
AB	+!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG
CAPSULE;ORAL		TACROLIMUS					
AB	CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan	NFTG
AB		EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan	NFTG
AB		EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan	NFTG

TADALAFIL

TABLET;ORAL		CIALIS					
	+ @ LILLY	2.5MG	N021368	004	Jan 07, 2008	Sep	DISC
TABLET, CHEWABLE;ORAL		TADALAFIL					
AB1	FOURRTS LABS	2.5MG	A217606	001	Aug 13, 2024	Nov	CAHN
AB1		2.5MG	A217606	001	Aug 13, 2024	Aug	NEWA
AB1		5MG	A217606	002	Aug 13, 2024	Nov	CAHN
AB1		5MG	A217606	002	Aug 13, 2024	Aug	NEWA
AB1		10MG	A217606	003	Aug 13, 2024	Nov	CAHN
AB1		10MG	A217606	003	Aug 13, 2024	Aug	NEWA
AB1		20MG	A217606	004	Aug 13, 2024	Nov	CAHN
AB1		20MG	A217606	004	Aug 13, 2024	Aug	NEWA
AB1	HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN
AB1		5MG	A208824	002	Oct 27, 2020	Mar	CAHN
AB1		10MG	A208824	003	Oct 27, 2020	Mar	CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar	CAHN
AB1	HIBROW HLTHCARE	2.5MG	A217606	001	Aug 13, 2024	Sep	CAHN
AB1		5MG	A217606	002	Aug 13, 2024	Sep	CAHN
AB1		10MG	A217606	003	Aug 13, 2024	Sep	CAHN
AB1		20MG	A217606	004	Aug 13, 2024	Sep	CAHN
AB1	SHANDONG	2.5MG	A216279	002	Dec 04, 2024	Nov	NEWA
AB1		5MG	A216279	003	Dec 04, 2024	Nov	NEWA
AB1		10MG	A216279	004	Dec 04, 2024	Nov	NEWA
AB1		20MG	A216279	001	Mar 04, 2024	Feb	NEWA
BX	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
BX		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
BX		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
BX		20MG	A211298	004	Oct 23, 2020	Jun	CTEC
TABLET, CHEWABLE;ORAL		CHEWTADZY					
	+ @ B BETTER	5MG	N218527	001	Jun 28, 2024	Aug	DISC
	+	5MG	N218527	001	Jun 28, 2024	Jun	NEWA
	+ @	10MG	N218527	002	Jun 28, 2024	Aug	DISC
	+	10MG	N218527	002	Jun 28, 2024	Jun	NEWA
	+ @	20MG	N218527	003	Jun 28, 2024	Aug	DISC
	+!	20MG	N218527	003	Jun 28, 2024	Jun	NEWA

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC		TAFLUPROST					
>D>	@ INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	Dec	CMFD
>A>	AT	0.0015%	A218002	001	Apr 05, 2024	Dec	CMFD
	@	0.0015%	A218002	001	Apr 05, 2024	May	DISC
AT		0.0015%	A218002	001	Apr 05, 2024	Mar	NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL		TALZENNA					
	+ PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA
	+	EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA
	+	EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA
	+	EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA
	+	EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA
	+!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL		TAMSULOSIN HYDROCHLORIDE					
	@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN
	@ NORVIUM BIOSCIENCE	0.4MG	A090408	001	Apr 27, 2010	Jul	CAHN
AB	SCIEGEN PHARMS INC	0.4MG	A078938	001	Apr 27, 2010	Nov	CAHN
	@ SUN PHARM INDS LTD	0.4MG	A090931	001	Jul 15, 2010	Oct	DISC
>A>	SYNTHON BV	0.4MG	A078801	001	Apr 27, 2010	Dec	CAHN
>D>	SYNTHON PHARMS	0.4MG	A078801	001	Apr 27, 2010	Dec	CAHN

TAVABOROLE

SOLUTION; TOPICAL		TAVABOROLE					
AB	! ENCUBE	5%	A211297	001	Oct 13, 2020	Mar	CHRS

TAZAROTENE

CREAM; TOPICAL		TAZAROTENE					
AB	PADAGIS ISRAEL	0.05%	A217075	001	Jul 15, 2024	Jul	NFTG
AB	+! ALLERGAN	0.05%	N021184	001	Sep 29, 2000	Jul	CFTG

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION		MYOVIEW					
	+! MEDI-PHYSICS	N/A	N020372	001	Feb 09, 1996	Jun	CAHN
	MYOVIEW 30ML						
	+! MEDI-PHYSICS	N/A	N020372	002	Jul 07, 2005	Jun	CAHN

TEDUGLUTIDE

POWDER; SUBCUTANEOUS		GATTEX KIT					
	+! TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Mar	CAIN

TELMISARTAN

TABLET; ORAL		TELMISARTAN					
AB	MANKIND PHARMA	20MG	A218157	001	Oct 15, 2024	Oct	NEWA
AB		40MG	A218157	002	Oct 15, 2024	Oct	NEWA
AB		80MG	A218157	003	Oct 15, 2024	Oct	NEWA

TEMAZEPAM

CAPSULE; ORAL		TEMAZEPAM					
	@ AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Oct	DISC
	@	15MG	A203482	002	May 23, 2016	Oct	DISC
	@	22.5MG	A203482	003	May 23, 2016	Oct	DISC
	@	30MG	A203482	004	May 23, 2016	Oct	DISC
AB	CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan	CAHN
AB		30MG	A071428	001	Jan 12, 1988	Jan	CAHN

TEMOZOLOMIDE

CAPSULE; ORAL		TEMOZOLOMIDE					
AB	ACCORD HLTHCARE	250MG	A201528	006	Feb 27, 2017	Nov	CHRS
AB	! AMNEAL PHARMS	250MG	A203691	006	May 08, 2015	Nov	CHRS
>A>	@ EXTROVIS	5MG	A205227	001	Jun 29, 2016	Dec	CAHN
	@	5MG	A205227	001	Jun 29, 2016	Jun	CAHN
>A>	@	20MG	A205227	002	Jun 29, 2016	Dec	CAHN
	@	20MG	A205227	002	Jun 29, 2016	Jun	CAHN
>A>	@	100MG	A205227	003	Jun 29, 2016	Dec	CAHN
	@	100MG	A205227	003	Jun 29, 2016	Jun	CAHN
>A>	@	140MG	A205227	004	Jun 29, 2016	Dec	CAHN
	@	140MG	A205227	004	Jun 29, 2016	Jun	CAHN
>A>	@	180MG	A205227	005	Jun 29, 2016	Dec	CAHN
	@	180MG	A205227	005	Jun 29, 2016	Jun	CAHN
>A>	@	250MG	A205227	006	Jun 29, 2016	Dec	CAHN
	@	250MG	A205227	006	Jun 29, 2016	Jun	CAHN
AB	HETERO LABS LTD V	5MG	A210030	001	Aug 23, 2024	Aug	NEWA
AB		20MG	A210030	002	Aug 23, 2024	Aug	NEWA
AB		100MG	A210030	003	Aug 23, 2024	Aug	NEWA

CAPSULE;ORAL
TEMOZOLOMIDE

AB		140MG	A210030	004	Aug 23, 2024	Aug	NEWA
AB		180MG	A210030	005	Aug 23, 2024	Aug	NEWA
AB		250MG	A210030	006	Aug 23, 2024	Aug	NEWA
	@ NIVAGEN PHARMS INC	5MG	A213328	001	Nov 23, 2021	Sep	DISC
	@	20MG	A213328	002	Nov 23, 2021	Sep	DISC
	@	100MG	A213328	003	Nov 23, 2021	Sep	DISC
	@	140MG	A213328	004	Nov 23, 2021	Sep	DISC
	@	180MG	A213328	005	Nov 23, 2021	Sep	DISC
	@	250MG	A213328	006	Nov 23, 2021	Sep	DISC
>D>	@ RISING	5MG	A205227	001	Jun 29, 2016	Dec	CAHN
>D>	@	20MG	A205227	002	Jun 29, 2016	Dec	CAHN
>D>	@	100MG	A205227	003	Jun 29, 2016	Dec	CAHN
>D>	@	140MG	A205227	004	Jun 29, 2016	Dec	CAHN
>D>	@	180MG	A205227	005	Jun 29, 2016	Dec	CAHN
>D>	@	250MG	A205227	006	Jun 29, 2016	Dec	CAHN

TENAPANOR HYDROCHLORIDE

TABLET;ORAL
XPHOZAH

	+ @ ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023	Apr	DISC
--	-----------------	--------------	---------	-----	--------------	-----	------

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
TENOFOVIR ALAFENAMIDE FUMARATE

AB	@ APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024	May	DISC
		EQ 25MG BASE	A213867	001	Mar 21, 2024	Mar	NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB	MYLAN LABS LTD	300MG	A079071	001	Feb 29, 2024	Feb	NEWA
AB	NORVIUM BIOSCIENCE	300MG	A079071	001	Feb 29, 2024	Sep	CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB	BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Jan	CMFD
AB		EQ 2MG BASE	A075667	002	Jul 28, 2000	Jan	CMFD
AB		EQ 5MG BASE	A075667	003	Jul 28, 2000	Jan	CMFD
AB		EQ 10MG BASE	A075667	004	Jul 28, 2000	Jan	CMFD

SOLUTION;ORAL
TEZRULY

	+! NOVITIUM PHARMA	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Oct	CMFD
	+ @	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Aug	DISC
	+!	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Jul	NEWA

TERBINAFINE

GEL;TOPICAL
LAMISIL

	@ KARO HLTHCARE	1%	N020846	001	Apr 29, 1998	Feb	CAHN
--	-----------------	----	---------	-----	--------------	-----	------

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL
LAMISIL

	@ KARO HLTHCARE	1%	N020749	001	Oct 17, 1997	Feb	CAHN
--	-----------------	----	---------	-----	--------------	-----	------

TABLET;ORAL
TERBINAFINE HYDROCHLORIDE

	@ CIPLA	EQ 250MG BASE	A077137	001	Jul 02, 2007	Mar	DISC
--	---------	---------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE;INJECTION
TERBUTALINE SULFATE

AP	AREVA PHARMS	1MG/ML	A200122	001	Nov 08, 2013	Apr	CAHN
>D>	! CHARTWELL INJECTABLE	1MG/ML	A076770	001	Apr 23, 2004	Dec	DISC
>A>	@	1MG/ML	A076770	001	Apr 23, 2004	Dec	DISC
>D>	AP HIKMA FARMACEUTICA	1MG/ML	A078630	001	May 20, 2009	Dec	CHRS
>A>	AP !	1MG/ML	A078630	001	May 20, 2009	Dec	CHRS

TERIFLUNOMIDE

TABLET; ORAL		TERIFLUNOMIDE							
	@ AMNEAL PHARMS CO	7MG		A209613	001	Sep 28, 2018	May	DISC	
	@	14MG		A209613	002	Sep 28, 2018	May	DISC	
	@ MYLAN	7MG		A209702	001	Feb 28, 2020	Sep	CAHN	
	@	7MG		A209702	001	Feb 28, 2020	Apr	DISC	
	@	14MG		A209702	002	Feb 28, 2020	Sep	CAHN	
	@	14MG		A209702	002	Feb 28, 2020	Apr	DISC	
	@ TORRENT	7MG		A209697	001	Apr 04, 2024	Oct	DISC	
AB	@	7MG		A209697	001	Apr 04, 2024	Mar	NEWA	
	@	14MG		A209697	002	Apr 04, 2024	Oct	DISC	
AB	@	14MG		A209697	002	Apr 04, 2024	Mar	NEWA	

TERIPARATIDE

SOLUTION; SUBCUTANEOUS
TERIPARATIDE

+! ALMAJECT 0.6MG/2.4ML (0.25MG/ML) N218771 001 Jun 04, 2024 Jun NEWA

TESTOSTERONE

GEL; TRANSDERMAL		ANDROGEL							
AB2	+ BESINS HLTHCARE	1.62% (20.25MG/1.25GM PACKET)		N022309	002	Sep 07, 2012	Nov	CMFD	
AB2	+	1.62% (40.5MG/2.5GM PACKET)		N022309	003	Sep 07, 2012	Oct	CMFD	
AB1	+	25MG/2.5GM PACKET		N021015	001	Feb 28, 2000	Oct	CMFD	
AB1	+	50MG/5GM PACKET		N021015	002	Feb 28, 2000	Oct	CMFD	
TESTIM									
AB2	+! ENDO OPERATIONS	50MG/5GM PACKET		N021454	001	Oct 31, 2002	Apr	CAHN	
TESTOSTERONE									
AB1	ENCUBE	25MG/2.5GM PACKET		A212984	003	Jul 11, 2024	Oct	NEWA	
GEL, METERED; TRANSDERMAL									
ANDROGEL									
AB1	+ BESINS HLTHCARE	12.5MG/1.25GM ACTUATION		N021015	003	Sep 26, 2003	Oct	CMFD	
TESTOSTERONE									
	! ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION		A204571	001	Aug 05, 2015	Jan	CTEC	
AB	!	10MG/0.5GM ACTUATION		A204571	001	Aug 05, 2015	Jan	CHRS	
AB1	!	12.5MG/1.25GM ACTUATION		A076737	003	Mar 09, 2015	Apr	CTEC	
AB1	ENCUBE	12.5MG/1.25GM ACTUATION		A212984	002	Feb 09, 2024	Apr	NEWA	
PELLET; IMPLANTATION									
TESTOPEL									
	! ENDO OPERATIONS	75MG		A080911	001		Apr	CAHN	
SOLUTION, METERED; TRANSDERMAL									
TESTOSTERONE									
AT	ENCUBE	30MG/1.5ML ACTUATION		A212301	001	Jan 11, 2021	Apr	CAHN	
AT	FEMPHARM	30MG/1.5ML ACTUATION		A212301	001	Jan 11, 2021	Mar	CAHN	

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

@ SUN PHARM INDS LTD 100MG/ML A201720 001 Jun 03, 2013 Oct DISC
@ 200MG/ML A201720 002 Jun 03, 2013 Oct DISC
@ WATSON PHARMS INC 200MG/ML A086030 001 Sep DISC

SOLUTION; INTRAMUSCULAR
AZMIRO

+! AZURITY 200MG/ML (200MG/ML) N216318 001 Jun 02, 2022 Oct CTNA
+! 200MG/ML (200MG/ML) N216318 001 Jun 02, 2022 Sep CMFD
+ @ 200MG/ML (200MG/ML) N216318 001 Jun 02, 2022 Jul CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

AO	EUGIA PHARMA	200MG/ML		A212659	001	Feb 28, 2024	Feb	NEWA	
AO		200MG/ML		A212659	001	Feb 28, 2024	Feb	NEWA	
AO	! HIKMA FARMACEUTICA	200MG/ML		A091120	001	Sep 18, 2012	Sep	CHRS	
	@ WATSON PHARMS INC	200MG/ML		A085598	001		Sep	DISC	

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

TLANDO

+! VERITY 112.5MG N208088 001 Mar 28, 2022 Jan CAHN
INJECTABLE;INTRAMUSCULAR

AVEED

+! ENDO OPERATIONS 750MG/3ML (250MG/ML) N022219 001 Mar 05, 2014 Apr CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB ADAPTIS 12.5MG A213316 001 Jan 22, 2020 Nov CAHN
AB 25MG A213316 002 Jan 22, 2020 Nov CAHN
AB SLATE RUN PHARMA 12.5MG A213316 001 Jan 22, 2020 Feb CAHN
AB 25MG A213316 002 Jan 22, 2020 Feb CAHN

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

>D> +! BAUSCH LOMB IRELAND 0.5% N210821 001 Mar 12, 2019 Dec CFTG
>A> AB1 +! 0.5% N210821 001 Mar 12, 2019 Dec CFTG
>A> AB1 SOMERSET THERAPS LLC 0.5% A217227 001 Dec 20, 2024 Dec NFTG

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB + AVET 250MG N050278 003 Oct CMFD
AB + 500MG N050278 001 Oct CMFD

SUSPENSION;ORAL

SUMYCIN

@ ENDO OPERATIONS 125MG/5ML A060400 001 May CAHN

TABLET;ORAL

SUMYCIN

STRIDES PHARMA 250MG A061147 001 Jan CMFD
! 500MG A061147 004 Jan CMFD

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEO-24

ENDO OPERATIONS 100MG A087943 002 Aug 22, 1983 Apr CAHN
+ 200MG A087943 001 Aug 22, 1983 Apr CAHN
300MG A087943 003 Aug 22, 1983 Apr CAHN
! 400MG A087943 004 Feb 28, 1992 Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

NOSTRUM PHARMS LLC 100MG A087400 003 Feb 21, 1985 Nov CTNA
200MG A087400 004 Feb 21, 1985 Nov CTNA
AB 300MG A087400 002 Jan 11, 1983 Nov CTNA
AB 450MG A087400 005 Aug 09, 2023 Nov CTNA
@ RHODES PHARMS 600MG A040086 001 Apr 15, 1996 Jul DISC
AB STRIDES PHARMA 300MG A215312 001 Sep 05, 2024 Aug NEWA
AB 450MG A215312 002 Sep 05, 2024 Aug NEWA
AB VELZEN PHARMA PVT 300MG A214950 001 Jan 30, 2023 Aug CAHN
AB 450MG A214950 002 Jan 30, 2023 Aug CAHN
AB ZYDUS LIFESCIENCES 300MG A218063 001 May 21, 2024 May CAHN
AB 450MG A218063 002 May 21, 2024 May CAHN
AB ZYDUS PHARMS 300MG A218063 001 May 21, 2024 May NEWA
AB 450MG A218063 002 May 21, 2024 May NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP ASPIRO 100MG/ML A218471 001 Nov 06, 2024 Oct NEWA
>D> AP STERISCIENCE 100MG/ML A217181 001 Oct 29, 2024 Dec CAHN
AP 100MG/ML A217181 001 Oct 29, 2024 Oct NEWA
>A> AP STERISCIENCE SPECCLTS 100MG/ML A217181 001 Oct 29, 2024 Dec CAHN

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

AP	BELOTECA	15MG/VIAL	A217559	001	Aug 20, 2024	Aug	NEWA
AP	MEITHEAL	15MG/VIAL	A216037	001	Dec 26, 2023	Jun	CAHN
AP		100MG/VIAL	A216037	002	Dec 26, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

	TEPYLUTE						
+!	SHORLA	15MG/1.5ML (10MG/ML)	N216984	001	Jun 25, 2024	Jun	NEWA

TICAGRELOR

TABLET; ORAL

	TICAGRELOR						
AB	DR REDDYS	90MG	A208541	001	Oct 29, 2024	Oct	NEWA
AB	PRINSTON INC	90MG	A208599	001	Aug 16, 2024	Aug	NEWA

TIGECYCLINE

POWDER; INTRAVENOUS

	TIGECYCLINE						
@	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	May	DISC

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL						
+!	THEA PHARMA	0.25%	N020439	001	Mar 31, 1995	Oct	CPOT
AT	+!	0.5%	N020439	002	Mar 31, 1995	Oct	CPOT
AT	+!	EQ 0.5% BASE	N020439	002	Mar 31, 1995	Oct	CTEC
	TIMOLOL						
@	EPIC PHARMA LLC	0.25%	A205309	001	Sep 30, 2016	Oct	CPOT
@		0.5%	A205309	002	Sep 30, 2016	Oct	CPOT
AT	SOMERSET	0.5%	A216654	001	Oct 10, 2024	Oct	NEWA

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE							
@	AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024	Jun	DISC	
AB		EQ 0.25% BASE	A216343	001	May 23, 2024	May	NEWA	
@		EQ 0.5% BASE	A216343	002	May 23, 2024	Jun	DISC	
AB		EQ 0.5% BASE	A216343	002	May 23, 2024	May	NEWA	
AB	SOMERSET THERAPS LLC	EQ 0.25% BASE	A210640	001	Sep 16, 2024	Sep	NEWA	
AB		EQ 0.5% BASE	A210640	002	Sep 16, 2024	Sep	NEWA	
	TIMOLOL MALEATE							
@	BAUSCH AND LOMB	EQ 0.25% BASE	A074778	001	Mar 25, 1997	Oct	DISC	
@		EQ 0.5% BASE	A074776	001	Mar 25, 1997	Oct	DISC	
AT1	CAPLIN	EQ 0.5% BASE	A218460	001	Aug 07, 2024	Jul	NEWA	
>A>	@	RENOVA PHARMS	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Dec	CAHN
@	SAPTALIS PHARMS	EQ 0.5% BASE	A074466	001	Mar 25, 1997	May	CAHN	
>D>	@	SCIEGEN PHARMS INC	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Dec	CAHN
AT1	SOMERSET	EQ 0.25% BASE	A217764	002	Jul 03, 2024	Jun	NEWA	
AT1		EQ 0.5% BASE	A217764	001	Jul 03, 2024	Jun	NEWA	
AT2	SOMERSET THERAPS LLC	EQ 0.5% BASE	A216653	001	Jul 03, 2024	Jun	NEWA	

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL

	THIOLA EC						
AB	+ MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan	CFTG
	TIOPRONIN						
AB	ENDO OPERATIONS	100MG	A217219	001	Feb 24, 2023	Jun	CMFD
AB		300MG	A217219	002	Feb 24, 2023	Jun	CMFD
AB	TEVA PHARMS INC	100MG	A216456	001	Jul 22, 2024	Jul	NEWA
AB		300MG	A216456	002	Jul 22, 2024	Jul	NEWA
AB	TORRENT	100MG	A216990	001	Jan 30, 2024	Jan	NFTG
AB		300MG	A216990	002	Jan 30, 2024	Jan	NEWA

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET; ORAL

	TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE							
>A>	AB	MSN	EQ 6.14MG BASE; 15MG	A214024	001	Jan 08, 2025	Dec	NEWA
>A>	AB		EQ 8.19MG BASE; 20MG	A214024	002	Jan 08, 2025	Dec	NEWA

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan	NEWA
+!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan	NEWA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan	NEWA
+!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan	NEWA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan	NEWA
+!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan	NEWA

MOUNJARO (AUTOINJECTOR)

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan	CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan	CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan	CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan	CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan	CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan	CTNA

ZEPBOUND

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar	NEWA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar	NEWA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar	NEWA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar	NEWA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar	NEWA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar	NEWA

ZEPBOUND (AUTOINJECTOR)

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar	CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar	CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar	CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar	CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar	CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar	CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	May	NEWA
AB		EQ 6MG BASE	A213365	002	May 13, 2024	May	NEWA
	@ ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May	CAHN
	@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May	CAHN
	@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May	CAHN
AB	SOMERSET THERAPS LLC	EQ 4MG BASE	A213365	001	May 13, 2024	Sep	CAHN
AB		EQ 6MG BASE	A213365	002	May 13, 2024	Sep	CAHN

SOLUTION;ORAL

>A> ONTRALFY

>A>	+!	FIDELITY BIOPHARMA	EQ 2MG BASE/5ML	N216190	001	Dec 12, 2024	Dec	NEWA
-----	----	--------------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

	@ ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May	CAHN
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May	CAHN
AB	GRAVITI PHARMS	EQ 4MG BASE	A218920	002	Aug 07, 2024	Jul	NEWA
AB		EQ 2MG BASE	A218920	001	Aug 07, 2024	Jul	NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

	@ NORVIUM BIOSCIENCE	300MG/5ML	A209554	001	Oct 13, 2017	Oct	CAHN
--	----------------------	-----------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	!	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr	CHRS
		TOBEX						
	+	@ NOVARTIS	0.3%	N050541	001		Apr	DISC

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP		SLATE RUN PHARMA	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Sep	CAHN
----	--	------------------	--------------------	---------	-----	--------------	-----	------

TOFACITINIB CITRATE

SOLUTION;ORAL		TOFACITINIB CITRATE					
	@ HIKMA	EQ 1MG BASE/ML		A216878	001	Sep 25, 2023	Oct DISC
AA		EQ 1MG BASE/ML		A216878	001	Sep 25, 2023	Apr CAHN
XELJANZ							
	+! PFIZER	EQ 1MG BASE/ML		N213082	001	Sep 25, 2020	Oct CTEC
TABLET, EXTENDED RELEASE;ORAL		TOFACITINIB					
	@ AUROBINDO PHARMA LTD	EQ 11MG BASE		A218462	001	Jun 03, 2024	Jun DISC
AB		EQ 11MG BASE		A218462	001	Jun 03, 2024	May NEWA
TOFACITINIB CITRATE							
>A>	AB	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Dec NEWA
XELJANZ XR							
>D>	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Dec CTEC
>A>	AB	+	EQ 11MG BASE	N208246	001	Feb 23, 2016	Dec CTEC
		+	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun CTEC
AB	+	EQ 11MG BASE		N208246	001	Feb 23, 2016	May CTEC

TOLAZAMIDE

TABLET;ORAL		TOLAZAMIDE					
	@ NATCO	250MG		A070259	001	Jan 02, 1986	Aug CAHN
	@	500MG		A070259	003	Mar 17, 1986	Aug CAHN

TOLCAPONE

TABLET;ORAL		TOLCAPONE					
	@ ENDO OPERATIONS	100MG		A204584	001	Mar 26, 2015	May CAHN
	@ PAR PHARM INC	100MG		A204584	001	Mar 26, 2015	Mar DISC

TOLMETIN SODIUM

CAPSULE;ORAL		TOLMETIN SODIUM					
	@ CHARTWELL RX	EQ 400MG BASE		A073462	001	Apr 30, 1992	Aug CAHN
	! RISING	EQ 400MG BASE		A073393	001	May 27, 1993	Oct CHRS
TABLET;ORAL		TOLMETIN SODIUM					
	@ CHARTWELL RX	EQ 200MG BASE		A073588	001	Jul 31, 1992	Aug CAHN
	@	EQ 600MG BASE		A074002	001	Sep 27, 1993	Aug CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL		TOLTERODINE TARTRATE					
AB	UNICHEM	2MG		A216917	001	Aug 27, 2024	Aug NEWA
AB		4MG		A216917	002	Aug 27, 2024	Aug NEWA
AB	UTOPIC PHARMS	2MG		A213858	001	Feb 02, 2021	Sep CAHN
AB		4MG		A213858	002	Feb 02, 2021	Sep CAHN

TOPIRAMATE

CAPSULE;ORAL		TOPIRAMATE					
AB	ALKEM LABS LTD	15MG		A218482	001	Jun 13, 2024	Jun NEWA
AB		25MG		A218482	002	Jun 13, 2024	Jun NEWA
	@ CHARTWELL RX	15MG		A079206	001	Oct 14, 2009	Aug CAHN
	@	25MG		A079206	002	Oct 14, 2009	Aug CAHN
AB	GLENMARK PHARMS LTD	15MG		A217869	001	Jul 16, 2024	Jul NEWA
AB		25MG		A217869	002	Jul 16, 2024	Jul NEWA
AB	SENORES PHARMS	15MG		A218642	001	Oct 10, 2024	Oct NEWA
AB		25MG		A218642	002	Oct 10, 2024	Oct NEWA
AB	STRIDES PHARMA	15MG		A078418	001	Oct 14, 2009	Apr CMFD
AB		25MG		A078418	002	Oct 14, 2009	Apr CMFD
	ZYDUS PHARMS USA INC	50MG		A078877	003	Oct 23, 2024	Oct NFTG
CAPSULE, EXTENDED RELEASE;ORAL		TOPIRAMATE					
	@ AJANTA PHARMA LTD	25MG		A215663	001	Aug 15, 2023	Feb DISC
	@	50MG		A215663	002	Aug 15, 2023	Feb DISC
	@	100MG		A215663	003	Aug 15, 2023	Feb DISC
	@	200MG		A215663	004	Aug 15, 2023	Feb DISC
AB2	AMTA	25MG		A218695	001	Dec 03, 2024	Nov NEWA
AB2		50MG		A218695	002	Dec 03, 2024	Nov NEWA

CAPSULE, EXTENDED RELEASE;ORAL
TOPIRAMATE

AB2		100MG	A218695	003	Dec 03, 2024	Nov	NEWA
AB2		150MG	A218695	004	Dec 03, 2024	Nov	NEWA
AB2		200MG	A218695	005	Dec 03, 2024	Nov	NEWA
AB1	LUPIN LTD	25MG	A215561	001	Jul 11, 2024	Jul	NEWA
AB1		50MG	A215561	002	Jul 11, 2024	Jul	NEWA
AB1		100MG	A215561	003	Jul 11, 2024	Jul	NEWA
AB1		200MG	A215561	004	Jul 11, 2024	Jul	NEWA
AB2	XIAMEN LP PHARM CO	25MG	A215638	001	Nov 05, 2024	Oct	NEWA
AB2		50MG	A215638	002	Nov 05, 2024	Oct	NEWA
AB2		100MG	A215638	003	Nov 05, 2024	Oct	NEWA
AB2		150MG	A215638	004	Nov 05, 2024	Oct	NEWA
AB2		200MG	A215638	005	Nov 05, 2024	Oct	NEWA

SOLUTION;ORAL
EPRONTIA

AB	+! AZURITY	25MG/ML	N214679	001	Nov 05, 2021	Oct	CFTG
AB	ALKEM LABS LTD	25MG/ML	A217795	001	Oct 31, 2024	Oct	NFTG

TABLET;ORAL
TOPIRAMATE

@	AIPING PHARM INC	25MG	A078499	001	Jan 07, 2010	Feb	CAHN
@		50MG	A078499	002	Jan 07, 2010	Feb	CAHN
@		100MG	A078499	003	Jan 07, 2010	Feb	CAHN
@		200MG	A078499	004	Jan 07, 2010	Feb	CAHN
@	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan	DISC
@		100MG	A076327	002	Mar 27, 2009	Jan	DISC
@		200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

@	RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Mar	CAHN
---	--------	------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS
TOPOTECAN HYDROCHLORIDE

@	MEITHEAL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N022453	001	Dec 20, 2012	Sep	DISC
---	----------	----------------------------------	---------	-----	--------------	-----	------

TOREMIFENE CITRATE

TABLET;ORAL
FARESTON

+ @	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Aug	DISC
AB	! RISING	EQ 60MG BASE	A208813	001	Dec 04, 2018	Aug	CHRS

TORSEMIDE

SOLUTION; INTRAVENOUS
DEMADEX

+ @	ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
+ @		20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR

TORSEMIDE

@	AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR
@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR
>A>	HIKMA	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Dec	CAHN
>A>	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Dec	CAHN
>D>	WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Dec	CAHN
@		20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR
>D>	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Dec	CAHN
@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR

TABLET;ORAL

DEMADEX

+ @	NORVIUM BIOSCIENCE	5MG	N020136	001	Aug 23, 1993	Jul	CAHN
+ @		10MG	N020136	002	Aug 23, 1993	Jul	CAHN
+ @		20MG	N020136	003	Aug 23, 1993	Jul	CAHN
+ @		100MG	N020136	004	Aug 23, 1993	Jul	CAHN

TORSEMIDE

AB	HERITAGE	5MG	A076894	001	May 31, 2005	Sep	CAHN
AB		10MG	A076894	002	May 31, 2005	Sep	CAHN
AB		20MG	A076894	003	May 31, 2005	Sep	CAHN
AB		100MG	A076894	004	May 31, 2005	Sep	CAHN

TOVORAFENIB

FOR SUSPENSION; ORAL
OJEMDA

+! DAY ONE BIOPHARMS 25MG/ML N218033 001 Apr 23, 2024 Apr NEWA

TABLET; ORAL
OJEMDA

+! DAY ONE BIOPHARMS 100MG N217700 001 Apr 23, 2024 Apr NEWA

TRAMADOL HYDROCHLORIDE

SOLUTION; ORAL
QDOLO

+ @ ATHENA 5MG/ML N214044 001 Sep 01, 2020 Oct DISC

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB GRAVITI PHARMS 100MG A075968 002 Aug 02, 2024 Jul NEWA

>D> AB IPCA LABS LTD 50MG A201973 001 Nov 16, 2012 Dec DISC

>A> @ 50MG A201973 001 Nov 16, 2012 Dec DISC

RUBICON 75MG A208708 004 Apr 04, 2024 Mar NFTG

AB ! 100MG A208708 002 Jun 28, 2019 Nov CHRS

AB 100MG A208708 002 Jun 28, 2019 Jul CTEC

AB SUN PHARM INDS INC 50MG A075964 001 Jun 19, 2002 Nov CHRS

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

@ ENDO OPERATIONS 100MG A200491 001 Jun 27, 2012 Apr CAHN

@ 200MG A200491 002 Jun 27, 2012 Apr CAHN

@ 300MG A200491 003 Jun 27, 2012 Apr CAHN

! LUPIN LTD 100MG A200503 001 Aug 29, 2011 Nov CTEC

200MG A200503 002 Aug 29, 2011 Nov CTEC

300MG A200503 003 Aug 29, 2011 Nov CTEC

@ SUN PHARM 100MG A091607 001 Dec 30, 2011 May DISC

@ 100MG A201384 001 Dec 07, 2011 Nov DISC

@ 200MG A201384 002 Dec 07, 2011 Nov DISC

@ 300MG A091607 003 Dec 30, 2011 May DISC

@ 300MG A201384 003 Dec 07, 2011 Nov DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

+ NOVARTIS EQ 0.5MG N204114 001 May 29, 2013 Aug CTEC

AB + EQ 0.5MG N204114 001 May 29, 2013 Jul CFTG

+! EQ 2MG N204114 003 May 29, 2013 Aug CTEC

AB +! EQ 2MG N204114 003 May 29, 2013 Jul CFTG

TRAMETINIB DIMETHYL SULFOXIDE

AB @ NOVUGEN EQ 0.5MG A219002 001 Aug 06, 2024 Aug DISC

EQ 0.5MG A219002 001 Aug 06, 2024 Jul NFTG

@ EQ 2MG A219002 002 Aug 06, 2024 Aug DISC

AB EQ 2MG A219002 002 Aug 06, 2024 Jul NFTG

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP HERITAGE 100MG/ML A202436 001 Feb 11, 2014 Sep CAHN

SOLUTION; INTRAVENOUS

TRANEXAMIC ACID

AP FRESENIUS KABI USA 1GM/100ML (10MG/ML) A218242 001 Aug 15, 2024 Aug NEWA

AP GLAND PHARMA LTD 1GM/100ML (10MG/ML) A218599 001 Apr 16, 2024 Apr NEWA

AP NEXUS 1GM/100ML (10MG/ML) A216877 001 Apr 16, 2024 Apr NEWA

TABLET; ORAL

TRANEXAMIC ACID

AB RUBICON 650MG A218320 001 Jun 11, 2024 May NEWA

TRANLYCPROMINE SULFATE

TABLET; ORAL

PARNATE

>A> AB +! ADVANZ PHARMA EQ 10MG BASE N012342 003 Aug 16, 1985 Dec CAHN

>D> AB +! CONCORDIA EQ 10MG BASE N012342 003 Aug 16, 1985 Dec CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

AT	GLAND PHARMA LTD	0.004%	A218159	001	Jul 12, 2024	Jul	NEWA
	@ LUPIN LTD	0.004%	A207040	001	May 03, 2024	Oct	DISC
AT		0.004%	A207040	001	May 03, 2024	Apr	NEWA
AT	SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Sep	NEWA

TRAZODONE HYDROCHLORIDE

SOLUTION;ORAL
RALDESY

+	KAMAT	10MG/ML	N218637	001	Nov 26, 2024	Nov	NEWA
---	-------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

	@ AIPING PHARM INC	100MG	A072483	001	Apr 30, 1990	Sep	CAHN
AB	CROSSMEDIKA SA	50MG	A211116	001	May 20, 2024	May	NEWA
AB		100MG	A211116	002	May 20, 2024	May	NEWA
AB		150MG	A211116	003	May 20, 2024	May	NEWA
AB		300MG	A211116	004	May 20, 2024	May	NEWA
AB	GRANULES	50MG	A218988	001	Aug 08, 2024	Aug	NEWA
AB		100MG	A218988	002	Aug 08, 2024	Aug	NEWA
AB		150MG	A218988	003	Aug 08, 2024	Aug	NEWA
AB		300MG	A218988	004	Aug 08, 2024	Aug	NEWA
AB	GRAVITI PHARMS	50MG	A217740	001	Aug 27, 2024	Aug	NEWA
AB		100MG	A217740	002	Aug 27, 2024	Aug	NEWA
AB		150MG	A217740	003	Aug 27, 2024	Aug	NEWA
AB		300MG	A217740	004	Aug 27, 2024	Aug	NEWA

TREPROSTINIL

>A> INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

>A> REMODULIN

>A>	+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Dec	CDFR
	+		0.2MG/ML	N021272	007	Sep 28, 2023	Oct	CDFR
	+		0.4MG/ML	N021272	008	Sep 28, 2023	Oct	CDFR
AP	+		1MG/ML	N021272	001	May 21, 2002	Oct	CDFR
AP	+		2.5MG/ML	N021272	002	May 21, 2002	Oct	CDFR
AP	+		5MG/ML	N021272	003	May 21, 2002	Oct	CDFR
AP	+		10MG/ML	N021272	004	May 21, 2002	Oct	CDFR
>A>	+		20MG/ML	N021272	005	Jul 30, 2021	Dec	CDFR

TREPROSTINIL

AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Oct	CDFR
AP		2.5MG/ML	A211574	002	Feb 11, 2021	Oct	CDFR
AP		5MG/ML	A211574	003	Feb 11, 2021	Oct	CDFR
AP		10MG/ML	A211574	004	Feb 11, 2021	Oct	CDFR
AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Oct	CDFR
AP		2.5MG/ML	A210214	002	May 22, 2020	Oct	CDFR
AP		5MG/ML	A210214	003	May 22, 2020	Oct	CDFR
AP		10MG/ML	A210214	004	May 22, 2020	Oct	CDFR
AP	ENDO OPERATIONS	1MG/ML	A209382	001	Sep 24, 2019	Oct	CDFR
AP		2.5MG/ML	A209382	002	Sep 24, 2019	Oct	CDFR
AP		5MG/ML	A209382	003	Sep 24, 2019	Oct	CDFR
AP		10MG/ML	A209382	004	Sep 24, 2019	Oct	CDFR
AP	SANDOZ	1MG/ML	A203649	001	Nov 30, 2017	Oct	CDFR
AP		2.5MG/ML	A203649	002	Nov 30, 2017	Oct	CDFR
AP		5MG/ML	A203649	003	Nov 30, 2017	Oct	CDFR
AP		10MG/ML	A203649	004	Nov 30, 2017	Oct	CDFR
AP	TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Oct	CDFR
AP		2.5MG/ML	A206648	002	Sep 26, 2019	Oct	CDFR
AP		5MG/ML	A206648	003	Sep 26, 2019	Oct	CDFR
AP		10MG/ML	A206648	004	Sep 26, 2019	Oct	CDFR

>D> INJECTABLE;IV (INFUSION), SUBCUTANEOUS

>D> REMODULIN

>D>	+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Dec	CDFR
	+		0.1MG/ML	N021272	006	Sep 28, 2023	Oct	CDFR
>D>	+		20MG/ML	N021272	005	Jul 30, 2021	Dec	CDFR
	+		20MG/ML	N021272	005	Jul 30, 2021	Oct	CDFR

POWDER;INHALATION

TYVASO DPI

+	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022	Nov	CHRS
+		0.08MG/INH	N214324	005	Oct 24, 2024	Oct	NEWA

TRETINOIN

		CAPSULE; ORAL							
		TRETINOIN							
AB		ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Apr	CAHN	
		CREAM; TOPICAL							
		TRETINOIN							
AB		ALEMBIC	0.1%	A217804	001	Apr 29, 2024	Apr	NEWA	
AB		ZYDUS LIFESCIENCES	0.1%	A218561	001	Apr 25, 2024	Apr	NEWA	
		GEL; TOPICAL							
		TRETINOIN							
		@ NORVIUM BIOSCIENCE	0.1%	A202026	001	Jul 17, 2013	Aug	CAHN	

TRIAMCINOLONE ACETONIDE

		INJECTABLE; INJECTION							
		TRIAMCINOLONE ACETONIDE							
AB		HIKMA	40MG/ML	A215254	001	Dec 09, 2024	Nov	NEWA	
		OINTMENT; TOPICAL							
		TRIAMCINOLONE ACETONIDE							
		@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN	
		@	0.5%	A211315	002	Mar 18, 2020	Jan	CAHN	
		@ COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC	
>A>	+	@ EXTROVIS	0.025%	N011600	003		Dec	CAHN	
		@	0.025%	N011600	003		Jun	CAHN	
>A>	+	@	0.1%	N011600	001		Dec	CAHN	
		@	0.1%	N011600	001		Jun	CAHN	
>D>	+	@ RISING	0.025%	N011600	003		Dec	CAHN	
>D>	+	@	0.1%	N011600	001		Dec	CAHN	
		PASTE; DENTAL							
		TRIAMCINOLONE ACETONIDE							
AT		RISING	0.1%	A040771	001	Jul 01, 2010	Sep	CAHN	

TRIAMCINOLONE HEXACETONIDE

		INJECTABLE; INJECTION							
		ARISTOSPAN							
	+	@ ANIKA THERAPS INC	5MG/ML	N016466	001		Oct	CAHN	
	+	@	20MG/ML	N016466	002		Oct	CAHN	

TRIAMTERENE

		CAPSULE; ORAL							
		DYRENIUM							
>A>	AB	+	ADVANSZ PHARMA	50MG	N013174	001		Dec	CAHN
>A>	AB	+	!	100MG	N013174	002		Dec	CAHN
>D>	AB	+	CONCORDIA	50MG	N013174	001		Dec	CAHN
>D>	AB	+	!	100MG	N013174	002		Dec	CAHN
		TRIAMTERENE							
AB		BIOCON GENERICS	50MG	A214768	001	Jul 06, 2022	Nov	CMFD	
		@	50MG	A214768	001	Jul 06, 2022	Oct	CAHN	
AB			100MG	A214768	002	Jul 06, 2022	Nov	CMFD	
		@	100MG	A214768	002	Jul 06, 2022	Oct	CAHN	
		@ HIBROW HLTHCARE	50MG	A214768	001	Jul 06, 2022	Sep	CAHN	
		@	100MG	A214768	002	Jul 06, 2022	Sep	CAHN	

TRIAZOLAM

		TABLET; ORAL							
		TRIAZOLAM							
>A>	AB		BRECKENRIDGE	0.125MG	A216890	001	Nov 08, 2022	Dec	CAHN
>A>	AB			0.25MG	A216890	002	Nov 08, 2022	Dec	CAHN
		@	HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC
		@		0.25MG	A074224	002	Jun 01, 1994	Feb	DISC
>D>	AB		SANDOZ	0.125MG	A216890	001	Nov 08, 2022	Dec	CAHN
>D>	AB			0.25MG	A216890	002	Nov 08, 2022	Dec	CAHN

TRIENTINE HYDROCHLORIDE

		CAPSULE; ORAL							
		TRIENTINE HYDROCHLORIDE							
AB		ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr	CAHN	

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

@ CHARTWELL RX EQ 10MG BASE/ML A085787 001 Apr 15, 1982 Aug CAHN

TRILACICLIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS

COSELA

+! PHARMACOSMOS EQ 300MG BASE/VIAL N214200 001 Feb 12, 2021 Sep CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB ! AVET LIFESCIENCES 300MG A205950 001 Nov 21, 2023 Aug CHRS

AB ! HERITAGE PHARMA AVET 300MG A205950 001 Nov 21, 2023 Oct CAHN

@ SUN PHARM INDUSTRIES 300MG A076570 001 Aug 28, 2003 Aug DISC

INJECTABLE; INJECTION

TIGAN

+! ENDO OPERATIONS 100MG/ML N017530 001 Apr CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

@ PANGEA EQ 25MG BASE/5ML N074374 001 Jun 23, 1995 Oct CAHN

+ @ EQ 50MG BASE/5ML N074973 001 Jan 24, 2000 Oct CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB BRECKENRIDGE EQ 25MG BASE A208127 001 Apr 15, 2016 Mar CAHN

AB ! EQ 50MG BASE A208127 002 Apr 15, 2016 Mar CAHN

AB EQ 100MG BASE A208127 003 Apr 15, 2016 Mar CAHN

TROMETHAMINE

SOLUTION; INJECTION

THAM

AP +! HOSPIRA 18GM/500ML (3.6GM/100ML) N013025 002 Nov CFTG

TROMETHAMINE

AP B BRAUN MEDICAL INC 18GM/500ML (3.6GM/100ML) A211558 001 Dec 09, 2024 Nov NFTG

>A> AP MILLA PHARMS 18GM/500ML (3.6GM/100ML) A213116 001 Dec 31, 2024 Dec NEWA

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE

AB UTOPIIC PHARMS 60MG A214760 001 Apr 30, 2021 Sep CAHN

TABLET; ORAL

TROSPIUM CHLORIDE

AB CHARTWELL RX 20MG A215781 001 Feb 16, 2022 Sep CAHN

AB MACLEODS PHARMS LTD 20MG A206472 001 Jun 18, 2024 Jun NEWA

AB ZAMEER PHARMS 20MG A215781 001 Feb 16, 2022 Feb CAHN

TROSPIUM CHLORIDE; XANOMELINE TARTRATE

CAPSULE; ORAL

COBENFY

+ BRISTOL-MYERS 20MG;EQ 50MG BASE N216158 001 Sep 26, 2024 Sep NEWA

+ 20MG;EQ 100MG BASE N216158 002 Sep 26, 2024 Sep NEWA

+! 30MG;EQ 125MG BASE N216158 003 Sep 26, 2024 Sep NEWA

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND EQ 0.0625MG BASE/INH N205382 001 Apr 30, 2014 Jan CPOT

UPADACITINIB

SOLUTION; ORAL

RINVOQ LQ

+! ABBVIE 1MG/ML N218347 001 Apr 26, 2024 Apr NEWA

UREA, C-14

CAPSULE;ORAL
PYTEST

+ @ AVENT 1uCi N020617 001 May 09, 1997 Sep DISC

URSODIOL

CAPSULE;ORAL
URSODIOL

AB HIBROW HLTHCARE 300MG A212452 001 Oct 30, 2019 Jul CAHN
! LGM PHARMA 200MG A205789 001 May 08, 2020 Aug CHRS

TABLET;ORAL
URSODIOL

AB ENDO OPERATIONS 250MG A202540 001 Feb 14, 2013 Apr CAHN
AB 500MG A202540 002 Feb 14, 2013 Apr CAHN
AB EPIC PHARMA LLC 250MG A214717 001 Aug 14, 2024 Aug NEWA
AB 500MG A214717 002 Aug 14, 2024 Aug NEWA

VADADUSTAT

TABLET;ORAL
VAFSEO

+ AKEBIA 150MG N215192 001 Mar 27, 2024 Mar NEWA
+ 300MG N215192 002 Mar 27, 2024 Mar NEWA
+! 450MG N215192 003 Mar 27, 2024 Mar NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

@ CIPLA EQ 500MG BASE A077135 001 May 24, 2010 Apr DISC
@ EQ 1GM BASE A077135 002 May 24, 2010 Apr DISC
AB GRAVITI PHARMS EQ 500MG BASE A079012 001 May 24, 2010 Jun CAHN
AB EQ 1GM BASE A079012 002 May 24, 2010 Jun CAHN
@ SANDOZ EQ 500MG BASE A077478 001 May 24, 2010 Sep DISC
@ EQ 1GM BASE A077478 002 May 24, 2010 Sep DISC

VALBENZAZINE TOSYLATE

CAPSULE;ORAL
INGREZZA

AB + NEUROCRINE EQ 40MG BASE N209241 001 Apr 11, 2017 Mar CFTG
AB + EQ 60MG BASE N209241 003 Apr 23, 2021 Jul CFTG
AB +! EQ 80MG BASE N209241 002 Oct 04, 2017 Mar CFTG

INGREZZA SPRINKLE

+ NEUROCRINE EQ 40MG BASE N218390 001 Apr 30, 2024 Apr NEWA
+ EQ 60MG BASE N218390 002 Apr 30, 2024 Apr NEWA
+! EQ 80MG BASE N218390 003 Apr 30, 2024 Apr NEWA

VALBENZAZINE TOSYLATE

AB LUPIN LTD EQ 40MG BASE A216064 001 Apr 05, 2024 Mar NFTG
AB EQ 80MG BASE A216064 002 Apr 05, 2024 Mar NFTG
>D> AB ZYDUS EQ 40MG BASE A216137 001 Aug 07, 2024 Dec CAHN
AB EQ 40MG BASE A216137 001 Aug 07, 2024 Jul NEWA
>D> AB EQ 60MG BASE A216137 002 Aug 07, 2024 Dec CAHN
AB EQ 60MG BASE A216137 002 Aug 07, 2024 Jul NFTG
>D> AB EQ 80MG BASE A216137 003 Aug 07, 2024 Dec CAHN
AB EQ 80MG BASE A216137 003 Aug 07, 2024 Jul NEWA
>A> AB ZYDUS LIFESCIENCES EQ 40MG BASE A216137 001 Aug 07, 2024 Dec CAHN
>A> AB EQ 60MG BASE A216137 002 Aug 07, 2024 Dec CAHN
>A> AB EQ 80MG BASE A216137 003 Aug 07, 2024 Dec CAHN

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL
VALGANCICLOVIR HYDROCHLORIDE

AB GPP EQ 450MG BASE A212876 001 Jun 11, 2024 May NEWA
AB SOMERSET THERAPS LLC EQ 450MG BASE A212876 001 Jun 11, 2024 Sep CAHN

VALPROIC ACID

CAPSULE;ORAL
VALPROIC ACID

@ EYWA 250MG A207611 001 Aug 05, 2019 Mar DISC
@ HIBROW HLTHCARE 250MG A207611 001 Aug 05, 2019 Jul CAHN
@ SUN PHARM INDS LTD 250MG A091037 001 Feb 22, 2013 May DISC

SYRUP; ORAL
VALPROIC ACID

AA	@ HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Mar	DISC
	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan	CAHN

VALRUBICIN

SOLUTION; INTRAVESICAL
VALSTAR PRESERVATIVE FREE

AO	+!	ENDO OPERATIONS	40MG/ML	N020892	001	Sep 25, 1998	Apr	CAHN
----	----	-----------------	---------	---------	-----	--------------	-----	------

VALSARTAN

TABLET; ORAL
VALSARTAN

AB		RYAN LABS	40MG	A218169	001	Aug 05, 2024	Oct	CAHN
AB			80MG	A218169	002	Aug 05, 2024	Oct	CAHN
AB			160MG	A218169	003	Aug 05, 2024	Oct	CAHN
AB			320MG	A218169	004	Aug 05, 2024	Oct	CAHN
AB		ZENARA	40MG	A218169	001	Aug 05, 2024	Jul	NEWA
AB			80MG	A218169	002	Aug 05, 2024	Jul	NEWA
AB			160MG	A218169	003	Aug 05, 2024	Jul	NEWA
AB			320MG	A218169	004	Aug 05, 2024	Jul	NEWA
AB		ZYDUS LIFESCIENCES	40MG	A218991	001	Jul 22, 2024	Jul	NEWA
AB			80MG	A218991	002	Jul 22, 2024	Jul	NEWA
AB			160MG	A218991	003	Jul 22, 2024	Jul	NEWA
AB			320MG	A218991	004	Jul 22, 2024	Jul	NEWA

VANCOMYCIN

SOLUTION; INTRAVENOUS, ORAL
VANCOMYCIN

>A>	+	@ HIKMA	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021	Dec	CAHN
>D>	+	@ XELLIA PHARMS APS	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021	Dec	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL
VANCOMYCIN HYDROCHLORIDE

	@	PAI HOLDINGS PHARM	EQ 125MG BASE	A065478	001	Apr 09, 2012	Feb	DISC
	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Feb	DISC

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

AP		HIKMA	EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Sep	CAHN
AP			EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Sep	CAHN
	@	MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug	CAHN
	@		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug	CAHN
	@	PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC
	@		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC
	@	SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr	DISC
	@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr	DISC
AP		SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Sep	CAHN
AP			EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Sep	CAHN
AP			EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Sep	CAHN
AP			EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Sep	CAHN

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CTNA
	+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CTNA
	+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CTNA

POWDER; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

	+!	MYLAN LABS LTD	EQ 1.75GM BASE/VIAL	N209481	005	Jun 26, 2024	Jul	NEWA
	+!		EQ 2GM BASE/VIAL	N209481	006	Jun 26, 2024	Jul	NEWA

SOLUTION; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

>A>	+	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Dec	CAHN
>A>	+		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Dec	CAHN
>A>	+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Dec	CAHN
>A>	+		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Dec	CAHN
>A>	+		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Dec	CAHN
>A>	+		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Dec	CAHN
>A>	+		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Dec	CAHN

SOLUTION; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

>D>	+	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Dec CAHN
>D>	+		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Dec CAHN
>D>	+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Dec CAHN
>D>	+		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Dec CAHN
>D>	+		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Dec CAHN
>D>	+		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Dec CAHN
>D>	+		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Dec CAHN
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
	+	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb CPOT
	+		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb CDFR
	+		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb CPOT
	+		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb CDFR
	+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb CPOT
	+		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb CDFR
	+		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb NEWA
	+		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb NEWA

VARENICLINE TARTRATE

TABLET; ORAL
VARENICLINE TARTRATE

AB		AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar NEWA
AB			EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar NEWA
AB		AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb NEWA
AB			EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb NEWA
>D>	AB	BIONPHARMA	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Dec CAHN
	AB		EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Oct CAHN
>D>	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Dec CAHN
	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Oct CAHN
	AB	DR REDDYS	EQ 0.5MG BASE	A215931	001	Oct 01, 2024	Sep NEWA
	AB		EQ 1MG BASE	A215931	002	Oct 01, 2024	Sep NEWA
	AB	INDOCO	EQ 0.5MG BASE	A219106	001	Oct 29, 2024	Oct NEWA
	AB		EQ 1MG BASE	A219106	002	Oct 29, 2024	Oct NEWA
	AB	MACLEODS PHARMS LTD	EQ 0.5MG BASE	A215048	001	Dec 09, 2024	Nov NEWA
	AB		EQ 1MG BASE	A215048	002	Dec 09, 2024	Nov NEWA
	AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Nov CAHN
	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Nov CAHN
	AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb NEWA
	AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb NEWA
>A>	AB	NE RX PHARMA	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Dec CAHN
>A>	AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Dec CAHN
	AB	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Sep CAHN
	AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Sep CAHN
	AB	SLATE RUN PHARMA	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jul NEWA
	AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Jul NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS
VASOPRESSIN

AP		DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr NEWA
AP		GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb NEWA
VASOPRESSIN IN SODIUM CHLORIDE 0.9%							
	+	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024	Jul NEWA
	+		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024	Jul NEWA
	+		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	Jul NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB		ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May NEWA
AB			EQ 75MG BASE	A217767	002	Jun 06, 2024	May NEWA
AB			EQ 150MG BASE	A217767	003	Jun 06, 2024	May NEWA
	@	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May CAHN
	@		EQ 75MG BASE	A078087	002	Mar 16, 2012	May CAHN
	@		EQ 150MG BASE	A078087	003	Mar 16, 2012	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

@	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
@		EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
@		EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC
@	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Oct	DISC
@		EQ 75MG BASE	A090071	002	Apr 15, 2011	Oct	DISC
@		EQ 150MG BASE	A090071	003	Apr 15, 2011	Oct	DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@	AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
@		EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
@		EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
@		EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
@		EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC
@	NORVIUM BIOSCIENCE	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

@	SUN PHARM	EQ 37.5MG BASE	A091272	001	Aug 18, 2010	Nov	DISC
@		EQ 75MG BASE	A091272	002	Aug 18, 2010	Nov	DISC
@		EQ 150MG BASE	A091272	003	Aug 18, 2010	Nov	DISC
@		EQ 225MG BASE	A091272	004	Jan 08, 2019	Nov	DISC
@	SWISS PHARM	EQ 75MG BASE	A214423	001	Jan 04, 2022	Aug	CAHN
@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	+	AZURITY	120MG	N019614	001	May 29, 1990	Aug	CAHN
AB	+		180MG	N019614	003	Jan 09, 1992	Aug	CAHN
AB	+		240MG	N019614	002	May 29, 1990	Aug	CAHN
	+		360MG	N019614	004	May 10, 1996	Aug	CAHN

VERELAN PM

	+	AZURITY	100MG	N020943	001	Nov 25, 1998	Aug	CAHN
	+		200MG	N020943	002	Nov 25, 1998	Aug	CAHN
	+		300MG	N020943	003	Nov 25, 1998	Aug	CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	2.5MG/ML	A216471	001	Apr 23, 2024	Nov	CMFD
	@		2.5MG/ML	A216471	001	Apr 23, 2024	May	DISC
AP			2.5MG/ML	A216471	001	Apr 23, 2024	Apr	NEWA
AP		HERITAGE	2.5MG/ML	A215829	001	Mar 17, 2022	Sep	CAHN

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr	CAHN
AP			10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr	CAHN

VERICIGUAT

TABLET;ORAL

VERQUVO

	+	MSD	2.5MG	N214377	001	Jan 19, 2021	Nov	CAHN
	+		5MG	N214377	002	Jan 19, 2021	Nov	CAHN
	+		10MG	N214377	003	Jan 19, 2021	Nov	CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+	BAUSCH LOMB IRELAND	15MG/VIAL	N021119	001	Apr 12, 2000	Jul	CAHN
--	---	---------------------	-----------	---------	-----	--------------	-----	------

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

@	PROPEL PHARMA	500MG/PACKET	A213390	001	Jul 29, 2021	Oct	DISC
---	---------------	--------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

VIGAFYDE

	+	PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024	Jun	NEWA
--	---	--------------	----------	---------	-----	--------------	-----	------

	TABLET; ORAL						
	VIGABATRIN						
AB	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Sep	CAHN
	<u>VINORELBINE TARTRATE</u>						
	INJECTABLE; INJECTION						
	VINORELBINE TARTRATE						
	@ RISING	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN
	<u>VORAPAXAR SULFATE</u>						
	TABLET; ORAL						
	ZONTIVITY						
	+ @ KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	May	DISC
	+!	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN
	<u>VORASIDENIB</u>						
	TABLET; ORAL						
	VORANIGO						
	+ SERVIER	10MG	N218784	001	Aug 06, 2024	Aug	NEWA
	+!	40MG	N218784	002	Aug 06, 2024	Aug	NEWA
	<u>VORICONAZOLE</u>						
	INJECTABLE; INTRAVENOUS						
	VORICONAZOLE						
AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA
>D>	AP	CHARTWELL RX	N208562	001	Mar 09, 2017	Dec	CAHN
AP		200MG/VIAL	N208562	001	Mar 09, 2017	Sep	CAHN
>A>	AP	HIKMA	N208562	001	Mar 09, 2017	Dec	CAHN
	@ NORVIUM BIOSCIENCE	200MG/VIAL	A210849	001	Oct 11, 2022	Jul	CAHN
	<u>VOXELOTOR</u>						
	TABLET; ORAL						
	OXBRYTA						
	+ @ GLOBAL BLOOD THERAPS	300MG	N213137	002	Oct 14, 2022	Oct	DISC
	+ @	500MG	N213137	001	Nov 25, 2019	Oct	DISC
	TABLET, FOR SUSPENSION; ORAL						
	OXBRYTA						
	+ @ GLOBAL BLOOD THERAPS	300MG	N216157	001	Dec 17, 2021	Oct	DISC
	<u>WARFARIN SODIUM</u>						
	TABLET; ORAL						
	WARFARIN SODIUM						
	@ BARR	1MG	A040145	001	Mar 26, 1997	Jun	DISC
	@	2MG	A040145	002	Mar 26, 1997	Jun	DISC
	@	2.5MG	A040145	003	Mar 26, 1997	Jun	DISC
	@	3MG	A040145	008	Nov 05, 1998	Jun	DISC
	@	4MG	A040145	004	Mar 26, 1997	Jun	DISC
	@	5MG	A040145	005	Mar 26, 1997	Jun	DISC
	@	6MG	A040145	009	Nov 05, 1998	Jun	DISC
	@	7.5MG	A040145	006	Mar 26, 1997	Jun	DISC
	@	10MG	A040145	007	Mar 26, 1997	Jun	DISC
>D>	AB	IPCA LABS LTD	A200104	001	Jun 27, 2013	Dec	DISC
>A>	@	1MG	A200104	001	Jun 27, 2013	Dec	DISC
>D>	AB	2MG	A200104	002	Jun 27, 2013	Dec	DISC
>A>	@	2MG	A200104	002	Jun 27, 2013	Dec	DISC
>D>	AB	2.5MG	A200104	003	Jun 27, 2013	Dec	DISC
>A>	@	2.5MG	A200104	003	Jun 27, 2013	Dec	DISC
>D>	AB	3MG	A200104	004	Jun 27, 2013	Dec	DISC
>A>	@	3MG	A200104	004	Jun 27, 2013	Dec	DISC
>D>	AB	4MG	A200104	005	Jun 27, 2013	Dec	DISC
>A>	@	4MG	A200104	005	Jun 27, 2013	Dec	DISC
>D>	AB	5MG	A200104	006	Jun 27, 2013	Dec	DISC
>A>	@	5MG	A200104	006	Jun 27, 2013	Dec	DISC
>D>	AB	6MG	A200104	007	Jun 27, 2013	Dec	DISC
>A>	@	6MG	A200104	007	Jun 27, 2013	Dec	DISC
>D>	AB	7.5MG	A200104	008	Jun 27, 2013	Dec	DISC
>A>	@	7.5MG	A200104	008	Jun 27, 2013	Dec	DISC
>D>	AB	10MG	A200104	009	Jun 27, 2013	Dec	DISC
>A>	@	10MG	A200104	009	Jun 27, 2013	Dec	DISC

ZINC CHLORIDE

INJECTABLE; INJECTION
 ZINC CHLORIDE
 AP SOMERSET EQ 1MG ZINC/ML A216152 001 Oct 16, 2024 Oct NEWA

ZINC SULFATE

SOLUTION; INTRAVENOUS
 ZINC SULFATE
 AP APOTEX EQ 10MG BASE/10ML (EQ 1MG BASE/ML) A218059 002 Oct 28, 2024 Oct NEWA
 AP EQ 25MG BASE/5ML (EQ 5MG BASE/ML) A218059 001 Jun 10, 2024 May NEWA
 AP NIVAGEN PHARMS INC EQ 10MG BASE/10ML (EQ 1MG BASE/ML) A214597 001 Jul 05, 2024 Jun NEWA
 AP EQ 25MG BASE/5ML (EQ 5MG BASE/ML) A214597 002 Jul 05, 2024 Jun NEWA
 AP EQ 30MG BASE/10ML (EQ 3MG BASE/ML) A214597 003 Jul 05, 2024 Jun NEWA
 AP SOMERSET THERAPS LLC EQ 25MG BASE/5ML (EQ 5MG BASE/ML) A216135 001 Jul 17, 2024 Jul NEWA
 AP EQ 30MG BASE/10ML (EQ 3MG BASE/ML) A216135 002 Jul 17, 2024 Jul NEWA

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS
 ZOLEDRONIC ACID
 @ HOSPIRA EQ 4MG BASE/5ML A090621 001 Mar 19, 2015 May DISC

ZOLMITRIPTAN

SPRAY; NASAL
 ZOLMITRIPTAN
 AB ! PADAGIS ISRAEL 5MG/SPRAY A212469 002 Sep 30, 2021 Feb CHRS
 TABLET; ORAL
 ZOLMITRIPTAN
 @ INVAGEN PHARMS 2.5MG A204284 001 Apr 09, 2014 Mar DISC
 @ 5MG A204284 002 Apr 09, 2014 Mar DISC
 AB SOMERSET THERAPS LLC 2.5MG A206973 001 Jun 30, 2017 Sep CAHN
 AB 5MG A206973 002 Jun 30, 2017 Sep CAHN

ZOLPIDEM TARTRATE

TABLET; ORAL
 ZOLPIDEM TARTRATE
 @ INVAGEN PHARMS 5MG A078184 001 Sep 07, 2007 Mar DISC
 @ 10MG A078184 002 Sep 07, 2007 Mar DISC
 TABLET; SUBLINGUAL
 ZOLPIDEM TARTRATE
 AB ENDO OPERATIONS 1.75MG A204229 001 Sep 11, 2017 Apr CAHN
 AB 3.5MG A204229 002 Sep 11, 2017 Apr CAHN
 AB 5MG A201509 001 Aug 01, 2016 May CAHN
 AB 10MG A201509 002 Aug 01, 2016 May CAHN
 TABLET, EXTENDED RELEASE; ORAL
 ZOLPIDEM TARTRATE
 @ ENDO OPERATIONS 6.25MG A078148 002 Apr 14, 2011 May CAHN
 @ 12.5MG A078148 001 Dec 03, 2010 May CAHN

ZONISAMIDE

CAPSULE; ORAL
 ZONEGRAN
 >A> AB + ADVANZ PHARMA 25MG N020789 003 Aug 22, 2003 Dec CAHN
 >A> + @ 50MG N020789 002 Aug 22, 2003 Dec CAHN
 >A> AB +! 100MG N020789 001 Mar 27, 2000 Dec CAHN
 >D> AB + CONCORDIA 25MG N020789 003 Aug 22, 2003 Dec CAHN
 >D> + @ 50MG N020789 002 Aug 22, 2003 Dec CAHN
 >D> AB +! 100MG N020789 001 Mar 27, 2000 Dec CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN

+ @ TARO	650MG	N018337	001		Oct	DISC
----------	-------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

@ SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011	Nov	DISC
----------------------	-------	---------	-----	--------------	-----	------

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

>D>	@ AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Dec	CMFD
>A>		250MG;125MG	A218359	001	Mar 26, 2024	Dec	CMFD
	@	250MG;125MG	A218359	001	Mar 26, 2024	Sep	DISC
		250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
		250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
	DR REDDYS	250MG;125MG	A218247	001	Aug 23, 2024	Aug	NEWA
	GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

ALEMBIC	0.25%	A209290	001	Oct 02, 2024	Sep	NEWA
GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
@ PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
	0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA

AZELASTINE HYDROCHLORIDE ALLERGY

APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
--------	----------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY

APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA
--------	----------------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
-------------------	--------	---------	-----	--------------	-----	------

LUMIFY PRESERVATIVE FREE

+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA
------------------------	--------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
>A>	@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Dec	CMFD
		5MG/5ML	A090474	002	Mar 30, 2009	Dec	CMFD
	@	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
	@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
	@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
		5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
	@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
	@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
	TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
		5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
	@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
>D>	@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Dec	CMFD
>A>		5MG/5ML	A090474	001	Mar 30, 2009	Dec	CMFD
	@	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
	@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
	@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
	@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR
	@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR
	TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR
		5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR
	@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR

CHILDREN'S ZYRTEC ALLERGY

>D>	+! J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Dec	CAHN
		5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR
>A>	+! KENVUE BRANDS	5MG/5ML	N022155	002	Nov 16, 2007	Dec	CAHN
>A>	CHILDREN'S ZYRTEC HIVES						
>A>	+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Dec	CTNA
>A>	+! KENVUE BRANDS	5MG/5ML	N022155	001	Nov 16, 2007	Dec	CAHN
	CHILDREN'S ZYRTEC HIVES RELIEF						
>D>	+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Dec	CTNA
	+!	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE

	INDOCO	10MG	A218895	001	Oct 03, 2024	Sep	NEWA
	CETIRIZINE HYDROCHLORIDE ALLERGY						
>D>	IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Dec	DISC
>A>	@	5MG	A202277	002	Mar 11, 2014	Dec	DISC
>D>		10MG	A202277	004	Mar 11, 2014	Dec	DISC
>A>	@	10MG	A202277	004	Mar 11, 2014	Dec	DISC
	CETIRIZINE HYDROCHLORIDE HIVES						
>D>	IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Dec	DISC
>A>	@	5MG	A202277	001	Mar 11, 2014	Dec	DISC
>D>		10MG	A202277	003	Mar 11, 2014	Dec	DISC
>A>	@	10MG	A202277	003	Mar 11, 2014	Dec	DISC
	ZYRTEC ALLERGY						
>D>	+ @ J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007	Dec	CAHN
>D>	+!	10MG	N019835	004	Nov 16, 2007	Dec	CAHN
>A>	+ @ KENVUE BRANDS	5MG	N019835	003	Nov 16, 2007	Dec	CAHN
>A>	+!	10MG	N019835	004	Nov 16, 2007	Dec	CAHN
>A>	ZYRTEC HIVES						
>A>	+ @ J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007	Dec	CTNA
>A>	+ @	10MG	N019835	006	Nov 16, 2007	Dec	CTNA
>A>	+ @ KENVUE BRANDS	5MG	N019835	005	Nov 16, 2007	Dec	CAHN
>A>	+ @	10MG	N019835	006	Nov 16, 2007	Dec	CAHN
	ZYRTEC HIVES RELIEF						
>D>	+ @ J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007	Dec	CTNA
>D>	+ @	10MG	N019835	006	Nov 16, 2007	Dec	CTNA

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	@ SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar	DISC
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
	@ SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar	DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018	Jun	CAHN
	UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Aug	NEWA

CLOTRIMAZOLE

CREAM;VAGINAL

TRIVAGIZOLE 3

	TARO	2%	N021143	001	Apr 12, 2000	Mar	CAHN
--	------	----	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

CIPLA	1%	A209903	001	Aug 03, 2018	Jul	CMKT
@ HIKMA	1%	A209484	001	Nov 21, 2018	Mar	DISC

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

PLD ACQUISITIONS LLC 38MG;200MG

A211404	001	Apr 11, 2024	Apr	NEWA
---------	-----	--------------	-----	------

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

AUROBINDO PHARMA LTD 10%

A217090	001	Mar 01, 2024	Feb	NEWA
---------	-----	--------------	-----	------

P AND L DEVELOPMENT 10%

A212385	001	Oct 07, 2022	Mar	CAHN
---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

ANDA REPOSITORY EQ 20MG BASE

A216149	001	Mar 15, 2023	Sep	CAHN
---------	-----	--------------	-----	------

DR REDDYS EQ 20MG BASE

A207198	001	Apr 30, 2024	Apr	NEWA
---------	-----	--------------	-----	------

GLENMARK SPECTL EQ 20MG BASE

A218092	001	Jun 11, 2024	May	NEWA
---------	-----	--------------	-----	------

GUARDIAN DRUG EQ 20MG BASE

A216149	001	Mar 15, 2023	Feb	CAHN
---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD EQ 20MG BASE

A214473	001	Jul 12, 2023	Apr	CMFD
---------	-----	--------------	-----	------

@ EQ 20MG BASE

A214473	001	Jul 12, 2023	Jan	DISC
---------	-----	--------------	-----	------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

CONTRACT PHARMACAL 10MG

A218003	001	May 28, 2024	May	NEWA
---------	-----	--------------	-----	------

20MG

A218003	002	May 28, 2024	May	NEWA
---------	-----	--------------	-----	------

GRAVITI PHARMS 10MG

A218461	001	Mar 14, 2024	Mar	NEWA
---------	-----	--------------	-----	------

20MG

A218461	002	Mar 14, 2024	Mar	NEWA
---------	-----	--------------	-----	------

@ SUN PHARM INDS LTD 10MG

A090283	001	Nov 17, 2009	Apr	DISC
---------	-----	--------------	-----	------

@ 20MG

A090283	002	Nov 17, 2009	Apr	DISC
---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AUROBINDO PHARMA LTD 0.05MG/SPRAY

A217088	001	May 10, 2024	May	NEWA
---------	-----	--------------	-----	------

@ HIKMA 0.05MG/SPRAY

A208024	001	Apr 17, 2019	Mar	DISC
---------	-----	--------------	-----	------

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM

A215777	001	Sep 14, 2023	Nov	CMFD
---------	-----	--------------	-----	------

@ EQ 200MG FREE ACID AND POTASSIUM

A215777	001	Sep 14, 2023	Mar	DISC
---------	-----	--------------	-----	------

SALT

PATHEON SOFTGELS EQ 200MG FREE ACID AND POTASSIUM

A217236	001	Feb 13, 2024	Mar	CAHN
---------	-----	--------------	-----	------

SALT

EQ 200MG FREE ACID AND POTASSIUM

A217236	001	Feb 13, 2024	Feb	NEWA
---------	-----	--------------	-----	------

SALT

SUSPENSION;ORAL

IBUPROFEN

ANNORA PHARMA 100MG/5ML

A210602	001	Nov 23, 2018	Sep	CAHN
---------	-----	--------------	-----	------

PAI HOLDINGS PHARM 100MG/5ML

A214789	001	Nov 08, 2024	Nov	NEWA
---------	-----	--------------	-----	------

SUSPENSION/DROPS;ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD 40MG/ML

A213506	001	Apr 08, 2024	Oct	DISC
---------	-----	--------------	-----	------

40MG/ML

A213506	001	Apr 08, 2024	Mar	NEWA
---------	-----	--------------	-----	------

TABLET;ORAL

IBUPROFEN

@ ADAPTIS 200MG

A071265	001	Oct 15, 1986	Sep	CAHN
---------	-----	--------------	-----	------

@ 200MG

A071265	002	Sep 10, 1987	Sep	CAHN
---------	-----	--------------	-----	------

200MG

A072299	001	Jul 01, 1988	Sep	CAHN
---------	-----	--------------	-----	------

DR REDDYS 200MG

A075661	001	Dec 12, 2001	Nov	CAHN
---------	-----	--------------	-----	------

ENDO OPERATIONS 200MG

A071229	001	Apr 01, 1987	May	CAHN
---------	-----	--------------	-----	------

@ 200MG

A071639	001	Feb 02, 1988	May	CAHN
---------	-----	--------------	-----	------

	TABLET;ORAL								
	IBUPROFEN								
	@	200MG			A072249	001	Jan 10, 1989	May	CAHN
	<u>KETOTIFEN FUMARATE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	ALAWAY								
>D>	BAUSCH AND LOMB INC	EQ 0.025% BASE			A208158	001	Sep 24, 2020	Dec	DISC
>A>	@	EQ 0.025% BASE			A208158	001	Sep 24, 2020	Dec	DISC
	KETOTIFEN FUMARATE								
	UNICHEM	EQ 0.025% BASE			A204059	001	Jun 01, 2020	Nov	CAHN
	<u>LEVONORGESTREL</u>								
	TABLET;ORAL								
	LEVONORGESTREL								
	NAARI PTE LTD	1.5MG			A207660	001	May 02, 2019	Apr	CMFD
	@ XIROMED	0.75MG			A202740	001	Sep 02, 2016	May	CAHN
		1.5MG			A202739	001	Oct 31, 2014	May	CAHN
	<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE</u>								
	TABLET;ORAL								
	LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE								
	@ SUN PHARM INDS LTD	2MG;125MG			A077500	001	Sep 06, 2006	May	DISC
	<u>LORATADINE</u>								
	SUSPENSION;ORAL								
	LORATADINE								
+!	TARO	1MG/ML			N021734	001	Oct 04, 2005	Aug	CAHN
	TABLET;ORAL								
	LORATADINE								
	ANDA REPOSITORY	10MG			A207569	001	Mar 12, 2019	Sep	CAHN
	MARKSANS PHARMA	10MG			A219223	001	Nov 21, 2024	Nov	NEWA
	<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	LORATADINE AND PSEUDOEPHEDRINE SULFATE								
	BIONPHARMA	10MG;240MG			A218017	001	May 14, 2024	May	NEWA
	<u>MICONAZOLE NITRATE</u>								
	CREAM;VAGINAL								
	MICONAZOLE NITRATE								
	@ COSETTE	2%			A074366	001	Feb 22, 1996	Apr	DISC
	CREAM, SUPPOSITORY;TOPICAL, VAGINAL								
	M-ZOLE 3 COMBINATION PACK								
	COSETTE	2%,200MG			A074926	001	Apr 16, 1999	Jun	CAHN
	SUPPOSITORY;VAGINAL								
	MICONAZOLE NITRATE								
	COSETTE	100MG			A073507	001	Nov 19, 1993	Jun	CAHN
	@	100MG			A074414	001	Apr 30, 1997	Apr	DISC
	<u>MINOXIDIL</u>								
	AEROSOL, FOAM;TOPICAL								
	MINOXIDIL (FOR MEN)								
	AUROBINDO PHARMA	5%			A218616	001	Apr 22, 2024	Apr	NEWA
	MINOXIDIL (FOR WOMEN)								
	AUROBINDO PHARMA	5%			A218616	002	Apr 22, 2024	Apr	NEWA
	SOLUTION;TOPICAL								
	MINOXIDIL (FOR MEN)								
	@ AUROBINDO PHARMA LTD	2%			A074767	001	Feb 28, 1997	Oct	DISC
	MINOXIDIL (FOR WOMEN)								
	@ AUROBINDO PHARMA LTD	2%			A074767	002	Nov 25, 1997	Nov	DISC
	TARO	2%			A218175	001	Nov 26, 2024	Nov	NEWA
	<u>MOMETASONE FUROATE</u>								
	SPRAY, METERED;NASAL								
	MOMETASONE FUROATE								
	@ APOTEX	0.05MG/SPRAY			A217438	001	Apr 23, 2024	Sep	DISC
		0.05MG/SPRAY			A217438	001	Apr 23, 2024	Apr	NEWA
	AUROBINDO PHARMA	0.05MG/SPRAY			A217498	001	Nov 22, 2024	Nov	NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL
NALOXONE HYDROCHLORIDE

AMNEAL	4MG/SPRAY	A217992	001	Apr 23, 2024	Apr	NEWA
TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Jun	CMKT

NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM

@ SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011	Jan	DISC
----------------------	-------	---------	-----	--------------	-----	------

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA	220MG;120MG	A211360	001	Jun 01, 2022	Jul	CMFD
------------------	-------------	---------	-----	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
NICOTINE

DIFGEN PHARMS	7MG/24HR	A074612	002	Jul 28, 2003	Sep	CAHN
	14MG/24HR	A074612	003	Oct 20, 1997	Sep	CAHN
	21MG/24HR	A074612	001	Oct 20, 1997	Sep	CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL
NICORETTE

+ HALEON US HOLDINGS	EQ 2MG BASE	N022360	001	May 18, 2009	Jan	CAHN
+!	EQ 4MG BASE	N022360	002	May 18, 2009	Jan	CAHN
NICOTINE POLACRILEX						
PPI-DAC	EQ 2MG BASE	A090711	001	Jul 10, 2009	Jun	CAHN
	EQ 2MG BASE	A203690	001	Oct 09, 2012	Jun	CAHN
	EQ 4MG BASE	A090711	002	Jul 10, 2009	Jun	CAHN
	EQ 4MG BASE	A203690	002	Oct 09, 2012	Jun	CAHN

NORGESTREL

TABLET;ORAL
OPILL

+! LABORATOIRE HRA	0.075MG	N017031	001		Feb	CMFD
--------------------	---------	---------	-----	--	-----	------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>	GLENMARK PHARMS INC	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Aug	CMFD
	SOMERSET	EQ 0.2% BASE	A215006	001	Dec 18, 2024	Dec	NEWA
	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Apr	CMKT

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

@ SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018	Nov	DISC
--------	--------------	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

DR REDDYS	20MG/PACKET;1.68GM/PACKET	A217784	001	May 09, 2024	May	NFTG
-----------	---------------------------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

PPI-DAC	17GM/PACKET	A090685	001	Oct 06, 2009	Jun	CAHN
	17GM/SCOOPFUL	A090685	002	Oct 06, 2009	Jun	CAHN

POVIDONE-IODINE

SPONGE;TOPICAL
E-Z SCRUB 201

+ @ BECTON DICKINSON	20%	N019240	001	Nov 29, 1985	Feb	DISC
E-Z SCRUB 241						
+ @ BECTON DICKINSON	10%	N019476	001	Jan 07, 1987	Feb	DISC

TERBINAFINEGEL;TOPICAL
LAMISIL AT

+! KARO HLTHCARE 1% N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDECREAM;TOPICAL
LAMISIL

+! KARO HLTHCARE 1% N020980 001 Mar 09, 1999 Feb CAHN

SOLUTION;TOPICAL
LAMISIL AT

+! KARO HLTHCARE 1% N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL
LAMISIL AT

+! KARO HLTHCARE 1% N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2024

NO DECEMBER 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Sep 28, 2031	DS DP U-1981			
	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11986468	Jul 28, 2037			U-2830	
	11986469	Jul 28, 2037			U-2830	
	11992486	Jul 28, 2037			U-2830	
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11986468	Jul 28, 2037			U-2830	
	11986469	Jul 28, 2037			U-2830	
	11992486	Jul 28, 2037			U-2830	
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031			U-3744	
	11896567	Oct 26, 2031			U-3745	
	12083087	Jul 17, 2035			U-3744	
	12083087	Jul 17, 2035			U-3745	
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	>A> 10398681	May 05, 2031	DP		>A> NCE	Nov 22, 2029
	>A> 10513497	Feb 16, 2038	DS			
	>A> 10842777	May 05, 2031			U-4046	
	>A> 11058668	Mar 22, 2039			U-4046	
	>A> 11260047	Aug 16, 2039	DP			
	>A> 11919865	Feb 16, 2038			U-4046	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	>A> 12005043	Aug 16, 2039	DP U-4046			
	>A> 12070449	Mar 22, 2039	U-4046			
	>A> 8877795	May 05, 2031	DP			
	>A> 9169214	May 05, 2031	DP U-4046			
	>A> 9642838	May 05, 2031	DS DP			
	>A> 9913826	Mar 14, 2033	U-4046			
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREO</u>						
N 216632 001	12128059	Jul 31, 2040	DP U-3713			
	12133859	Jul 31, 2040	DP			
	12138278	Jul 31, 2040	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462	Apr 29, 2033	DS DP			
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12016873	May 15, 2035	U-2414			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001					D-194	Oct 04, 2027
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037	U-3447			
	11918685	Oct 06, 2037	U-3448			
	12053461	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
<u>AMOXICILIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREPITANT - CINVANTI</u>						
N 209296 001	12115254	Sep 18, 2035	DP			
	12115255	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
	12115254	Sep 18, 2035	DP			
	12115255	Sep 18, 2035	DP			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 001	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 002	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 003	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 004	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIPIPRAZOLE - OPIPZA</u>						
N 216655 001	11331315	Nov 03, 2040	DP			
	11701352	Dec 15, 2041	DP			
<u>ARIPIPRAZOLE - OPIPZA</u>						
N 216655 002	11331315	Nov 03, 2040	DP			
	11701352	Dec 15, 2041	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - OPIPZA</u>						
N 216655 003	11331315	Nov 03, 2040	DP			
	11701352	Dec 15, 2041	DP			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 001	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 002	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	12121506	Feb 16, 2044	DP			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001					I-953	Oct 29, 2027
					I-954	Oct 29, 2027
					ODE-499	Oct 29, 2031
					ODE-500	Oct 29, 2031
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002					I-953	Oct 29, 2027
					I-954	Oct 29, 2027
					ODE-499	Oct 29, 2031
					ODE-500	Oct 29, 2031
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE*	Oct 29, 2028
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	12083179	Sep 10, 2033	DP U-2310			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	12090148	Jul 29, 2041	U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
	>A> 12168069	Jun 07, 2037	DP			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	12016875	Jul 11, 2034	U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	12060354	Mar 08, 2042	U-2726			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			
	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	11999744	Apr 10, 2040	U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	12053482	May 14, 2029	U-2950			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	12053482	May 14, 2029	U-2950			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					M-306	Jun 21, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					M-306	Jun 21, 2027
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	12097202	Jul 14, 2042	U-4014			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036		U-3883	I-943	Mar 22, 2027
	11926584	Jun 19, 2040		U-3873	I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036		U-3224	I-943	Mar 22, 2027
	10912751	Mar 14, 2036		U-3884	I-945	Mar 22, 2027
	11744816	Mar 14, 2036		U-3692		
	11744816	Mar 14, 2036		U-3883		
	11926584	Jun 19, 2040		U-3873		
	7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	11795176	Jan 13, 2042	DS U-713			
	9763953	Dec 01, 2026	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	11795176	Jan 13, 2042	DS U-713			
	9763953	Dec 01, 2026	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	11795176	Jan 13, 2042	DS U-713			
	9763953	Dec 01, 2026	U-713			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
	11986456	Feb 19, 2040	U-3947			
	>A> 12156946	Feb 03, 2028	DP			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12053546	Jun 29, 2032	DP			
	12070629	Dec 30, 2030	DP U-3987			
	12133919	May 23, 2041	DP U-3987			
	>A> 12156946	Feb 03, 2028	DP			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	12116346	Mar 09, 2035	DS			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	12116346	Mar 09, 2035	DS			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942	Feb 23, 2027
					M-305	Apr 24, 2027
					ODE-468	Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942	Feb 23, 2027
	7390791*PED	Oct 17, 2025			ODE-468	Feb 23, 2031
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942	Feb 23, 2027
	7390791*PED	Oct 17, 2025			ODE-468	Feb 23, 2031
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	12005069	Sep 23, 2042	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	12005069	Sep 23, 2042	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001 >A>	RE50218	Mar 05, 2029	DP U-1834			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	11666567	Apr 30, 2032	U-4015			
	11666567	Apr 30, 2032	U-4016			
	11666567	Apr 30, 2032	U-4017			
	11666567	Apr 30, 2032	U-4018			
<u>BUDESONIDE - EOHLIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
	12144890	Jan 22, 2041	DP U-4033			
	12151024	Jan 22, 2041	DP U-4037			
	12156940	Jul 02, 2044	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
	12144890	Jan 22, 2041	DP U-4033			
	12151024	Jan 22, 2041	DP U-4037			
	12156940	Jul 02, 2044	DP			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	004				I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430	001	11883373	Jan 23, 2043	U-3419		
		11896563	Dec 01, 2041	U-3419		
		11925636	Jan 20, 2043	U-3419		
		11969421	Nov 05, 2034	U-3419		
		11986444	Feb 15, 2043	U-3419		
		12036191	Feb 15, 2043	U-3419		
		12042473	Feb 23, 2043	U-3419		
		12109178	Nov 05, 2034	U-3419		
		12146889	Feb 23, 2043	U-3419		
	>A>	12156914	Jan 20, 2043	DP		
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001	11998542	Jul 02, 2034	U-1583		
		12048769	Nov 08, 2027	U-1585		
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499	001	12138264	Sep 15, 2031	DP		
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888	001	12138264	Sep 15, 2031	DP U-3348		
	>A>	RE50189	Nov 27, 2031	U-3348		
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888	002	12138264	Sep 15, 2031	DP U-3348		
	>A>	RE50189	Nov 27, 2031	U-3348		
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	001	12128039	Feb 10, 2032	DP U-1617		
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	002	12128039	Feb 10, 2032	DP U-1617		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	001	12128039	Feb 10, 2032	DP U-1220		
		12128039	Feb 10, 2032	DP U-1480		
		12128039	Feb 10, 2032	DP U-2488		
		12128039	Feb 10, 2032	DP U-3225		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	002	12128039	Feb 10, 2032	DP U-1220		
		12128039	Feb 10, 2032	DP U-1480		
		12128039	Feb 10, 2032	DP U-2488		
		12128039	Feb 10, 2032	DP U-3225		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	003	12128039	Feb 10, 2032	DP U-1220		
		12128039	Feb 10, 2032	DP U-1480		
		12128039	Feb 10, 2032	DP U-2488		
		12128039	Feb 10, 2032	DP U-3225		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	11154509	Apr 25, 2028	U-3815		
		9498486	Apr 25, 2028	U-3814		
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690	001	11986446	Mar 15, 2033	U-3017	ODE-361	Jul 21, 2027
		11986446	Mar 15, 2033	U-3324	PED	Jan 21, 2028
	>A>	12138233	Feb 22, 2041	U-4044		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	>A> 10617668	May 11, 2031	DP U-2441			
	>A> 10617668	May 11, 2031	DP U-2632			
	>A> 10617668	May 11, 2031	DP U-2794			
	>A> 10617668	May 11, 2031	DP U-2795			
	>A> 10617668	May 11, 2031	DP U-2796			
	>A> 10617668	May 11, 2031	DP U-2797			
	>A> 10617668	May 11, 2031	DP U-2798			
	>A> 10617668	May 11, 2031	DP U-2799			
	>A> 10617668	May 11, 2031	DP U-493			
	>A> 10617668*PED	Nov 11, 2031				
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	>A> 10617668	May 11, 2031	DP U-2441			
	>A> 10617668	May 11, 2031	DP U-2632			
	>A> 10617668	May 11, 2031	DP U-2794			
	>A> 10617668	May 11, 2031	DP U-2795			
	>A> 10617668	May 11, 2031	DP U-2796			
	>A> 10617668	May 11, 2031	DP U-2797			
	>A> 10617668	May 11, 2031	DP U-2798			
	>A> 10617668	May 11, 2031	DP U-2799			
	>A> 10617668	May 11, 2031	DP U-493			
	>A> 10617668*PED	Nov 11, 2031				
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943582*PED	Aug 26, 2029				
	7943788	Jul 14, 2027	DS DP			
	7943788*PED	Jan 14, 2028				
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025	U-2441			
	>A> 8222219	Apr 11, 2025	U-2632			
	>A> 8222219	Apr 11, 2025	U-493			
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP		U-2441	
	>A> 8513202	Dec 03, 2027	DS DP		U-2632	
	>A> 8513202	Dec 03, 2027	DS DP		U-493	
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	>A> 7943582	Feb 26, 2029	DS DP		U-2441	
	>A> 7943582	Feb 26, 2029	DS DP		U-2632	
	>A> 7943582	Feb 26, 2029	DS DP		U-493	
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP		U-2441	
	>A> 8513202	Dec 03, 2027	DS DP		U-2632	
	>A> 8513202	Dec 03, 2027	DS DP		U-493	
	>A> 8513202*PED	Jun 03, 2028				
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	>A> 7943582	Feb 26, 2029	DS DP		U-2441	
	>A> 7943582	Feb 26, 2029	DS DP		U-2632	
	>A> 7943582	Feb 26, 2029	DS DP		U-493	
	>A> 7943582*PED	Aug 26, 2029				
	>A> 7943788	Jul 14, 2027	DS DP			
	>A> 7943788*PED	Jan 14, 2028				
	>A> 8222219	Apr 11, 2025			U-2441	
	>A> 8222219	Apr 11, 2025			U-2632	
	>A> 8222219	Apr 11, 2025			U-493	
	>A> 8222219*PED	Oct 11, 2025				
	>A> 8513202	Dec 03, 2027	DS DP		U-2441	
	>A> 8513202	Dec 03, 2027	DS DP		U-2632	
	>A> 8513202	Dec 03, 2027	DS DP		U-493	
	>A> 8513202*PED	Jun 03, 2028				
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP		U-2781	
	11865102	Apr 26, 2039	DS DP		U-3236	
	11865102	Apr 26, 2039	DS DP		U-3277	
	11963937	Jun 17, 2035			U-2780	
	11963937	Jun 17, 2035			U-2781	
	12064399	Jun 17, 2035			U-3988	
	12064399	Jun 17, 2035			U-3989	
	12102619	Mar 01, 2041			U-3233	
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	12084449	Nov 19, 2027			U-2813	
	7767675	Nov 19, 2032	DS DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	12084449	Nov 19, 2027			U-2813	
	7767675	Nov 19, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
	12128141	Oct 07, 2034	DP U-219			
	>A> 12178918	Oct 07, 2034	DP			
	>A> 12178919	Oct 07, 2034	DP U-219			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
	12128141	Oct 07, 2034	DP U-219			
	>A> 12178918	Oct 07, 2034	DP			
	>A> 12178919	Oct 07, 2034	DP U-219			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
	12128141	Oct 07, 2034	DP U-219			
	>A> 12178918	Oct 07, 2034	DP			
	>A> 12178919	Oct 07, 2034	DP U-219			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
	12128141	Oct 07, 2034	DP U-219			
>A>	12178918	Oct 07, 2034	DP			
>A>	12178919	Oct 07, 2034	DP U-219			
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CEPHALEXIN - CEPHALEXIN</u>						
A 218817 001					CGT	Apr 09, 2025
<u>CEPHALEXIN - CEPHALEXIN</u>						
A 218817 002					CGT	Apr 09, 2025
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			
<u>CIPROFLOXACIN HYDROCHLORIDE - CIPROFLOXACIN HYDROCHLORIDE</u>						
A 217887 001					>A> CGT	Jun 11, 2025
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	8143240	Jan 12, 2026	U-2942			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>CLOMIPHENE CITRATE - CLOMIPHENE CITRATE</u>						
A 216739 001					CGT	May 18, 2025
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - LODOCO</u>						
N 215727 001	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>COPPER - PARAGARD T 380A</u>						
N 018680 001					D-193	Jun 28, 2027
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	12102696	Sep 03, 2041	DP			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 001	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001					>A> ODE-503	Dec 13, 2031
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002					>A> ODE-503	Dec 13, 2031
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003					>A> ODE-503	Dec 13, 2031
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001					>A> ODE-503	Dec 13, 2031
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					CGT	Dec 21, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
	12150956	Jul 01, 2041	U-3899			
	12150957	Jul 01, 2041	U-3899			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
	12150956	Jul 01, 2041	U-3899			
	12150957	Jul 01, 2041	U-3899			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRY'S</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
	12150956	Jul 01, 2041	U-3900			
	12150957	Jul 01, 2041	U-3900			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP		Y	
	8633162	Aug 27, 2024	U-1479		Y	
	8642556	Aug 27, 2024	DP		Y	
	8648048	Aug 27, 2024	U-1483		Y	
	8685930	Aug 27, 2024	DP		Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	9248191	Aug 27, 2024	U-1479	Y		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	12059449	Apr 01, 2042	DP U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-3565			
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001	12076319	Aug 02, 2038	U-3933		NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS U-3933		ODE-476	Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002	12076319	Aug 02, 2038	U-3933		NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS U-3933		ODE-476	Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7456254	Jun 30, 2025	U-2139		PED	Dec 12, 2027
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	12053502	Aug 28, 2038	U-3981			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	12053502	Aug 28, 2038	U-3981			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIQ</u>						
N 214985 001					>A> M-310	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIQ</u>						
N 214985 002					>A> M-310	Sep 30, 2027
<u>DASATINIB - DASATINIB</u>						
A 202103 001					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 002					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 003					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 004					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 001					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 002					PC	Mar 02, 2025
<u>DASATINIB - PHYRAGO</u>						
N 216099 001					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 002					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 003					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 004					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 005					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 006					M-307	Dec 05, 2026
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12036219	Jun 02, 2034	U-3967			
	12138257	May 01, 2032	DP			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	12090190	Jun 15, 2030	DP U-4003			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	12090190	Jun 15, 2030	DP U-4003			
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900 001	10561659	May 04, 2037	U-3976		NCE	Jul 25, 2029
	11919907	May 21, 2041	DP U-3976			
	12076323	May 04, 2037	U-3976			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	>A> 12144889	Apr 26, 2041	U-1680			
	>A> 12150896	Oct 07, 2036	U-1680			
	>A> 12150896	Oct 07, 2036	U-3455			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 001					CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 002					CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	12138247	Jan 12, 2043	U-4029			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	12138247	Jan 12, 2043	U-4029			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP >A> ODE-501	Apr 26, 2027 Apr 26, 2031
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP >A> ODE-501	Apr 26, 2027 Apr 26, 2031
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP >A> ODE-501	Apr 26, 2027 Apr 26, 2031
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP >A> ODE-501	Apr 26, 2027 Apr 26, 2031
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP >A> ODE-501	Apr 26, 2027 Apr 26, 2031
<u>DOCETAXEL - BEIZRAY</u>						
N 218711 001	11419842	May 16, 2036	DP U-4027			
	11419842	May 16, 2036	DP U-4028			
	11419842	May 16, 2036	DP U-881			
	11419842	May 16, 2036	DP U-937			
	11419842	May 16, 2036	DP U-946			
	12090134	May 16, 2036	DP U-4027			
	12090134	May 16, 2036	DP U-4028			
	12090134	May 16, 2036	DP U-881			
	12090134	May 16, 2036	DP U-937			
	12090134	May 16, 2036	DP U-946			
	12090135	May 16, 2036	DP			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Aug 30, 2032	DS DP U-2394			
	8486975	Aug 30, 2032	DS DP U-2630			
	8486975	Aug 30, 2032	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Aug 30, 2032	DS DP U-2395			
	8486975	Aug 30, 2032	DS DP U-2629			
	8486975	Aug 30, 2032	DS DP U-3307			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	12083090	May 18, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	12083090	May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
	7732430	Mar 02, 2026	DP U-3152			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 001	8399520	Dec 25, 2025	DS DP U-3523			
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 002	8399520	Dec 25, 2025	DS DP U-3523			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	11185519	Mar 30, 2037		U-3955	NCE	Jun 10, 2029
	11331292	Mar 30, 2037		U-1854	ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037		U-1854		
	11857523	Mar 30, 2037		U-3955		
	7632870	Sep 09, 2024		DP		
	7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	12102637	Aug 20, 2038		DP		
	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	12102637	Aug 20, 2038		DP		
	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	12083227	Aug 20, 2038		DP U-2842		
	7419983	Jul 06, 2029	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031		DP U-3032		
	10081621	Mar 25, 2031		DP U-3157		
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027		U-3028		
	8324242	Aug 05, 2027		U-3144		
	8354427	Jul 06, 2026		U-3029		
	8354427	Jul 06, 2026		U-3145		
	8415387	Nov 12, 2027		U-3028		
	8415387	Nov 12, 2027		U-3144		
	8598181	May 01, 2027		U-3028		
	8598181	May 01, 2027		U-3144		
	8629162	Jun 24, 2025		U-3030		
	8629162	Jun 24, 2025		U-3146		
	9670163	Dec 28, 2026		DP U-3031		
	9670163	Dec 28, 2026		DP U-3155		
	9931334	Dec 28, 2026		DP U-3031		
	9931334	Dec 28, 2026		DP U-3155		
	9974781	Apr 09, 2027		DP U-3028		
	9974781	Apr 09, 2027		DP U-3144		
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	12097187	Mar 14, 2033		U-3475		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	12115179	Feb 11, 2030		U-4023		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	12115179	Feb 11, 2030		U-4023		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215	002				ODE-457	Jan 07, 2029
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389	001	10945950	Sep 15, 2035	DP	NCE	Jun 26, 2029
		9062047	Aug 21, 2031	DS U-3962		
		9956171	Sep 15, 2035	DP U-3962		
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
A 217721	001				>A> CGT	Jun 18, 2025
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994	002	12029710	Jan 22, 2040	U-3963		
<u>EPINEPHRINE - NEFFY</u>						
N 214697	001	10576156	Feb 06, 2038	DP		
		10682414	Feb 06, 2039	U-3979		
		11173209	Feb 06, 2038	U-3979		
		11191838	Feb 06, 2039	DP U-3979		
		11717571	Feb 06, 2039	U-3979		
		11744895	Feb 06, 2039	U-3979		
		11918655	Feb 06, 2039	DP U-3979		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875	001	12133837	Mar 21, 2039	DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875	002	12133837	Mar 21, 2039	DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875	003	12133837	Mar 21, 2039	DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875	004	12133837	Mar 21, 2039	DP		
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875	005	12133837	Mar 21, 2039	DP		
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388	001	10683499	Aug 25, 2034	DS DP U-2378	NCE	Dec 21, 2028
		8101743	Apr 01, 2025	DS DP	ODE-461	Dec 21, 2030
		9127276	May 01, 2034	DS		
		9181549	May 01, 2034	DS		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	001	10478494	Aug 13, 2036	U-3902	I-930	Jan 19, 2027
		10898482	Feb 09, 2036	DP U-2518		
		10898482	Feb 09, 2036	DP U-3065		
		10898482	Feb 09, 2036	DP U-3066		
		10898482	Feb 09, 2036	DP U-3067		
		10898482	Feb 09, 2036	DP U-3805		
		10898482	Feb 09, 2036	DP U-3806		
		10898482	Feb 09, 2036	DP U-3807		
		11077106	Feb 02, 2038	U-3196		
		11077106	Feb 02, 2038	U-3808		
		11684620	Feb 09, 2036	U-3805		
		11684620	Feb 09, 2036	U-3806		
		11684620	Feb 09, 2036	U-3807		
		12037644	Oct 18, 2035	U-3972		
		9464071	Apr 28, 2031	U-3805		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	002	10478494	Aug 13, 2036	U-3902	I-930	Jan 19, 2027
		10898482	Feb 09, 2036	DP U-2518		
		10898482	Feb 09, 2036	DP U-3065		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 003					CGT	Apr 22, 2025
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Nov 21, 2032	U-2316			
	10258630	Nov 21, 2032	U-2317			
	10398708	Nov 21, 2032	U-2317			
	10398708	Nov 21, 2032	U-2614			
	10471072	Nov 21, 2032	U-2316			
	10471072	Nov 21, 2032	U-2317			
	10568891	Nov 21, 2032	U-2316			
	10568891	Nov 21, 2032	U-2317			
	10668082	Nov 21, 2032	U-2316			
	10668082	Nov 21, 2032	U-2317			
	10888516	Nov 21, 2032	U-2316			
	10888516	Nov 21, 2032	U-2317			
	11065197	Nov 21, 2032	DP			
	11116717	Nov 21, 2032	DP			
	11123283	Nov 21, 2032	DP			
	9180091	Nov 21, 2032	DP U-2316			
	9180091	Nov 21, 2032	DP U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Nov 21, 2032	U-2316			
	10258630	Nov 21, 2032	U-2317			
	10398708	Nov 21, 2032	U-2317			
	10398708	Nov 21, 2032	U-2614			
	10471072	Nov 21, 2032	U-2316			
	10471072	Nov 21, 2032	U-2317			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10568891	Nov 21, 2032	U-2316			
	10568891	Nov 21, 2032	U-2317			
	10668082	Nov 21, 2032	U-2316			
	10668082	Nov 21, 2032	U-2317			
	10888516	Nov 21, 2032	U-2316			
	10888516	Nov 21, 2032	U-2317			
	11065197	Nov 21, 2032	DP			
	11116717	Nov 21, 2032	DP			
	11123283	Nov 21, 2032	DP			
	9180091	Nov 21, 2032	DP U-2316			
	9180091	Nov 21, 2032	DP U-2317			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
	>A> 7300935	Jan 28, 2026	DS			
	>A> 8058280	Jan 28, 2026	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001					NP	Jul 22, 2027
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			
	>A> 12156866	Jan 06, 2036	U-4047			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	12097206	May 03, 2033	U-4013			
	12097206*PED	Nov 03, 2033				
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001					NPP PED	Jul 01, 2027 Jan 01, 2028
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	12036290	Nov 27, 2041	DP U-3614			
	12036290	Nov 27, 2041	DP U-3615			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042	U-2450			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168 001	7344702	May 26, 2026	DS		NCE	Sep 27, 2029
	8226929	Jun 21, 2028		U-4011		
	8936777	Jun 30, 2031		U-4011		
	9161997	Feb 04, 2026	DS DP	U-4011		
	9603951	May 02, 2031		U-4011		
	9687571	Nov 01, 2032	DP	U-4011		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	12083270	Apr 04, 2031	U-2133		I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	12042504	Jan 11, 2039	DP			
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	10174061	Oct 21, 2035	DP U-4030			
	10730895	Oct 21, 2035	DS			
	9446059	Oct 21, 2035	DS DP U-4030			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 08, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 08, 2028
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001					NP	Oct 07, 2025
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	12109277	Mar 09, 2036	U-4002			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	12144801	Aug 10, 2037	U-4034			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	>A> 7329689	Jan 15, 2026	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032	U-3885			
	9867799	Feb 03, 2032	U-3885			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036	U-3254			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036	U-3254			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
	12151020	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	12076403	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	12076403	Nov 02, 2031	DP			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROCORTISONE SODIUM SUCCINATE - HYDROCORTISONE SODIUM SUCCINATE</u>						
A 214050 001					CGT	Mar 25, 2025
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 001					PC	Apr 12, 2025
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 002					PC	Nov 11, 2024
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 003					PC	Dec 02, 2024
<u>HYDROXYUREA - XROMI</u>						
N 216593 001					NP ODE-470	Apr 04, 2027 Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
	8476284	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					M-14	Aug 24, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10004746	Jun 03, 2031	U-3846			
	10004746	Jun 03, 2031	U-3847			
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10463668	Oct 24, 2034	U-2970			
	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10478439	Jun 03, 2031	U-3842			
	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933 001					NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMATINIB MESYLATE - IMKELDI</u>						
N 219097 001	11957681	Apr 27, 2040	DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033		U-3956		
	9388415	Sep 09, 2024		U-3956		
	9388416	Sep 09, 2024		U-3956		
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033		U-3956		
	9388415	Sep 09, 2024		U-3956		
	9388416	Sep 09, 2024		U-3956		
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030		U-1455		
	11850245	Apr 30, 2030		U-172		
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 001	10851091	Jul 01, 2036	DS DP		NCE	Oct 10, 2029
	11028100	Apr 26, 2038	DS DP			
	11760753	Jul 01, 2036		U-4024		
	8242104	Sep 27, 2030	DS DP			
	8343955	Sep 27, 2030		U-4024		
	9650393	Jul 01, 2036	DS DP	U-4024		
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 002	10851091	Jul 01, 2036	DS DP		NCE	Oct 10, 2029
	11028100	Apr 26, 2038	DS DP			
	11760753	Jul 01, 2036		U-4024		
	8242104	Sep 27, 2030	DS DP			
	8343955	Sep 27, 2030		U-4024		
	9650393	Jul 01, 2036	DS DP	U-4024		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	10093663	Jul 14, 2034		U-3980	I-949	Aug 07, 2027
	11723901	Aug 30, 2038		U-3980	NCE	Dec 05, 2028
	11951101	Jul 15, 2041		U-3895	ODE-456	Dec 05, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	10093663	Jul 14, 2034	U-3980		I-949	Aug 07, 2027
	11723901	Aug 30, 2038	U-3980		NCE	Dec 05, 2028
	11951101	Jul 15, 2041	U-3895		ODE-456	Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11344552	Aug 19, 2036	U-3824		I-932	Feb 13, 2027
	12059497	Oct 15, 2036	DP		ODE-463	Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP	Dec 08, 2026
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	11951212	Apr 14, 2035	DP U-3894			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	12065432	Dec 04, 2028	U-3984			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	12065432	Dec 04, 2028	U-3984			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	12065432	Dec 04, 2028	U-3983			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	12065432	Dec 04, 2028	U-3983			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	12065432	Dec 04, 2028	U-3983			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LANDIOLOL HYDROCHLORIDE - RAPIBLYK</u>						
N 217202 001				>A> NCE		Nov 22, 2029
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11986554	Apr 21, 2036	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12071423	Jul 06, 2040	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12071423	Jul 06, 2040	DP			
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11020385	Mar 14, 2034	U-1524			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	9593098	Oct 13, 2035	DS DP U-3985			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	9593098	Oct 13, 2035	DS DP U-3985			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001 >A>	11944611	Aug 28, 2041	U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001 >A>	11944611	Aug 28, 2041	U-3507			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036		U-3996		
	12083112	Mar 03, 2036		U-3997		
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036		U-3996		
	12083112	Mar 03, 2036		U-3997		
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 001	RE46791	Jan 18, 2029	DS DP		NP ODE* ODE* ODE-495 ODE-497	Aug 30, 2027 Nov 08, 2024 Jun 05, 2030 Aug 30, 2031 Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 002	RE46791	Jan 18, 2029	DS DP		NP ODE* ODE* ODE-495 ODE-497	Aug 30, 2027 Nov 08, 2024 Jun 05, 2030 Aug 30, 2031 Aug 30, 2031
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12064434	Apr 14, 2036	DP		I-951	Sep 17, 2027
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	8962630	Dec 09, 2029	U-3998			
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9416136	Aug 20, 2029	U-3998			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
	9868739	Nov 09, 2031	U-3998			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	9617303	Mar 22, 2028	U-4001			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	12133878	Dec 18, 2037	DP			
<u>LEVACETYLLLEUCINE - AONEURSA</u>						
N 219132 001					NCE ODE-498	Sep 24, 2029 Sep 24, 2031
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040	U-3821			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	12128083	Nov 06, 2035	DP			
<u>LOFEXIDINE HYDROCHLORIDE - LOFEXIDINE HYDROCHLORIDE</u>						
A 218613 001					CGT	Feb 24, 2025
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2025	U-3070			
	8828356	Oct 17, 2025	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2025	U-3070			
	8828356	Oct 17, 2025	U-3070			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
	12115246	May 03, 2033	DP U-4025			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
	12115246	May 03, 2033	DP U-2985			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	12070459	Aug 30, 2039	DP U-3362			
	12070459	Aug 30, 2039	DP U-3363			
	12090155	Jul 07, 2040	DP U-4000			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
	12128043	Aug 30, 2039	DP U-3362			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	12128043	Aug 30, 2039	DP U-3363			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031
	12144873	Jul 25, 2038	U-4036			
	12144873*PED	Jan 25, 2039				
	12151003	Jul 25, 2038	DP U-4036			
	12151003*PED	Jan 25, 2039				
	>A> 12161732	Jul 25, 2038	DP U-4036			
	>A> 12161732*PED	Jan 25, 2039				
	>A> 12168063	Jul 25, 2038	DP U-4036			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-3290		ODE-471	Mar 13, 2031
	11229647	Feb 12, 2040	U-3974			
	11229661	Oct 26, 2032	U-3850			
	11260053	May 26, 2031	U-3290			
	11260053	May 26, 2031	U-3974			
	11376251	Oct 26, 2032	U-3290			
	11376251	Oct 26, 2032	U-3974			
	11497745	Feb 12, 2040	U-3290			
	11497745	Feb 12, 2040	U-3974			
	11918578	Feb 12, 2040	U-3290			
	11918578	Feb 12, 2040	U-3974			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002	10512657	Oct 26, 2032	U-3973		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-3973		ODE*	Sep 29, 2028
					ODE*	Mar 13, 2030
					ODE*	Mar 13, 2031
					ODE-490	Jul 24, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	RE50050	Jun 19, 2034	DS DP			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
	12115156	Dec 11, 2038	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	>A> 12171772	Aug 08, 2031	DS			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOHEXITAL SODIUM - METHOHEXITAL SODIUM</u>						
A 215488 001					>A> CGT	Jun 10, 2025
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 001	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 002	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 003	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 004	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 005	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 006	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 007	10265308	Feb 03, 2037	DP U-4032			
	10695336	Feb 03, 2037	U-4032			
	9707217	Feb 03, 2037	DP			
	9827234	Feb 03, 2037	U-4032			
	9855258	Feb 03, 2037	DP U-4032			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
	12097210	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	12042488	May 30, 2038	DS			
	12042489	May 30, 2038	DS U-2371			
	12042490	May 30, 2038	U-2371			
	12109205	May 30, 2038	DS U-2371			
	RE48608	Oct 20, 2031	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
	>A> 12161656	May 12, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	12138311	Oct 01, 2030	U-1631			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - EMROSI</u>						
N 219015 001	10905664	Jan 07, 2039	U-4043		>A> NP	Nov 01, 2027
	11191740	Jan 07, 2039	U-4043			
	11364212	Jan 07, 2039	U-4043			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	12064442	Sep 04, 2034	U-3297			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
	12097284	Aug 16, 2039	DP			
	12097285	Aug 16, 2039	DP U-1752			
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 001					CGT	Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 002					CGT	Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 001					CGT	Mar 24, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 002					CGT	Mar 24, 2025
<u>NALMEFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)</u>						
N 218590 001	10279131	Jul 31, 2031	DP		NP	Aug 07, 2027
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	11185642	Aug 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALMEFFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)</u>						
N 218590 001	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11813435	Feb 25, 2035	DP			
	11857547	Nov 05, 2039	DP			
	11865112	Nov 05, 2039	DP	U-3630		
	8021335	Oct 04, 2026	DP			
	8496619	Aug 21, 2031	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9364610	Aug 21, 2031	DP			
	9364611	Aug 21, 2031	DP			
	9446195	Aug 21, 2031	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	11975096	Aug 26, 2034	DP		NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11020385	Mar 14, 2034	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	12042494	Nov 18, 2030	DP	U-3522		
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
A 215592 001					CGT	May 21, 2025
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
A 215592 002					CGT	May 21, 2025
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 001	10874671	Feb 18, 2040	DP			
	11793809	Feb 18, 2040	DP			
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 002	10874671	Feb 18, 2040	DP			
	11793809	Feb 18, 2040	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	12110277	Jul 08, 2042	DP			
	12116347	Aug 09, 2039	DP			
	12138246	May 19, 2043	U-3754			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042		DP		
	11612588	Jul 08, 2042		DP	U-3754	
	11807611	Sep 08, 2042		DP	U-3754	
	11820748	Aug 09, 2039		DP		
	11844780	Sep 08, 2042		DP	U-3754	
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039		DP		
	11884635	Aug 09, 2039		DP		
	11905255	Aug 09, 2039		DP		
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	12011434	May 19, 2043		U-3754		
	12011435	May 19, 2043		U-3754		
	12036207	May 19, 2043		U-3754		
	12110277	Jul 08, 2042		DP		
	12116347	Aug 09, 2039		DP		
	12138246	May 19, 2043		U-3754		
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042		DP		
	11612588	Jul 08, 2042		DP	U-3754	
	11807611	Sep 08, 2042		DP	U-3754	
	11820748	Aug 09, 2039		DP		
	11844780	Sep 08, 2042		DP	U-3754	
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039		DP		
	11884635	Aug 09, 2039		DP		
	11905255	Aug 09, 2039		DP		
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	12011434	May 19, 2043		U-3754		
	12011435	May 19, 2043		U-3754		
	12036207	May 19, 2043		U-3754		
	12110277	Jul 08, 2042		DP		
	12116347	Aug 09, 2039		DP		
	12138246	May 19, 2043		U-3754		
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS	DP	U-3903	
	11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS	DP	U-3903	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 003	12097170	Mar 08, 2041	DP U-3995			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	12013403	Mar 04, 2036	U-1941			
	12013403	Mar 04, 2036	U-1942			
	12013403	Mar 04, 2036	U-1943			
	12013403	Mar 04, 2036	U-1944			
	12013403	Mar 04, 2036	U-2093			
	12013403	Mar 04, 2036	U-2094			
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	10342850	May 15, 2038	DP			
	11052196	Nov 03, 2040	U-4007			
	11052196	Nov 03, 2040	U-4008			
	11052196	Nov 03, 2040	U-4009			
	11246991	Nov 03, 2040	U-4007			
	11246991	Nov 03, 2040	U-4008			
	11246991	Nov 03, 2040	U-4009			
	11534553	Nov 03, 2040	U-4007			
	11534553	Nov 03, 2040	U-4008			
	11534553	Nov 03, 2040	U-4009			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12091394	Jun 20, 2039	DS			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
	12144810	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
	12144810	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS U-2986			
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					NFP	Apr 24, 2027
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12053463	May 16, 2039	DS DP			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
	12042539	Jul 16, 2039	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	12129247	Jan 11, 2032	U-4038			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	12129247	Jan 11, 2032	U-4038			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289		I-952	Sep 25, 2027
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	10183020	Jan 02, 2035	DP U-4010			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	8946235	Aug 08, 2032	DS DP U-4010			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-4010			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289		I-952	Sep 25, 2027
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	10183020	Jan 02, 2035	DP U-4010			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	8946235	Aug 08, 2032	DS DP U-4010			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-4010			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 004	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 001	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 002	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 003	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 004	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 004	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 005	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 006	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12023312	Aug 31, 2031	U-3966			
	12138245	Jun 08, 2037	U-4031			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001					NPP	Aug 12, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PATISIRAN SODIUM - ONPATTRO</u>						
N 210922 001					M-270	Jan 13, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
	>A> 12161730	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
	>A> 12161730	Mar 16, 2037	U-665			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001					M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002					M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003					M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004					M-308	Sep 13, 2027
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039	U-3804			
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031	U-3685			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
	>A> 12070513	Jul 31, 2029	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - OLOSI</u>						
N 217836 001	11974986	Aug 18, 2037	U-3741			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12109193	Sep 14, 2041	DP		ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12109193	Sep 14, 2041	DP		ODE-451	Dec 01, 2030
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	12146003	Jun 05, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u>						
N 213498 001	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192 11963958	Apr 03, 2039 Apr 03, 2039	U-2952 U-2828			
<u>PREDNISOLONE ACETATE - PREDNISOLONE ACETATE</u>						
A 216935 001					CGT	Apr 09, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	11478428	Dec 23, 2039	DP U-4026		NCE	Oct 25, 2029
	11554112	Apr 01, 2039	U-4026		GAIN	Oct 25, 2034
	12109197	Apr 01, 2039	U-4026			
	7795243	Jun 03, 2029	DS DP U-4026			
<u>PRUCALOPRIDE SUCCINATE - PRUCALOPRIDE SUCCINATE</u>						
A 218492 001					>A> CGT	Jun 24, 2025
<u>PRUCALOPRIDE SUCCINATE - PRUCALOPRIDE SUCCINATE</u>						
A 218492 002					>A> CGT	Jun 24, 2025
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	10881617	Jun 18, 2038	DP			
	10925833	Jun 18, 2038	DP			
	10987311	Jun 18, 2038	DP			
	11229606	Jun 18, 2038	DP			
	11478425	Jun 18, 2038	DP U-4012			
	11666536	Jun 18, 2038	DP			
	11911515	Jun 18, 2038	DP			
	12042559	Jun 18, 2038	DP			
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018 002	>A> 12161761	Jan 24, 2038	DP			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	12097198	Sep 29, 2037	U-3020			
	12144809	Sep 29, 2037	U-4035			
	>A> 7300935	Jan 28, 2026	DS			
	>A> 8058280	Jan 28, 2026	DS DP			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3835			
	11975012	May 28, 2041	U-3836			
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3833			
	11903953	May 28, 2041	U-3834			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3833			
	11975012	May 28, 2041	U-3834			
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
					ODE-483	Jun 13, 2031
					ODE-488	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		ODE*	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		ODE-488	Jun 13, 2031
	9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033		U-3861	NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP	U-3861		
	11986481	Sep 17, 2033		U-3861		
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12048692	Aug 29, 2039		U-2440		
	7288657	Oct 31, 2028	DS			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001	>A> 10683302	Jun 08, 2037	DS DP		NCE	Nov 15, 2029
	>A> 11479557	Jun 08, 2037	DP U-4045		>A> ODE-502	Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002	>A> 10683302	Jun 08, 2037	DS DP		NCE	Nov 15, 2029
	>A> 11479557	Jun 08, 2037	DP U-4045		>A> ODE-502	Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003	>A> 10683302	Jun 08, 2037	DS DP		NCE	Nov 15, 2029
	>A> 11479557	Jun 08, 2037	DP U-4045		>A> ODE-502	Nov 15, 2031
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12064434	Apr 14, 2036	DP		I-950	Sep 17, 2027
	8962630	Dec 09, 2029		U-1981		
	8962630	Dec 09, 2029		U-2355		
	8962630	Dec 09, 2029		U-2356		
	8962630	Dec 09, 2029		U-3265		
	8962630	Dec 09, 2029		U-3266		
	8962630	Dec 09, 2029		U-3975		
	8962630	Dec 09, 2029		U-3999		
	9416136	Aug 20, 2029		U-1981		
	9416136	Aug 20, 2029		U-2355		
	9416136	Aug 20, 2029		U-2356		
	9416136	Aug 20, 2029		U-3265		
	9416136	Aug 20, 2029		U-3266		
	9416136	Aug 20, 2029		U-3975		
	9416136	Aug 20, 2029		U-3999		
	9868739	Nov 09, 2031		U-1981		
	9868739	Nov 09, 2031		U-2355		
	9868739	Nov 09, 2031		U-2356		
	9868739	Nov 09, 2031		U-3265		
	9868739	Nov 09, 2031		U-3266		
	9868739	Nov 09, 2031		U-3975		
	9868739	Nov 09, 2031		U-3999		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP	U-1153		
	7125879	Apr 21, 2025	DS DP	U-1307		
	7125879	Apr 21, 2025	DS DP	U-1740		
	7125879	Apr 21, 2025	DS DP	U-3353		
	7125879	Apr 21, 2025	DS DP	U-3874		
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP	U-3874		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
	12023325	Aug 12, 2040	U-3960			
	12023326	Aug 12, 2040	U-3959			
	12023327	Aug 12, 2040	U-3958			
	12023328	Dec 30, 2040	U-3957			
	12059410	Aug 12, 2040	U-3153			
	12059411	Aug 12, 2040	U-3971			
	12064422	Dec 30, 2040	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
	12122789	Apr 15, 2041	DS DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 001	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 002	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 003	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 004	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 005	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 006	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 007	12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RITILECITINIB TOSYLATE - LITFULO</u>						
N 215830 001	12077533	Dec 03, 2034	U-3994			
	12116368	Oct 17, 2041	DS			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	11992480	Jun 07, 2037	U-3748			
	12005051	Jun 07, 2037	U-3748			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	10940142	Jun 07, 2037	DP		NS	Jul 09, 2027
	11129818	Aug 25, 2037	U-3970			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3970			
	11992480	Jun 07, 2037	U-3970			
	12005051	Jun 07, 2037	U-3970			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3970			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11992480	Jun 07, 2037	U-3773		NP	Dec 15, 2026
	12005051	Jun 07, 2037	U-3773			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	10272058	Mar 19, 2035	U-1854		NCE	Aug 14, 2029
	11406611	Mar 19, 2035	U-1854		ODE-486	Aug 14, 2031
	11596614	Mar 19, 2035	U-1854			
	7301050	Aug 02, 2025	DS DP			
	7709682	Sep 13, 2026	DS			
	9486428	Mar 19, 2035	U-1854			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
	12150957	Jul 01, 2041	U-4039			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
	12150957	Jul 01, 2041	U-4039			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
	12150957	Jul 01, 2041	U-4039			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 002	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	12138250	Oct 10, 2038	U-3949			
	12138250	Oct 10, 2038	U-3950			
	12138250	Oct 10, 2038	U-3951			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	>A> 11833248	Feb 01, 2039	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	>A> 11833248	Feb 01, 2039	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	>A> 11833248	Feb 01, 2039	DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	12061183	Mar 05, 2036	DP			
	12133844	Jun 29, 2036	U-4040			
	12133844	Jun 29, 2036	U-4041			
	12133844	Jun 29, 2036	U-4042			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	12128021	Jul 21, 2037	U-4022			
	12138239	Jul 21, 2037	DP			
	12144793	Jul 21, 2037	DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			
<u>SOPFIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	10383846	Mar 14, 2034	U-2398		NCE	Jun 20, 2029
	10947192	May 22, 2034	U-2398			
	10952990	May 22, 2034	U-2398			
	10959983	May 22, 2034	U-2398			
	10961191	May 22, 2034	U-2398			
	11026919	May 22, 2034	DP U-2398			
	11034652	May 22, 2034	DP U-2398			
	11052067	May 22, 2034	DP U-2398			
	11084788	May 22, 2034	DP U-2398			
	11123325	Jul 20, 2037	DP U-2398			
	11566000	May 22, 2040	DS DP			
	11584715	May 22, 2040	DS DP			
	8147809	Mar 26, 2027	DS DP			
	8628759	Nov 13, 2026	U-2398			
	9220707	Mar 14, 2034	U-2398			
	9492429	Mar 14, 2034	DP U-2398			
	9895350	Mar 14, 2034	U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	12102609	Dec 30, 2042	U-3693			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	12102609	Dec 30, 2042	U-3693			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE*	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		ODE-493	Sep 05, 2031
	9993461	Mar 29, 2030	U-3993			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		ODE-493	Sep 05, 2031
	9993461	Mar 29, 2030	U-3993			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	12033733	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	RE44733	Jan 27, 2026	DS DP U-1794			
	RE44733*PED	Jul 27, 2026				
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	RE44733	Jan 27, 2026	DS DP U-1794			
	RE44733*PED	Jul 27, 2026				
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	12090139	Jun 16, 2030	DP			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	12097183	Jan 29, 2036	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	12083103	May 30, 2028	U-2678			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	12083103	May 30, 2028	U-2678			
<u>TADALAFIL - TADLIQ</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	12049457	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			
<u>TAZAROTENE - TAZAROTENE</u>						
A 217075 001					CGT	Mar 08, 2025
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	12128137	May 11, 2038	DP U-2368			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12016856	Dec 30, 2029	DS DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TERAZOSIN HYDROCHLORIDE - TEZRULY</u>						
N 218139 001	11224572	Jan 18, 2042	DP U-3990			
	11224572	Jan 18, 2042	DP U-3991			
<u>TESTOSTERONE CYPIONATE - AZMIRO</u>						
N 216318 001	12138271	Mar 25, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12011503	Oct 16, 2040	DP U-3964			
	12011503	Oct 16, 2040	DP U-3965			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 215312 001					CGT	Mar 26, 2025
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	11975013	Aug 16, 2041	DP			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001					D-192	Jun 07, 2027
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039	U-3855		M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIZANIDINE HYDROCHLORIDE - ONTRALFY</u>						
N 216190 001 >A>	12042484	May 07, 2042	DP U-2779			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002				I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003				I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513	001	7378423	May 29, 2027	DS DP	NP	Mar 16, 2026
		7378423*PED	Nov 29, 2027		ODE-428	Mar 16, 2030
		8703781	Oct 15, 2030	DS DP U-3564	PED	Sep 16, 2026
		8703781*PED	Apr 15, 2031		PED	Sep 16, 2030
		8835443	Jun 10, 2025	U-3564		
		8835443*PED	Dec 10, 2025			
<u>TRAVOPROST - IDOSE TR</u>						
N 218010	001				NP	Dec 13, 2026
<u>TRAZODONE HYDROCHLORIDE - RALDESY</u>						
N 218637	001	>A> 8133893	Mar 13, 2029	DS DP		
<u>TREPROSTINIL - TYVASO</u>						
N 022387	001	11826327	Feb 03, 2042	U-3749		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	001	11826327	Feb 03, 2042	U-3749	NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	002	11826327	Feb 03, 2042	U-3749	NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	003	11826327	Feb 03, 2042	U-3749	NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	004	11826327	Feb 03, 2042	U-3749	NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	005	10130685	Aug 23, 2025	DP		
		10421729	Apr 01, 2035	DP		
		10772883	Jun 11, 2030	DP		
		11723887	Dec 15, 2028	DS		
		11826327	Feb 03, 2042	U-3749		
		9593066	Dec 15, 2028	DS		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	001	9604901	Dec 15, 2028	DS	Y	
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496	005	9604901	Dec 15, 2028	DS	Y	
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200	001	11040042	Oct 25, 2031	DP		
<u>TROFINETIDE - DAYBUE</u>						
N 217026	001	11827600	Jul 12, 2042	DS DP U-3556		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TROMETHAMINE - TROMETHAMINE</u>						
A 213116	001				>A> CGT	Jul 01, 2025
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158	001	10238643	Jul 21, 2030	DP	NCE	Sep 26, 2029
		10265311	Jul 21, 2030	U-3513		
		10369143	Jul 21, 2030	U-3513		
		10369144	Jul 21, 2030	DP U-3513		
		10695339	Jul 21, 2030	U-3513		
		10925832	Sep 27, 2039	DP		
		10933020	Sep 27, 2039	DP U-3513		
		11452692	Sep 27, 2039	U-3513		
		11471413	Sep 27, 2039	U-3513		
		11890378	Sep 27, 2039	DP U-3513		
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158	002	10238643	Jul 21, 2030	DP	NCE	Sep 26, 2029
		10265311	Jul 21, 2030	U-3513		
		10369143	Jul 21, 2030	U-3513		
		10369144	Jul 21, 2030	DP U-3513		
		10695339	Jul 21, 2030	U-3513		
		10925832	Sep 27, 2039	DP		
		10933020	Sep 27, 2039	DP U-3513		
		11452692	Sep 27, 2039	U-3513		
		11471413	Sep 27, 2039	U-3513		
		11890378	Sep 27, 2039	DP U-3513		
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158	003	10238643	Jul 21, 2030	DP	NCE	Sep 26, 2029
		10265311	Jul 21, 2030	U-3513		
		10369143	Jul 21, 2030	U-3513		
		10369144	Jul 21, 2030	DP U-3513		
		10695339	Jul 21, 2030	U-3513		
		10925832	Sep 27, 2039	DP		
		10933020	Sep 27, 2039	DP U-3513		
		11452692	Sep 27, 2039	U-3513		
		11471413	Sep 27, 2039	U-3513		
		11890378	Sep 27, 2039	DP U-3513		
<u>TUCATINIB - TUKYSA</u>						
N 213411	001	11207324	Apr 27, 2038	U-3783		
		11666572	Apr 27, 2038	U-3783		
		12048698	Apr 27, 2038	U-3783		
<u>TUCATINIB - TUKYSA</u>						
N 213411	002	11207324	Apr 27, 2038	U-3783		
		11666572	Apr 27, 2038	U-3783		
		12048698	Apr 27, 2038	U-3783		
<u>UBROGEPANT - UBRELVY</u>						
N 211765	001	11857542	Dec 22, 2041	U-3786		
		11925709	Jan 30, 2035	DP		
<u>UBROGEPANT - UBRELVY</u>						
N 211765	002	11925709	Jan 30, 2035	DP		
		12070450	Dec 22, 2041	U-3992		
<u>UPADACITINIB - RINVOC</u>						
N 211675	001	11365198	Oct 17, 2036	U-3275	I-946	Apr 26, 2027
		11365198	Oct 17, 2036	U-3946	NPP	Apr 26, 2027
		11512092	Oct 17, 2036	U-3275	ODE-481	Apr 26, 2031
		11512092	Oct 17, 2036	U-3371		
		11512092	Oct 17, 2036	U-3487		
		11512092	Oct 17, 2036	U-3946		
		11773106	Oct 17, 2036	U-3275		
		11773106	Oct 17, 2036	U-3371		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	12077545	Oct 17, 2036	DP			
	12103933	Oct 17, 2036	DP			
	12110297	Oct 17, 2036	DP			
	12110298	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	12091415	Oct 17, 2036	DP		NPP	Apr 26, 2027
	12110298	Oct 17, 2036	DS DP		ODE-481	Apr 26, 2031
	12116373	Oct 17, 2036	DP			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	12110298	Oct 17, 2036	DS DP		NPP	Apr 26, 2027
	12134621	Oct 17, 2036	DP		ODE-481	Apr 26, 2031
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO LO</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	12110298	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP U-3876			
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036	U-3876			
	11857543	Jun 09, 2034	U-3876			
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028	U-3876			
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027	U-3876			
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034	U-3876			
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12102638	Mar 22, 2040	U-3045			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12016857	Aug 16, 2039	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	12121523	Sep 04, 2029	U-727			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	12121523	Sep 04, 2029	U-727			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	12121523	Sep 04, 2029	U-727			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2025	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					I-948	Jul 17, 2027
<u>VORASIDENIB - VORANIGO</u>						
N 218784 001	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VORASIDENIB - VORANIGO</u>						
N 218784 002	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001	12049628	Jul 28, 2036	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZINC CHLORIDE - ZINC CHLORIDE</u>						
A 216152 001					CGT	Apr 14, 2025
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm